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Abstract	
Current	transplant	immunosuppression	regimens	have	numerous	limitations.	Recent	
evidence	suggests	histone	deacetylase	inhibitors	(HDACis)	may	represent	a	class	of	drug	
with	immunosuppressive	properties.	This	study	initially	assessed	a	panel	of	experimental	
and	established	HDACis	and	identified	a	novel	HDAC6-specific	inhibitor	(KA1010)	to	
compare	with	cyclosporin	(CyA)	with	the	pan-HDACi	suberoylanilide	hydroxamic	acid	(SAHA)	
further	in	models	of	alloreactivity.		
	
Proliferation	and	MLR-based	assays	were	used	to	determine	the	immunosuppressive	effect	
of	compounds,	and	a	murine	model	of	allogeneic	skin	transplantation	was	adopted	to	assess	
the	in	vivo	effects	of	HDAC6	inhibition.	
	
KA1010	displayed	superior	inhibitory	effects	on	the	activation	of	peripheral	mononuclear	
cells	using	in	vitro	models	of	transplantation.	In	a	one-way	MLR,	KA1010	(5μΜ)	reduced	
parent	cell	proliferation	from	92%	to	64%	(p=0.001).	A	two-way	MLR,	adopting	IFN-γ	
production	as	a	marker	of	alloresponse,	resulted	in	up	to	91%	reduction.	Dose-response	
curves	revealed	dose-dependent	profiles	with	a	greater	potency	of	HDACis	over	CyA	(IC50	
values	of	82.0nM	and	13.4nM	for	KA1010	and	SAHA).	
	
Mice	treated	with	KA1010	displayed	no	significant	features	of	skin	allograft	rejection	upon	
histological	analysis	at	70	days	and	graft	survival	of	80%	in	subjects	treated	with	160mg/kg.	
Immunological	assessment,	revealed	a	significant	increase	in	CD4+CD25+FoxP3+	regulatory	
T	cells	(from	18%	to	25%,	p=0.0002)	and	a	corresponding	reduction	in	CD4+	T	cells	(from	
58%	to	42%,	p=0.0009).	
	
HDAC6	may	represent	an	optimal	target	for	future	immunosuppressant	therapeutics	with	a	
particular	role	in	transplantation.	In	this	thesis,	we	have	demonstrated	a	superior	
immunosuppressive	effect	of	KA1010	over	both	CyA	and	SAHA,	in	the	models	of	
allotransplantation	adopted.	
	
The	salient	findings	in	this	study	have	been	collated	in	an	article	paper	which	has	been	
accepted	for	publication	in	the	peer-reviewed	journal,	Transplantation	(see	Appendix	1).	 	
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1 Introduction	
1.1 	Historical	Background	
In	 1902,	 Emerich	 Ullman	 performed	 the	 first	 reported	 successful	 experimental	
transplantation	 of	 a	 kidney	 between	 dogs	 (Ullman	 1914).	 The	 graft	 survived	 5	 days.	
Subsequent	 attempted	 xenografts	 proved	 unsuccessful,	 and	 Ullman	 abandoned	 further	
renal	transplant	research.		
In	 1912,	 Alexis	 Carrel,	 ‘the	 father	 of	 transplantation’,	 was	 awarded	 the	 Nobel	 Prize	 in	
Physiology	 or	 Medicine.	 He	 pioneered	 surgical	 techniques,	 particularly	 in	 vascular	
anastomosis	that	are	still	 in	common	practice	today.	He	also	demonstrated	techniques	for	
preserving	 organs	 and	 blood	 vessels	 and	 later	 developed	 an	 early	 perfusion	 pump.	 He	
famously	went	on	to	say	in	1914	“the	technical	problems	of	transplantation	were	essentially	
solved,	but	until	 some	method	was	developed	to	prevent	 the	 reaction	of	 the	organism	to	
the	foreign	tissue,	there	would	be	no	clinical	application	of	organ	transplantation”	(Morris	
2004).	Following	Carrels’	work,	a	number	of	experimental	transplants	were	attempted	but	
failed,	primarily	due	to	graft	rejection.	
In	 1933,	 the	 Ukrainian	 surgeon,	 Professor	 Yurii	 Voronoy	 performed	 the	 first	 human	 to	
human	cadaveric	transplant	(Matevossian	et	al.	2009).	He	grafted	a	kidney	from	a	60-year-
old	deceased	brain	trauma	male	(Blood	Group	B)	into	a	26-year-old	female	(Blood	Group	O).	
The	recipient	was	in	end-stage	renal	failure	as	a	result	of	mercury	intoxication,	and	despite	
the	ABO	blood	group	incompatibility,	produced	a	urine	output	of	5mls/hr	up	to	the	second	
post-operative	 day.	 The	 recipient	 subsequently	 died	 on	 the	 fourth	 post-operative	 day,	
though	there	was	no	vascular	thrombosis	of	the	graft	vessels.		
2	
	
	
Figure	1-1	Implantation	in	the	groin	of	the	first	homotransplantation	performed	by	
Voronoy	in	1933	
During	 the	 Second	World	War,	 a	 zoologist	 named	Peter	Medawar	was	 studying	burn	 and	
wound	healing.	He	recognised	that	skin	grafts	only	worked	when	the	graft	came	from	the	
recipient	 and	 researched	 extensively	 the	 mechanisms	 of	 transplant	 rejection.	 His	 work	
would	represent	the	start	of	an	evolving	area	of	research;	that	of	transplant	immunology.		
In	conjunction	with	Thomas	Gibson,	Medawar	published	a	series	of	papers	on	graft	rejection	
and	 how	 it	 was	mediated	 by	 immune	 cells	 (Gibson	 &	Medawar	 1943),	 (Medawar	 1944).	
They	 demonstrated	 that	 the	 process	 of	 rejection	 in	 both	 human	 and	 rat	 tissue	 was	
characterised	by	 specificity	and	memory	 for	donor	 tissue	and	 that	 it	was	accompanied	by	
infiltration	of	leucocytes.		However,	it	was	an	Australian	virologist,	Frank	Macfarlane	Burnet	
who	 first	 introduced	 the	 concept	 of	 self	 and	 non-self,	 to	 immunology	 (the	 ability	 of	 the	
immune	system	to	discriminate	between	cells	of	its	own	body	and	foreign	antigens).	In	his	
landmark	text	–	‘The	Production	of	Antibodies’	he	postulated	that	‘self’	was	defined	during	
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embryogenesis.	He	later	went	on	to	describe	his	clonal	selection	theory	in	order	to	explain	
why	antibodies	are	not	produced	against	antigens	on	our	own	cells.		
1.1.1 Early	Immunosuppression	
In	 1948,	 Merck	 Company	 produced	 the	 first	 commercially	 available	 adrenal	 cortical	
hormone,	 Cortone	 (cortisone).	 Initially,	 Medawar	 et	 al.	 suggested	 that	 the	
immunosuppressive	 effects	 of	 cortone	 were	 of	 limited	 significant	 benefit.	 	 By	 the	 early	
1950’s,	 a	 number	 of	 groups	 were	 again	 attempting	 human	 kidney	 transplantation.	 The	
surgical	technique	had	by	now	changed	somewhat	and	grafts	were	implanted	into	the	right	
iliac	fossa	with	vascular	anastomosis	to	the	iliac	vessels.	The	results	were	modest	with	grafts	
surviving	 up	 to	 3	 weeks	 on	 the	 immunosuppressive	 regimen	 of	 adrenocorticotrophic	
hormone	(ACTH)	or	cortone.	However	subsequent	studies	by	Medawar	et	al.	demonstrated	
that	 long-term	 graft	 acceptance	 was	 dependent	 upon	 the	 induction	 of	 tolerance.	 It	 was	
generally	 accepted	 that	 the	weak	 steroid	effect	of	 cortone	was	 simply	 insufficient	 and	 its	
use	was	side-lined.		
One	of	the	centres	carrying	out	transplants	in	the	early	1950’s	was	the	Peter	Bent	Brigham	
Hospital	 in	 Boston.	 Here,	 David	 Hume’s	 group	 reported	 on	 a	 series	 of	 nine	 transplants	
performed	 (Hume	 et	 al.	 1955).	 They	made	 several	 important	 conclusions,	 principally	 that	
pre-operative	blood	transfusion	and	the	matching	of	donor	and	recipient	blood	groups	were	
important.	However,	with	little	confidence	in	the	pharmacological	agents	used	at	the	time,	
it	was	believed	that	the	immunosuppressive	effect	of	endogenous	uraemia	was	more	likely	
to	 be	 responsible	 for	 the	 short	 periods	 of	 function	 before	 rejection.	 Effective	
immunosuppression	remained	elusive.		
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In	December	1954,	Joseph	Murray	performed	the	first	successful		human	kidney	transplant	
(in	 terms	 of	 long	 term	 survival)	 at	 Peter	 Bent	 Brigham	 Hospital	 in	 Boston	 (Merrill	 et	 al.	
1956).	By	applying	the	knowledge	gleaned	by	E.	C.	Padgett	(Padgett	1932)	and	J.	B.	Brown	
(Brown	1937)	in	the	1930’s	which	showed	that	genetic	identity	was	necessary	for	successful	
skin	grafting	between	monozygotic	twins,	he	transplanted	the	kidney	of	a	23	year	old	male	
into	 his	 twin	 brother,	 who	 was	 suffering	 advanced	 glomerulonephritis.	 The	 recipient	
survived	 for	 eight	 years	 before	 succumbing	 to	 a	 recurrence	 of	 glomerulonephritis	 in	 the	
originally	 unaffected	 kidney.	 This	 success	 provided	 a	 catalyst	 for	 a	 series	 of	 successful	
transplants	 between	 twins	 (Murray,	 Merrill,	 &	 Harrison	 1958)	 and	 highlighted	 several	
important	lessons	on	the	technical	and	ethical	issues,	however	significant	deficiencies	in	the	
immunological	 treatment	 of	 patients	 remained	 and	 the	 future	 of	 transplantation	 had	
essentially	hit	an	immunosuppressive	‘brick	wall’.		
By	the	late	1950’s	total	body	irradiation	with	allograft	bone	marrow	rescue	was	gaining	
acceptance	as	a	viable	immunosuppressive	therapy.	This	involved	pre-conditioning	the	
recipients	with	total	body	irradiation	(without	donor	bone	marrow,	instead	their	own	bone	
marrow	was	recovered	and	infused	back	post-transplant).	Unfortunately,	there	were	
difficulties	in	controlling	total	body	irradiation	and	as	a	consequence,	unacceptably	high	
levels	of	graft-versus-host	disease	were	occurring.	Though	this	technique	was	refined	to	a	
sublethal	irradiation	alone	regimen,	there	remained	a	high	incidence	of	overwhelming	
sepsis	and	mortality.	It	did,	however,	provide	a	significant	breakthrough,	allowing	the	first	
successful	allotransplants,	one	by	the	Boston	group	(Merrill	et	al.	1960)	and	five	by	a	group	
in	France	(Hamburger	et	al.	1962;Kuss	et	al.	1962).	Despite	these	being	isolated	successes	
among	a	large	number	of	failures,	it	soon	became	apparent	that	myelotoxicity	needed	to	be	
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avoided	and	the	momentum	was	thus	provided	to	continue	research,	with	the	resulting	
emergence	of	chemical	immunotherapy.		
The	first	major	breakthrough	in	the	development	of	cytostatic	drugs	(that	is	drugs	which	
inhibit	cell	growth	and	multiplication)	came	in	1959	with	the	discovery	by	Robert	Schwartz	
and	William	Dameshek	in	Boston,	that	6-Mercaptopurine	(6-MP)	reduced	the	antibody	
response	in	rabbits	to	human	serum	albumin	(Schwartz	&	Dameshek	1959).	They	further	
reported	that	a	short	course	of	6-MP	in	addition	to	administration	of	antigen,	induced	a	
long-term	failure	to	respond	to	this	antigen.	Effectively	they	had	induced	tolerance.	
However,	as	they	stated,	its	clinical	use	in	human	transplantation	was	prevented	by	
‘development	of	resistance’	to	the	drugs	and	its	‘toxicity	in	humans’.		
1.1.2 Azathioprine	
During	this	period,	a	young	surgeon	by	the	name	of	Roy	Calne	was	unsuccessfully	using	
radiation	in	a	series	of	canine	renal	transplants.	He,	fortunately,	sought	the	advice	of	
Kendrick	Porter,	a	professor	of	pathology	at	St	Marys	Hospital	London	who	had	recently	
worked	with	Schwartz.	Porter	introduced	Calne	to	the	potential	benefits	of	6-MP	and	in	
1960,	Calne	published	his	results	demonstrating	its	effectiveness	in	prolonging	renal	graft	
survival	in	dogs	(Calne	1960).		He	postulated	the	mechanism	of	action	was	‘either	by	a	non-
specific	toxic	effect	on	the	immune	system	or	by	a	true	specific	production	of	immune	
tolerance’	[i.e.,	by	the	graft	as	antigen].	Shortly	after	this,	at	the	suggestion	of	Peter	
Medawar,	Calne	travelled	to	Boston	to	join	Joseph	Murray	at	the	Brigham	Hospital.	On	his	
way,	he	visited	George	Hitchings	and	Gertrude	Elion	at	the	Burroughs	Welcome	Research	
Laboratories	in	New	York.	They	had	originally	provided	Schwartz	and	Dameshek	with	6-MP,	
and	encouraged	Calne	to	study	a	new	derivative	called	BW57-322	(later	termed	
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Azathioprine).	Murray	and	Calne	quickly	demonstrated	that	Azathioprine	was	a	more	
successful	immunosuppressant	than	6-MP,	with	fewer	toxic	side-effects	(Calne	1961;Calne	
&	Murray	1961).	Though	their	results	were	far	from	conclusive,	several	groups	around	the	
world	began	to	trial	azathioprine	as	a	chemical	immunosuppressant	in	human	renal	
transplantation,	with	variable	success.	The	Boston	group	treated	27	transplant	recipients,	
nine	of	whom	survived	greater	than	a	year,	including	the	notable	case	of	Melvin	Doucette,	a	
24-year	old	accountant	who	was	transplanted	in	April	1962	(Murray	et	al.	1963);	(Murray,	
Wilson,	&	O'Connor	1967).	He	survived	18	months	and	was	considered	to	be	the	first	
successful	unrelated	renal	allograft.	Calne	himself,	who	had	returned	to	London,	treated	
eight	recipients	with	Azathioprine,	with	only	two	surviving.	In	addition,	two	transplant	
teams	from	Paris,	Professor	Jean	Hamburger	and	Dr	Rene	Kuss,	reported	only	one	long	term	
survivor	out	of	28	transplants.	There	was	a	general	feeling	amongst	the	transplant	
community	that	the	wider	use	of	Azathioprine	as	an	immunosuppressant	was	going	to	be	
limited	by	a	narrow	and	difficult	to	manage	therapeutic	range,	resulting	ultimately	in	a	
similar	fate	to	that	of	irradiation.		
However,	a	major	breakthrough	in	correlating	these	variable	results	into	an	effective	clinical	
strategy	came	in	September	1963	at	the	National	Research	Council	Conference	in	
Washington.		Here	almost	everyone	involved	in	transplantation	met	(a	mere	25	people)	and	
presented	their	results.	Amongst	them	was	Thomas	Starzl	from	the	Veterans	Administration	
Hospital	in	Colorado.	Despite	having	only	been	involved	in	transplantation	for	less	than	a	
year,	he	presented	impressive	results	on	a	series	of	33	patients,	twenty-seven	of	which	were	
still	alive	with	functioning	kidneys	(Starzl,	Marchioro,	&	Waddell	1963).	He	had	found	that	
episodes	of	acute	rejection	could	be	effectively	managed	with	pulses	of	high-dose	steroids.		
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There	were	additional,	practical	observations	made	at	the	meeting	that	would	ultimately	
contribute	to	the	rapid	proliferation	of	transplant	programs	around	the	world.	Amongst	
them,	it	was	noted	that	blood-type	mismatch	was	incompatible	with	graft	survival	and	that	
the	flushing	and	cooling	of	donor	organs	was	beneficial.	There	was	also	a	broad	acceptance	
that	patient	mortality	was	not	a	direct	result	of	graft	rejection	in	a	significant	number	of	
cases.	As	a	result	of	this	landmark	conference,	over	the	next	few	years,	transplant	centres	
expanded	in	number	from	less	than	ten	to	nearly	one	hundred	around	the	world.	The	use	of	
Azathioprine	and	steroids	were	further	refined	and	became	standard	practice	for	the	next	
twenty	years	with	a	resulting	proliferation	in	successful	transplantation	internationally.		
1.1.3 Cyclosporin	
There	were	few	further	developments	in	transplant	immunology	until	the	advent	of	
cyclosporin	in	the	early	1980’s.	The	Swiss	pharmaceutical	company,	Sandoz	(now	Novartis)	
Laboratories	encouraged	their	employees	to	collect	naturally	occurring	organisms	which	
could	potentially	be	developed	as	antifungal	antibiotics.	A	soil	sample,	collected	by	a	Sandoz	
employee	while	on	holiday	in	Norway	in	1970	was	presented	to	Jean-Francois	Borel	for	
further	testing.	Borel	found	this	sample	contained	the	fungi	Tolypocladium	flatum	and	one	
of	its	metabolites,	a	peptide	labelled	#24-556.	This	compound	displayed	little	anti-microbial	
activity;	however	it	was	found	to	have	an	immunosuppressive	effect	with	an	unusually	low	
level	of	toxicity.	In	contrast	to	the	cytostatic	immunosuppressants	in	use	at	the	time,	#24-
556	had	a	selective	activity	on	lymphocytes.	This	specificity	resulted	in	fewer	side	effects,	in	
particular,	the	myelotoxic	effects	immunosuppressed	patients	were	experiencing	with	
current	regimens	(Azathioprine	and	steroids).		Given	Borel	had	an	immunology	background,	
he	recognised	this	immunosuppressive	effect	and	was	keen	to	investigate	further.	By	the	
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end	of	1973,	the	potential	immunosuppressive	effects	of	#24-556	had	been	confirmed	in	a	
number	of	animal	studies.	At	this	stage,	Sandoz	did	not	deem	transplantation	as	an	area	
lucrative	enough	to	justify	further	investment.	However,	the	potential	of	#24-556	was	
recognised	as	a	possible	treatment	for	rheumatoid	arthritis,	and	further	research	was	
therefore	funded.	Compound	#24-556	was	subsequently	named	cyclosporin	A	(or	CyA,	
originating	from	cyclical	peptide	of	spore	origin).	
By	1976,	Borel	had	published	his	first	paper	on	the	subject	(Borel	et	al.	1976)	in	which	he	
succinctly	summarised	the	effects	of	cyclosporin	A:	
1. Selective	for	lymphocytes,	mainly	for	T-helper	cells	but	sometimes	for	T-effector	
cells	
2. Suppressed	antibody-	and	cell-mediated	immunity	and	chronic	(but	not	acute)	
inflammation	
3. Inhibited	the	induction	phase	of	lymphoid	cell	proliferation,	affecting	early	mitogenic	
triggering	but	not	mitosis	
4. Not	toxic	to	lymphocytes	(its	effect	being	reversible)	
5. Was	effective	on	all	mammals	tested	(mouse,	rat,	guinea	pig,	rabbit,	monkey,	dog)	
6. Had	no	cardiovascular,	psychotropic	or	other	pharmacological	effect	which	would	
seriously	limit	its	effectiveness	in	man	
In	April	1976,	Borel	presented	these	findings	at	the	spring	meeting	of	the	British	Society	for	
Immunology.	Amongst	the	delegates	were	Roy	Calne	and	David	White,	a	member	of	Calne’s	
transplant	group	in	Cambridge.	Calne	and	White	obtained	samples	of	cyclosporin	from	Borel	
and	began	carrying	out	their	own	transplantation	studies	in	rats.	Their	initial	results	were	
remarkable,	and	they	rapidly	began	testing	in	dogs	(Calne	et	al.	1978a;Calne	&	White	1977)	
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in	which	orthotopic	allograft	survival	was	ten	times	greater	compared	to	azathioprine	and	
steroid	treatment.	Encouraged	by	these	results,	Calne	commenced	trials	in	humans.	His	
initial	results	published	in	The	Lancet	(Calne	et	al.	1978b)	reported	5	out	of	7	mismatched	
cadaveric	transplant	recipients	were	successfully	discharged	from	hospital.	These	initial	
results	were	encouraging;	however	nephrotoxic	and	hepato-toxic	side	effects	had	been	
noted.	The	next	year,	he	published	a	landmark	paper	in	the	history	of	transplant	
immunology	(Calne	et	al.	1979),	though	several	negative	issues	were	highlighted.	Principally,	
that	Cyclosporin	use	resulted	in	i)	a	high	incidence	of	lymphoma,	ii)	normal	graft	function	
was	not	achieved	in	any	recipients	and	iii)	a	high	patient	mortality.	These	effects	were	
initially	treated	as	rejection,	but	it	eventually	transpired	that	they	were	actually	secondary	
to	over-suppression.	International	interest	in	cyclosporin	had	already	been	stimulated.	The	
following	year,	Thomas	Starzl	published	results	combining	Cyclosporin	with	a	steroid,	as	he	
had	done	with	Azathioprine	(Starzl	et	al.	1980).	This	allowed	the	dose	of	cyclosporin	to	be	
reduced	resulting	in	far	less	nephrotoxic	side	effects	while	retaining	its	immunosuppressive	
properties.	The	results	were	impressive	with	21	out	of	22	kidney	transplant	patients	
surviving	more	than	a	year.	Following	further	refinement,	cyclosporin	was	approved	for	use	
as	a	transplant	immunosuppressant	by	the	US	Food	and	Drugs	Agency	in	November	1983.	It	
rapidly	became	the	cornerstone	of	immunosuppressant	regimens	around	the	world.	
1.1.4 Tacrolimus	
During	1984,	in	remarkably	similar	fashion	to	the	discovery	of	cyclosporin,	another	
macrolide	immunosuppressant	was	isolated	from	the	fungus	Streptomyces	tsukubaensis,	in	
soil	collected	from	Mount	Tsukuba,	Japan.	Isolated	by	Kino	et	al.	(Kino	et	al.	1987),	it	was	
originally	named	FK506	and	was	subsequently	given	the	generic	name,	tacrolimus.		
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Initial	experiments	involving	tacrolimus	quickly	established	that	it	has	a	similar	mechanism	
of	action	to	cyclosporin	by	inhibiting	interleukin-2	(IL-2)	production,	but	in	a	far	more	potent	
manner	(30-100	times	more	potent).	Subsequent	in	vitro	animal	testing,	however,	divided	
opinion	on	its	potential	clinical	application.	Scientists	at	the	University	of	Pittsburgh	
concluded	that	tacrolimus	was	a	remarkably	effective	drug	with	minimal	side	effects,	in	
contrast	to	results	published	from	the	UK	condemning	the	drug	for	its	‘intolerable’	side	
effects	((Calne,	Collier,	&	Thiru	1987),	(Collier,	Thiru,	&	Calne	1987),	(Todo	et	al.	1987),	
(Murase	et	al.	1987)).	Unsurprisingly,	the	first	clinical	trials	involving	tacrolimus	were	
therefore	carried	out	in	Pittsburgh	and	began	in	January	1989,	led	by	Starzl.	Initially,	the	use	
of	tacrolimus	was	restricted	to	rescue	therapy	for	liver	allograft	recipients	undergoing	
chronic	rejection	or	those	in	whom	cyclosporin	caused	significant	side	effects.	The	results	of	
this	trial,	presented	at	the	1990	Congress	of	the	Transplantation	Society	in	San	Francisco,	
were	so	impressive,	that	in	the	spring	of	the	same	year	Starzl	extended	the	use	of	tacrolimus	
to	first-line	therapy	in	liver	transplant	recipients.	Of	120	transplant	recipients	treated	with	
tacrolimus	and	low-dose	prednisolone,	there	was	an	87.5%	graft	survival	(Todo	et	al.	1990).	
They	also	reported	fewer	side	effects	and	a	more	advantageous	therapeutic	index	when	
compared	with	cyclosporin.		
The	potential	of	tacrolimus	was	now	gaining	momentum	with	the	establishment	of	multi-
centre	trials	in	both	the	USA	(The	US	Multicentre	FK506	Liver	Study	Group)	and	Europe	
(European	FK506	Multicentre	Liver	Study	Group).	Both	published	similar	findings	in	1994	(	
1994a;	1994b)	and	found	that,	compared	with	cyclosporin,	patients	receiving	tacrolimus	
(and	low-dose	steroid)	had	significantly	fewer	episodes	of	acute	rejection	and	the	episodes	
that	did	occur	were	far	less	severe.	As	a	result,	tacrolimus	was	approved	for	commercial	use	
in	the	US	in	June	1994	and	two	months	later	in	the	UK.		
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1.2 	Mechanisms	of	Action		
The	agents	described	have	varied	mechanisms	in	which	they	act	as	an	immunosuppressant	
in	the	transplant	setting	(Figure	1-2).	
Allograft	
Cell	 HLA	
Antigens
Antigen	
Presenting	
Cell
IL-1 IL-2
CD4
CD8
CD4
B
NK
CD8
CD4
CD4 CD4
B
B B
NK
NK NK
CD8
CD8 CD8
Prednisolone Cyclosporine
Tacrolimus	
Azathioprine	
HLA	Class	I
HLA	Class	II
CD3
IL-2
	
Figure	1-2	Mechanisms	of	action	of	established	immunosuppressants	
1.2.1 Prednisolone	
Prednisolone	is	a	non-specific	anti-inflammatory	and	immunosuppressive	synthetic	
glucocorticoid	steroid.	Its	effect	is	mediated	primarily	by	binding	to	intracellular	
glucocorticoid	receptors.	These	receptors	in	the	absence	of	glucocorticoid	exist	as	an	
oligomeric	complex	bound	to	heat	shock	proteins	(HSP’s)	in	the	cytoplasm.	By	binding	to	
these	complexes,	glucocorticoids	initiate	a	conformational	change	which	results	in	
dissociation	from	the	HSP.	The	complex	then	translocates	to	the	nucleus	where	it	binds	to	
glucocorticoid-responsive	genes	resulting	in	increased	transcription.	One	of	the	genes	up-
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regulated	is	the	interleukin-1	receptor	antagonist	(IL-1RA).	One	of	the	functions	of	IL-1	is	to	
act	as	a	co-stimulator	for	helper	T-cell	activation.	By	inhibiting	antigen-presenting	cell	(APC)	
IL-1	production,	helper	T-cells	are	unable	to	proliferate	into	Th1	cells	and	thus	activate	
cytotoxic	T	cell	proliferation,	a	key	aspect	of	cell-mediated	immunity.	Prednisolone	also	
dampens	the	humoral	arm	of	the	immune	system	by	inhibiting	IL-6	production	(an	inducer	
of	B-cell	activation).	As	a	non-specific	agent,	prednisolone	has	many	other	immunological	
(e.g.,	inhibition	of	several	other	cytokines	including	IL-2,	IL-3,	IL-4,	etc.)	and	non-
immunological	targets.	As	a	result,	there	are	many	varied	side	effects	associated	with	
steroid	therapy,	and	therefore,	its	use	is	kept	to	a	minimum,	with	an	increasing	number	of	
steroid-free	regimens	being	used	in	transplantation.	
1.2.2 Azathioprine	
Azathioprine	is	a	pro-drug	of	6-mercaptopurine	(6-MP)	which	is	increasingly	being	replaced	
with	more	modern	immunosuppression,	though	it	does	still	have	a	role	in	some	regimens	as	
an	anti-proliferative	agent.	Once	absorbed,	azathioprine	undergoes	a	reductive	cleavage	of	
the	thioether	portion	of	the	molecule,	which	results	in	6-MP.		6-MP	is	then	further	
metabolised	(primarily	via	methylation)	into	several	active	products,	the	most	important	of	
which	is	methyl-thioinosine	monophosphate	(MeTIMP).	This	active	metabolite	is	a	purine-
synthesis	inhibitor	and	thus	inhibits	DNA	and	RNA	synthesis	in	rapidly	proliferating	cells,	
such	as	T-	and	B-cells.	Since	its	discovery,	several	other	metabolites	of	azathioprine	have	
been	found	to	have	an	immunosuppressive	role,	including	Thioguanosine	triphosphate	
(TGTP),	which	sends	activated	T	cells	into	apoptosis.				
As	with	prednisolone,	azathioprine	does	not	have	a	particularly	specific	target	profile	and	
due	to	its	effects	on	DNA/RNA	synthesis	it	has	a	wide	variety	of	side	effects,	including	
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anaemia	secondary	to	bone	marrow	deficiency	and	an	increased	risk	of	several	cancers	
including	lymphoma	and	skin	cancers	(O'Donovan	et	al.	2005).		
1.2.3 Cyclosporin	
Cyclosporin	is	a	polypeptide	of	11	amino	acids	which	has	very	poor	solubility	in	water.	For	
this	reason,	it	has	undergone	an	evolutionary	process	in	terms	of	its	development	as	a	
suspension	/	emulsion	formula.	The	first	Cyclosporin	formula	available	(Sandimmune®)	had	
very	poor	bioavailability	and	high	pharmacokinetic	variability.	Its	successor	(Neoral®)	was	
therefore	developed	as	a	micro-emulsion	with	an	improved	profile.		
Cyclosporin	blockades	intracellular	T-cell	signalling	by	binding	to	its	cytoplasmic	
immunophilin,	cyclophilin	(Figure	1-3).	Under	normal	circumstances,	activated	T-cells	
increase	intracellular	calcium,	which	binds	calmodulin,	and	activates	the	enzyme	
calcineurin.	Once	activated,	this	calcineurin	complex	dephosphorylates	the	cytoplasmic	
transcription	factor	NFAT	(nuclear	factor	of	activated	T-cells).		Once	dephosphorylated,	
NFAT	translocates	to	the	nucleus	and	increases	IL-2	gene	transcription	and	ultimately	T-cell	
proliferation.	By	binding	to	cyclophilin,	cyclosporin	forms	a	complex	which	inhibits	the	
function	of	calcineurin	and	thus	prevents	IL-2	release.		
Unfortunately,	cyclosporin	is	not	without	its	side	effects.	Though	generally	considered	less	
toxic	than	earlier	immunosuppressants,	there	is	plenty	of	evidence	documenting	the	
adverse	effects	cyclosporin	can	have	on	recipients.	Among	these,	the	primary	effect	is	
nephrotoxicity.	There	are	a	number	of	mechanisms	by	which	cyclosporin	damages	the	graft,	
and	the	true	reasons	are	likely	multifactorial	though	vascular	dysfunction	is	clearly	
implicated	and	this	may	well	be	through	stimulated	TGF-β	production	leading	to	interstitial	
fibrosis	(Naesens,	Kuypers,	&	Sarwal	2009).		
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Figure	1-3	Mechanism	by	which	cyclosporin	exerts	its	effect	on	IL-2	blockade	
1.2.4 Tacrolimus	
The	pathway	by	which	tacrolimus	acts	is	very	similar	to	that	of	cyclosporin	though	it	does	
differ	significantly	in	terms	of	structure	(it	is	a	macrolide	antibiotic)	and	potency	(50-100	
times	more	potent).	As	with	cyclosporin,	tacrolimus	is	a	calcineurin	inhibitor	which	prevents	
the	dephosphorylation	of	NFAT.	It	differs	in	mechanism	by	binding	to	the	immunophilin	
FK506	binding	protein;	its	subsequent	downstream	effects,	however,	are	similar	(Figure	1-
3).		
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1.3 The	Current	Status	of	Transplant	Immunosuppression	
Solid	organ	transplantation	has	transformed	survival	for	patients	with	end-stage	liver,	
kidney,	pancreas,	lung	and	cardiac	disease.	A	common	factor	in	determining	the	success	of	
solid	organ	transplantation	is	the	need	for	lifelong	immunosuppression	to	prevent	rejection	
by	the	host	immunity.	While	the	incidence	of	acute	rejection	has	been	markedly	reduced	
and	side	effect	profiles	much	improved,	chronic	rejection	and,	ultimately,	long-term	graft	
survival	remains	largely	unchanged		(Meier-Kriesche	et	al.	2004).	Current	
immunosuppressive	strategies	remain	associated	with	undesirable	side	effects,	such	as	
renal	injury,	diabetes	and	cardiovascular	disease	(Halloran	2004;Jardine	et	al.	2005;Ojo	et	al.	
2003).	Therapeutic	approaches	geared	towards	achieving	immune	tolerance	have	so	far	
evaded	the	field,	and	thus	new	immunosuppressive	strategies	with	better	toxicity	profiles	
continue	to	be	sought.		
	
1.4 T	cell	development	
In	order	to	fully	understand	the	rejection	process,	it	is	first	necessary	to	consider	the	role	of	
the	key	mediator	-	T	cells.		
The	development	of	T	cells	begins	as	precursors,	which	migrate	from	the	bone	marrow	to	
the	thymus.	The	thymic	cortex	is	the	major	site	of	thymocyte	proliferation,	with	a	complete	
turnover	of	cells	approximately	every	72	hours.	These	thymic	T	cells	(or	thymocytes)	
undergo	a	process	of	phenotypic	change	which	generates	a	diverse	T-cell	receptor	(TCR)	
repertoire.	Via	a	subsequent	process	of	positive	and	negative	selection,	antigen-specific	
naive	cells	are	generated	which	then	move	into	the	medulla,	where	they	undergo	further	
differentiation	and	selection.	The	majority	(98%)	of	thymocytes	generated	will	undergo	
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apoptosis	in	the	thymus	at	this	stage.	Finally,	surviving	cells	migrate	into	the	secondary	
lymphoid	organs	and	tissues	of	the	body	where	they	can	respond	to	antigens.	
1.4.1 Thymocyte	development	
Beta,	Positive	and	Negative	selection	
The	process	of	positive	and	negative	selection	within	the	thymus	will	ultimately	determine	T	
cell	lineage.		
Beta	selection	
Immature	thymocytes	(haematopoietic	precursors	that	have	derived	from	the	bone	marrow	
and	colonised	the	thymus)	lack	CD4	and	CD8	expression	and	are	termed	double	negative	
cells.	These	double	negative	cells	will	eventually	give	rise	to	either	αβ	(90%	of	the	total	
number	of	cells)	or	γδ	T	cell	receptor	expressing	cells	(Robey	&	Fowlkes	1994).	Those	cells	
destined	for	the	αβ-TCR	population	first	express	the	adhesion	molecule	CD44	followed	by	
CD25	(Interleukin-2	receptor	α	chain).	As	they	progress	through	development,	cells	continue	
to	express	CD25	but	CD44	expression	reduces.	This	CD25	positive	population	subsequently	
undergoes	beta	selection	(Godfrey	et	al.	1993).	
	In	order	to	produce	a	diverse	T	cell	receptor	repertoire	(to	maximise	recognition	of	an	array	
of	antigen	peptides),	the	T	cell	receptor	gene	in	this	CD4-CD8-CD25+	population	undergoes	
extensive	rearrangement.	This	first	involves	rearrangement	of	the	TCR-β	chain,	followed	by	
its	pairing	with	a	pre-Tα	chain	to	produce	a	pre-TCR.	This	process	results	in	a	large	number	
of	non-functional	TCRs,	and	this	population	are	excluded	through	apoptosis	at	this	stage	
(termed	β	selection).		
Having	successfully	undergone	beta	selection,	thymocytes	now	have	the	ability	to	express	a	
TCR	on	their	surface.	However,	in	order	to	be	functional,	these	TCRs	must	be	able	to	interact	
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with	the	major	histocompatibility	complex	(MHC)	of	antigen	presenting	cells	(APCs).	
Selecting	out	those	thymocytes	with	non-functional	TCRs	is	termed	positive	selection.		
Positive	selection	
To	bind	to	MHC,	the	TCR	requires	a	co-receptor	(either	CD8	in	the	case	of	MHC	I	or	CD4	in	
the	case	of	MHC	II).	In	order	to	facilitate	this,	the	thymocyte	will	express	both	co-receptors,	
therefore	transforming	them	from	a	double	negative	to	a	double	positive,	CD4+CD8+	
phenotype	(Robey	&	Fowlkes	1994).	If	these	cells	are	capable	of	binding	to	MHC	(either	
class),	they	receive	a	survival	signal	via	the	TCR.	Approximately	90%	of	the	thymocyte	
population	are	incapable	of	binding	MHC	at	this	stage	and	undergo	apoptosis.		
Depending	upon	which	MHC	the	thymocyte	is	most	capable	of	recognising	will	determine	
which	of	the	co-receptors	(CD4	and	CD8)	is	down	regulated	and	ultimately	determine	to	
which	T	cell	subset	the	thymocyte	is	destined	(Kaye	et	al.	1989;Kruisbeek	et	al.	
1985;Marusic-Galesic,	Longo,	&	Kruisbeek	1989;Teh	et	al.	1988).	Only	CD4	is	upregulated.	
Cells	which	successfully	bind	to	MHC	class	I	will	down-regulate	CD4	and	become	cytotoxic	T	
cells	(Tc	cells),	those	which	bind	MHC	class	II	will	down-regulate	CD8,	upregulate	CD4	and	
become	helper	T	cells	(Th	cells).	This	process	is	positive	selection	and	the	resulting	cells	are	
termed	single	positive	thymocytes.		
Negative	selection	
The	next	stage	in	T	cell	development	involves	the	migration	of	these	single	positive	
thymocytes	to	the	cortico-medullary	junction	of	the	thymus.	Here	they	are	exposed	to	APC	
cells	which	have	a	high	expression	of	self-peptide.	Those	cells	which	have	evolved	TCRs	
which	recognise	and	have	a	high	affinity	to	this	self-antigen	are	selected	out	and	undergo	
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apoptosis	(approximately	5%	of	the	population	of	cells	to	reach	this	stage).	Without	this	
process,	cells	able	to	recognise	self-antigen	in	the	periphery	would	represent	a	danger	to	
the	hosts	by	activating	its	own	immune	system	against	themselves,	and	subsequent	
autoimmune	disorders.	Cells	surviving	this	process,	with	a	low	affinity	to	self-antigens,	but	a	
high	affinity	to	foreign	antigens	constitute	the	precursor	population	for	conventional	T	cells.	
It	is	at	the	later	end	of	this	stage	that	cells	with	an	intermediate	affinity	for	self-peptide	
escape	negative	selection	and	are	selected	out.	These	cells	are	destined	to	become	the	
regulatory	T	cell	lineage	(see	below).		
After	undergoing	these	various	selection	steps,	the	single	positive	thymocytes	reside	in	the	
thymus	for	another	1	to	2	weeks	where	they	continue	exposure	to	self-antigens	and	
undergo	additional	maturational	processes	(the	detail	of	which	is	complex	and	beyond	the	
scope	of	this	thesis).	Finally	upon	departure	from	the	thymus,	they	enter	the	peripheral	
circulation	as	mature	T	lymphocytes.		
1.4.2 T	cell	subsets	
T	cells	function	by	secreting	soluble	mediators	through	cell	contact-dependent	mechanisms.	
They	can	be	classified	into	various	subsets	depending	upon	their	function	and	the	
phenotypic	difference	in	their	surface	markers.		
Effector	T	cells	were	originally	thought	to	have	terminally	differentiated	phenotypes,	but	
there	is	a	growing	body	of	evidence	that	suggests	these	cells	have	an	inherent	plasticity.	T	
cells	can	have	a	mixed	phenotype	and	have	the	ability	to	convert	from	one	subtype	to	
another.		
Many	T	cell	subsets	have	been	characterised	and	can	be	differentiated	by	their	cell	surface	
markers,	transcription	factors,	effector	molecules	and	function.		
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Cell	 Surface	
phenotype	
Transcription	
factors	
Effector	
molecules	
secreted	
Function	
NA
IV
E	
CD4	αβ	T	
cells	
αβ	TCR,	CD3,	
CD4,	CCR7,	
CD62L,	IL-7R	
(CD127)	
THPOK	 		 Patrol	via	lymph	nodes	scanning	MHC	Class	II	
complexes	on	APCs	for	the	antigen.	Following	
activation,	naive	CD4	cells	differentiate	into	
effector	or	regulatory	T	cells,	can	also	give	rise	
to	memory	T	cells	
CD8	αβ	T	
cells	
αβ	TCR,	CD3,	
CD8,	CCR7,	
CD62L,	IL-7R	
(CD127)	
RUNX3	 		 Patrol	via	lymph	nodes	scanning	MHC	Class	I	
complexes	on	APCs	for	antigen.	Following	
activation,	differentiate	into	CTLs	and	memory	
T	cells	
CY
TO
TO
XI
C	
Cytotoxic	
T	cells	
(CTLs)	
αβ	TCR,	CD3,	
CD8	
EOMES,	T-
bet,	BLIMP1	
Perforin,	
granzyme,	
IFNγ	
Protect	host	from	viral	infection	and	cancer	by	
killing	infected/transformed	cells.		
HE
LP
ER
	
T	helper	
(Th1)	
cells	
αβ	TCR,	CD3,	
CD4,	IL-12R,	
IFNγR,	CXCR3	
T-bet,	
STAT4,	
STAT1	
IFNγ,	IL-2,	
LTα	
Promote	protective	immunity	against	
intracellular	pathogens.	By	secreting	IFNγ	
induce	activation	of	macrophages.	
Development	regulated	by	IL-12	
Th2	cells	 αβ	TCR,	CD3,	
CD4,	IL-4R,	IL-
33R,	CCR4,	IL-
17RB,	CRTH2	
GATA3,	
STAT6,	
DEC2,	MAF	
IL-4,	IL-5,	
IL-13,	IL-
10	
Promote	humoral	response	and	host	defence	
against	extracellular	parasites.	Can	also	
potentiate	allergic	reactions	and	asthma.	
Development	regulated	by	IL-4,	IL-25	&	IL-33	
Th9	cells	 αβ	TCR,	CD3,	
CD4	
PU1	 IL-9,	IL-10	 Involved	in	host	defence	against	extracellular	
parasites.	Despite	IL-10	production	(anti-
inflammatory),	promote	allergic	inflammation	
Th17	
cells	
αβ	TCR,	CD3,	
CD4,	IL-23R,	
RORγt,	
STAT3,	RORα	
IL-17A,	IL-
17F,	IL-21,	
Promote	protective	immunity	against	
extracellular	bacteria	&	fungi	(also	
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CCR6,	IL-1R,	
CD161	
IL-22,	
CCL20	
autoimmune	and	inflammatory	disease).	
Generated	in	the	presence	of	TGFβ	&	IL-6/IL-
21.	Maintained	by	IL-23	&	IL-1	
Th22	
cells	
αβ	TCR,	CD3,	
CD4,	CCR10	
AHR	 IL-22	 Involved	in	inflammatory	skin	diseases.	Role	in	
host	defence	remains	unclear	
TFH	cells	 αβ	TCR,	CD3,	
CD4,	CXCR5,	
SLAM,	OX40L,	
CD40L,	ICOS,	
IL-21R,	PD1	
BCL-6,	STAT3	 IL-21	 Provide	germinal	centre	responses	and	
provide	help	for	B	cell	class	switching	
RE
GU
LA
TO
RY
	
TR1	cells	 αβ	TCR,	CD3,	
CD4	
Not	known	 IL-10	 Immunosuppression	(mediated	by	IL-10).	
Generated	from	naive	cells	in	the	presence	of	
TGF-β	&	IL-27	(or	in	the	presence	of	
immunosuppressive	drugs,	Vit	D3	and	
Dexamethasone	
Natural	
Treg	cells	
αβ	TCR,	CD3,	
CD4,	CD25,	
CTLA4,	GITR	
FOXP3,	
STAT5,	
FOXO1,	
FOXO3	
IL-10,	
TGFβ,	IL-
35	
Generated	in	the	thymus.	Mediate	
immunosuppression	&	tolerogenic	responses	
Inducible	
Treg	cells	
αβ	TCR,	CD3,	
CD4,	CD25,	
CTLA4,	GITR	
FOXP3,	
STAT5,	
FOXO1,	
FOXO3,	
SMAD2,	
SMAD3,	
SMAD4	
IL-10,	
TGFβ	
Generated	from	naive	T	cells,	and	in	some	
cases	depend	on	TGFβ	&	IL-2	for	
differentiation.	Mediate	immunosuppression	
&	tolerogenic	responses	
M
EM
O
RY
	 Central	
memory	
CCR7,	CD44,	
CD62L,	TCR,	
BCL-6,	BCL-
6B,	MBD2,	
IL-2,	
CD40L,	
Reside	in	secondary	lymphoid	organs,	
mounting	responses	to	antigens.	Following	
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T	cells	 CD3,	IL-7R,	IL-
15R	
BM1	 Low	levels	
IL-4,	IFNγ,	
IL-17A	
stimulation,	rapidly	proliferate	into	effector	T	
cells	
Effector	
memory	
T	cells	
CD62L,	CD44,	
TCR,	CD3,	IL-
7R,	IL-15R,	
CCR7	
BLIMP1	 Inflammat
ory	
cytokines	
Found	in	peripheral	tissues.	Provide	
immediate	protection	upon	antigen	challenge	
through	production	of	effector	cytokines	
NK
T	
Natural	
Killer	T	
cells	
NK1.1,	
SLAMF1,	
SLAMF6,	
TGFβR	
PLZF	 IL-4,	IFNγ,	
IL-17A	
Both	pro-	&	anti-inflammatory	function.	
Modulate	immune	responses	in	cancer,	
autoimmunity,	allergy,	infection	and	GvHD	
γδ
	
γδ	T	cells	 γδ	TCR,	CD3	 		 IFNγ,	IL-
17A,	IL-
17F,	IL-22	
Both	pro-	&	anti-inflammatory	function.	
Characteristics	of	both	innate	and	adaptive	
immunity	
CD
8α
α	
CD8αα	T	
cells	
αβ	or	γδ	TCR,	
CD3,	CD8αα,	
B220	
		 IL-10,	
TGFβ	
Can	develop	intra-	or	extra-thymically.	Express	
αβ	or	γδ	TCRs.	Can	have	regulatory	function	
through	production	of	IL-10	&	TGFβ	
	
Table	1-1	T	cell	subsets	involved	in	immune	response	
1.4.3 T	cell	receptor	
Antigen	recognition	by	T	cells	(specifically	their	T-cell	receptors	–	TCRs)	is	the	key	event	in	
the	activation,	proliferation	and	differentiation	of	alloreactive	T	cells.	The	TCR	is	a	
heterodimer	composed	of	two	transmembrane	polypeptide	chains	covalently	linked	by	a	
disulphide	bridge	(Figure	1-4).		
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Variable	‘V’	region
Constant	‘C’	region
Disulphide
bridge
Cell	membrane
α β
ε δ γ ε
CD3 CD3
	
	
Each	chain	of	the	TCR	is	composed	of	a	Constant	(C)	region	and	a	Variable	(V)	region.	A	short	
cytoplasmic	chain	on	the	C	region	anchors	the	TCR	to	the	cell	membrane.	The	V	region	is	
responsible	for	binding	to	the	MHC:antigen	complex.	Within	this	region,	there	are	short	
stretches	of	amino	acids	which	confer	variability	between	TCRs	and	allow	them	to	recognise	
and	bind	to	a	diverse	number	of	antigens.		
In	order	to	be	expressed	and	function,	the	TCR	requires	the	co-expression	of	an	invariant	
complex	termed	CD3.	Once	the	TCR	has	bound	the	MHC:antigen	complex,	CD3	facilitates	
signal	transduction,	which	subsequently	results	in	a	signalling	cascade	and	ultimately	T-cell	
activation.	This	function	has	been	exploited	in	terms	of	transplantation	through	the	
development	of	OKT3	(a	monoclonal	antibody	to	CD3)	as	a	potent	immunosuppressive	for	
use	in	T-cell	mediated	rejection.		
	
	
Figure	1-4	The	T-cell	receptor	complex	-	highly	variable	alpha	(α)	and	beta	
(β)	chain	expressed	as	part	of	a	complex	with	the	invariant	CD3	chain	
molecules	
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1.5 The	T	cell	response	
1.5.1 CD4/CD8	
The	two	major	subsets	of	mature	T	cells	are	CD4+	‘helper’	T	cells	and	CD8+	‘cytotoxic’	T	cells.	
They	are	defined	by	the	presence	of	either	the	CD4	or	CD8	transmembrane	coreceptor	
protein,	necessary	in	the	activation	pathway	of	T	cells.	The	primary	role	of	these	
coreceptors	is	to	bind	their	respective	MHC	class	II	(CD4)	or	I	(CD8)	molecule	inferring	a	
degree	of	stability	on	the	TCR:MHC/antigen	complex	and	facilitating	downstream	signalling	
during	the	activation	process.		
In	terms	of	transplantation,	once	activated,	the	CD4+	T	cells	differentiate	into	effector	cells	
which	have	the	potential	to	cause	graft	damage	through	cytokine	production,	most	likely	in	
a	chronic	setting.	CD8+	T	cells	differentiate	into	cytotoxic	T	cells	(CTLs)	either	through	the	
direct	or	indirect	pathway.	If,	via	the	indirect	pathway,	the	CTLs	are	self-MHC	restricted	and,	
therefore,	do	not	affect	the	graft.	However,	if	they	are	generated	via	the	direct	pathway,	
they	are	able	to	target	class	I	MHC	nucleated	cells	within	the	graft.	These	T	cells	are	likely	to	
play	a	key	role	in	acute	rejection.		
1.5.2 Costimulation	
In	addition	to	the	TCR	complex	described	(signal	1),	T	cells	require	a	second	signal	in	order	
to	fully	activate	(signal	2).	This	second	signal	is	in	the	form	of	a	costimulatory	molecule,	
found	on	the	T	cell	surface,	which	binds	to	its	own	specific	ligand	on	APCs	(Li,	Rothstein,	&	
Sayegh	2009).	It	has	become	increasingly	evident	that	as	well	as	positive	signals	which	
promote	T-cell	activation	(co-stimulatory	pathway),	there	are	a	number	of	co-pathways	
which	have	the	converse	effect	and	can	attenuate	or	even	terminate	the	immune	response	
(co-inhibitory	pathway)	(Boenisch,	Sayegh,	&	Najafian	2008).	Without	this	costimulatory	
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signal,	T	cells	activated	via	the	TCR	alone	become	apoptotic	or	anergic.	The	costimulatory	
pathway	also	promotes	stabilisation	of	the	TCR:MHC/antigen	complex	allowing	the	
downstream	transduction	of	signals	which	activate	the	calcineurin,	MAP	kinase	and	nuclear	
factor	κB	pathways.		
Over	the	last	decade,	a	number	of	costimulatory	molecules	(Table	1-2)	which	have	both	
negative	and	positive	impacts	on	T	cell	fate	have	been	identified.	One	of	the	most	studied	
pathways	and	most	relevant	to	transplantation	is	the	interaction	of	the	B7	molecules	(also	
known	as	CD80	and	CD86)	on	the	APC,	with	the	CD28	molecule	of	the	T-cell.	CD28	is	
expressed	on	the	surface	of	all	CD4+	cells	and	approximately	50%	of	CD8+	T	cells	and	its	
interaction	with	B7	molecules	leads	to	increased	transcription	of	the	pro-inflammatory	
cytokine,	interleukin-2	(IL-2)	(Jenkins	et	al.	1991).		
T	Cell	 APC	 Effect		 Comments	 Study	
CD28	
B7-1	(CD86)	 +	 B7-1	and	B7-2	can	both	provide	T	cell	
costimulation	through	CD28	
(Acuto	&	Michel	2003)	
B7-2	(CD80)	 +	
PD1	 PDL-1,	PDL-2	 -	
PD-1	can	be	induced	on	CD4+,	CD8+	T,	NK,	
and	B	cells	and	monocytes,	and	ligation	
delivers	an	T	cell	inhibitory	signal	
(Durrbach	et	al.	2010)	
CTLA4	
B7-1(CD86)	 -	 CTLA-4	binding	to	B7-1	and	B7-2	inhibits	T	
cell	proliferation	
(Larsen	et	al.	2006)	
B7-2	(CD80)	 -	
ICOS	 ICOS-L,	B7h	 +	
In	experimental	studies,	anti-ICOS	blocking	
mAb	can	significantly	prolong	allograft	
survival	
(Ozkaynak	et	al.	2001)	
CD28	 B7-H3	 +	
B7-H3	is	induced	in	dendritic	cells;	
monocytes;	and	T,	B,	and	NK	cells	and	
increases	T	cell	proliferation	
(Steinberger	et	al.	
2004)	
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TNF-R	 TNF	 +	
The	TNF-R	regulates	dual	T	cell	functions	
through	apoptosis	and	also	TRAF-mediated	
T	cell	activation.	
(Durrbach	et	al.	2010)	
CD40L,	
CD154	
CD40	 +	
CD40	engagement	activates	B	cell	antibody	
production	and	upregulates	expression	of	
the	B7	family	
(Durrbach	et	al.	2010)	
OX40	 OX40L	 +	
OX40	is	expressed	on	activated	CD4	and	the	
Th2	T	cells	and	activates	B	cell	proliferation	
(Acuto	&	Michel	2003)	
CD27	 CD70	
+	
CD27	activation	induces	high	levels	of	IL-2	
and	TNF-α	
(Yamada	et	al.	2005)	
+	
Blockade	of	CD27	may	prevent	chronic	
allograft	vasculopathy	
CD	=	cluster	of	differentiation;	CTLA	=	cytolytic	T	lymphocyte	antigen;	ICOS	=	induced	costimulatory	
molecule;	IL-2	=	interleukin-2;	mAb	=	monoclonal	antibody;	NK	=	natural	killer;	PD	=	programmed	death;	
Th2	=	T	helper	type	2;	TNF-α	=	tumor	necrosis	factor–α;	TNF-R	=	tumor	necrosis	factor	receptor;	TRAF	=	
tumor	necrosis	factor	receptor	associated	factor.	
	
Table	1-2	Costimulatory	molecules	involved	in	a	T	cell	response	
Adapted	from	(Souba	et	al.	2013)	
	
Following	this	interaction	and	activation,	the	co-inhibitory	molecule,	cytotoxic	lymphocyte	
antigen-4	(CTLA-4)	is	rapidly	upregulated	by	the	T-cell.	CTLA-4	also	binds	to	the	B7	molecule,	
with	an	affinity	10-20	times	more	than	that	of	CD28.	Through	this	mechanism,	CTLA-4	
inhibits	T-cell	activation	and	thus	limits	proliferation	and	the	alloresponse.	In	2011,	
Belatacept,	a	human	fusion	protein	which	combines	a	fragment	of	the	human	IgG1	molecule	
with	an	extracellular	portion	of	CTLA-4	was	approved	for	therapeutic	use	as	an	
26	
	
immunosuppressant	in	renal	transplantation.	Early	results	on	its	effectiveness	are	mixed	
but,	on	the	whole,	encouraging	(Vincenti	et	al.	2012).		
1.5.3 Signal	Transduction	
Activation	of	the	TCR	through	antigen	recognition	is	followed	by	a	phosphorylation	cascade	
which	ultimately	results	in	the	upregulation	of	certain	transcription	factors	and	determines	
the	fate	of	the	activated	T	cell	(Figure	1-5	T	cell	activation	signal	transduction	pathway).	
Following	TCR	activation,	cytoplasmic	protein	kinases,	phosphorylate	the	TCR/CD3	complex	
resulting	in	recruitment	of	the	ZAP-70	(zeta-associated	protein	of	70	kDa)	tyrosine	kinase	
which	further	phosphorylates	an	array	of	adapter	molecules.	From	here	a	number	of	
divergent	pathways	are	facilitated	including	the	calcineurin,	protein	kinase	C	(PKC)	and	
mitogen-activated	protein	kinase	(MAP	kinase)	pathways.	These	pathways	eventually	
reconverge	to	generate	a	number	of	transcription	factors	(NFAT,	NFκB	and	AP-1)	leading	to	
upregulation	of	genes	involved	in	proliferation	and	differentiation.		
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1.5.4 Cytokine	production	
Many	of	the	genes	upregulated	as	a	consequence	of	TCR	activation	result	in	the	production	
of	numerous	cytokines	which	act	as	mediators	of	effector	T	cell	function.	These	cytokines	
determine	the	fate	of	the	naive	T	cell	and	ultimately	their	differentiation	into	various	helper	
T	–cell	subsets.		
	
	
	
Figure	1-5	T	cell	activation	signal	transduction	pathway	
Adapted	from	(Chandraker,	Sayegh,	&	Singh	2012)	
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1.6 Allorecognition	
The	first	step	in	the	allorecognition	response	to	a	transplanted	graft	is	to	recognise	that	the	
tissue	is	foreign,	through	the	presentation	of	non-self	antigens	(as	opposed	to	recognising	
host	‘self’	antigens)	achieved	through	two	distinct	mechanisms	(Figure	1-6).	This	is	
dependent	on	whether	or	not	donor	antigen	is	presented	through	recipient	APCs	or	donor	
APCs.	If	presentation	is	via	the	donor	APC,	this	is	termed	the	‘direct	pathway’	and	is	the	
dominant	mechanism	in	the	acute	rejection	process.	Conversely,	if	antigen	is	presented	via	
the	recipient	APC,	it	is	termed	the	‘indirect	pathway’,	this	mechanism	predominates	in	
chronic	rejection	(Game	&	Lechler	2002).	The	direct	pathway	is	significantly	more	potent	
(~100:1)	than	the	indirect	pathway	in	terms	of	T	cell	activation	(Lechler	et	al.	1990).	
	
Donor	
APC
Donor	
APC
Recipient
APC
CD8+
T	cell
CD4+
T	cell
CD4+
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CTL B	cell Macrophage
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Cytokine	production
T	cell	differentiation
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Direct	Allorecognition Indirect	Allorecognition
Alloantibodies
	
	
Figure	1-6	CD8+	cytotoxic	T	cells	(CTLs)	are	generated	via	the	direct	pathway.	
CD4+	helper	T	cells,	generated	via	the	direct	and	indirect	pathway	enhance	CTL	
activity	and	alloantibody	production	by	B	cells	
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A	third	mechanism	has	been	proposed,	termed	the	‘semi-direct	pathway’.	This	pathway	
involves	the	transfer	of	intact	MHC	molecules	between	donor	and	recipient	APCs,	rather	
than	just	antigen	alone	(Herrera	et	al.	2004).	These	intact	molecules	are	then	presented	
directly	to	host	T	cells,	thus	stimulating	the	immune	alloresponse.		
1.6.1 Direct	Pathway	
Most	episodes	of	acute	rejection	are	mediated	by	the	direct	pathway.	Also	termed	the	
‘endogenous	class	I	pathway’,	it	is	active	in	nearly	all	cells.	When	allogeneic	T	cells	are	
cultured	together	(MLR	or	Mixed	Lymphocyte	Reaction)	they	will	respond	with	extreme	
potency	(Bach	&	Hirschhorn	1964).	This	response	is	due	in	part	to	the	extensive	number	of	
precursor	T	cells	and	results	in	the	activation	of	a	large	number	of	cytotoxic	T	cells.	In	
transplantation,	the	direct	pathway	relies	on	the	allorecognition	of	donor	leucocytes	
(principally	dendritic	cells)	expressing	class	I	(recognised	by	CD8+	T	cells)	and	class	II	
(recognised	by	CD4+	T	cells)	endogenous	peptides.		
This	direct	pathway	is	of	particular	importance	in	the	early	stages	of	transplantation	during	
which	a	large	number	of	APCs,	with	the	potential	to	initiate	an	alloresponse,	are	present	
within	the	donor	graft.	However,	their	numbers	are	finite	and	if	a	response	is	not	
maintained	the	relative	importance	of	this	mechanism	in	terms	of	rejection	recedes.	
However,	the	indirect	response	is	able	to	maintain	a	long-term	level	of	activity	through	a	
renewed	pool	of	recipient	APCs,	which	can	result	in	chronic	rejection.		
1.6.2 Indirect	Pathway	
The	indirect	pathway,	in	contrast	to	the	direct	pathway,	describes	antigen	presentation	via	
recipients	APCs	and	is	essentially	the	‘normal’	mechanism	of	T-cell	stimulation.	Therefore,	in	
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theory,	all	proteins	in	the	donor	graft	(different	to	the	recipient)	have	the	potential	to	
stimulate	an	immune	response.	Three	mechanisms,	by	which	donor	antigen	is	presented,	
have	been	postulated:	
- Graft	antigen	is	deposited	into	the	host	circulation	and	taken	up	by	host	DCs	within	
secondary	lymphoid	tissue	
- Donor	cells	migrate	directly	to	host	lymphoid	tissue	and	are	engulfed	by	host	APCs	
- Recipient	APCs	migrate	through	the	graft	‘picking	up’	donor	antigen	en	route	to	
secondary	lymphoid	tissue	
Seminal	studies	by	Lechler	and	Batchelor	(Lechler	&	Batchelor	1982a;Lechler	&	Batchelor	
1982b)	demonstrated	that	DCs	were	the	most	likely	cell	responsible	for	presenting	donor	
antigen	and	thus	activating	naive	host	T	cells	(as	in	the	direct	pathway).	They	further	
demonstrated	that	by	depleting	rat	MHC-incompatible	renal	grafts	of	leucocyte	passenger	
cells	(by	temporarily	implanting	the	graft	in	an	interim	host)	the	grafts	were	ultimately	
accepted	without	immunosuppression,	in	certain	donor/recipient	combinations,	but	not	in	
others,	thus	suggesting	that	it	was	not	the	recipient	APCs	stimulating	an	immune	response	
(Lechler	&	Batchelor	1982b).	Further	evidence	for	this	mechanism	of	antigen	presentation	
by	migrating	DCs	from	the	donor	graft	to	secondary	lymphoid	tissue	were	demonstrated	in	
studies	by	Larsen	et	al.	(Larsen	et	al.	1990;	Larsen,	Morris,	&	Austyn	1990).		
	
1.7 Patterns	of	rejection	
Graft	rejection	has	classically	been	defined	by	the	period	of	time	following	implantation,	at	
which	it	occurs,	with	immediate	losses	termed	hyperacute	(HAR),	early	losses	termed	acute	
(AR)	and	long-term	/	late	losses	termed	chronic	(CR).	Although	these	terms	continue	to	be	
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used,	the	events	are	not	necessarily	time	specific	and	AR	can	occur	at	any	stage	after	
transplantation	(Busch,	Galvanek,	&	Reynolds,	Jr.	1971).	Though	indistinct	in	terms	of	
timing,	these	terms	of	rejection	can	be	characterised	based	on	specific	mechanisms.	
Hyperacute	rejection	(HAR)	will	usually	occur	within	minutes	to	hours	following	reperfusion	
and	is	mediated	by	pre-existing	humoral	immunity.	Acute	rejection,	which	happens	to	a	
greater	or	lesser	degree	in	all	transplants,	occurs	anytime	from	one	week	to	several	years	
following	reimplantation,	though	most	commonly	within	the	first	3	months	(Humar	et	al.	
2000)	and	is	predominantly	mediated	by	the	formation	of	cellular	immunity.	Chronic	
rejection	often	occurs	months	to	years	after	the	onset	of	acute	rejection	and	is	mediated	by	
both	the	humoral	and	cellular	immune	responses,	usually	manifesting	as	fibrosis.		
1.7.1 Hyperacute	Rejection	
Hyperacute	rejection	is	an	antibody-mediated	process	which,	fortunately,	due	to	the	advent	
of	crossmatching,	is	a	relatively	rare	occurrence.	It	is	mediated	by	pre-formed	antibodies	
within	the	host	recognising	donor	HLA	antigen	on	the	vascular	endothelium	of	the	graft.	This	
results	in	activation	of	the	complement	cascade	leading	to	necrosis,	platelet	deposition	and	
localised		coagulation	(Colvin	2007).		
1.7.2 Acute	Rejection	
Acute	rejection	typically	occurs	within	the	first	six	months	after	transplantation	and	can	be	
divided	into	two	mechanistic	categories	–	a)	Acute	cellular	rejection	(T-cell	mediated)	or	b)	
Humoral	rejection	(antibody	mediated	or	acute	vascular	rejection).		
	
Acute	cellular	rejection	–	Up	to	90%	of	rejection	episodes	are	classified	as	cellular	(Bates	et	
al.	1999).	Immature	dendritic	cells	from	within	the	graft,	transport	antigen	to	the	recipient’s	
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secondary	lymphoid	tissue.	Along	the	way,	these	dendritic	cells	mature	into	APCs	(Larsen,	
Morris,	&	Austyn	1990).	Though	the	donor	graft	will	have	an	extensive	supply	of	DCs,	
recipient	DCs	also	contribute	to	the	process	by	circulating	through	the	graft.	The	mature	
dendritic	cells	subsequently	activate	the	recipient	T	cells	within	the	host	secondary	
lymphoid	tissue,	resulting	in	T	cell	differentiation	and	ultimately	graft	damage.		
	
Humoral	rejection	–	The	main	feature	of	this	type	of	rejection	is	inflammation	causing	rapid	
graft	dysfunction.	Antibodies	against	HLA-molecules,	endothelial	cell	antigens	and	ABO	
blood	group	antigens	on	endothelial	and	red	cells	can	all	mediate	rejection	(Nankivell	&	
Alexander	2010).	These	donor-specific	antibodies	(DSAs)	may	be	either	preformed	or	
develop	de	novo	(Terasaki	&	Mizutani	2006).	The	process	is	characterised	by	the	presence	of	
arteritis	secondary	to	the	binding	of	donor-specific	IgG	antibodies	against	endothelial	cell	
alloantigens.	This	leads	to	complement	activation	and	antibody-dependent	cellular	
cytotoxicity	(ADCC)	resulting	in	vascular	injury.		
	
With	modern	immunosuppression	(induction	therapy,	calcineurin	inhibitor,	mycophenolate	
and	steroids)	the	incidence	of	acute	rejection	is	currently	between	10-20%	(Ekberg	et	al.	
2007;	Gaston	et	al.	2009;	Vincenti	et	al.	2005).		
1.7.3 Chronic	Rejection	
Chronic	rejection	is	less	well	defined	than	the	other	types	of	rejection.	It	is	a	multi-factorial	
process	and	involves	both	antibody-	and	cell-mediated	pathways	as	well	as	non-
immunological	factors.	It	affects	30-40%	of	renal	grafts	within	5	years.	The	most	widely	
accepted	cause	of	CR	is	prior	episodes	of	AR.	Non-immune	causes	are	numerous	and	include	
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delayed-graft	function,	calcineurin	inhibitor	toxicity,	hypertension,	diabetes	and	
hyperlipidaemia.		
Immunologically,	the	indirect	pathway	of	allorecognition	dominates	and	CR	may	also	reflect	
antibody	responses	to	antigen	mismatches	not	suppressed	by	immunosuppressive	agents.	
This	is	supported	by	several	studies	demonstrating	the	presence	of	circulating	anti-HLA	
antibodies	against	Class	I	and	II	MHC	molecules	and	complement	deposition	in	graft	vessels	
(Colvin	2009).		
1.8 Rejection	of	the	Transplanted	Graft	
The	rejection	of	transplanted	organs	remains	one	of	the	biggest	barriers	to	modern	
transplantation.	Despite,	the	huge	advances	in	matching	donors	and	recipients	and	the	
development	of	immunosuppressive	pharmaceuticals,	there	still	exists	a	degree	of	rejection	
in	all	transplanted	grafts	(unless	identical	twins).	The	mechanism	by	which	rejection	occurs	
is	complex	and	is	mediated	by	both	an	adaptive	(cellular	and	humoral)	and	innate	immune	
response.		
1.8.1 Innate	Immunity	
The	innate	immune	response	in	isolation	is	not	capable	of	mediating	graft	rejection.	It	
represents	the	first	line	of	defence	and	in	contrast,	to	the	adaptive	response	which	takes	
several	days	to	become	effective	can	mount	an	immediate	response	against	pathogens.	It	is	
made	up	of	cells	and	molecules,	highly	conserved	between	species,	which	can	differentiate	
between	self	and	non-self	and	does	not	require	the	recognition	of	specific	antigens.		
As	a	consequence	of	the	organ	retrieval	process	and	subsequent	reimplantation,	certain	
ischemia-reperfusion	injuries	occur	within	the	graft	with	the	result	that	molecules	termed	
damage-associated	molecular	patterns	(DAMPs),	and	pathogen-associated	molecular	
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patterns	(PAMPs)	are	released.	These	molecules	are	recognised	by	specific	pattern-
recognition	receptors	(PRRs)	such	as	Toll-like	receptors,	expressed	by	host	macrophages,	
neutrophils,	natural	killer	(NK)	cells	and	dendritic	cells	(DCs).	Once	DAMPs	such	as	heat	
shock	protein	(HSP)	activate	these	PRRs,	several	responses	are	stimulated.	In	the	first	
instance,	gene	transcription	is	induced	which	results	in	the	production	of	pro-inflammatory	
cytokines,	chemokines	and	adhesion	molecules,	the	result	of	which	is	an	early	inflammatory	
response.	For	example,	the	release	of	tumour	necrosis	factor-alpha	(TNF-α)	causes	vascular	
endothelial	activation	and	subsequent	leucocyte	transmigration	into	tissues.	In	addition	to	
this	direct	effect,	ligands	of	TLR	receptors	also	stimulate	DCs	to	act	as	antigen-presenting	
cells,	and	via	this	mechanism	contribute	to	the	adaptive	immune	response.		
1.8.2 Adaptive	Immunity	
The	adaptive	and	innate	immune	responses	are	not	separate	entities	and	in	the	rejection	
process	are	co-dependent	through	several	different	mechanisms.	For	example,	cytokine	/	
chemokine	production	following	T	cell	activation	can	recruit	cells	of	the	innate	response	
such	as	NK	cells	and	macrophages	(Pratt,	Basheer,	&	Sacks	2002).	Conversely,	some	of	the	
associated	molecular	pattern	molecules	have	chemoattractant	properties	on	T	cells	(Guani-
Guerra	et	al.	2010).	
Adaptive	immunity	involves	recipient	T	(cell-mediated	response)	and	B	cells	(humoral	
response)	recognising	specific	donor	antigen	and	is	considered	the	primary	immune	
response	to	transplanted	tissue.	It	was	first	recognised	in	transplantation	by	Snell	and	
Gorer,	who	described	skin	grafts		transplanted	between	different	strains	(allogeneic)	of	
inbred	mice	led	to	graft	rejection	(Gorer,	Lyman,	&	Snell	1948).	This	finding	led	to	the	
identification	of	the	major	histocompatibility	complex	(MHC).	In	humans,	this	is	located	on	
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chromosome	6	and	its	protein	products	are	termed	human	leucocyte	antigens	(HLA).	The	
HLA	genes	are	an	extremely	polymorphic	region	within	the	MHC	and	are	divided	into	three	
groups,	depending	upon	their	structure,	function	and	distribution	(Klein	&	Sato	2000a).	HLA	
Class	I	genes	encode	for	HLA-A,	HLA-B	and	HLA-C	antigens,	normally	expressed	on	almost	all	
nucleated	cells.	These	antigens	are	recognised	exclusively	by	CD8+	T	cells	and	regulate	direct	
antigen	presentation.	HLA	Class	II	genes	encode	for	HLA-DP,	HLA-DQ	and	HLA-DR	antigens	
and	are	only	expressed	on	B	lymphocytes,	activated	T	lymphocytes	and	antigen	presenting	
cells	(APCs)	–	dendritic	cells,	monocytes	and	macrophages	(Klein	&	Sato	2000).	They	are	
recognised	by	CD4+	T	cells	and	regulate	the	indirect	antigen	pathway.	The	Class	III	genes	
encode	for	several	components	of	the	complement	system.	
	In	transplantation,	the	effects	of	HLA-A,	HLA-B	and	HLA-DR	antigens	have	the	greatest	
impact	on	graft	rejection	(Opelz	et	al.	1991).	In	the	first	6	months,	an	HLA-DR	mismatch	is	
most	important,	with	HLA-B	emerging	as	significant	over	the	initial	2	years	and	HLA-A	
mismatch	resulting	in	a	long	term	effect	(Morris	et	al.	1999;	Opelz	et	al.	1999;	Takemoto	et	
al.	2000;	Zantvoort	et	al.	1996).		
	
1.9 Histone	Deacetylase	(HDAC)	
Central	to	this	study	is	the	potential	role	histone	deacetylase	inhibitors	have	in	modifying	
the	immune	response	to	a	transplanted	organ.	The	primary	substrate	for	these	compounds	
are	HDACs,	though	their	effects	are	not	limited	exclusively	to	these	targets,	as	will	be	
explained.	
Histones	are	a	family	of	important	chromosomal	proteins	which	are	integral	to	the	
organisation	of	eukaryotic	DNA	in	chromosomes.	The	organisation	and	function	of	DNA	is	
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achieved	through	the	addition	of	proteins	including	core	histones	(H2A,	H2B,	H3	and	H4)	
which	together	form	the	complex	structure,	chromatin.	Conformational	changes	in	
chromatin	(and	thus	changes	in	protein	function)	can	be	affected	by	altering	their	
acetylation	status.		
	
In	the	early	1960s,	it	was	first	discovered	that	histone	proteins	undergo	acetylation	(Allfrey,	
Faulkner,	&	Mirsky	1964;	Phillips	1963).	However,	it	was	not	until	the	mid-1990s	with	the	
identification	of	histone	acetyl	transferases	(HATs)	and	histone	deacetylases	(HDACs)	that	
the	link	between	histone	modification	and	the	resultant	change	in	gene	activity	was	
established.	Acetylation	of	histones	are	a	responsibility	of	HATs	and	this	process	often	
results	in	transcriptional	activation.		Conversely,	HDACs	cleave	acetyl	groups	resulting	in	
deacetylation	and	generally	an	opposite	effect	on	transcription	(Pazin	&	Kadonaga	1997).	
Specifically,	the	process	of	deacetylation	takes	place	by	the	removal	of	acetyl	groups	from	
the	lysine	amino	acids	of	the	histone	tail.	This	conformational	change	results	in	a	positive	
charge	which	in	turn	allows	a	high-affinity	bond	to	form	between	the	histone	molecule	and	
DNA	–	effectively	a	‘closed’	state.	In	this	‘closed’	deacetylated	state,	transcription	factors	
are	unable	to	gain	access	to	DNA	binding	sites,	with	a	resultant	reduction	in	gene	
expression.	This	role	of	HDACs	has	led	to	them	being	extensively	studied	as	targets	for	
pharmacological	manipulation	in	a	wide	range	of	indications.		
	
The	first	HDACs	were	identified	in	1996	(Taunton,	Hassig,	&	Schreiber	1996).	Currently,	18	
human	HDACs	have	been	at	least	partially	characterised;	of	which	11	are	zinc-dependent	
(Table	1-3,	Figure	1-7).	They	are	classified	according	to	their	homology	to	yeast	HDACs	(as	
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well	as	location	and	enzymatic	activity).	The	remaining	7	are	NAD+	dependent	HDACs	and	
are	termed	Sirtuins.	They	are	classified	as	Class	III	HDACs.	
	
	
Yeast	
Counterpart	 Size	 Location	 Expression	 aa	
Class	I	
HDAC1	
RPD3	
58	 Nucleus	
Ubiquitous	
482	
HADC2	 58	 Nucleus	 488	
HDAC3	 50	 Nucleus/Cytoplasm	 428	
HDAC8	 44	 Nucleus	 377	
Class	IIa	
HDAC4	
HDA1	
120	 Nucleus/Cytoplasm	
Specific	
1084	
HDAC5	 130	 Nucleus/Cytoplasm	 1122	
HDAC7	 110	 Nucleus/Cytoplasm	 855	
HDAC9a	 160	 Nucleus/Cytoplasm	 1011	
ClassIIb	
HDAC6	
HDA2	
160	 Nucleus/Cytoplasm	
Specific	
1215	
HDAC10	 70	 Nucleus/Cytoplasm	 669	
Class	IV	
HDAC11	 RPD3/HDA1	 39	 Nucleus	 Ubiquitous	 347	
	
Table	1-3	Classification	of	histone	deacteylases	
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Figure	1-7	Cellular	distribution	of	histone	deacetylases	
Though,	they	have	maintained	their	traditional	name	the	effect	of	HATs	and	HDACs	are	not	
limited	exclusively	to	the	deacetylation	of	histones	and	they,	in	fact,		have	a	wide	range	of	
non-histone	targets	(Minucci	&	Pelicci	2006).	As	mentioned	previously,	the	specific	target	of	
HDACs	is	not	the	histone	protein	itself	but	is,	in	fact,	a	lysine	amino	acid.	Therefore	HDACs,	
given	their	broad	distribution	can	affect	the	function	of	an	enormous	number	of	non-
histone,	lysine-containing	proteins.	These	non-histone	proteins,	including	transcription	
factors	and	regulators	of	DNA	repair,	replication	and	recombination	are	all	affected	by	
acetylation	(Yang	&	Seto	2007).	HDACs	(and	HATs)	should,	therefore,	be	more	accurately	
termed	lysine	deacetylases	(lysine	acetylase	transferases).		
	
Acetylation	(and	deacetylation)	can	have	a	number	of	effects	on	non-histone	proteins.		
- Protein	stability.	Ubiquitination	is	a	similar	post-translational	process	to	acetylation	
whereby	the	lysine	amino	acid	residue	is	targeted.	In	this	case,	however,	ubiquitin	is	
HDAC1	
HDAC	2 
HDAC	8 
HDAC	11 
HDAC	3 
HDAC	4 
HDAC	5 
HDAC	7 
HDAC	9 
HDAC	6 
HDAC	10 
- Localised	mainly	within	
the	nucleus	
- Primary	role	in	cell	
survival	and	proliferation	
(knockout	analysis)	
-		 Shuttle	between	nucleus	and				
cytoplasm	
-		 Primarily	tissue	specific	role	
(knockout	analysis)	
25 
Cytoplasm 
Nucleus		
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attached	to	the	substrate	protein.	The	result,	as	with	acetylation,	is	an	alteration	in	
protein	structure	and	consequently	function.	As	both	these	processes	compete	for	
the	same	target,	they	can,	therefore,	interact	and	confer	instability	upon	the	
substrate	protein.	For	example,	HDAC	deacetylation	may	lead	to	the	exposure	of	
lysine	residues	and	ubiquitination	resulting	in	protein	instability.		
- Protein	–	protein	interactions.	One	such	example	involves	the	acetylation	of	signal	
transducer	and	activator	of	transcription	factor	3	(STAT3)	which	is	activated	by	
cytosolic,	cytokine	signalling.	This	acetylation	results	in	dimerisation	of	STAT3	and	
nuclear	translocation.		
- Protein	localisation.	The	acetylation	status	of	a	protein	can	have	an	effect	on	its	
geographical	localisation	with	the	cell.	For	example,	the	multi-functional	high-
mobility	group	box	1	(HMGB1)	protein	(a	cytokine	mediator	of	inflammation	
secreted	by	immune	cells	such	as	macrophages)	will	undergo	acetylation	during	the	
inflammatory	process.	In	this	acetylated	state	the	protein	is	shuttled	from	the	
nucleus	to	the	cytoplasm	in	preparation	of	the	inflammatory	response.		
- DNA	binding.	Hyper-acetylation	of	transcription	factor	histones	can	often	result	in	
increased	DNA	binding	which	can	subsequently	affect	transcriptional	activity.		
Though	these	examples	have	highlighted	the	upregulating	effects	of	acetylation,	this	is	
not	always	the	case	and	often	the	binding	of	transcriptional	factors	to	DNA	can	be	
impaired.	This	therefore,	would	suggest	that	HATs	and	HDACs	work	in	a	synergistic	
manner	in	order	to	coordinate	a	number	of	cellular	functions.		
	
	
40	
	
1.10 The	role	of	histone	deacetylases	in	immunity	
A	more	detailed	description	of	the	role	of	HDACs	and	inhibitors	on	the	innate	and	adaptive	
immune	systems	can	be	found	in	the	Discussion	section	
1.10.1 Innate	immunity	
A	role	for	HDACs	has	been	implicated	in	a	number	of	aspects	of	the	innate	immune	system.		
Of	particular	note,	however,	in	the	innate	immune	system	is	the	influence	HDACs	can	have	
over	the	Toll-like	receptor	(TLR)	and	interferon	(IFN)	signalling	pathways.		
Though	current	evidence	using	pan-HDACis	(Roger	et	al.	2011)	suggests	that	HDACs	may	
have	a	positive	effect	on	TLR	and	IFN	signalling	pathways,	it	conversely	also	provides	
support	for	the	investigation	of	HDAC	specific	inhibitors	in	manipulating	targeted	beneficial	
mechanisms	to	the	dampening	of	the	allograft	immune	response.		
1.10.2 Adaptive	immunity	
HDACs	can	influence	a	broad	range	of	features	of	the	adaptive	immune	system	through	the	
modulation	of	signalling	pathways	(Shakespear	et	al.	2011).	
B	lymphocyte	and	function	
HDACs	have	a	direct	effect	on	the	development	and	function	of	lymphocytes.	For	example,	
murine	studies	have	shown	that	if	one	or	both	of	either	HDAC1	or	HDAC2	are	eliminated	in	
conditionally	targeted	mice,	B	cell	development	is	arrested	at	an	early	stage.	However	if	
either	of	these	enzymes	are	present,	then	development	proceeds	as	normal	(Yamaguchi	et	
al.	2010).	Interestingly,	it	is	not	only	the	early	development	of	B	cells	that	is	dependent	on	
HDAC	1	and/or	2	and	the	same	study	also	found	that	selective	deletion	of	both	enzymes	in	
mature	B	cells	resulted	in	cellular	apoptosis	under	stimulating	conditions.		
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Of	particular	relevance	to	the	work	presented	in	this	study	is	the	effect	knocking	out	HDAC6	
has	on	immunoglobulin	levels	in	mice.	It	was	found	that	HDAC6-/-	mice	subjected	to	an	
antigen	challenge	produced	lower	levels	of	IgG	and	IgM	(Zhang	et	al.	2008).	However,	it	is	
unclear	as	to	whether	or	not	this	is	a	result	of	a	direct	effect	on	B	cells	or	due	to	an	indirect	
effect	on	immune	synapse	formation	(Serrador	et	al.	2004)	and/or	lymphocyte	migration	
(Cabrero	et	al.	2006)	(see	below	for	effects	of	HDAC6).		
1.11 Histone	deacetylase	6	
Of	increasing	interest	throughout	this	study	is	the	targeted	pharmacological	inhibition	of	
HDAC6.	As	mentioned	previously,	one	of	the	unique	features	of	this	class	IIb	enzyme	is	that	
it	is		predominantly	located	in	the	cytoplasm	(Verdel	et	al.	2000),	but	retains	the	ability	to	
undergo	nuclear	translocation.	As	it	is	predominantly	located	in	the	cytoplasm,	histone	is	
unlikely	to	be	its	primary	substrate.		
First	discovered	in	humans	in	the	late	1990s	by	Grozinger	et	al.	(Grozinger,	Hassig,	&	
Schreiber	1999)	and	in	mice	by	Verdel	(Verdel	&	Khochbin	1999),	it	is	the	largest	of	the	
HDAC	proteins	with	1,216	amino	acids.	It	is	unique	among	the	class	II	HDACs	(and	indeed	
among	the	zinc-dependent	HDACs)	in	that	it	contains	two	active,	functionally	independent	
catalytic	domains	(Figure	1-8).	The	role	and	integration	of	these	two	domains	have	been	the	
subject	of	differing	views	among	researchers.	Early	data	suggested	that	they	acted	
independently	(Grozinger,	Hassig,	&	Schreiber	1999),	however	subsequent	research	
challenged	this	and	suggested	that	these	two	domains	act	synergistically	(Zhang	et	al.	2003;	
Zhang	et	al.	2006)	or	that	activity	is	at	least	mediated	by	the	second	domain	(Zou	et	al.	
2006).	Though	no	clear	evidence	has	been	produced	to	delineate	the	roles	of	these	
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domains,	it	would	appear	that	the	second	domain	(DD2),	has	the	principal	role	in	terms	of	
function.		
	
	
	
	
Figure	1-8	Structure	of	HDAC6.	NES	–	nuclear	exportation	signal,	DD1	&	DD2	–	
deacetylating	domain,	SE14	–	cytoplasmic	anchoring	signal,	ZnF-UBP	–	ubiquitin	binding	
domain	
HDAC6	has	a	C-terminal	zinc-finger	ubiquitin	binding	domain	(ZnF-UBP)	and	a	specific	
tertadecapeptide	repeat	domain	(SE14)	which	in	combination	with	two	leucine-rich	nuclear	
export	sequences	(NES),	promote	cytosolic	retention	(Bertos	et	al.	2004).	The	discovery	of	
this	ZnF-UBP	domain	(Seigneurin-Berny	et	al.	2001)	has	implicated	its	role	in	a	number	of	
cell	signalling	pathways	that	are	not	only	dependent	upon	acetylation	but	also	upon	
ubiquitination.	Indeed,	HDAC6	has	been	shown	to	have	the	highest	affinity	yet	discovered	
for	ubiquitin	(Boyault	et	al.	2006).			
	
Given	its	unique	structure	and	location	(cytoplasmic)	among	the	HDAC	family,	HDAC6	is	well	
placed	as	a	novel	target	for	manipulation,	and	further	research	into	its	role	is	well	justified.		
To	date,	three	key	substrates	of	HDAC6	have	been	identified;	α-tubulin,	HSP90	and	
cortactin.	
1.11.1 Molecular	functions	of	HDAC6	
α-tubulin	
NLS	 NES	 DD1	 DD2	
ZnF-
UBP	NES	
SE14	N	 C	
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HDAC6	has	an	important	role	in	the	deacetylation	of	a	number	of	proteins.	Its	earliest	and	
probably	its	most	widely	researched	function	is	in	regulating	cytoskeletal	dynamics	through	
the	acetylation	of	α-tubulin	(Hubbert	et	al.	2002),	which	together	with	β-tubulin	make	up	
microtubules.	These	microtubules	are	intracellular	structures	which	have	a	number	of	roles	
including	nucleic	and	cell	division,	intracellular	transport	and	organisation	of	intracellular	
structure	as	well	as	cell	motility.	The	effect	of	HDAC6	deacetylation	on	the	α-tubulin	
substrate	is	very	much	dependent	upon	the	type	and	location	of	the	cell	expressing	the	
substrate	and	results	in	changes	in	cell	division,	intracellular	trafficking,	cell-cell	interactions	
and	cell	migration	(Janke	&	Bulinski	2011).		
Both	in-vitro	and	in	vivo	evidence	has	demonstrated	that	over	expression	of	HDAC6	results	
in	complete	deacetylation	of	microtubules	and	that	its	inhibition	results	in	increased	levels	
of	α-tubulin	(Hubbert	et	al.	2002;	Zilberman	et	al.	2009)	
HSP-90	
By	demonstrating	its	reversible	deacetylation,	heat	shock	protein	90	(HSP90)	was	first	
discovered	to	be	a	substrate	of	HDAC6	in	2005	(Kovacs	et	al.	2005).		
HSP90	is	a	well-characterised,	chaperone	protein	which	has	a	critical	role	in	intracellular	
transport,	cell	signalling,	maintenance,	protein	folding	and	degradation.	In	the	unstressed	
cell,	it	accounts	for	1-2%	of	cellular	proteins	and	maintains	a	key	role	in	cellular	
homoeostasis.	However,	in	the	stressed	cell,	it	can	account	for	4-6%	of	cellular	proteins	
(Crevel	et	al.	2001)	and	is	integral	to	a	cells	stress	response.	
In	the	unstressed	cell,	HSP90	binds	to	and	regulates	the	enzyme	heat-shock	transcription	
factor	1	(HSF1)	and	maintains	it	in	its	inactive	form.	However,	in	times	of	stress,	an	increase	
in	misfolded	ubiquitinated	proteins	results	in	dissociation	of	the	complex	as	HDAC6	aims	to	
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bind	the	free	protein	complexes.	This	results	in	activation	of	HSF1	and	subsequent	activation	
of	HSP90	(and	a	protective	cellular	response).		
Cortactin	
Cortactin	is	a	monomeric,	cytoplasmic	protein,	which	when	stimulated	(deacetylated	by	
HDAC6)	is	involved	in	actin	remodelling	and	cell	motility	/	migration	(Wu	&	Parsons	1993).	
Studies	have	demonstrated	that	the	over	expression	of	HDAC6	results	in	polymerisation	of	
actin,	whereas	HDAC6	knockout	results	in	the	opposite	effect	and	reduced	cell	motility	
(Zhang	et	al.	2007).		
1.11.2 Anti-inflammatory	effects	of	HDAC6	
During	periods	of	infection	or	inflammation,	a	pro-inflammatory	response	is	mounted	in	
order	to	deal	with	the	toxic	insult.	This	response	is	often	limited,	in	the	acute	setting	by	an	
anti-inflammatory	response,	once	the	stimulating	source	has	been	dealt	with.	However,	in	
the	setting	of	a	chronic	stimulus	(such	as	an	allograft),	the	pro-inflammatory	state	can	be	
persistent.	One	of	the	key	modulators	of	the	pro-inflammatory	response	are	FoxP3	
expressing	regulatory	T	cells	(see	below	for	the	role	of	Tregs	in	the	transplant	setting).	These	
cells	play	a	key	role	in	controlling	the	expression	of	inflammatory	cytokines	and	dampen	the	
activation	of	effector	T	cells,	thus	promoting	immunological	homoeostasis	(Fontenot,	Gavin,	
&	Rudensky	2003b).	There	now	exists	an	increasing	body	of	evidence	which	is	attempting	to	
delineate	the	role	that	HDACs	play	in	this	process,	by	promoting	the	expression	of	pro-
inflammatory	genes	(Shakespear	et	al.	2011)	and	the	potential	therapeutic	benefits	histone	
deacetylase	inhibition	may	have	in	terms	of	anti-inflammation.		
In	addition	to	this	apparent	histone	modulated	effect	of	histone	deacetylates	on	
inflammation,	the	potential	role	of	deacetylating	non-histone	targets	in	this	setting	have	
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also	been	examined	and	contribute	to	the	core	hypothesis	of	the	evidence	provided	in	this	
thesis.	Principally,	the	ability	of	HDAC6	to	regulate	FoxP3+	regulatory	T	cells	through	HSP90	
modulation	(de	Zoeten	et	al.	2011).		
	
1.12 Histone	deaectylase	inhibitors	(HDACis)	
A	class	of	drugs	attracting	increasing	attention	for	their	immunomodulatory	effects	are	the	
histone	deacetylase	inhibitors	(HDACis).	HDACis	were	first	identified	over	a	decade	ago	as	
potential	anti-cancer	agents	(Richon	&	O'Brien	2002),	and	the	majority	of	research	on	their	
function	has	been	carried	out	in	this	area.	The	most	notable	of	these,	the	pan-HDACi	
suberoylanilide	hydroxamic	acid	(SAHA,	Vorinostat)	was	approved	by	the	FDA	in	2006	for	
the	treatment	of	T	cell	lymphoma.	Subsequently,	in	2009,	Romidepsin	(FK228,	Istodax)	
achieved	FDA	approval	for	the	same	indication,	and	more	recently	Panobinostat	(LBH-589,	
Farydak)	was	approved	for	the	treatment	of	multiple	myeloma.	Through	the	development	
of	these	drugs,	the	effect	of	HDACi	on	the	cell	cycle	and	the	subsequent	impact	on	reduced	
tumour	growth	is	relatively	well	documented.	However,	the	potential	effects	of	HDACi	on	
the	immune	system	are	far	less	well	characterised.	In	preclinical	models	of	organ	
transplantation,	pan-HDACis	have	been	shown	to	confer	efficacy	(Kinugasa	et	al.	2008;	
Kinugasa	et	al.	2009),	and	many	of	these	have	been	shown	to	potentiate	the	suppressive	
function	of	Tregs	(Akimova	et	al.	2010;	Lucas	et	al.	2009;	Tao	et	al.	2007;	Tao	et	al.	2007).	
However,	the	broad	mechanism	of	action	of	pan-HDACis	and	their	resultant	side	effect	
profiles,	such	as	thrombocytopenia,	have	limited	their	clinical	application	thus	far	to	cancer	
only	(Kelly	et	al.	2003;	Strevel,	Ing,	&	Siu	2007)	
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More	recently	however,	isoform-selective	HDACis	have	been	developed,	which	retain	target	
potency	but	which	have	an	improved	toxicity	profile.	Such	efforts	have	rekindled	research	in	
identifying	the	role	of	specific	histone	deacetylases	(HDACs)	in	the	pathogenesis	of	disease.	
Hancock	and	colleagues	have	recently	demonstrated	that	inhibition	of	class	II	HDACs	
(HDAC4-7,	HDAC9	and	HDAC10)	results	in	the	mediation	of	immunosuppression.	Of	
particular	note,	is	the	inhibition	of	HDAC7,	HDAC9	(class	IIa)	(Tao	&	Hancock	2008)	and	
HDAC6	(Class	IIb)	(Beier	et	al.	2012;	de	Zoeten	et	al.	2011)	which	appear	to	have	the	most	
significant	effect	on	Treg	function.	In	the	case	of	HDAC6,	inhibition	leads	to	an	apparent	
increased	expression	of	FoxP3,	which	is	critical	to	the	development	and	immunosuppressive	
function	of	Tregs.	It	is	this	potential	effect	of	HDACis	on	Tregs	which	is	central	to	the	hypothesis	
of	this	project	that	they	may	have	benefit	as	an	immunosuppressive	therapy	in	
transplantation.		
HDACis	affect	a	conformational	change	through	the	acetylation	of	histone,	resulting	in	a	
reduced	affinity	for	DNA.	This	alteration	in	chromatin	structure	exposes	the	DNA	and	
therefore	facilitates	enhanced	gene	transcription.	The	mechanism	by	which	histone	
deacetylation	occurs	has	already	been	discussed	earlier	in	this	chapter,	and	the	long	list	of	
non-histone	protein	substrates	of	HDACs	already	described.	The	potential	targets	therefore	
of	HDACis	is	similarly	extensive	and	includes	transcription	factors,	structural	proteins	and	
signalling	molecules	all	of	which	may	be	involved	in	immunomodulatory	processes.	
HDACis	are	a	diverse	set	of	compounds	with	differing	biological	activities	and	specificities.		
They	are	generally	classified	into	four	broad	structural	categories	(hydroxamic	acids,	
synthetic	benzamides,	cyclic	peptides	and	short	chain	fatty	acids	(Figure	1-19).	
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Hydroxamic	Acids	(eg	SAHA)	
	
	
Synthetic	benzamides	(eg	MS275)	
	
Cyclic	peptides	(eg	FK228)	
	
Short	chain	fatty	acids	(eg	valproic	acid)	
	
	
Figure	1-9	Structural	class	(and	example)	of	HDACi	
Of	these	HDACi	subtypes,	the	most	widely	researched	and	currently	most	successful	in	
terms	of	clinical	application	are	the	hydroxamic	acids.	In	general,	these	historically,	have	
tended	to	be	non-specific	in	inhibiting	HDACs;	however	due	to	burgeoning	interest	in	the	
development	of	selective	and	specific	compounds	in	order	to	improve	efficacy	and	side	
effect	profiles	a	number	of	‘cleaner’	compounds	have	been	developed.	One	of	these	
recently	engineered	compounds	is	the	HDAC6	specific	inhibitor,	KA1010.	This	thesis	will	
describe	how	this	compound	was	selected	from	a	panel	of	potential	HDACi	compounds	and	
assessed	as	a	potentially	superior	immunosuppressant	compared	to	current	therapies	and	
pan-HDAC	inhibitors.		
1.12.1 A	novel	HDAC6-specific	inhibitor	–	KA1010	
48	
	
The	hydroxymate	structure	of	KA1010	closely	resembles	that	of	SAHA	(Figure	1-10)	with	an	
additional	benzene	ring	at	the	N-terminus	and	is	highly	selective	for	HDAC6.		
	
Figure	1-10	Structure	and	HDAC-specificity	of	KA1010	
It	is	a	novel,	engineered	compound	not	currently	licensed	for	clinical	use	and	its	potential	
applications	in	other	clinical	settings	(as	with	several	other	HDACi	compounds)	such	as	
inflammation	are	under	investigation.	Its	development	has	been	undertaken	by	Karus	
therapeutics	and	they	have	kindly	supplied	samples	of	the	compound	for	the	purpose	of	this	
study.	
	
1.13 The	role	of	regulatory	T	cells	in	transplantation	
One	of	the	most	researched	areas	in	transplantation	over	recent	years	is	the	potential	role	
FoxP3+	regulatory	T	cells	(Tregs)	may	have	in	developing	new	immunosuppressive	strategies.	
Tregs	possess	a	unique	function	among	the	T	cell	population	in	that	they	are	able	to	naturally	
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limit	immune	responses	and,	in	the	normal	healthy	subject	prevent	autoimmunity	(for	
example,	prevention	of	materno-fetal	allograft	rejection).	Strategies	harnessing	this	cellular	
immune	compartment	by	promoting	their	function,	expansion	or	adoptive	transfer	may	lead	
to	alternative	immunosuppressive	modalities	(De	Serres,	Sayegh,	&	Najafian	2009;	Feng	et	
al.	2011;	Roncarolo	&	Battaglia	2007;	Wood	&	Sakaguchi	2003).	
1.13.1 Discovery	of	Tregs	
In	1970	Gershon	and	Kondo	(Gershon	&	Kondo	1970),	first	identified	a	population	of	T	cells	
(suppressor	T	cells)	with	a	modulatory	effect	on	immune	responses.	These	cells	were	
characterised	by	the	expression	of	either	Lyt-1	or	Lyt-2	and	were	found	to	be	present	in	
both	the	CD4+	and	CD8+	subset	populations.	However,	attempts	to	identify	the	encoding	
gene	region	thought	to	be	responsible	for	these	specialised	cells	proved	fruitless	and	
interest	in	further	research	dwindled.		
It	would	not	be	until	1995	when	Shimon	Sakaguchi	published	his	seminal	paper	in	the	
Journal	of	Immunology	that	Tregs	were	first	recognised	(Sakaguchi	et	al.	1995)	as	a	separate	
immunomodulatory		T	cell	population.	He	demonstrated	the	existence	of	a	subpopulation	of	
T	cells,	expressing	the	IL-2	receptor	α-chain	(CD25)	present	in	the	normal	immune	system,	
making	up	approximately	5%	of	the	T	cell	population.	He	showed	that	the	removal	of	this	
population	of	T	cells	from	normal	mice	resulted	in	autoimmune	disease	analogous	to	
conditions	such	as	type	I	diabetes,	autoimmune	thyroiditis	and	autoimmune	arthritis	in	
humans.	He	concluded	that	this	population	of	T	cells	were	responsible	for	maintaining	
natural	self-tolerance	and	its	depletion,	results	in	a	number	of	autoimmune	diseases.		
Sakaguchi’s	findings	prompted	intense	research	into	the	characteristics	of	Tregs.	In	2001,	it	
was	identified	that	an	X	chromosome	mutation	of	the	FoxP3	gene	in	mice	was	responsible	
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for	the	severe	autoimmune	condition	seen	in	Scurfy	mice	(Brunkow	et	al.	2001).	The	human	
equivalent	of	the	FoxP3	gene	was	rapidly	found	to	be	responsible	for	an	analogous	
condition	known	as	IPEX	(immune	dysregulation,	polyendocrinopathy,	enteropathy,	X-linked	
syndrome)	characterised	again	by	severe	autoimmunity	and	leading	to	type	I	diabetes,	
thyroiditis,	inflammatory	bowel	disease	and	severe	allergy	(Bennett	et	al.	2001;	Chatila	et	al.	
2000;	Wildin	et	al.	2001).	Finally,	following	this	discovery,	several	groups	began	to	link	the	
phenotypical	similarities	between	Scurfy	mice	and	those	which	had	undergone	Treg	
depletion.	In	2003,	it	was	reported	that	FoxP3	was	essential	for	Treg	development	and	
function	(Fontenot,	Gavin,	&	Rudensky	2003;	Hori,	Nomura,	&	Sakaguchi	2003;	Khattri	et	al.	
2003).	FoxP3	mRNA	was	found	to	be	a	feature	of	CD4+CD25+	cells	but	was	not	present,	even	
despite	activation	in	CD4+CD25-	cells.	However,	retroviral	transduction	of	the	FoxP3	gene	
into	CD4+CD25-	cells	transformed	them	into	functional	and	phenotypical	Treg-like	cells.		
1.13.2 Types	of	regulatory	T	cells	
It	is	now	widely	accepted	that	CD4+FoxP3+	Tregs	can	be	classified	broadly	into	two	groups,	
depending	up	on	their	ontology,	namely	natural	Treg	(nTreg)	or	induced	(or	adaptive)	Treg	
(iTreg).	However,	these	cells	typically	lack	homogeneity	and	it	is	likely	that	this	classification	
is	over-simplistic.		
1.13.3 Natural	Tregs	
The	more	homogenous	of	these	two	populations	are	the	natural	Tregs.	They	are	derived	in	
the	thymus	(Sakaguchi	et	al.	1995)	from	immature	CD4+CD8+	T	cells	(see	thymocyte	
development	above)	and	migrate	out	to	the	periphery	where	they	make	up	5-10%	of	CD4+	T	
cells.	The	characteristic	expression	of	CD25	is	acquired	quite	late	in	its	development	at	the	
CD4+CD8-	single	positive	thymocyte	stage.	The	critical	factor	which	appears	to	determine	
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whether	a	thymocyte	takes	the	conventional	CD4+CD25-	lineage	route	of	development	or	
the	Treg	route	is	the	degree	of	affinity	the	TCR	has	to	self-peptides.	Typically,	those	
thymocytes	with	a	higher	(intermediate)	affinity	for	antigen	will	develop	as	Tregs	(von	&	
Jaeckel	2001).	
The	involvement	of	the	NF-κβ	pathway	seems	to	have	a	significant	role	in	nTreg	development	
and	its	level	of	thymic	activation	directly	correlates	with	the	degree	of	FoxP3	induction	and	
Treg	differentiation	(Long	et	al.	2009).	However,	its	precise	role	remains	unclear.	
What	is	clearer	is	the	dependence	of	co-stimulatory	molecules	on	nTreg	development.	
Murine	studies	looking	at	mice	deficient	in	CD28	(Keir	&	Sharpe	2005),	CD80/86,	CD40	
(Paust	et	al.	2004)	and	IL-2rβ	(Malek	et	al.	2002)	produce	fewer	numbers	of	less	suppressive	
nTregs.	IL-2	and	TGF-β	are	also	important	in	nTreg	development.	Though	Tregs	express	high	
levels	of	the	IL-2	receptor	(CD25),	they	are	unable	to	produce	IL-2	themselves	and	are	
therefore	dependent	on	paracrine	production	for	continued	survival.	The	role	of	TGF-β	is	
less	clear	though	it	has	been	shown	to	be	necessary	to	maintain	FoxP3	expression	in	nTregs	
(Marie	et	al.	2005).	
1.13.4 Induced	Tregs	
Induced	Tregs	typically	arise	from	the	conversion	of	naive	CD4+FoxP3-	conventional	T	cells	
(Tconv)	in	the	periphery	following	one	of	a	number	of	stimuli.	Two	main	types	of	iTreg	have	
been	identified,	based	on	the	cytokine	which	induces	them.	Type	1	regulatory	T	cells	(Tr1)	
are	induced	by	IL-10	(Groux	et	al.	1997;	Vieira	et	al.	2004)	and	T	helper	3	(Th3)	cells	are	
induced	by	TGF-β	(Weiner	2001).	Appropriately,	each	subset	exerts	its	inhibitory	effect	
through	the	secretion	of	the	same	cytokine	which	stimulated	its	differentiation.		
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The	conversion	of	FoxP3-	T	cells	to	FoxP3+	iTregs	has	also	been	shown	to	be	induced	in	the	
presence	of	IL-4	and	IL-13,	without	the	presence	of	either	IL-10	or	TGF-β	(Skapenko	et	al.	
2005).		
1.13.5 Function	of	Tregs	
The	role	of	Tregs	in	the	immune	system	is	of	great	interest.	The	therapeutic	potential	of	these	
cells	in	terms	of	dampening	the	alloimmune	response	and	ultimately	achieving	transplant	
tolerance	is	of	enormous	clinical	interest.	Applications	expanding	the	Treg	population	are	
relevant	to	transplantation,	and	their	benefits	in	other	disease	processes	such	as	the	
treatment	of	inflammation,	oncology	and	autoimmune	disease	are	well	recognised	(Kohm	et	
al.	2002;	Maloy	et	al.	2003;	Workman	et	al.	2009).		
	
Though	nTregs	and	iTregs	have	broadly	similar	mechanisms	in	terms	of	suppression	and	are	
phenotypically	alike,	their	proliferative	stimuli	are	quite	different.	As	described,	nTregs	rely	
on	the	response	of	thymocytes	to	self-peptide	in	order	to	stimulate	their	expansion.	iTregs	on	
the	other	hand,	are	stimulated	through	a	weaker	TCR	mechanism	in	response	to	exogenous	
peripheral	antigens	(Apostolou	&	von	2004;	Kretschmer	et	al.	2005).	As	a	result,	iTregs	tend	
to	be	stimulated	in	response	to	anti-inflammatory	cytokines	in	a	setting	of	inflammation.	
Another	difference	between	the	two	subsets	is	the	dependence	upon	CD28	as	a	co-factor	
(which	is	necessary	for	nTregs,	but	not	required	for	iTregs	(Apostolou	et	al.	2002;	Kretschmer	
et	al.	2005)).	Of	note,	studies	have	demonstrated	that	the	in	vitro	expansion	of	CD28	
stimulated	iTregs	actually	results	in	cells	with	unstable	FoxP3	expression	and	reduced	survival	
(Floess	et	al.	2007).	Furthermore,	if	these	cells	are	developed	in	the	absence	of	CD28,	they	
remain	fully	functional	even	after	in	vivo	transfer	(Taylor,	Lees,	&	Blazar	2002).		
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Over	recent	years,	there	has	been	an	expansion	of	theories	as	to	the	mechanisms	by	which	
Tregs	infer	suppression	on	their	targets.	Many	of	these	theories	are	diverse	and	the	reality	is	
that	they	are	all	likely	to	contribute	to	varying	degrees,	depending	upon	factors	such	as	the	
environment	and	the	cell	type	targeted.	However,	further	work	is	still	required	to	clarify	
how	these	various	mechanisms	interplay.		
Tregs	have	the	ability	to	suppress	a	multitude	of	cell	types,	including	dendritic	cells	(DCs),	
natural	killer	T	cells	(NKT),	B	cells	and	CD8+	and	CD4+	T	cells	(Miyara	&	Sakaguchi	2007).	The	
resulting	effect	of	Treg	suppression	on	target	cells	can	be	equally	as	varied	as	the	mechanism	
by	which	they	act.	This	can	range	from	down-regulating	growth	factors	such	as	IL-2	(Wing,	
Fehervari,	&	Sakaguchi	2006)	to	lysing	targets	through	granzyme	B	and	perforin	(Gondek	et	
al.	2005;	Grossman	et	al.	2004).		
The	mechanisms	by	which	Tregs	manifest	suppression	can	be	broadly	divided	into	five	
categories	(Figure	1-11);	
1. Cell-to-cell	contact	
Through	TCR	activation	(Thornton	&	Shevach	2000),	Tregs	are	able	to	suppress	Teff	
cells	by	inhibiting	their	transcription	of	IL-2	(mRNA)	(Thornton	et	al.	2004;	Thornton	
&	Shevach	1998)	and	by	consuming	IL-2	(de	la	et	al.	2004).	The	precise	mechanism	of	
this	effect	is	unclear,	but	it	appears	that	TGF-β	and	IL-10	are	not	implicated.		
2. Dendritic	cell	modulation	
Tregs	can	inhibit	DC	function	through	two	mechanisms.	The	first	is	to	inhibit	
indoleamine	2,3-dioxygenase	(IDO)	resulting	in	reduced	tryptophan,	necessary	for	
cell	division.	This	is	through	the	binding	of	CTLA-4	to	CD80/86	on	DCs	(Fallarino	et	al.	
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2003).	The	second	Treg:DC	interaction	involves	the	sending	of	inhibitory	signals	via	
LAG-3	to	MHC	class	II	molecules	(Liang	et	al.	2008).			
3. Inhibitory	cytokines		
One	of	the	most	widely	studied	mechanisms	by	which	Tregs	modulate	immune	
responses	is	through	the	release	of	immunosuppressive	cytokines	such	as	IL-10	(Ito	
et	al.	2008),	TGF-β	(Levings,	Sangregorio,	&	Roncarolo	2001),	IL-35	(Chaturvedi	et	al.	
2011)	and	galectin-1	(Shevach	2009;	Sojka,	Huang,	&	Fowell	2008).		
4. Metabolic	disruption	
Hydrolysis	of	extracellular	ATP	via	ectoenzymes	CD39	and	CD73	results	in	adenosine	
production	(Deaglio	et	al.	2007).	This	adenosine	then	binds	to	the	adenosine	specific	
A2A	receptor	on	Teff,	disrupting	the	cyclic	AMP	(cAMP)	dependent	secretion	of	
cytokines	(Bopp	et	al.	2007).		
5. Cytolysis	
Activated	Tregs	have	the	ability	to	mediate	lysis	of	Teff	cells	through	the	release	of	
granzyme	B	/	perforin.	This	mechanism	requires	CD18	mediated	adhesion	(Grossman	
et	al.	2004).		
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Figure	1-11	Treg	mechanisms	of	action	
Adapted	from	Frontiers	in	Immunology	(Caridade,	Graca,	&	Ribeiro	2013)	
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1.14 Aim	of	the	study	
The	aim	of	this	study	therefore	was	to	assess	the	potential	immunosuppressive	function	of	
histone	deacetylase	inhibitors	through	the	modulation	of	regulatory	T	cells,	and	consider	
whether	or	not	this	group	of	compounds	may	have	a	therapeutic	role	in	transplantation.	We	
were	able	to	compare	the	effects	of	the	established	immunosuppressant	(CyA)	with	
established	pan-HDACis,	in	clinical	use	for	other	indications	(SAHA).	In	addition,	through	an	
industrial	partnership	we	were	able	to	obtain	and	assess	the	effect	of	a	number	of	cleaner,	
engineered	HDACi	compounds	with	more	selective	or	specific	inhibitory	profiles.	After	
considering	a	panel	of	HDACis,	we	were	then	able	to	focus	further	studies	in	the	form	of	
transplantation	models	on	those	compounds	considered	to	have	the	greatest	potential	
(KA1010).		
1.15 Overview	
Chapter	2	describes	the	various	methods	employed	during	the	course	of	this	study.		
The	findings	of	this	study	are	then	presented	over	three	results	chapters.	They	are	broadly	
categorised	into	the	following:	
• Cellular	effects	of	Histone	deacetylase	inhibitors	(Chapter	3)	
• Effect	of	histone	deacetylation	on	in	vitro	models	of	allotransplantation	(Chapter	4)	
• Ex	vivo	effects	of	histone	deacetylase	inhibition	on	allotransplantation	(Chapter	5)	
Chapter	3	identifies	the	HDAC	targets	of	interest	in	relevant	cell	types	and	examines	the	
proliferative	effects	of	a	panel	of	novel	and	established	HDACis	on	several	cell	lines.	In	
addition	to	this	toxicity	and	viability	of	treated	cells	are	assessed.	This	chapter	also	examines	
the	effects	of	HDACi	on	regulatory	T	cells	and	their	suppressive	effect	in	a	Treg	suppression	
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assay.	The	chapter	concludes	with	data	on	the	effects	of	HDACi	on	lymphocyte	subset	
expression.		
Chapter	4	builds	on	findings	from	the	previous	studies	and	considers	the	effects	of	HDACi	
(KA1010	and	SAHA)	as	well	as	Cyclosporin	A	on	several	in	vitro	models	of	transplantation.	
The	basis	for	this	is	a	mixed	lymphocyte	reaction	(MLR)	and	both	one-	and	two-way	types	
were	used.	A	novel	adaptation	of	the	one-way	MLR	was	further	developed	in	order	to	
demonstrate	autologous	preservation.	Finally	results	examining	the	effect	of	HDACi	on	T-cell	
activation	markers	and	MLR	cytokine	release	are	presented.		
Chapter	5,	the	final	results	chapter	focusses	on	the	in	vivo	effects	of	HDACi	(specifically	
KA1010	+/-	Rapamycin)	on	a	murine	skin	model	of	transplantation.	Data	pertaining	to	graft	
survival	are	presented	along	with	the	physiological	effects	of	HDACi.	This	chapter	concludes	
with	results	demonstrating	the	effect	KA1010	has	on	relevant	T	cell	subsets	ex	vivo.		
The	final	chapter	in	this	thesis	discusses	the	above	results	in	further	detail	and	considers	
how	these	findings	add	to	the	current	evidence	relating	to	a	potential	immunosuppressive	
role	for	HDAC6	inhibition.	Possible	mechanisms	of	action	are	also	postulated	and	areas	for	
further	study	are	highlighted.		
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Chapter	2	-	Materials	and	Methods	
2 Materials	and	Methods	
2.1 Compounds	
HDACi	compounds	were	supplied	by	Karus	Therapeutics	Ltd,	Oxford,	UK	in	powder	form.	
They	were	dissolved	in	dimethyl	sulfoxide	(DMSO)	at	a	concentration	of	10mM	and	stored	
at	-80°C.	For	experimental	use,	they	were	diluted	in	Roswell	Park	Memorial	Institute	Media	
(RPMI)	supplemented	with	10%	human	albumin	solution	(HAS).	Cyclosporin	A	(CyA;	Sigma-
Aldrich,	Dorset,	UK)	was	supplied	in	powder	form	and	dissolved	in	DMSO	to	make	a	
50mg/ml	stock	solution.		
	
2.2 Isolation	of	PBMCs	
Peripheral	blood	cells	(PBMCs)	were	isolated	from	healthy	donors	by	Ficoll-Paque	PLUS	
density	centrifugation	(GE	Healthcare,	Buckinghamshire,	UK)	from	20ml	of	heparinised	
blood	collected	from	healthy	volunteers.	Blood	was	diluted	1:1	at	37°C	with	sterile	
supplemented	RPMI	(containing	10%	FCS,	1%	Penicillin-Streptomycin	and	1%	Glutamine),	
gently	mixed	and	divided	into	10ml	aliquots	and	carefully	layered	onto	6ml	of	Ficcol-Paque	
Plus	and	centrifuged	at	2100rpm	for	20	minutes.	Due	to	their	low	density,	PBMCs	form	a	
visible	layer	at	the	interface	between	Ficoll	and	blood.	After	carefully	removing	this	
lymphocyte-containing	layer	of	cells,	they	were	transferred	to	a	fresh	tube	and	washed	with	
supplemented	RPMI	by	centrifuging	at	1700rpm	for	10	minutes.	A	second	wash	was	
performed	before	finally	suspending	the	cells	in	10ml	of	supplemented	RPMI.	Cell	number	
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and	density	was	calculated	using	a	haemocytometer	after	staining	with	filtered	Tryptophan	
blue.		
All	reagents	were	obtained	from	Sigma-Aldrich	unless	otherwise	stated	and	plastic	labware	
from	BD-Falcon	UK.		
	
2.3 Western	Blot	Analysis	
10%	SDS-PAGE	gels	were	constructed.	To	make	the	resolving	gel	12ml	Protogel	(Fisher	
Scientific,	Ireland)	was	added	to	10.5ml	of	distilled	water,	7.5ml	of	1.5M	Tris	(pH	8.8)	and	
300µl	10%	SDS.	150µl	of	10%	APS	and	30µl	of	TEMED	were	added	to	the	solution	before	
allowing	the	gel	to	set	in	the	cassette.	The	stacking	gel	consisted	of	2.6ml	Protogel	(Fisher	
Scientific,	Ireland),	12.2ml	of	distilled	water,	5ml	of	0.5M	Tris	(pH	6.8)	and	200µl	10%	SDS.	
100µl	of	10%	APS	and	20µl	of	TEMED.		
Proteins	were	denatured	by	suspending	a	pellet	of	1	x	106	cells	in	0.5ml	PBS	in	a	large	
eppendorf.	A	pellet	of	cells	was	reformed	by	centrifuging	at	3000rpm	for	5	minutes.	The	PBS	
was	pipette	off	and	the	pellet	allowed	to	dry.	The	pellet	of	cells	was	then	resuspended	in	
20µl	of	SDS	buffer	(50mM	Tris	pH	6.8,	2%	SDS,	10%	Glycerol,	1%	β<Mercaptoethanol,	
12.5mM	EDTA	and	0.02%	Bromophenol	Blue)	and	boiled	at	100°C	for	5	minutes.	After	a	
further	centrifuge	at	13,000rpm	for	1	minute	samples	were	loaded	onto	the	gel	in	20µl	
aliquots.		
Samples	were	resolved	at	100	volts	until	the	dye	reached	the	bottom	of	the	gel.	The	
stacking	gel	was	removed	and	samples	were	transferred	onto	a	nitrocellulose	membrane	
(Amersham	Hybond-P	membrane,	GE	Lifesciences)	which	had	been	pre-soaked	for	5	
seconds	in	methanol	prior	to	being	soaked	in	transfer	buffer	(25Mm	Tris,	182Mm	Glycine	
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and	10%	methanol)	for	five	minutes.	Samples	were	then	transferred	at	10	volts	for	90	
minutes	and	the	membrane	blocked	overnight	in	10%	blocking	buffer	(PBS	Tween	with	BSA).	
Three	washes	were	then	carried	out	using	blocking	buffer	before	the	addition	of	the	primary	
antibody	(see	below).	
The	primary	antibody	was	incubated	with	the	sample	overnight	and	an	identical	washing	
undertaken	to	that	described	previously.	The	secondary	antibody	(anti-mouse	IgG	
horseradish	peroxidise	linked	whole	antibody	at	a	concentration	of	1/2000	(eBioscience,	
Hatfield,	UK))	was	added	to	the	sample	and	incubated	for	a	further	1	hour.	The	membrane	
was	washed	again	and	incubated	for	2-3	minutes	with	Amersham	Enhanced	
Chemiluminescence	reagent	(GE	Healthcare,	Uppsala,	Sweden)	before	loading	onto	cassette	
for	developing.		
Western	Blotting	was	performed	to	demonstrate	the	presence	of	the	specific	target	of	
interest,	HDAC6.	Standard	Western	Blotting	procedures	were	performed	using	a	monoclonal	
anti-HDAC6	antibody	(Sigma-Aldrich,	Dorset,	UK).	Briefly,	T	cell	subsets	were	separated	
using	immunomagnetic	negative	selection	kits	(Stemcell	Technologies,	Grenoble,	France;	
Miltenyi	Biotec	Ltd,	Surrey,	UK).	One	million	cells	were	denatured	in	sodium	dodecyl	
sulphate	(SDS)	buffer	and	transferred	onto	a	Polyvinylidene	fluoride	(PVDF)	membrane.	
Blots	were	probed	using	a	mouse	monoclonal	anti-HDAC6	antibody	(1/500).	The	secondary	
antibody	was	anti-mouse	IgG	horseradish	peroxidise	linked	whole	antibody	–	1/2000	
(eBioscience,	Hatfield,	UK).	Detection	was	performed	using	an	Amersham	Enhanced	
Chemiluminescence	reagent	(GE	Healthcare,	Uppsala,	Sweden).	Consistent	sample	loading	
in	each	well	was	confirmed	by	reblotting	with	actin	antibody.	
2.4 Antibodies	
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Blots	were	probed	using	monoclonal	anti-HDAC	antibodies	(obtained	from	Sigma-Aldrich,	
Dorset,	UK)	at	a	concentration	of	1/500.	The	antibodies	used	were:	
- anti-HDAC2	
- anti-HDAC3	
- anti-HDAC4	
- anti-HDAC6	
- anti-HDAC9	
2.5 Toxicity	assay	
In	order	to	assess	toxicity	a	FITC	Annexin	V	apoptosis	detection	kit	was	used	(BD	
Pharmingen).	After	isolating	PBMCs,	cells	were	re-suspended	at	a	density	of	1x106	cells	/	ml	
in	supplemented	RPMI	and	cultured	in	200µl	aliquots	in	a	96	well	round-bottomed	plate	for	
72	hours	at	37°C.	The	culture	media	was	supplemented	with	compound	of	interest.	
Following	the	culture	period,	cells	were	washed	twice	in	cold	PBS	and	re-suspended	in	1x	
Binding	Buffer	at	a	concentration	of	1	x	106	cells/ml.	100	µl	of	the	solution	(1	x	10^5	cells)	
was	then	transferred	to	a	5	ml	culture	tube	and	5	µl	of	FITC	Annexin	V	and	5	µl	PI	added.	
Following	gentle	vortex,	the	cells	were	incubated	for	15	minuntes	at	room	temperature	in	
the	dark.	Finally,	400	µl	of	1x	Binding	Buffer	was	added	to	each	tube	and	flow	cytometry	
analysis	undertaken	within	1	hr.	
Flow	cytometry	was	undertaken	using	a	BD	FACSCanto	II	flow	cytometer	(Becton	Dickinson	
and	Co,	New	Jersey,	USA)	and	FlowJo	software	(Tree	Star	Inc,	Oregon,	USA).	PE	–	side	
scatter,	FITC	–	forward	scatter.		
2.6 Jurkat	Cell	proliferation	assay	
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A	resazurin-based	system	was	used	to	calculate	Jurkat	cell	proliferation.	Firstly,	Jurkat	cells	
were	cultured	in	supplemented	RPMI	in	a	96-well	round-bottomed	plate	at	a	density	of	
5000	(or	50,000)	cells	/	ml	at	37°C	for	up	to	five	days.	The	media	was	supplemented	with	
sodium	azide	(negative	control),	PMA	or	LTA	(positive	control)	or	compound	of	interest	
(HDACi)	at	a	range	of	doses	described	in	the	results.	Untreated	serial	dilution	controls	were	
also	undertaken	so	a	standard	curve	could	be	produced	for	extrapolation	purposes.	
Following	the	culture	period,	10µl	of	sterile	0.01%	Resazurin	was	added	to	each	well	and	
after	gentle	shaking,	the	plate	incubated	for	a	further	four	hours.	After	a	further	brief	
shaking	relative	fluorescence	units	(RFU)	were	then	measured	using	a	spectrophotometer	
(filter	pair	-	excitation	=	530-570	nm	and	emission	=	590-620	nm).	The	standard	curve	was	
calculated	and	relative	cell	numbers	extrapolated	using	the	best	fit	line	equation.				
2.7 PBMC	proliferation	assay	
CFSE	was	used	to	assess	the	proliferation	of	PBMCs	(CellTrace	cell	proliferation	kit,	
Invitrogen,	Paisley,	UK).		Freshly	isolated	PBMCs	were	prepared	in	the	standard	fashion	and	
suspended	in	supplemented	RPMI	at	a	concentration	of	1	x	106	cells	/	ml.	A	5mM	stock	
solution	of	CFSE	was	prepared	by	dissolving	50µg	in	18µL	of	DMSO.	This	was	further	diluted	
in	PBS	before	before	adding	to	the	cell	media	at	a	concentration	of	1µM.	Cells	were	then	
incubated	for	10	minutes	at	37°C	for	ten	minutes.	Any	free	dye	was	then	removed	by	
washing	five	times	in	culture	media.	The	CFSE-stained	cells	were	then	resuspended	in	
supplemented	RPMI	at	a	concentration	of	1	x	106	cells	/	ml	and	distributed	in	200µl	aliquots	
into	a	96-well	round-bottomed	plate	(media	was	supplemented	with	appropriate	
concentration	of	compound	of	interest).		
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Following	the	incubation	period,	cells	were	washed	in	RPMI	and	proliferation	was	assessed	
using	a	BD	FACS	Canto	II	flow	cytometer	to	assess	cell	division.	
2.8 Regulatory	T	cell	suppression	assay	
Isolation	of	regulatory	T	cells	was	undertaken	using	the	MACS	CD4+	CD25+	Regulatory	T	Cell	
Isolation	Kit	(Miltenyi-Biotec).	Numbers	of	freshly	isolated	PBMCs	were	calculated	and	
suspended	in	90µl	cold	buffer	(PBS	pH	7.2	+	0.5%	BSA	+	2Mm	EDTA)	per	107	cells.	10µl	of	
CD4+	T	cell	Biotin-Antibody	cocktail	was	added	per	107	cells,	mixed	well	and	refrigerated	for	
5	minutes.	20µl	of	Anti-Biotin	MicroBeads	were	then	added	followed	by	a	further	10	minute	
refrigeration	period.	The	cell	suspension	was	passed	through	a	separation	column	and	the	
unlabelled	CD4+	enriched	effluent	collected.	After	two	washes	with	cold	PBS,	the	cell	
suspension	was	centrifuged	at	300xg	for	ten	minutes	and	the	supernatant	aspirated.	The	
pellet	was	suspended	in	90µl	of	buffer	and	10µl	of	CD25	MicroBeads	added.	The	suspension	
was	then	refrigerated	for	15	minutes,	washed	in	PBS	and	suspended	in	500µl	of	buffer.		
The	suspension	was	then	applied	to	a	second	separation	column	and	the	unlabelled	effluent	
collected	(CD25-	fraction).	The	CD25+	fraction	was	then	retrieved	from	the	column	by	rinsing	
with	3	x	500µl	washes	and	enriched	by	passing	through	a	further	column.		
Once	isolated,	the	CD4+CD25+	regulatory	T	cells	were	cultured	with	1µM	CFSE-labelled	(as	
above)	CD4+	responder	cells	and	proliferation	assessed	using	flow	cytometry.	Media	was	
enriched	with	compound	of	interest	at	various	doses	(see	Results)	to	assess	HDACi	effect.	
Following	assay	development,	stimulation	was	achieved	using	Dynabeads	(Invitrogen,	
Paisley,	UK).	According	to	manufacturer	protocol	these	were	washed	in	buffer	(PBS	+	0.1%	
BSA	+	2mM	EDTA,	pH	7.4)	and	re-suspended	in	culture	medium.	Cultures	were	undertaken	
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in	a	96-well	plate	and	Dynabeads	were	added	at	a	cell	to	bead	ratio	of	1:1.	Following	the	5	
day	assay	incubation	period,	beads	were	removed	using	a	magnet	prior	to	flow	cytometry	
analysis	of	responder	cell	proliferation.		
2.9 Effect	of	HDACi	on	lymphocyte	subset	expression	
Freshly	isolated	PBMCs	were	diluted	to	a	density	of	1	x	106	cells	/	ml	and	cultured	in	200µl	
aliquots	for	up	to	five	days	in	a	96-well	round	bottomed	plate.	The	media	was	
supplemented	with	compound	of	interest	where	appropriate.		
Following	the	culture	period,	cells	were	washed	in	RPMI	and	stained	using	the	following	
antibodies	(BD	Biosciences):	
Antibody	 Fluorochrome	 Concentration	
CD4	 APC	 1:100	
CD8	 PerCP	 1:100	
CD3	 FITC	 1:100	
CD19	 PE	 1:100	
	
2.10 PBMC	Irradiation	Assay	
Gamma	irradiation	causes	DNA	damage	to	PBMCs	and	results	in	cells	no	longer	able	to	
proliferate	or	produce	de	novo	protein	but	with	otherwise	normal	function.	In	order	to	
achieve	an	irradiated	population	of	cells,	freshly	isolated	PBMCs	were	suspended	in	sterile	
supplemented	RPMI	(containing	10%	FCS,	1%	Penicillin-Streptomycin	and	1%	Glutamine)	
and	exposed	to	varying	degrees	of	radiation	using	a	standard	laboratory	irradiator.		
2.11 One-way	MLR	
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A	one-way	mixed	lymphocyte	reaction	(MLR)	assay	was	adopted	as	a	model	of	in	vitro	
alloreactivity.	PBMCs	were	prepared	from	two	allogeneic	donors.	Responder	cells	(105)	
labelled	with	1µM	CFSE	were	cultured	with	105	stimulator	cells	(irradiated	at	20	Gy)	for	
seven	days	in	a	96-well	round	bottom	plate	in	AIM	V	media	supplemented	with	+	10%	
human	serum	together	with	compound	of	interest	(CyA,	SAHA	and	KA1010).	Suppression	of	
alloreactivity	was	measured	by	loss	of	CFSE	staining	intensity	in	the	parent	population,	
measured	using	a	FACSCanto	flow	cytometer	(Becton	Dickinson	and	Co,	New	Jersey,	USA)	
and	FlowJo	software	(Tree	Star	Inc,	Oregon,	USA).	
2.12 One-way	MLR	–	Killing	Assay	
A	one-way	mixed	lymphocyte	reaction	(MLR)	assay	was	adopted	as	a	model	of	in	vitro	
targeted	alloreactivity	by	assessing	the	response	of	both	allogeneic	and	autologous	
responders	in	the	same	assay.	PBMCs	were	prepared	from	two	allogeneic	donors.	
Allogeneic	responder	cells	(50,000	cells)	were	labelled	with	FITC	Mouse	Anti-Human	CD45	
antibody	(Becton	Dickinson	and	Co,	New	Jersey,	USA)	at	a	concentration	of	1/2000	or	1/100.	
The	autologous	population,	in	order	to	facilitate	discrimination	between	the	two	
populations,	was	stained	with	the	same	antibody	at	a	concentration	of	1/600	or	with	APC-
H7	Mouse	Anti-Human	CD45	antibody	(Becton	Dickinson	and	Co,	New	Jersey,	USA)	at	a	
concentration	of	1/100.	Unlabelled	stimulator	cells	(100,000	cells	per	assay)	were	irradiated	
at	20	Gy.		Populations	were	combined	as	required	and	cultured	for	varying	lengths	of	time	in	
a	96-well	round	bottom	plate	supplemented	with	RPMI	(containing	10%	FCS,	1%	Penicillin-
Streptomycin	and	1%	Glutamine)	together	with	compound	of	interest	(CyA,	SAHA	and	
KAR3000).	Suppression	of	alloreactivity	was	measured	by	assessing	the	staining	intensity	of	
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target	populations,	measured	using	a	FACSCanto	flow	cytometer	(Becton	Dickinson	and	Co,	
New	Jersey,	USA)	and	FlowJo	software	(Tree	Star	Inc,	Oregon,	USA).	
2.13 Two-way	MLR	
For	a	two-way	MLR,	the	suppressive	activity	of	HDACis	was	compared	with	Cyclosporin	for	
their	ability	to	inhibit	IFN-γ	release	by	allogeneic	PBMCs.	The	premise	of	the	two-way	MLR	is	
similar	to	the	one-way	MLR	except	that	targets	were	not	irradiated,	allowing	allorecognition	
by	both	donor	and	recipient.	The	technique	is	otherwise	similar.	Supernatant	was	aspirated	
from	two-way	MLR	cultures	and	IFN-γ	release	assessed	using	an	ELISA	kit	(below).		
2.14 Interferon-γ	ELISA	
IFN-γ	release	was	measured	using	the	eBioscience™	Human	IFN-γ	ELISA	Ready-SET-Go®	kit	
(eBioscience,	Hatfield,	UK)	as	per	manufacturer’s	instructions	–	briefly,	these	consisted	of	
the	following:	
A	Corning	Costar	9018	ELISA	plate	was	coated	with	100	μL/well	of	capture	antibody	in	1X	
Coating	Buffer	(stock	solution	diluted	to	1	in	10).	The	plate	was	sealed	and	incubated	
overnight	at	2-8°C.	After	incubation,	the	wells	were	aspirated	and	washed	3	times	with	>250	
μL/well	wash	buffer	(allowing	~	1	minute	for	soaking	during	each	wash	step	to	increase	the	
effectiveness	of	the	washes).	Following	this,	the	plate	was	blotted	on	absorbent	paper	to	
remove	any	residual	buffer.	
The	next	step	was	to	block	the	wells	with	200	μL/well	of	1	x	ELISA/ELISPOT	Diluent	(1	part	5	
x	ELISA/ELISPOT	Diluent	with	4	parts	DI	water)	and	incubate	the	plate	at	room	temperature	
for	1	hour.	The	wells	were	then	aspirated	and	a	further	wash	undertaken	using	wash	buffer.		
DI	water	was	used	to	reconstitute	lyophilized	standards	and	allowed	to	sit	for	15	minutes	
with	gentle	agitation	prior	to	diluting	further.	A	series	of	standard	concentrations	were	then	
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plated	to	produce	a	standard	curve	-	using	1	x	ELISA/ELISPOT	Diluent,	reconstituted	
standard	was	diluted	to	prepare	the	maximum	standard	concentration	(according	to	
individual	lots	certificate	of	analysis).	100	μL/well	of	top	standard	concentration	was	then	
added	to	the	appropriate	wells	and	2-fold	serial	dilutions	of	the	top	standards	performed	to	
make	the	standard	curve	for	a	total	of	8	points.	At	least	two	wells	with	100	μL/well	of	1	x	
ELISA/ELISPOT	Diluent	only	to	serve	as	plate	blanks	were	also	used.	
The	plate	was	next	sealed	and	incubated	overnight	at	2-8°	followed	by	a	repeat	wash	step	
(as	above,	repeated	5	times).		
100	μL/well	of	detection	antibody	diluted	in	1	x	ELISA/ELISPOT	Diluent	was	then	added	to	
each	well,	the	plate	sealed	and	incubated	at	room	temperature	for	one	hour.	Again	the	
plate	was	then	washed	5	times	(as	above)	and	100	μL/well	of	Avidin-HRP	diluted	in	1	x	
ELISA/ELISPOT	Diluent	added	to	each	well.	The	plate	was	then	sealed	and	incubated	at	room	
temperature	for	30	minutes	a	further	wash	(as	above,	repeated	seven	times).		
100	μL/well	of	1	x	TMB	(Tetramethylbenzidine)	solution	was	added	to	each	well	and	the	
plate	incubated	at	room	temperature	for	15	minutes	after	which	50	μL	of	Stop	Solution	was	
added	to	each	well.	
Finally,	the	plate	was	read	using	at	450nm	using	an	ELISA	plate	reader	(Promega	Glomax	
Plate	Reader)	and	the	data	was	analysed	using	GraphPad	Prism	version	5.	
2.15 T	cell	activation	marker	assay	
A	standard	two-way	MLR	was	undertaken	as	described	above.	In	order	to	assess	the	effect	
of	compound,	the	assays	were	treated	by	supplementing	the	culture	media	with	either	CyA	
(500nM),	SAHA	(20nM		&	2μM)	or	KA1010		(10nM	→	10μM).	Cells	were	harvested	from	the	
culture	at	various	time	points	(0,24,48	&	72h)	and	washed	in	RPMI.	They	were	then	stained	
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for	cell	surface	markers	CD3	(APC-H7),	CD8	(PE),	CD69	(FITC),	CD25	(APC)	and	HLA-DR	
(PerCP)	and	assessed	using	standard	flow	cytometry	protocols.		
2.16 Multiplex	cytokine	assay	
To	assess	cytokine	release	in	MLR	culture	supernatant	a	standard	Human	13plex	flow	
cytomix	kit	from	eBiosciences	(Hatfield,	UK)	was	used.		In	summary,	the	protocol	consisted	
of	preparing	antigen	standards	as	per	manufacturers’	guidelines.		The	kit	consisted	of	
premixed	beads	in	a	96-well	plate.	To	each	well,	50μl	of	supernatant	was	added	and	the	
plate	sealed	and	shaken	at	room	temperature	for	120	minutes.	The	plates	were	washed	
twice	in	buffer	and	25μl	of	detection	antibody	added	to	each	well.	The	plate	was	resealed	
and	shaken	for	30	minutes	at	room	temperature.	After	2	further	washes	50μl	of	
Streptavidin-PE	was	added	to	each	well.	The	plate	was	resealed	again	and	shaken	at	room	
temperature	for	a	further	30	minutes.	Two	further	washes	were	undertaken	and	the	beads	
resuspended	in	120μl	of	reading	buffer.	After	a	final	shake	for	5	minutes	the	plates	were	
read	on	a	Luminex	100	machine.			
2.17 Flow	cytometry	
All	flow	cytometry	was	undertaken	using	standard	protocols	as	per	the	manufacturers	
guidelines	using	a	FACSCanto	flow	cytometer	(Becton	Dickinson	and	Co,	New	Jersey,	USA)	
and	FlowJo	software	(Tree	Star	Inc,	Oregon,	USA).	
Antibodies	for	all	procedures	were	supplied	by	Becton	Dickinson	and	Co	(New	Jersey,	USA).	
2.18 Allogeneic	murine	skin	transplant	model	
5-6	week	old	male	C57BL/6	(B6,	H-2b)	and	BALB/c	(H-2d)	mice,	bred	 	 	
	were	used	as	recipients	and	donors	respectively.	All	mice	were	
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bred	in	pathogen-free	conditions	and	housed	in	conventional	conditions.	Donor	mice	were	
euthanized	in	accordance	with	the	University’s	standard	operating	procedure	(SOP).	Donor	
sites	were	cleaned	with	an	alcohol-based	preparation	and	full-thickness	grafts	were	
procured	from	both	the	ear	and	abdominal	skin.	Tissue	was	placed	on	ice.	The	ear	graft	was	
prepared	by	splitting	the	ventral	collagenous	flap	from	the	dorsal	skin	and	this	was	floated	
in	PBS.	The	abdominal	graft	was	prepared	by	removing	fat	from	the	subcutaneous	surface	
and	again	floated	in	PBS.		
Recipient	mice	were	anaesthetised	and	post-op	analgesia	administered	intraperitoneally.	
Recipient	graft	sites	were	prepared	by	removing	a	1cm2	patch	of	skin	after	shaving	and	skin	
preparation.	Each	recipient	received	an	ear	graft	to	the	left	dorsum	and	abdominal	graft	to	
the	right	dorsum.	Grafts	were	removed	from	the	PBS	and	placed	on	the	graft	bed.	Excess	
PBS	was	removed	using	a	sterile	Q-tip	and	the	graft	trimmed	so	that	it	lied	flat	within	the	
graft	bed.	The	graft	was	then	secured	using	7-0	polypropylene	sutures	and	sterile	non-
adherent	gauze	placed	over.	Finally,	a	sterile	dressing	was	secured	and	the	recipient	placed	
in	a	clean	cage	to	recover.		
The	sterile	dressing	was	removed	4-5	days	later	and	graft	site	examined.	
Immunosuppression	was	administered	daily,	commencing	on	the	day	of	surgery	via	the	
intraperitoneal	route	and	this	was	combined	with	daily	graft	inspection	(after	dressings	are	
removed).		
Following	the	experimental	period,	recipient	mice	were	euthanized	in	accordance	with	the	
University’s	SOP.	Graft	sites	were	excised	encompassing	a	perimeter	of	normal	non-
transplanted	recipient	skin,	frozen	and	stored	at	-80°C	before	further	analysis	(histology).	In	
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addition	to	the	retrieval	of	skin,	recipient	spleen	and	lymph	nodes	were	also	harvested,	
frozen	and	stored	at	-80°C.		
2.19 Statistical	analysis		
All	data	presented	as	mean	+/-	the	standard	error	of	the	mean	(SEM).	Statistical	analysis	of	
individual	compounds	was	performed	with	a	two-tailed	unpaired	t-test,	using	GraphPad	
Prism.	When	the	effect	of	several	compounds	was	assessed	(MLR	assays)	a	one-way	or	two-
way	ANOVA	was	used	to	evaluate	the	overall	effect	of	compounds.	Statistical	significance	of	
effect	of	compounds	of	interest	in	these	assays	was	compared	to	control	using	a	Tukeys	
multiple	comparison	test.	A	p	value	of	less	than	0.05	was	considered	to	be	of	statistical	
significance.	
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Chapter	3	-	Results	
3 Cellular	effects	of	Histone	deacetylase	inhibitors	
3.1 Introduction	
As	described,	histone	deactylase	inhibitors	comprise	a	large	group	of	compounds	which	
have	effects	on	a	range	of	targets	(and	consequently	cell	function).	In	order,	therefore,	to	
assess	the	suitability	of	such	compounds	as	potential	immunosuppressants	it	is	important	to	
delineate	both	the	desirable	and	non-desirable	cellular	effects.	A	series	of	in	vitro	
experiments	were	designed	in	order	to	evaluate	some	of	the	more	pertinent	effects	in	
relation	to	transplantation.	However,	before	the	effects	of	HDACis	could	be	evaluated	in	any	
detail,	it	was	important	to	first	confirm	the	presence	of	histone	deacteylase	proteins	in	
human	cellular	tissues	of	interest	(principally	PBMCs	and	Jurkat	cells)	and	specifically	within	
relevant	T	cell	subsets.	SAGE	data	obtained	from	the	Human	Transcriptome	Map	(Caron	et	
al.	2001)	provides	a	broad	overview	of	HDAC	tissue	distribution.	This	demonstrates	the	
widespread	expression	of	HDACs	1,	2,	3,	5,	6,	7	and	10	throughout	the	majority	of	tissues	
studied.	HDACs	8	and	9	appear	to	be	expressed	more	in	tumor	cells	than	healthy	cells	and	
this	difference	is	observed	to	a	greater	extent	in	the	case	of	HDAC4	(de	Ruijter	et	al.	2003).	
In	this	study,	the	presence	of	HDACs	in	experimental	tissue	was	achieved	through	
established	Western	blot	techniques.		
Once	the	presence	of	HDACs	in	target	cells	had	been	established,	more	specific	effects	of	
HDACi	compounds	could	be	assessed.	The	first	of	these	was	to	assess	toxicity.	The	majority	
of	data	currently	available	relating	to	toxicity	is	from	oncology	trials	where	HDACis	are	
generally	used	in	higher	concentrations	than	would	be	anticipated	for	an	
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immunomodulatory	role.	In	addition	to	this	data,	further	evidence	supporting	HDACis	as	
well	tolerated	compounds	would	be	suggested	from	their	established	use	in	the	treatment	
of	conditions	such	as	epilepsy	(sodium	valproate)	with	very	few	recognised	side	effects.	In	
this	study,	a	toxicity	assay	assessing	cellular	apoptosis	and	necrosis	using	Propidium	iodide	
(PI)	and	Annexin	V	staining	was	employed	to	compare	the	effects	of	both	established	and	
novel	HDACis.		
As	described	previously,	HDACs	can	affect	many	substrates	with	a	resultant	alteration	in	a	
number	of	cell	processes	including	proliferation	(Xu,	Parmigiani,	&	Marks	2007).	It	is	this	
very	function	which	provides	HDACis	with	a	role	in	oncological	management.	In	order	to	
compare	the	effects	of	both	established	and	novel	HDACis	on	proliferation	a	number	of	
assays	were	undertaken.	These	involved	a	mitogen	stimulated	assay	in	which	either	Jurkat	
cells	or	PBMCs	were	cultured	in	the	presence	of	HDACi.	Two	techniques	were	utilised	in	
quantifying	proliferation	–	1)	Resazurin	reduction	(for	Jurkat	cells)	and	2)	CFSE-dilution	(for	
PBMCs).		
The	hypothesis	for	this	study	considers	the	potential	modulatory	effects	of	HDAC	inhibition	
on	the	upregulation	of	regulatory	T	cells.	It	has	been	suggested	that	pan-HDAC	inhibition	
(Wang	et	al.	2009),	selective	HDAC	inhibition	(Reilly	et	al.	2008)	and	specific	HDAC	inhibition	
(de	Zoeten	et	al.	2010	;de	Zoeten	et	al.	2011)	can	affect	the	function	of	this	unique	T	cell	
subset.	In	order	to	test	this	hypothesis,	the	effects	of	a	number	of	HDACi	compounds	were	
assessed	in	a	regulatory	T	cell	suppression	assay,	similar	to	that	developed	by	Sakaguchi	
(Takahashi	et	al.	1998)	in	the	late	1990s.	This	comprised	of	assessing	the	effect	of	HDACi	
treatment	on	isolated	regulatory	T	cells	in	autologous	assays	and	comparing	responder	CD4+	
T	cell	proliferation.		
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To	further	delineate	the	potential	effects	of	HDACi	compounds	on	lymphocyte	physiology,	a	
T	and	B	cell	subset	marker	assay	was	employed	in	which	PBMCs	were	cultured	and	stained	
for	specific	markers	of	interest.		
Limited	data	exists	with	regards	to	the	effects	of	HDACi	on	non-regulatory	T	cells.	Finally,	to	
consider	the	non-Treg	modulated	effect	of	HDACi	on	T	cell	responses,	a	T	cell	activation	
marker	assay	was	developed.	This	consisted	of	culturing	PBMCs	in	the	presence	of	HDACi	
compound	and	staining	the	resulting	cells	with	identifiable	markers	to	establish	which	
subsets	are	affected.		
	
3.2 HDAC	Expression	in	PBMCs	
Current	evidence	suggests	the	inhibitory	function	of	HDAC	inhibition	is	mediated	through	
regulatory	T	cells	(Tao	et	al.	2007).	In	order	to	demonstrate	the	presence	of	the	principal	
HDAC	targets	in	human	PBMCs,	Western	blot	analysis	was	undertaken	(see	Materials	and	
Methods	for	design).	This	demonstrated	that	CD4+CD25+	regulatory	T	cells	(in	addition	to	
CD4-	and	CD4+CD25-	cells)	do	indeed	carry	a	number	of	HDAC	proteins,	supporting	the	
hypothesis	that	HDACi	action	may	be	mediated	through	Treg	upregulation.		
	
3.2.1 HDAC	2	
HDAC2	is	a	member	of	the	Class	I	family	of	HDACs.	It	is	principally	localised	to	the	nucleus	
and	has	a	fairly	ubiquitous	expression	throughout	human	cells.		
Western	Blot	analysis	demonstrates	expression	throughout	CD4-	and	CD4+	T	cell	subsets	
(Figure	3-1).	β-actin	was	used	to	confirm	uniform	protein	loading.	
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Figure	3-1	Expression	of	HDAC2	in	Jurkat	lysate	and	human	PBMCs.	(The	lower	panel	
demonstrates	β-actin	control	samples,	which	were	similar	for	all	subsequent	
experiments.)	
3.2.2 HDAC	3	
Another	member	of	the	Class	I	family	of	HDACs,	HDAC3	is	similar	to	HDAC2	with	respect	to	
its	widespread	distribution	in	terms	of	cell	type.	However,	though	primarily	localised	to	the	
nucleus	of	cells,	it	can	be	distributed	throughout	the	cytoplasm.		
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Western	blot	analysis	demonstrates	a	presence,	though	reduced	expression	of	HDAC3	in	
human	regulatory	T	cells	compared	to	cytotoxic	CD4+	T	cells	and	CD4-	T	cells	(Figure	3-2).	
  
	
Figure	3-2	Expression	of	HDAC3	in	Jurkat	lysate	and	human	PBMCs	
	
3.2.3 HDAC4	
HDAC4	belongs	to	the	Class	IIa	group	of	HDACs.	This	group	tends	to	be	localised	to	muscle,	
heart	and	brain	tissue.	In	terms	of	intracellular	distribution,	they	are	more	diffuse	than	Class	
I	HDACs	and	have	the	ability	to	shuttle	between	the	nucleus	and	the	cytoplasm	(dependent	
upon	the	phosphorylation	of	specific	serine	residues	(Parra	&	Verdin	2010)).		
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Western	blot	data	suggests	HDAC4	is	expressed	in	all	T	cell	subsets	assessed	(Figure	3-3).	
  
		
Figure	3-3	Expression	of	HDAC4	in	Jurkat	lysate	and	human	PBMCs	
	
3.2.4 HDAC6	
HDAC6	is	a	member	of	the	Class	IIb	family	and	is	widely	expressed,	though	is	located	
primarily	in	heart,	liver	and	kidney	tissue.	HDAC6	is	unique	amongst	HDACs	in	that	it	is	
predominantly	located	in	the	cytoplasm,	principally	due	to	the	presence	of	specific	domains	
within	the	protein	(NES	&	SE14)	(na-Masangkay	&	Sakamoto	2011).		Its	reported	role	in	
modulating	the	suppressive	activity	of	regulatory	T	cells	(de	Zoeten	et	al.	2011)	and	its	
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potential	pharmacological	manipulation	identifies	it	as	a	possible	target	for	
immunomodulation	therapy	(in	not	only	transplantation,	but	other	clinical	fields	such	as	
inflammation).		
Western	blot	analysis	confirms	its	presence	within	the	T	cell	subsets	assessed	including	
regulatory	T	cells	(	
Figure	3-4).		
	
Figure	3-4	Expression	of	HDAC6	in	Jurkat	lysate	and	human	PBMCs	
3.2.5 HDAC9	
As	with	HDAC4,	HDAC9	belongs	to	class	IIa.	Characteristic	of	this	particular	group	is	its	
tissue-specific	expression,	and	as	such	HDAC9	tends	to	be	localised	to	cardiac	and	skeletal	
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muscle,	placenta	and	pancreas	tissue.	Again	its	intracellular	distribution	is	more	diffuse	
(shuttling	between	nucleus	and	cytoplasm)	than	the	typically	localised	Class	I	HDACs.	Along	
with	HDAC6,	HDAC9	expression	has	also	been	implicated	in	regulatory	T	cell	viability	and	
function	(Akimova	et	al.	2012).		
Western	blot	analysis	confirms	the	presence	of	HDAC9	in	the	cell	populations	studied	
(Figure	3-5).		
	
Figure	3-5	Expression	of	HDAC9	in	Jurkat	lysate	and	human	PBMCs	
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3.3 HDACi	Toxicity	
To	further	assess	the	role	of	HDACi	as	a	potential	immunosuppressant,	the	toxic	effects	on	
cell	viability	were	assessed.	This	was	achieved	using	a	well-established	technique	of	staining	
treated	PBMCs	with	Propidium	iodide	(PI)	and	Annexin	V	and	assessing	cell	survival	using	
flow	cytometry.		
The	application	of	PI	(a	membrane	impermeant	dye)	relies	on	dye	exclusion.	The	excitation	
fluorescence	of	PI	is	enhanced	significantly	through	the	binding	of	nucleic	acids	(such	as	
nuclear	DNA).	Therefore,	for	PI	to	become	detectable,	the	cell	membrane	must	be	breached	
(Figure	3-6A).	This	feature	makes	it	an	eminently	useful	compound	in	identifying	late	
apoptotic	/	necrotic	cells.		
In	combination	with	Annexin	V,	flow	cytometry	analysis	is	able	to	differentiate	the	stage	of	
cell	degradation	by	identifying	cells	at	an	early	apoptotic	stage.		Annexin	V	relies	upon	the	
externalisation	of	phosphotidylserine	(PS)	from	the	inner	leaflet	of	the	cell	membrane	
during	apoptosis.	Fluorescently	labelled	Annexin	V,	binds	strongly	to	PS	and,	therefore,	
allows	the	identification	of	early	apoptotic	cells.		
After	staining,	flow	cytometry	analysis	identifies	the	viability	of	treated	cells	(Figure	3-6B).	
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Figure	3-6	The	role	of	PI	and	Annexin	V	in	identifying	non-viable	cells	
In	this	assay,	freshly	isolated	PBMCs	from	individual	healthy	donors	were	either	untreated	
(control)	for	3	days,	untreated	and	stimulated	with	PHA	or	treated	for	a	total	of	3	days	with	
compound	of	interest	(Cyclosporin	A,	SAHA,	KA1010	or	KA1050	at	two	doses).	KA1050	is	a	
novel,	less	specific	HDAC6i	and	part	of	the	panel	of	compounds,	along	with	KA1010	supplied	
by	Karus	therapeutics.		
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Cells	at	day	0	demonstrated	an	as	expected	largely	healthy	pattern	with	97-98%	of	cells	
staining	viable	(Figure	3-7).		
	
Figure	3-7	Viability	staining	of	untreated	PBMCs	
Untreated	/	unstimulated	PBMCs	demonstrated	a	stable	pattern	of	degradation	over	the	
initial	forty	eight	hours	with	approximately	82%	of	cells	remaining	viable	(Figure	3-8A).	By	
day	three,	this	figure	had	declined	to	52%	of	cells	remaining	viable,	with	a	significant	
number	of	cells	progressing	to	an	early	apoptotic	or	apoptotic	state.	In	comparison,	
untreated	/	stimulated	PBMCs	underwent	a	similar	pattern	over	the	initial	two	days;	
however	by	day	three,	the	viable	population	had	fallen	to	just	22%,	with	a	far	greater	
proportion	of	cells	in	the	early	apoptotic	(50%)	and	apoptotic	(23%)	stage	(Figure	3-8B)		
Cyclosporin-treated	unstimulated	cells	underwent	minimal	significant	degradation	in	terms	
of	viable	population,	which	maintained	a	total	proportion	of	approximately	70-80%,	
regardless	of	the	dose	used	(Figure	3-8C).	However	at	the	higher	dose	of	5µM,	the	non-
viable	group	of	cells	underwent	greater	progression	from	early	apoptosis	to	apoptosis	and	
necrosis	when	compared	to	those	PBMCs	treated	at	the	lower	dose	of	500nM	(Figure	3-8D).		
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Figure	3-8	Effect	of	CyA	or	HDACi	treatment	on	the	cell	viability	of	PBMCs	over	72	hours	
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The	addition	of	the	pan-HDAC	inhibitor,	SAHA,	resulted	in	a	slight	trend	toward	viable	cell	
survival,	particularly	up	to	day	2.	At	both	the	lower	dose	of	20nM	and	higher	dose	of	2µM,	
this	was	particularly	evident	at	day	1	with	~90%	viable	PBMCs	compared	to	80%	in	control	
conditions	(Figure	3-8,	E-F).	By	day	3,	at	the	higher	dose,	however,	there	was	significant	
reduction	in	the	viable	cell	population	with	a	concomitant	increase	in	both	early	apoptotic	
and	apoptotic	populations.	This	remained	less	profound	than	control.	
HDAC6-specific	inhibition	(KA1010	&	KA1050)	at	the	lower	dose	of	100nM	had	a	similar	
effect	on	cell	viability	profile	to	SAHA	(20nM).	Again	this	was	generally	more	favourable	
toward	cell	viability	compared	with	control.	This	effect	was	most	profound	using	KA1050	at	
the	lower	dose	(Figure	3-8H).	By	day	3,	at	the	higher	doses	selected	KA1010	had	the	most	
favourable	viability	profile	of	the	compounds	tested.	KA1050,	at	this	higher	dose,	however,	
proved	to	have	a	significantly	toxic	effect	with	just	23%	of	cells	remaining	viable	(Figure	
3-8I).		
3.4 Effect	of	HDAC	Inhibition	on	Jurkat	Cell	Proliferation	
A	Resazurin-based	assay	was	used	to	assess	the	dose-dependent	effect	of	a	panel	of	HDACis	
on	a	human	T-cell	lymphocyte	(Jurkat)	cell	line.	This	assay	depends	upon	the	reduced	
environment	of	growing	cells	which	converts	the	oxidised	non-fluorescent	blue	form	
(resazurin)	to	the	reduced	fluorescent	red	form	(resofurin)	(Figure	3-9).		
	
Figure	3-9	Reduction	of	Resazurin,	resulting	in	the	fluorescent	form,	resofurin	
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Fluorescence	is	then	measured	using	a	spectrophotometer.	The	signal	generated	is	
proportional	to	the	number	of	living	cells	in	the	sample	(to	a	sensitivity	of	~80cells/well).		
Firstly,	a	standard	curve	must	be	generated	in	order	to	calibrate	the	assay.	This	was	
produced	by	accurate	serial	dilution	of	a	known	number	of	cells	(from	200,000	cells	to	0	
cells	/	well,	Figure	3-10)	in	a	96-well	plate.	Resazurin	(10%	by	volume)	was	then	added	to	
each	well	(in	triplicate)	and	the	assay	incubated	for	twenty	four	hours.	Absorption	was	
measured	using	a	spectrophotometer	and	a	standard	curve	generated	(Figure	3-11).	
200,000	cells/well		
100,000	cells/well		
50,000	cells/well		
25,000	cells/well		
12,500	cells/well		
6,250	cells/well		
3,125	cells/well		
0	cells/well	(media	only)		
	
Figure	3-10	Serial	dilution	of	cell	number,	in	order	to	produce	standard	curve	
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Figure	3-11	Typical	Resazurin	standard	curve	for	calculating	Jurkat	cell	number	
From	the	best	fit	line	for	this	data	(with	an	R2	value	of	>0.95)	the	quadratic	equation	of	the	
curve	was	calculated	and	applied	to	the	measured	data	from	treated	samples.	Cell	numbers	
were	then	extrapolated	from	this	quadratic	equation	and	plotted.		
Controls		
By	way	of	control,	Jurkat	cells	were	treated	with:	
- Negative	Control		
- Sodium	Azide	(NaN3)	–	0.01%	-	1%	
- Positive	Control	
- Phorbol	myristate	acetate	(PMA)	–	1ng/ml	-	50ng/ml	
- Lipoteichoic	acid	(LTA)	–	0.5µg/ml	-	10µg/ml	
Sodium	azide	is	a	highly	dissolvable	cytotoxin	which	acts	by	inhibiting	the	mitochondrial	
respiratory	chain	and	induces	cell	death	by	apoptosis	(Weyermann,	Lochmann,	&	Zimmer	
2005).		
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PMA	and	LTA	are	potent	mitogens.	PMA	acts	as	a	proliferation	stimulant	by	activating	the	
signal	transduction	enzyme	PKC	(protein	kinase	C).	LTA	effects	binding	to	TLR-2	receptor	and	
induces	NF-κβ	and	mitogen-associated	PK	(MAPK).	
50,000	Jurkat	cells	/	well	were	cultured	for	24	hours	in	the	presence	of	the	control	
compounds	at	the	concentrations	below:	
	 NaN3	 PMA	 LTA	
	 0.01%	 1ng/ml	 0.5µg/ml	
0.1%	 5ng/ml	 1.0µg/ml	
0.5%	 10ng/ml	 5.0µg/ml	
1.0%	 50ng/ml	 10.0µg/ml	
	
Table	3-1	Sodium	azide	and	mitogen	concentrations	used	to	assess	Jurkat	cell	proliferation	
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Figure	3-12	Negative	(NaN3)	and	positive	(PMA,	LTA)	controls	
Sodium	azide	had	a	demonstratable	dose-dependent	negative	effect	on	Jurkat	cell	number,	
with	a	concentration	of	1%	almost	completely	eliminating	any	cell	viability	(Figure	3-12A).	
However,	the	positive	controls	had	no	discernible	effect	on	cell	number	regardless	of	
concentration	(Figure	3-12,	B-C).	This	was	likely	due	to	the	weak	stimulatory	effect	PMA	has	
on	T	cells	in	the	absence	of	Ionomycin.	In	the	case	of	LTA,	though	traditionally	considered	an	
activator	of	lymphocytes,	recent	evidence	suggests	it	has	a	suppressive	effect	in	terms	of	
effector	T	cell	proliferation	and	function	(Son	et	al.	2013).		
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3.4.1 Established	HDACis	
Before	assessing	a	panel	of	novel	HDACi	compounds,	HDACis	in	clinical	use	or	undergoing	
clinical	trials	for	indications	other	than	transplantation	were	evaluated	(Table	3-2).	Again,	
cells	were	treated	and	cultured	for	24	hours	before	cell	numbers	calculated.	In	this	assay,	
100,000	cells	were	cultured	/	well	in	sextuplet.		
HDACi	 Structure	 Target	 Notes	 Concentration	
Sodium	Valproate	
(VSA)	
Short	chain	fatty	
acid	
	
Class	I	&	IIa	
(HDAC	1-9,	
except	6)	
Undergoing	phase	
II	trials	(AML)	
1.25mM	–	
10mM	
Trichostatin		
(TSA)	
Hydroxamic	acid	
	
Class	I,	IIa,	IIb	
&	IV	(HDAC	1-
11)	
Poor	
pharmacokinetics	
(primarily	
academic	interest)	
5nM	–	500nM	
Suberoylanilide	
hydroxamic	acid	
(SAHA)	
Hydroxamic	acid	
	
Class	I,	IIa,	IIb	
&	IV	(HDAC	1-
11)	
First	to	be	
approved	as	
treatment	in	
certain	malignant	
conditions	(CTCL)	
0.625µM	–	
5µM	
	
Table	3-2	Established	HDACis	currently	in	clinical	use	or	undergoing	clinical	trial	
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Figure	3-13	Effect	of	HDACi	compounds	on	Jurkat	cell	proliferation	
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These	established	compounds	had	a	moderate,	dose-dependent	effect	on	Jurkat	cell	
number	at	the	lower	concentrations	used.	In	the	case	of	all	three	compounds,	this	trend	was	
not	extended	to	the	highest	dose	used	(Figure	3-13,	A-C).	Interpretation	of	this	data	would	
suggest	that	these	compounds	had	no	significant	effect	on	Jurkat	cell	number	when	treating	
for	24	hours.	The	protocol	was	therefore	modified	to	extend	the	culture	period	and	alter	the	
density	of	cells.	
3.4.2 Experimental	HDACis	
In	order	to	identify	potential	experimental	compounds	of	interest,	a	panel	of	10	HDACis	
were	assessed.	At	this	stage,	their	structure,	specificty	etc.	were	blinded	and	the	
compounds	were	merely	identified	by	a	unique	code.	The	only	information	supplied	with	
these	compounds	was	their	molecular	weight	and	effective	dose	range,	in	order	to	enable	
experimental	design.	The	compounds	used	are	listed	in	Table	3-3.		
Code		 MW	(g.mol-1)		 Range		 Concentration	used	(nM)		
KA001.1		 486.61		 1nM	–	1µM		 1,	10,	100,	1000	
KA005.1		 264.32		 10nM	–	10µM		 10,	100,	1000,	10000	
KA008.6		 540.70		 1nM	–	1µM	 1,	10,	100,	1000	
KA088.2		 515.69		 1nM	–	1µM	 1,	10,	100,	1000	
KA1010		 314.38		 10nM	-10µM		 10,	100,	1000,	10000	
KA146.2		 544.68		 1nM	–	1µM	 1,	10,	100,	1000	
KA147.3		 612.68		 1nM	–	1µM	 1,	10,	100,	1000	
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KA172.1		 547.65		 1nM	–	1µM	 1,	10,	100,	1000	
KA185.1		 546.66		 1nM	–	1µM	 1,	10,	100,	1000	
KA1005.3		 297.38		 10nM	-10µM		 10,	100,	1000,	10000	
	
Table	3-3	Panel	of	experimental	HDACis	
Jurkat	cells	were	cultured	at	a	density	of	5000	cells	/	well	in	a	96-well	plate.	Media	was	
supplemented	with	compound	of	interest	at	day	0.	Cell	numbers	were	calculated	at	24,	72	
and	120	hours	using	the	above	described	Resazurin	method.		
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Figure	3-14	A-D	Effect	of	controls	(PMA	and	NaN3)	and	experimental	compounds	on	Jurkat	cell	proliferation	over	time
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Figure	3-14	E-H	Effect	of	experimental	compounds	on	Jurkat	cell	proliferation	
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Figure	3-14	I-L	Effect	of	experimental	compounds	on	Jurkat	cell	proliferation
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Positive	and	negative	controls	had	an	expected	effect	on	Jurkat	cell	number.	The	addition	of	
PMA	resulted	in	a	time-dependent	trend	towards	cell	proliferation	and	would	suggest	that	
the	previously	described	controls	were	not	cultured	for	a	sufficient	time	period	to	
demonstrate	an	effect.	This	trend	was	also	dose	dependent	toward	the	later	end	of	the	
assay	(120	hours)	with	PMA	at	a	concentration	of	100nM	resulting	in	a	52%	increase	in	cell	
number	compared	to	a	concentration	of	1nM	(Figure	3-14A).		
NaN3	had	a	typically	negative	effect	on	cell	number,	with	few	surviving	at	seventy	two	hours	
and	beyond,	regardless	of	dose	(Figure	3-14	B).	At	twenty	four	hours	of	culture,	increasing	
concentration	of	NaN3	resulted	in	a	significant	deterioration	in	cell	survival.	At	a	
concentration	of	1%,	just	22%	of	cells	survived	compared	to	survival	at	0.01%	concentration.	
With	regards	to	the	panel	of	experimental	compounds	(Figure	3-14,	C-L)	there	were	few	
general	conclusions	that	could	be	made	and	there	was	little	consistency	in	overall	trends.	
However,	at	twenty	four	hours,	most	compounds	had	a	minimal	effect	on	cell	numbers	
regardless	of	dose.	This	trend	was	also	generally	true	at	seventy	two	hours.	By	one	hundred	
and	twenty	hours	there	is	a	general	trend	toward	cell	survival	with	increasing	dose.		
Increasing	dose	of	KA001.1	had	an	initial	negative	effect	on	cell	number	(Figure	3-14	C),	and	
numbers	did	not	recover	over	time	though	by	one	hundred	and	twenty	hours	the	survival	of	
cells	treated	with	1000nM	was	317%	that	of	those	treated	with	10nM.		
Cells	treated	with	KA005.1	underwent	a	similar	trend	(Figure	3-14	D)	to	that	of	KA001.1,	
though	there	was	an	absence	of	late	effect	(one	hundred	and	twenty	hours)	with	a	degree	
of	recovery	of	cell	numbers	irrespective	of	dose.		
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The	effect	in	terms	of	numbers	on	cells	treated	with	compounds	KA008.6,	KA088.2,	KA1010	
and	KA146.2	(Figure	3-14,	E-H)	was	roughly	similar.	All	four	compounds	had	a	negligible	
effect	on	cell	numbers	over	the	initial	twenty-four-hour	treatment	period,	regardless	of	
dose.	At	seventy	two	hours	there	was	a	general	trend	toward	increased	cell	survival	with	
increased	dose	but	this	was	not	significant.	However,	at	one	hundred	and	twenty	hours	this	
effect	was	more	profound.		
Treatment	with	KA147.3	and	KA185.1	(Figure	3-14,	I	&	K)	had	no	significant	effect	on	cell	
numbers	during	the	first	seventy	two	hours	of	culture.	At	one	hundred	and	twenty	hours	
there	was	a	dose-dependent	protective	effect	in	terms	of	cell	numbers	but	no	significantly	
proliferative	effect.		
As	with	KA147.3,	KA172.1	(Figure	3-14	J)	had	no	demonstrable	effect	on	cell	numbers	at	
twenty	four	hours.	Beyond	this	period,	effect	was	less	predictable	than	with	other	
compounds	though	in	general	there	was	favourable	cell	survival	across	all	concentrations	
compared	to	the	majority	of	other	compounds	examined	(similar	to	KA005.1	and	KA1005.3).			
Finally,	KA1005.3	(Figure	3-14	L)	had	an	initially	negative	dose	dependent	effect	on	cell	
number	survival	(at	twenty	four	hours).	By	seventy-two	hours	the	effects	of	the	higher	
doses	studied	had	become	less	profound	and	by	the	later	stages	(one	hundred	and	twenty	
hours)	had	reversed	with	improved	cell	survival	at	the	lower	dose	range	compared	with	the	
majority	of	compounds	assessed.		
In	conclusion,	none	of	the	novel	compounds	assessed	had	a	significantly	toxic	effect	on	
Jurkat	cell	survival	in	terms	of	numbers	of	viable	cells	over	the	treatment	period.		Four	of	
the	compounds	(KA005.1,	KA1010,	KA172.1	and	KA1005.3)	were	notable	for	improved	cell	
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survival	/	proliferation	at	one	hundred	and	twenty	hours.	The	variable	effect	of	the	
compounds	in	terms	of	cell	survival	/	proliferation	over	time	and	dose	suggests	that	there	is	
significant	heterogeneity	between	these	HDACis	and	that	there	is	still	likely	a	large	number	
of	targets	on	which	they	act,	despite	their	nominal	specificty.		
	
3.5 Effect	of	HDAC	Inhibition	on	PBMC	proliferation	
Following	the	Jurkat	cell	proliferation	assay,	a	number	of	HDACi	compounds	were	selected	
in	order	to	assess	their	effect	on	human	PBMCs.	As	a	well	characterised	HDACi,	the	effect	of	
SAHA	was	compared	to	compounds	KA1010,	KA185.1	and	KA146.2.	These	experimental	
compounds	were	selected	based	on	their	heterogenous	effect	on	Jurkat	cell	proliferation.	
In	order	to	assess	proliferation,	100,000	freshly	isolated	PBMCs	per	well	were	stained	with	
1µM	of	CFSE	and	cultured	for	five	days	at	37°C.	The	culture	was	performed	in	the	absence	
or	presence	of	IL-2	(50U/ml)	to	assess	its	effect.	After	five	days,	cells	were	also	stained	with	
7-AAD	in	order	to	assess	viability	(7-aminoactinomycin	D	is	a	useful	fluorescent	intercalator	
that	can	be	used	to	assess	viability).	When	bound	to	DNA,	7-AAD	undergoes	a	spectral	shift	
so	that	it	can	be	detected	with	flow	cytometry.	In	healthy	cells	7-AAD	is	excluded.		
The	experimental	compounds	were	used	at	similar	concentrations	to	those	assessed	in	the	
Jurkat	cell	proliferation	assay	(Table	3-4);	
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Code	 Concentration	used	(nM)	
SAHA	 1,	10,	100,	1000	
KA1010		 0.1,	1,	10,	100	
KA185.1		 0.1,	1,	10,	100	
KA146.2	 1,	10,	100,	1000	
	
Table	3-4	Concentrations	of	HDACis	
3.5.1 Controls	
Firstly	the	effect	of	IL-2	was	assessed	in	the	presence	or	absence	of	stimulant	(Dynabeads).	
	
	
	
91.09	 88.53	
A		 	 Unstimulated,	No	IL-2	 B		 	 Stimulated,	No	IL-2	
7-AAD	à	
99	
	
	 	
Figure	3-15	PBMC	proliferation	under	control	conditions	
The	effect	of	IL-2	on	PBMC	proliferation	was	minimal	(Figure	3-15).	However,	as	expected	
stimulation	had	a	significant	impact	on	proliferation.	Cell	viability	was	consistently	around	
90%	regardless	of	conditions	as	demonstrated	with	7-AAD	staining.		
3.5.2 Compounds	of	interest	
Following	condition	optimisation,	the	effect	of	selective	and	non-selective	HDACi	on	
stimulated	human	leucocyte	proliferation	was	assessed.	A	CFSE	dilution	assay	was	adopted	
using	anti-CD3/CD28	stimulation	beads	on	bulk	PBMC	populations	(Skov	et	al.	2003).	Cells	
were	cultured	for	five	days	in	the	presence	of	HDACi	of	interest	and	in	the	presence	or	
absence	of	IL-2.		
As	expected,	anti-CD3/CD28	stimulation	induced	potent	proliferation	at	five	days,	with	an	
average	of	only	14.8%	of	the	parental	population	not	proliferating	(Figure	3-16	C).	Both	
HDAC6-selective	(KA1010)	and	non-selective	HDAC	inhibition	(SAHA)	showed	activity	
insuppressing	anti-CD3/CD28-induced	proliferation	(Figure	3-16	&	Figure	3-17).	
SAHA	
90.25	 92.32	
C	 	 	Unstimulated,	IL-2	[50U/ml]	 D	 	 	Stimulated,	IL-2	[50U/ml]	
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At	doses	of	1nM	to	100nM,	SAHA	showed	a	similar,	modest	inhibitory	effect	on	
proliferation,	preventing	the	division	of	an	additional	5-7%	of	the	parent	population	over	
control	(Figure	3-16).	However	at	a	concentration	of	1000nM,	there	was	a	significant	
increase	in	suppression	of	division	(Figure	3-20	&	Figure	3-21).	This	was	particularly	evident	
in	the	absence	of	IL-2	(Figure	3-16	E)	where	parent	population	remaining	after	five	days	
increased	from	14.8%	to	55.8%.	In	the	presence	of	IL-2,	a	dose	of	1000nM	was	still	sufficient	
to	result	in	reduced	proliferation	but	to	a	lesser	degree	(16.7%	for	control	vs.	38.9%)	(Figure	
3-16	F).		
KA1010	
In	contrast,	KA1010	displayed	a	more	pronounced	dose-dependent	effect	on	proliferation	
(Figure	3-17).	The	presence	of	IL-2	had	a	negligible	effect.	At	a	concentration	of	1µM,	
KA1010	was	effective	at	reducing	division	of	the	parent	population	to	65.9%	(21%	reduction	
compared	to	control,	compared	to	an	equivalent	dose	reduction	with	SAHA	to	78%)	with	cell	
viability	found	to	be	similar	to	control	(Figure	3-20).	In	the	presence	of	IL-2,	this	dose	was	
slightly	less	effective,	reducing	division	from	83.3%	in	the	untreated	control	to	67.3%	(Figure	
3-21).		
At	equivalent	concentrations,	KA1010	produced	an	inhibitory	effect	on	cell	division,	superior	
to	SAHA	(two-way	ANOVA	p=0.002,	F=13.97).	At	the	lower	dose	of	1nM	this	inhibitory	effect	
represented	a	4.7%	and	6.8%	reduction	over	control	for	SAHA	and	KA1010,	respectively.	At	
the	higher	dose	of	1000	nM,	these	figures	increase	to	9.0%	and	22.6%.		
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Figure	3-16	FACS	data	demonstrating	the	effect	of	SAHA	on	PBMC	proliferation	
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Figure	3-17	FACS	data	demonstrating	the	effect	of	KA1010	on	PBMC	proliferation	
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Figure	3-18	FACS	data	demonstrating	the	effect	of	KA185.1	on	PBMC	proliferation	
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Figure	3-19	FACS	data	demonstrating	the	effect	of	KA146.2	on	PBMC	proliferation
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KA185.1	
In	the	absence	of	IL-2,	KA185.1	had	a	negligible	effect	on	suppression	(Figure	3-20);	
however	in	the	presence	of	IL-2,	its	effect	was	considerably	more	profound	(Figure	
3-21).	At	a	dose	of	100nM,	under	these	conditions,	KA185.1	suppressed	an	
additional	27.6%	of	the	parent	population	greater	than	control.	Indeed,	in	the	
presence	of	IL-2,	KA185.1	was	the	most	effective	HDACi	compound	tested.		
KA146.2	
KA146.2	was	the	least	effective	PBMC	proliferation	suppressor	tested.	In	the	non-IL-
2	conditions,	it	had	a	broadly	similar,	minimal	effect	(Figure	3-20).	In	the	presence	of	
IL2,	the	suppressive	effect	of	KA146.2	was	essentially	the	same	as	control	(Figure	
3-21).	At	the	higher	dose	of	100nM,	it	had	a	slightly	proliferative	effect	with	just	
10.7%	of	the	parent	population	remaining	undivided	after	5	days.	However,	this	
difference	was	not	statistically	significant.		
This	assay	provides	information	regarding	a	possible	mechanism	of	action	of	the	
compounds	tested.	It	would	suggest	that	the	suppressive	effects	of	SAHA	and	
KA1010	are	independent	of	IL-2.	The	suppressive	effect	of	KA185.1	is	significantly	
dependent	upon	the	presence	of	IL-2	and	KA146.2	has	no	notable	inhibitory	action	
on	PBMC	proliferation.		
106	
	
0.1 1 10 100 1,000
0
20
40
60
80
SAHA
KA146.2
KA185.1
KA1010
HDACi	(nM)
Su
pp
re
ss
io
n	
–	
Pa
re
nt
	p
op
ul
at
io
n	
(%
)
	
Figure	3-20	Effect	of	HDACi	on	PBMCs	(no	IL-2)	
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Figure	3-21	Effect	of	HDACi	on	PBMCs	(with	IL2)	
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3.6 Regulatory	T	cell	Suppression	Assay	
The	aim	of	this	assay	was	to	reproduce	conditions	similar	to	those	used	by	Sakaguchi	
et	al.	(Miyara	et	al.	2009)	to	demonstrate	the		suppressive	function	of	FoxP3+	
regulatory	T	cells.	Once	this	had	been	achieved	the	assay	was	then	modified,	with	
the	addition	of	HDACis,	in	order	to	assess	their	effect	on	Treg	function.		
In	order	to	achieve	this,	it	was	first	necessary	to	isolate	the	CD4+	subset	of	T	cells	
and,	from	this	subset	isolate	the	CD4+CD25+	regulatory	T	cells.	This	was	done	using	a	
magnetic-activated	cell	separation	(MACS)	method.		
	
MACS	separation	involves	several	stages.	First	CD4-	cells	are	negatively	selected	from	
PBMCs	using	magnetic	nanoparticles	coated	with	a	panel	of	antibodies	(Table	3-5,	
Figure	3-22	A).	The	remaining	CD4+CD25+	fraction	is	then	positively	selected	out	by	
labelling	the	cells	with	CD25+	nanoparticles	(Figure	3-22	C).	The	retained	cells	from	
the	magnetic	eluting	column	are	retrieved	and	tested	for	purity	using	flow	cytometry	
(Figure	3-22	D).				
	
	
PBMCS	
(~40	x	106)
CD4- CD4+CD25-
(15	x	106)
CD4+CD25+
(5	x	105)
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Antibody		 Cellular	Reactivity		
CD8		 T	cells,	NK	cells	(MHC	Class	I)		
CD14		 Monocytes,	Granulocytes,	DCs,	B	cells		
D16		 Granulocytes		
CD19		 B	cells		
CD36		 Monocytes,	Platelets,	Endothelial	cells		
CD56		 NK	cells		
CD123		 Myeloid	precursors		
TCRγ/δ		 Intraepithelial	lymphocytes		
CD235a		 Erythroid	cells		
	
Table	3-5	Antibody	cocktail	for	negative	selection	
	
Regulatory	T	cells	account	for	2.5-4%	of	peripheral	blood.		The	typically	reported	
yield	of	regulatory	T	cells	from	human	PBMCs	using	this	type	of	isolation	method	is	
in	the	region	of	1-2%.	This	was	broadly	true	throughout	this	study.	A	purity	of	around	
90%	is	typical	of	the	published	data	(Tiemessen	et	al.	2007).	Typically,	85-90%	purity	
was	experienced	using	this	method.		
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CD4-	fraction	
	
CD4+CD25-	fraction	
	
CD4+CD25+	fraction	
	
CD4+CD25+FoxP3+	fraction	
	
Figure	3-22	Representative	data	of	flow	cytometry	analysis	of	isolated	T	cell	
subsets	using	MACS	separation	
The	next	step	was	to	culture	the	CD4+CD25-	T	cells	(responders)	with	CD4+CD25+	
(suppressor)	cells.	1	ml	of	cells	were	cultured	in	a	24-well	round	bottomed	plate	at	a	
concentration	of	100,000	cells/ml.	Lymphocyte	proliferation	was	measured	using	
carboxyfluorescein	diacetate	succinimidyl	ester	(CFSE)	dilution.	Fluorescent	CFSE	
covalently	binds	to	intracellular	molecules	and	following	cell	division,	distributes	to	
daughter	cells,	halving	in	fluorescence.	This	protocol	allows	the	detection	of	up	to	8	
A	
D	C	
B	
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cell	divisions	(Quah,	Warren,	&	Parish	2007).	Responder	cells	were	labelled	with	
CFSE	at	a	concentration	of	0.5µM.	
Suppressor	cells	were	added	to	the	culture	in	increasing	numbers	and	responder	
proliferation	was	assessed.	Cells	were	cultured	in	the	following	fashion:	
0:1				(0	:	100,000)		
1:16		(6250	:	100,000)	
1:8				(12,500	:	100,000)		
1:4				(25,000	:	100,000)		
1:2				(50,000	:	100,000)		
Table	3-6	Suppressor:	Responder	cell	numbers	
Cultures	were	stimulated	with	PMA	(100ng/ml)	and	Ionomycin	(1µg/ml)	and	
incubated	for	3	days	at	37°C.	Proliferation	was	then	assessed	using	flow	cytometry.		
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1	:	16
0	:	1
	
Figure	3-23	Flow	cytometry	data	demonstrating	regulatory	T	cell	suppression	of	
CD4+	T	cells	(PMA/Ionomycin	stimulation)	
As	Figure	3-23	demonstrates,	increasing	numbers	of	regulatory	T	cells	had	no	effect	
on	the	proliferation	of	responder	T	cells	and	indeed	the	CFSE-labelled	CD4+	
population	failed	to	suggest	any	division	had	occurred.	This	was	likely	due	to	
technical	failure	as	responder	cells	did	not	produce	a	positive	signal	on	flow	
cytometry,	even	in	the	responder	alone	population.		There	may	also	have	been	a	lack	
of	stimulatory	effect	of	PMA	and	Ionomycin,	which	is	an	established	stimulus	for	
cytokine	release	assays	(Han	et	al.	2012),	but	not	necessarily	suppression	assays.		
Therefore,	a	series	of	optimisation	assays	were	undertaken	in	order	to	determine	
the	ideal	conditions	for	subsequently	assessing	the	in	vitro	effect	of	HDACis.	
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3.6.1 CFSE	Optimisation	Assay	
	In	order	to	optimise	the	concentration	of	CFSE	to	be	used,	a	simple	titration	model	
was	devised	whereby	1	x	106	cells/ml	of	PBMCs	were	stained	with	one	of	three	
concentrations.	CFSE	‘brightness’	was	assessed	using	flow	cytometry.		
		
	
Figure	3-24	Optimisation	of	CFSE	staining	of	PBMCs.	Flow	cytometry	data	
demonstrating	effect	of	varying	concentrations	of	CFSE	
All	three	concentrations	of	CFSE	resulted	in	a	bright	signal	(Figure	3-24)	of	similar	
intensity.	A	concentration	of	CFSE	at	1µM	was	therefore	found	to	be	most	
satisfactory	and	this	was	consistent	with	published	data	(Quah,	Warren,	&	Parish	
2007).			
CFSE	[0µM]	 CFSE	[1µM]	 CFSE	[5µM]	 CFSE	[10µM]	
[10µM]	
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3.6.2 Stimulant	Optimisation	Assay	
Optimisation	studies	were	designed	in	order	to	compare	a	panel	of	commonly	used	
stimulants	at	standard	concentration.	The	stimulants	used	were:	
Invitrogen	T-Activator	CD3/CD28	Dynabeads®	
These	inert	beads	are	similar	in	size	to	antigen-presenting	cells	and	are	covalently	
bonded	to	anti-CD3	and	anti-CD28	antibodies.	They	activate	and	expand	the	T-cell	
population	by	providing	primary	and	co-stimulatory	signals	to	T	cells.	They	are	
commonly	used	at	a	bead-to-cell	ratio	of	1:1.	
PMA	and	Ionomycin	
Phorbol	12-myristate	13-acetate	(PMA)	is	a	mitogen	derived	from	the	Croton	plant.	
It	stimulates	T	cells	by	direct	activation	of	Protein	Kinase	C	(similar	to	diacylglycerol,	
activates	PKC).		Ionomycin	synergizes	with	PMA	in	enhancing	the	activation	of	PKC	
(Chatila	et	al.	1989)	and	increasing	release	of	IFN-γ,	TNF-α,	IL-2	and	IL-4.	Typical	
concentrations	of	PMA	and	Ionomycin	are	10ng/ml	and	1µg/ml	respectively.	
Con	A	
Concanavalin	A	(Con	A)	is	a	lectin	protein	originally	extracted	from	the	jack-
bean,	Canavalia	ensiformis	which	acts	as	a	lymphocyte	mitogen.	Con	A	has	a	strong	
affinity	for	cell-surface	glycoproteins	and	once	irreversibly	bound,	induces	
proliferation	through	a	mechanism	of	indirectly	cross-linking	the	T	cell	receptor.	
Typical	concentration	for	the	use	of	Con	A	as	a	stimulant	is	2µg/ml.	
Mitenyi-Biotec	MACS	T	Cell	Activation	Kit	
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The	MACS	T	Cell	Activation	kit	works	on	a	similar	principle	to	the	Invitrogen	
Dynabeads®.	The	kit	consists	of	Anti-Biotin	MACSiBead	Particles	and	biotinylated	
antibodies	against	human	CD2,	CD3,	and	CD28.	Anti-Biotin	MACSiBead	Particles	
loaded	with	the	biotinylated	antibodies	mimic	antigen-presenting	cells	and	activate	
resting	T	cells.	This	kit	is	typically	used	at	a	bead-to-cell	ratio	of	1:2.	
Anti-CD3	Antibody	
The	use	of	a	monoclonal	anti-CD3	antibody	is	the	most	direct	way	of	inducing	T	cell	
activation	and	stimulation.	T	cell	receptor	recognition	of	anti-CD3	mAb	mimics	
recognition	of	antigen	and	thus	triggers	signal	transduction	and	proliferation	
(Garbrecht,	Russo,	&	Weksler	1988).	In	this	assay,	a	concentration	of	0.5µg/ml	was	
used.		
PBMCs	were	stained	with	CFSE	at	a	concentration	of	1µM	and	cultured	at	37°C	for	4	
days.	Culture	media	consisted	of	RPMI	with	10%	FCS	plus	the	stimulant	under	
investigation	at	the	appropriate	dose.	Media	for	the	negative	control	did	not	contain	
any	additional	stimulant.	Proliferation	was	assessed	by	measuring	CFSE	degradation	
using	flow	cytometry	analysis.		
	
115	
	
	
	
	
Figure	3-25	Effect	of	stimulant	on	proliferation	of	PBMCs	with	or	without	addition	
of	IL-2	to	culture	media	
All	stimulants	used	produced	a	degree	of	proliferation	though	Dynabeads	and	ConA	
were	the	most	effective.	The	presence	of	IL-2	in	the	culture	media	did	not	have	any	
significant	impact	(consistent	with	the	findings	of	previous	assays).	
A	No	IL-2	
B	IL-2	[20U/ml]	
←CFSE	
←CFSE	
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Figure	3-26	Raw	FACS	data	demonstrating	effect	of	stimulant	on	proliferation	of	
CFSE-labelled	PBMCs	
31.51	
84.45	
46.52	
71.81	
59.83	
60.70	
29.59	
84.23	
64.05	
68.01	
54.52	
54.27	
←CFSE	
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The	most	significant	proliferation	occurred	in	those	assays	treated	with	either	
Dynabeads	or	Con	A	(Figure	3-25).	Of	the	Dynabead	stimulated	PBMC	population,	
84.23%	of	the	parent	population,	underwent	proliferation	(compared	to	29.59%	in	
the	unstimulated	population	(Figure	3-26)).	Cell	viability	was	also	comparable	to	the	
untreated	population	(73.24%	vs.	80.26%)	and	was	considerably	better	than	most	of	
the	other	stimulants	tested.		
Con	A	treatment	consistently	resulted	in	significant	proliferation	(68.01%),	but	
further	analysis	demonstrated	a	poor	level	of	cell	viability	(41.11%).	Cell	viabilities	of	
<50%	were	also	seen	for	the	other	mitogens	tested	(PMA/Ionomycin).	Unexpectedly,	
the	lowest	degree	of	viability	was	seen	in	those	PBMCs	treated	with	the	MACS	T	cell	
activation	kit.	The	reasons	for	this	are	unclear,	particularly	as	the	principles	of	
mechanism	are	similar	to	the	Dynabead	kit,	though	this	was	not	pursued	further.		
Anti-CD3	mAb	treatment	resulted	in	proliferation	of	54.27%	of	the	parent	
population.	The	addition	of	IL-2	to	the	culture	media	only	resulted	in	a	subtle	
improvement	in	stimulation	to	60.70%.	This	figure	was	expected	to	be	somewhat	
higher	due	to	the	synergistic	mechanism	by	which	CD3	activation	results	in	induction	
of	IL-2	receptors,	which	can	then	respond	to	exogenous	IL-2.		
3.6.3 Regulatory	T	Cell	Suppression	Assay	(revised)	
The	regulatory	T	cell	suppression	assay	was	therefore	repeated	using	CFSE	as	a	
marker	for	proliferation	and	Invitrogen	T-Activator	CD3/CD28	Dynabeads®	as	
stimulus.	A	bead-to-cell	ratio	of	1:1	was	used	and	the	assays	were	cultured	for	72	
hours.	CFSE	was	added	to	the	wells	at	a	concentration	of	1µM.	Beads	were	removed	
prior	to	flow	cytometry	analysis.		
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Figure	3-27	Effect	of	Dynabead	stimulation	on	regulatory	T	cell	suppression	assay	
CFSE	at	a	concentration	of	1µM	effectively	stained	responder	CD4+	T	cells	(Figure	
3-27	A).	Proliferation	of	this	responder	population	was	effectively	inhibited	in	a	ratio-
dependent	manner	by	the	addition	of	regulatory	T	cells	(Figure	3-27	B-F).	Stimulation	
B	
C	
D	
E	
A	
F	
G	
←CFSE	
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of	the	assay	using	anti-CD3	anti-CD28	Dynabeads	resulted	in	increased	proliferation	
of	responders	compared	to	unstimulated	assays	(Figure	3-27	G).	
3.6.4 Effect	of	HDACi	on	Regulatory	T	cell	Suppression	Assay	
Following	this	series	of	optimisation	studies,	the	above	assay	was	repeated	with	the	
addition	of	HDACi	compounds.	Suppressor	(CD4+CD25+)	cells	were	isolated	from	
fresh	PBMCs	using	the	MACS	separation	technique	as	above.		
These	cells	were	cultured	in	increasing	numbers	with	responder	cells	at	37°C	for	five	
days	(Table	3-7).		
	
Table	3-7	Suppressor	to	responder	ratio	in	Treg	suppression	assay	
Responder	cells	(CD4+CD25-)	from	the	same	donor	were	labelled	with	1µM	CFSE.	
Proliferation	was	measured	using	flow	cytometry.	HDACis	were	added	to	the	culture	
media	at	the	following	doses;	
• SAHA	(50nM)	
• KA146.2	(5nM)	
1:16		(6250	:	100,000)
1:8				(12,500	:	100,000)
1:4				(25,000	:	100,000)
1:2				(50,000	:	100,000)
1:1				(100,000	:	100,000)
0:1				(0 :	100,000)
1:0				(100,000	:	0)
Suppressor	 :	Responder
CD4+CD25+ :	CD4+CD25-
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• KA185.1	(25nM)	
• KA1010	(100nM)	
Untreated	stimulated	and	unstimulated	controls	demonstrated	a	typically	
suppressive	effect	of	CD4+CD25+	on	CD4+	cells	(Figure	3-28)	with	stimulated	cells	
having	a	significantly	greater	effect.	The	greater	the	proportion	of	Treg	to	Teff	cells,	
the	less	the	degree	of	proliferation	of	parent	population	(as	per	the	published	data).		
	
Figure	3-28	Regulatory	T	cell	suppression	assay	untreated	controls	(stimulated	and	
unstimulated	
The	addition	of	a	panel	of	HDACi	compounds	had	broadly	similar	effects	in	terms	of	
suppression	(Figure	3-30).	The	general	trend	toward	increased	suppression	of	
proliferation	was	maintained	in	the	presence	of	all	compounds.	However,	in	these	
1:1
24.58 74.59
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19.82 78.88
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17.63 75.90
1:815.38
71.61
1:16
14.74 57.98
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0:1
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1:16
stimulated	conditions	the	degree	of	proliferation	of	effector	T	cells	was	significantly	
reduced	compared	to	untreated	stimulated	control,	to	a	degree	similar	to	those	seen	
in	the	untreated,	unstimulated	control.		
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Figure	3-29	Raw	data	demonstrating	effect	of	HDACi	on	stimulated	regulatory	T	cell	
suppression	assay	
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Figure	3-30	Effect	of	HDACi	on	stimulated	regulatory	T	cell	suppression	assay	
In	the	presence	of	KA185.1	(at	a	concentration	of	25nM)	90.33%	of	the	parent	
population	remained	undivided	at	a	1:1	effector	to	responder	ratio	(Figure	3-29	C).	
This	was	marginally	the	most	effective	compound	at	this	ratio.		
With	an	effector	to	responder	ratio	of	1:16,	KA146.2	was	the	most	effective,	
maintaining	a	parent	population	of	63.61%	(Figure	3-29	B).	KA185.1	at	this	ratio,	was	
however	notably	less	effective	than	the	other	compounds	tested	with	a	non-
proliferated	parent	population	of	51.55%.		
By	significantly	increasing	the	apparent	suppressive	function	of	regulatory	T	cells	in	
this	assay,	the	notion	that	HDACis	mediate	their	immunosuppressive	potential	via	
their	modulation	is	supported.	It	is	not	clear	however	from	this	assay	as	to	whether	
or	not	this	effect	of	HDACis	is	mediated	through	upregulation	of	Treg	function	or	if	
there	is	an	effect	on	Treg	number.			
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3.7 Effect	of	HDAC	inhibition	on	lymphocyte	subset	expression	
With	an	apparent	effect	on	PBMC	proliferation	and	regulatory	T	cells,	an	assay	was	
developed	to	assess	the	effect	HDAC	inhibition	has	on	the	expression	of	specific	
lymphocyte	subsets.	Freshly	isolated	PBMCs	were	cultured	for	five	days	in	the	
presence	of	SAHA,	KA146.2,	KA185.1	or	KA1010	at	the	same	concentrations	used	
previously.	Following	culture,	the	cells	were	stained	for	recognised	(though	not	
strictly	specific)	antibodies	(Table	3-8)	and	subset	expression	assessed	using	flow	
cytometry.		
Antibody	 Fluorochrome	 Notes	
CD4	 APC	 Effector	T	cell	population	
CD8	 PerCP	 Cytotoxic	T	cell	population	
CD3	 FITC	 T	cells	(T	cell	receptor)	
CD19	 PE	 B	cells	
	
Table	3-8	Lymphocyte	subset	antibody	staining	panel	
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3.7.1 Controls	
The	subset	expression	in	the	untreated	culture	was	assessed.	Assays	were	either	
stimulated	or	unstimulated	and	the	effect	of	media	IL-2	supplementation	assessed.		
Day	0		
	
	
	 	 	
Day	5	
Unstimulated		
No	IL-2		
	 	 	
Day	5	
Unstimulated		
With	IL-2		
	 	 	
Day	5	
Stimulated	
No	IL-2		
	 	 	
Day	5	
Stimulated	
With	IL-2		
		 	 	
Figure	3-31	Raw	data	for	lymphocyte	subset	expression	under	control	conditions	
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As	the	control	samples	above	demonstrate	(Figure	3-31),	once	again,	IL-2	has	a	
negligible	effect	on	the	differentiation	and	expression	of	lymphocyte	subsets	over	
the	course	of	a	five	day	culture.	However,	stimulation	with	the	use	of	Dynabeads	did	
have	a	notable	effect.	In	the	presence	of	IL-2,	stimulation	resulted	in	a	46.3%	
reduction	in	CD19	expression	and	CD3	expression	increased	by	20.3%.	Within	the	T	
cell	subset,	CD4+	T	cells	reduced	by	16.6%	and	CD8+	T	cells	increased	by	35.7%.	This	is	
in	contrast	to	typical,	unstimulated	PBMC	expression	where	CD19+	B	cells	number	~	
15%	and	CD3+	T	cells	~45-70%.	Of	these	CD3+	T	cells,	typically	~25-60%	are	CD4+	and	
5-30%	are	CD8+.	
Therefore,	the	assay	was	repeated	under	stimulating	conditions	in	the	absence	of	IL-
2,	as	this	more	likely	reflects	the	immunological	environment	of	an	immune	
response	as	stimulated	by	allogeneic	transplantation.	Media	was	supplemented	with	
compounds	of	interest	added	at	increasing	concentrations.		
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Figure	3-32	Raw	data	flow	cytometry	analysis	of	lymphocyte	differentiation	
following	PBMC	culture	in	the	presence	of	SAHA	
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KA146.2	
Day	0		
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Figure	3-33	Raw	data	flow	cytometry	analysis	of	lymphocyte	differentiation	
following	PBMC	culture	in	the	presence	of	KA146	
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KA185.1	
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Figure	3-34	Raw	data	flow	cytometry	analysis	of	lymphocyte	differentiation	
following	PBMC	culture	in	the	presence	of	KA185.1	
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KA1010	
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Figure	3-35	Raw	data	flow	cytometry	analysis	of	lymphocyte	differentiation	
following	PBMC	culture	in	the	presence	of	KA1010	
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Figure	3-36	Summary	of	effects	of	HDAC	inhibition	(after	5	days)	on	B	and	T	cell	
marker	expression	(hashed	lines	represent	marker	expression	at	day	0	of	
stimulated	PBMCs)	
This	data	demonstrates	a	stark	contrast	between	the	effects	of	SAHA	and	the	other	
HDACi	assessed.	Even	at	the	lowest	dose	of	1µM,	treatment	with	SAHA	results	in	a	
notable	conformational	change	in	subset	markers.	There	was	a	reduction	in	CD3	and	
CD8+	expression	of	13.7%	and	14.9%	respectively	(Figure	3-32,	Figure	3-36).	CD19+	
and	CD4+	increased	by	188.8%	and	7.1%	respectively.	At	the	higher	concentration	of	
1000µM,	these	changes	were	considerably	more	profound.	CD3+	expression	reduced	
by	69.2%	and	CD8+	by	88.5%.	CD19+	expression	increased	by	1078.9%	and	CD4+	by	
181.0%.		
The	effect	of	the	other	HDACi	compounds	assessed	was	more	marginal	(Figure	3-36).	
Of	note,	while	there	was	relative	stability	in	the	expression	of	CD3+	T	cells	(~85%)	in	
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the	group	of	cells	treated	with	the	higher	dose	of	KA146.2,	there	was	an	18.0%	
reduction	in	CD8+	and	a	reciprocal	18.2%	increase	in	CD4+	expression.		
The	effect	of	KA185.1	was	to	reduce	CD3+	expression	by	11.0%	and	increase	CD19+	
expression	by	96.41%.	This	fall	in	T	cell	numbers	was	reflected	in	a	19.1%	reduction	
in	CD4+	expression	and	relative	stability	of	CD8+	expression.		
In	many	respects,	the	most	relevant	effects	were	seen	with	KA1010	treatment.	There	
was	a	negligible	effect	on	the	overall	expression	of	B	cells	(CD19+)	and	T	cells	(CD3+).	
However	with	increasing	dose	there	was	a	reduction	in	CD8+	expression	by	17.0%	
and	concomitant	increase	in	CD4+	expression	by	31.1%	(at	a	dose	of	1000	µM),	which	
partially	restored	the	pre-stimulated	status	of	a	normal	CD4:CD8	profile.	Though	the	
effect	of	1010	was	significantly	less	profound	than	SAHA,	its	effect	may	have	more	
clinical	relevance	in	an	immune	response	dampening	role,	though	it	is	unclear	as	to	
which	CD4+	T	cell	subset/s	may	have	accounted	for	this	(i.e.	was	this	effect	a	result	of	
increased	T	regs	or	another	phenotype?).	
Conclusion	
After	demonstrating	effects	on	proliferation	with	relative	safety	in	terms	of	toxicity,	
the	effects	of	HDACi	compounds	were	assessed	in	a	series	of	in	vitro	models	of	
allotransplanataion.	It	was	decided	to	rationalise	the	compounds	based	on	the	above	
experiments	and	their	novelty	and	their	potential	application.	Therefore,	KA185	and	
KA146	(potent	pan-HDACi	from	the	synthetic	depsipeptide	class)	were	dropped	from	
further	assessment,	and	the	novel	HDAC6i,	KA1010	taken	forward	along	with	the	
well	characterised	pan-HDACi,	SAHA.		
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Chapter	4	-	Results	
4 Effect	of	histone	deacetylation	on	in	vitro	models	of	
allotransplantation	
	
4.1 Introduction	
The	previous	chapter	demonstrated	the	basic	in	vitro	effects	of	HDACi	in	terms	of	
cellular	physiology.	Western	blot	analysis	identified	the	presence	of	HDACs,	the	
primary	target	of	HDACis.	Proliferation	and	toxicity	studies	showed	that	HDACis	have	
an	underlying	anti-proliferative	effect	and	in	the	context	of	these	studies,	these	
compounds	are	generally	safe.	Finally	Treg	suppression	assays	revealed	an	
immunosuppressive	effect	which	was	augmented	through	HDAC	inhibition.	With	
these	results	in	mind,	the	next	step	was	to	assess	the	role	of	HDACi	in	in	vitro	models	
of	transplantation,	namely	through	a	mixed	lymphocyte	reaction.		
Mixed	lymphocyte	(or	leucocyte)	reactions	provide	an	in	vitro	method	for	evaluating	
allogeneic	responses	and	provide	a	robust	method	by	which	to	assess	the	potential	
physiological	role	of	HDAC	inhibition	in	transplantation.	They	were	first	developed	
over	40	years	ago	(Bach	&	Hirschhorn	1964;	Bain,	Vas,	&	Lowenstein	1964)	and	are	
now	a	well-established	immunological	and	pharmacological	tool,	often	used	by	the	
pharmaceutical	industry	to	assess	the	viability	of	potential	new	drugs.		
The	MLR	relies	on	the	MHC-T	cell	receptor	interaction	and	allows	evaluation	of	T-cell	
activation	and	proliferation	in	laboratory	conditions	(O'Flaherty	et	al.	2000).	There	
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are	three	principal	forms	–	one-way,	two-way	and	three-way.	In	this	study,	only	one-
way	and	two-way	have	been	used.		
A	one-way	MLR	consists	of	a	responder	population	of	lymphocytes	(whose	
proliferation	is	assessed)	and	a	stimulator	population	(which	are	rendered	non-
proliferative,	see	below).	In	this	model	the	stimulator	population	represents	the	
essentially	passive	target	(graft)	to	the	responder	population	(recipient).	A	two-way	
MLR	differs	from	a	one-way	in	that	both	populations	are	able	to	proliferate.	It	could	
be	argued	that	this	better	represents	a	model	of	transplantation	as	donor	organs	not	
only	present	antigen	but	also	carry	immunocompetent	cells	such	as	T,	B	and	NK	cells	
(Richter	et	al.	1994;	Schlitt	et	al.	1993).	These	cells	can	leave	the	graft,	and	it	has	
been	demonstrated	that	they	can	circulate	in	the	host	for	significant	periods	of	time	
(Richter	et	al.	1995;	Schlitt	et	al.	1993).	The	ability	of	these	cells	to	stimulate	an	
immunological	response	is	demonstrated	in	cases	of	graft-versus-host	disease	
(GVHD)	occurring	after	solid	organ	transplantation	(Jamieson	et	al.	1991;	Schlitt	et	al.	
1995).		
It	may	be	concluded	therefore	that	a	two-way	MLR	could	be	used	to	represent	the	
early	stages	of	the	immune	response	following	transplantation	and	that	the	longer	
term	response	is	better	represented	through	a	one-way	assay.		
The	following	chapter	presents	data	assessing	the	effect	of	HDAC	inhibition	on	MLR-
type	assays	and	compares	these	effects	with	the	established	immunosuppressant	
cyclosporin	A	(CyA).		
In	terms	of	MLR	assay	development	(one-way),	it	was	first	necessary	to	optimise	the	
conditions	under	which	the	stimulator	population	was	rendered	non-proliferative.	γ-
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irradiation	was	preferred	over	an	anti-mitotic	agent	such	as	mitomycin	C	as	the	later	
has	been	shown	to	have	significant	effects	on	the	cellular	metabolism	(and	CD154	
expression)	of	treated	cells	and	subsequent	stimulatory	effect	(Roy	et	al.	2001).		
	
4.2 PBMC	Irradiation	Assay	
In	order	to	undertake	a	mixed	lymphocyte	reaction	(MLR)	assay	it	was	first	necessary	
to	optimise	a	reliable	method	of	rendering	the	stimulator	PBMCs	unable	to	undergo	
division,	yet	maintain	cell	viability	(and	be	able	to	present	alloantigens	as	well	as	
produce	cytokines).	As	mentioned	above,	there	are	two	established	methods	for	
achieving	this.	The	first	is	to	treat	PBMCs	with	an	anti-proliferative	drug	such	as	
mitomycin	C,	which	acts	by	cross-linking	DNA	strands,	thereby	preventing	cell	
proliferation.	The	alternative	method	is	to	use	γ-irradiation	to	irreversibly	damage	
cellular	DNA	and	thus	prevent	replication.	However,	excessive	irradiation	also	has	
the	potential	to	cause	extensive	damage,	such	that	apoptosis	occurs.	Therefore,	it	
was	first	necessary	to	establish	the	optimal	dose	PBMCs	could	be	treated	at,	so	that	
they	are	no	longer	able	to	proliferate	but	still	maintain	viability	and	are	thus	able	to	
act	as	antigen-presenting	cells	(APCs).	
In	order	to	achieve	this,	an	assay	was	undertaken	whereby	freshly	isolated	PBMCs	
were	irradiated	at	increasing	doses	from	0	to	50	Gy	and	then	cultured	for	one	to	four	
days.	Survival	and	viability	was	assessed	through	7-AAD	staining	and	flow	cytometry.		
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Figure	4-1	PBMC	survival	following	irradiation	
	
Figure	4-2	PBMC	viability	following	irradiation	
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Figure	4-3	Representative	raw	data	of	effect	of	irradiation	on	PBMC	survival	/	
viability	
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This	data	demonstrates	a	dose/time	dependent	effect	of	γ-irradiation	on	PBMC	
survival	and	viability.	Irradiating	cells	regardless	of	dose,	resulted	in	a	considerable	
reduction	in	terms	of	cell	survival	(Figure	4-1)	to	the	extent	that	by	day	3	post-
exposure	survival	drops	from	64%	in	the	untreated	population	to	23%	in	those	cells	
treated	with	the	lowest	dose	of	10Gy.	There	was,	however,	less	of	a	contrast	
between	untreated	and	treated	cells	in	terms	of	cell	viability;	though	a	dose	
dependent	effect	was	still	evident	(Figure	4-2).	Without	irradiation	treatment,	93%	
of	cells	retain	their	viability,	and	this	reduces	to	75%	with	treatment	at	a	dose	of	
10Gy.	Beyond	this,	there	does	seem	to	be	a	notable	drop	in	cell	viability	from	20Gy	
treatment	(65%)	to	30Gy	(42%).		
Reviewing	this	data	as	a	whole,	a	dose	of	20Gy	irradiation	was	deemed	to	provide	
the	optimal	condition	at	which	to	treat	stimulator	cells	for	the	purpose	of	an	MLR	
and	this	would	be	consistent	with	the	majority	of	the	published	data.		
	
4.3 Mixed	Lymphocyte	Reaction	(MLR)	–	One-Way	
4.3.1 Effect	of	compounds	
The	first	MLR	undertaken	in	this	series	of	experiments	was	a	one-way	study	in	which	
the	stimulating	population	is	irradiated	in	order	to	render	it	viable	but	without	the	
ability	to	undergo	cell	division	as	described	above.	These	cells	therefore	merely	act	
as	foreign	alloantigens.		
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Figure	4-4	One-way	MLR	–	PBMCs	treated	with	CyA	[200ng/ml)	
In	this	initial	experiment	freshly	isolated	PBMCs,	irradiated	with	20Gy	were	cultured	
at	a	density	of	1	x	106	cells/ml	with	equal	numbers	of	CFSE-labelled	[1µM]	responder	
cells	from	an	allogeneic	donor.	Responder	cell	proliferation	was	assessed	at	days	3,	5	
and	7	in	the	presence	or	absence	of	CyA	(at	a	concentration	of	200ng/ml).	
At	day	0,	as	expected	a	non-proliferated,	unstained	population	was	observed	in	the	
stimulator	only	control	wells	(Figure	4-4	A).	The	responder	population	stained	well	
for	CFSE.	In	the	MLR	and	CyA	wells,	just	fewer	than	50%	of	the	cells	stained	for	CFSE	
demonstrating	an	approximately	1:1	ratio	of	stimulators	to	responders.		
CFSE	
92.65	
45.63	 45.19	
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From	days	3	to	7,	the	stimulator	only	population	underwent	steady	degradation	until	
very	few	viable	cells	remained	by	the	end	of	the	assay	(Figure	4-4,	B-D).	Conversely,	
the	unstimulated	responder	population	underwent	negligible	division	as	would	be	
predicted.	In	the	untreated	MLR,	there	was	appreciable	division	of	the	responder	
parent	population	suggesting	an	allogeneic	response	was	underway.	This	response	
was	significantly	suppressed	in	the	CyA	assay	so	that	minimal	proliferation	of	the	
parent	population	occurred.		
The	conditions	of	this	assay	were	repeated,	in	order	to	better	quantify	the	effect	of	
CyA	as	well	as	assess	the	effects	of	the	addition	of	the	following	HDACi	compounds:	
• SAHA		 –		 0.5µM	or	5µM		
• KA1010		 –		 0.5µM	or	5µM		
Once	again	the	stimulator	population	underwent	steady	degradation	over	time	
without	any	significant	division	(Figure	4-5).	It	was	also	noted	that	there	was	an	
apparent	greater	degree	of	proliferation,	suggesting	a	more	potent	alloresponse	in	
the	untreated	MLR	compared	to	the	previous	experiment	(Figure	4-4).	However,	this	
was	not	quantified	in	the	previous	experiment	and,	therefore,	cannot	be	
commented	on	further.		
Analysis	of	the	MLR	in	the	presence	of	CyA	demonstrated	reduced	proliferation	of	
the	parent	population	(92%	vs.	75%,	p=0.01)	at	day	seven	(Figure	4-7).	This	
observation	did	extend	beyond,	to	the	end	of	the	assay	–	day	ten	(Figure	4-5).		
This	was	also	the	case	with	the	addition	of	HDACi	to	the	culture	media	(Figure	4-6);	
at	a	dose	of	500nM,	SAHA	reduced	division	of	the	parent	population	from	92%	to	
80%	(p=0.01)	at	day	seven.	This	was	reduced	further	to	49%	(p=0.001)	when	treated	
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with	a	higher	dose	of	5µM.	However,	analysis	of	the	flow	cytometry	plots	suggested	
that	the	vast	majority	of	responders	were	apoptotic	(in	the	region	of	75-80%),	and	at	
5µM	SAHA	had	notable	toxicity,	which	clinically	would	be	unacceptable.		
KA1010,	at	a	dose	of	0.5µM,	had	a	modest	inhibitory	effect	on	proliferation,	
reducing	the	parent	population	by	just	a	further	5%	(to	87%,	p=0.2).	However,	at	a	
dose	of	5µM,	the	non-proliferating	parent	population	remaining	after	seven	days	
was	significantly	inhibited,	with	just	64%	(p=0.001)	undergoing	one	or	more	
divisions.		
	At	this	dose,	KA1010	was	the	most	effective	inhibitory	agent,	with	an	acceptably	
non-toxic	effect	on	PBMCs.		
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Figure	4-5	Representative	data	for	one-way	MLR	–	Controls	and	PBMCs	treated	with	CyA	[200ng/ml)	for	ten	days	
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Figure	4-6	Representative	data	for	one-way	MLR	–	PBMCs	treated	with	SAHA	and	KA1010	for	ten	days	
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Figure	4-7	CyA	and	HDACi	treatment	(for	seven	days)	in	MLR	conditions	results	in	
significant	inhibition	of	labelled	lymphocytes	compared	to	responders	in	the	untreated	
MLR	(Asterisks	represent	p	value	as	calculated	using	Tukeys	multiple	comparison	test,	
n=4)	
4.4 Mixed	Lymphocyte	Reaction	–	One-way	Killing	Assay	
After	demonstrating	that	HDAC	inhibition	can	indeed	dampen	an	immune	response	in	a	one	
way	MLR,	a	killing	assay	was	developed	to	elucidate	whether	or	not	allogeneic	(as	would	be	
expected)	or	autologous	targets	are	affected.		
4.4.1 CD45	
CD45,	also	known	as	the	leucocyte	common	antigen	(LCA)	is	a	high	molecular	weight	trans-
membrane	protein	associated	with	all	haematopoetic	cells.		It	is	required	for	T	and	B	cell	
activation	and	exists	in	at	least	five	isoforms	which	may	be	expressed	in	cells	of	differing	
*					p	≤	0.05
**			p	≤0.01
***		p	≤	0.001	
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lineage	or	activation	status.	Given	its	abundant	expression	amongst	leucocytes,	it	lends	
itself	as	a	useful	marker	for	labelling	populations	involved	in	this	particular	allogeneic	MLR.		
This	can	be	achieved	by	staining	responder	(or	target)	cells	with	anti-CD45	antibody,	which	
will	bind	to	a	common	region	of	the	CD45	antigen,	regardless	of	isoform.		
4.4.2 Assay	development	
In	this	assay,	two	freshly	isolated	PBMC	populations	from	allogeneic	donors	were	labelled	
with	an	anti-CD45	antibody,	conjugated	to	the	fluorochrome	FITC.	Two	different	
concentrations	were	used	to	differentiate	between	the	two	populations	(Figure	4-8)	on	flow	
cytometry.	These	cells	were	then	co-cultured	with	unlabelled,	irradiated	(20Gy)	stimulators,	
autologous	to	one	of	the	responder	populations.	The	assays	were	cultured	for	24	hours	in	
the	presence	or	absence	of	HDACi	or	CyA.	Flow	cytometry	was	used	to	assess	for	killing	of	
the	allogeneic	responder	(T1)	population.		
	
Figure	4-8	Experimental	layout	for	one-way	killing	assay	
Donor	1 Donor	2
Labelled with	
1/2000	anti-
CD45-FITC	Ab
Target	1
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1/600	anti-CD45-
FITC	Ab
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100,000	
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Pre-culture	assessment	of	cell	staining	demonstrated	two	distinct	responder	(target)	
populations	and	an	unstained	stimulator	population.	When	combined	(in	the	absence	of	
stimulator	cells),	the	two	target	populations	remain	distinct	in	terms	of	staining,	with	
roughly	equal	numbers	in	each	population.	Analysis	of	the	stimulator	population	revealed	a	
negative	staining	population.		
After	staining,	flow	cytometry	of	the	T1:T2	control	samples	demonstrated	two	distinct	
populations	at	a	ratio	of	approximately	1:1	(Figure	4-9).	
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Figure	4-9	Control	demonstrating	two	distinct	responder	populations	based	on	staining	
antibody	concentration	
Following	this,	compounds	of	interest	were	added	to	the	culture	media	and	the	effect	on	
killing	response	assessed.	KA172,	a	highly	potent	pan-HDACi	was	utilised	in	several	of	these	
experiments	in	order	to	compare	effect	with	SAHA	(and	KA1010).	As	can	be	seen,	from	the	
flow	cytometry	plots	(Figure	4-10),	the	addition	of	compounds	did	not	result	in	any	
significant	alteration	in	allogeneic	versus	autologous	survival.	However,	these	results	proved	
difficult	to	interpret	as	the	unstained	stimulator	population	was	difficult	to	distinguish	from	
the	allogeneic	T1	population	(with	a	weaker	concentration	of	staining	antibody).		
In	the	untreated	control	assay,	there	was	an	approximately	4:1	ratio	of	effectors	+	
allogeneic	targets	to	autologous	targets.	From	this	data,	there	appeared	to	be	minimal	
killing	of	autologous	targets,	but	as	mentioned	assessment	of	the	allogeneic	(T1)	population	
proved	difficult.	The	addition	of	CyA	or	HDACi	did	not	affect	this	ratio	and,	therefore,	had	no	
apparent	immunomodulatory	effect.		This	led	to	the	conclusion	that	this	assay	may	not	be	
sufficiently	sensitive	due	to	the	possibility	that	responders	may	be	proliferating	as	quickly	as	
they	are	being	killed.	In	addition	to	this,	it	may	also	be	plausible	that	the	staining	strategy	
adopted	resulted	in	unstained	stimulators	merging	with	responders	cells	stained	with	low	
dose	(1:2000)	conjugated	antibody,	making	discrimination	between	the	two	groups	at	
analysis	indiscernible.	
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Figure	4-10	Effect	compound	on	autologous	and	allogeneic	responder	cell	population	in	a	one-way	MLR	killing	assay
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Therefore,	this	assay	was	revised	and	an	alternative	fluorochrome	used	in	order	to	better	
differentiate	populations	of	interest.	As	previously,	an	allogeneic	target	population	was	
isolated	and	stained	with	a	conjugated	anti-CD45	antibody.	Again,	the	antibody	was	
conjugated	with	the	FITC	fluorochrome	but	now	a	concentration	of	1/100	was	used.	As	
previously,	the	second	target	population	was	stained	with	anti-CD45	antibody,	but	on	this	
occasion	conjugated	to	an	alternative	fluorochrome	(APC-H7)	with	an	entirely	different	
excitation	wavelength	compared	to	FITC	(and	a	concentration	of	1/100	used).	The	allogeneic	
stimulator	population	was	irradiated	at	20Gy.	The	assay	was	cultured	for	24	hours	and	a	
second	time	point	at	18	hours	incorporated.		
	
	
Figure	4-11	Gating	strategy	for	modified	killing	assay	using	untreated	culture	(assessed	at	
18	hours)	
Target	cells	
(T1	&	T2)
T2	(APC)	– Autologous	donor
T1	(FITC)	– Allogeneic	donor
Effector	cells
CD45-FITC
CD45-APC-H7
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Flow	cytometry	analysis	of	the	untreated	control	sample	demonstrated	an	improved	
delineation	between	target	cell	populations,	making	analysis	more	reliable	(Figure	4-11).			
Analysis	of	the	control	groups	at	18	and	24	hours	demonstrates	that	this	delineation	is	
maintained.		
	
Figure	4-12	Effect	of	compound	on	one-way	killing	assay	at	18	hours	
Untreated
CyA
(250ng/ml)
SAHA	(0.5µM) SAHA	(5µM)
KA172	
(0.5µM)
KA172	
(5µM)
KA1010	
(0.5µM)
KA1010	
(5µM)
CD45-FITC
CD45-APC
37.30	
62.54	
62.48	
37.43	
62.66	
37.14	
63.22	
36.74	
63.36	
36.48	
58.51	
41.44	
61.45	
38.45	
59.31	
40.44	
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Figure	4-13	Effect	of	compound	on	one-way	killing	assay	at	24	hours	
Untreated
CyA
(250ng/ml)
SAHA	(0.5µM) SAHA	(5µM)
KA172	
(0.5µM)
KA172	
(5µM)
KA1010	
(0.5µM)
KA1010	
(5µM)
CD45-FITC
CD45-APC
69.46	
30.47	
65.90	
34.10	
63.31	
36.56	
64.46	
35.41	
31.05	
63.86	
35.07	
67.63	
32.31	
37.99	
68.75	
62.01	
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Figure	4-14	Comparative	effects	of	compound	on	target	cell	population	in	one-way	MLR.	
Difference	in	relative	number	of	cells	at	18	hours	(A)	and	at	24	hours	(B).		Change	over	
time	in	target	cell	population	differential	(C)	
As	expected	throughout	all	treatment	conditions	the	autologous	T2	population	
predominated	over	the	allogeneic	T1	population	in	terms	of	numbers.	The	relative	number	
of	allogeneic	cells	also	reduced	over	time	(24	hours	compared	to	18	hours).	This	is	
represented	in	Figure	4-14	by	calculating	the	difference	between	T2	and	T1	at	each	time	
point.	This	difference	represents	relative	killing	of	the	allogeneic	population	over	the	
autologous.	Therefore,	a	calculated	difference	which	is	less	than	the	untreated	control	can	
be	interpreted	as	relative	preservation	of	the	allogeneic	population	and	may	represent	a	
degree	of	immunosuppression	by	the	compound	of	interest.		
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At	18	hours,	only	KA172	[5µM]	and	KA1010	[5µM]	resulted	in	any	apparent	preservation	of	
the	allogeneic	population	(Figure	4-14	A).	At	24	hours,	however,	though	these	same	
compounds	represented	the	most	effective	immunomodulatory	agents.	All	the	HDACis	
assessed	resulted	in	a	degree	of	allogeneic	population	preservation.		
The	dynamic	effect	of	compounds	was	also	assessed	by	calculating	the	percentage	change	in	
target	cell	population	between	the	two	timepoints	(Figure	4-14	C).	This	demonstrated	that	
the	effect	of	most	compounds	assessed	(all,	with	the	exception	of	KA172	[5µM])	was	to	slow	
down	the	rate	of	differential	population	killing	and	this	may	also	represent	an	
immunomodulatory	effect.		
4.4.3 Effect	of	compounds	on	one-way	killing	assay	
Given	this	positive	finding,	the	above	assay	was	repeated	under	similar	conditions	with	an	
extended	time	frame	by	assessing	target	cell	population	killing	at	days	1,	2	and	3.	In	order	to	
improve	accuracy	of	the	assay,	counting	beads	were	used	in	the	flow	cytometry	analysis.	
This	involved	calibrating	a	known	number	of	counting	beads	in	the	form	of	red	carboxylated	
spheres.	Once	a	concentration	for	these	beads	was	established,	it	was	possible	to	
extrapolate	numbers	of	cells	/	well,	using	the	formula;	
A/B	×	C/D	=	concentration	of	sample	as	cells/μL	
Where	A	=	number	of	cell	events,	B	=	number	of	bead	events,	C	=	assigned	bead	count	of	
the	lot	(beads/50	μL)	and	D	=	volume	of	sample	(μL).		
Flow	cytometry	analysis	of	control	samples	demonstrated	a	definable	staining	of	target	
populations	(Figure	4-15)	and	no	staining	of	effector	population.		
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Figure	4-15	Control	samples	for	extended	one-way	MLR	killing	assay	at	day	0	
	
Figure	4-16	Effect	of	compound	on	killing	assay	at	24	hours	
Target	1	(Donor	1)
- Allogeneic
Target	2	(Donor	2)
- Autologous Effector	(Donor	2)
Untreated CyA
(250ng/ml)
SAHA	
(0.5µM)
SAHA	
(5µM)
KA172	
(0.5µM)
KA172	
(5µM)
KA1010	
(0.5µM)
KA1010	
(5µM)
CD45-FITCC
D4
5-
AP
C-
H7
97.81	
97.67	
		100.00	
16.03	
67.06	
20.47	
60.49
20.59	
60.60	
19.58	
61.87	
17.16	
66.46	
19.48	
60.75	
20.75	
59.04	
19.19	
60.73	
16.91	
19.03	
18.68	
16.29	
19.77	
18.46	
20.06	 20.04	
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Figure	4-17	Effect	of	compound	on	killing	assay	at	48	hours	
	
Figure	4-18	Effect	of	compound	on	killing	assay	at	72	hours	
Untreated CyA
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(0.5µM)
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(5µM)
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10.74	
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Figure	4-19	Effect	of	treatment	on	absolute	cell	number	
Over	the	course	of	the	treatment	period,	there	was	a	steady	decline	in	cell	numbers	(Figure	
4-19).	After	24	hours	the	untreated	allogeneic	population	reduced	by	29.5%	and	by	98.9%	at	
72	hours	representing	only	400	detectable	cells.	The	addition	of	CyA	at	a	dose	of	250ng/ml	
had	no	demonstrable	effect	over	control	on	preserving	target	cells	in	the	first	48	hours	and	
only	a	minimal	effect	at	72	hours,	resulting	in	a	modest	62%	increase	in	cell	number	over	
target	(equivalent	to	646	cells).		
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Figure	4-20	Relative	effect	of	compound	on	allogeneic	target	population	in	extended	
killing	assay	
The	addition	however	of	HDACi	did	have	a	measurable	effect	on	cell	numbers.	At	24	hours	
this	effect	was	modest	(Figure	4-20)	and	in	keeping	with	previous	data.	By	48	hours	there	
were	a	considerably	greater	proportion	of	allogeneic	cells	surviving	(in	the	region	of	1.7	–	
2.25	times	greater	than	control).	In	the	case	of	KA1010	[0.5µM]	and	KA172	[0.5µM],	the	
protective	effect	plateaued.	For	the	other	compounds	assessed	(KA172	[5	µM],	SAHA	
[0.5µM],	[5µM]	and	KA1010	[5µM])	there	was	further	proportional	preservation	of	the	
allogeneic	population,	with	the	higher	doses	proving	most	effective.	By	72	hours,	SAHA	
[5µM]	treatment	resulted	in	a	3.66-fold	increase	and	KA1010	[5µM]	a	4.41-fold	increase.		
Though	these	results	demonstrated	a	degree	of	allogeneic	preservation	in	the	presence	of	
HDAC	inhibition,	there	still	remained	a	number	of	persistent	targets	in	the	untreated	control	
assay.	This	was	notable	as	it	would	be	expected	that	this	untreated	allogeneic	population	
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would	be	completely	absent	after	48-72	hours	of	MLR.	Therefore,	this	assay	was	adapted	by	
priming	the	effector	cells	first	with	both	autologous	and	allogeneic	cells	prior	to	assessing	
the	effect	of	MLR	with	and	without	compounds	of	interest	(Figure	4-21).	This	was	achieved	
by	culturing	the	effector	population	with	irradiated	targets	at	days	0,	7	and	14,	prior	to	
commencing	the	MLR	proper	at	day	21.	Target	populations	were	then	assessed	at	24	hours	
and	72	hours	(days	22	and	24	of	the	assay	respectively).	
	
Figure	4-21	Schematic	representation	of	modified	primed	MLR	
	
	
	
	
	
Day	22 Day	24Day	0 Day	7 Day	14 Day 21
PBMCs	isolated
Donor	1
Donor	2
Target	1
(Irradiated)
Target 2
(Irradiated)
Effectors
Culture Effectors
Target 1
(Irradiated)
Target	2
(Irradiated)
MLR
Cultured	@	37°C	in	
supplemented	RPMI	
+/- compound
Culture	restimulated
with	irradiated	PBMCs	
from	donor	1	&	2
Anti-CD45	
FITC
Anti-CD45	
APC
5x105 cells
5x105 cells
1x106 cells
Target	killing	
assessed	on	FACS
Cultured	@	37°C
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Figure	4-22	MLR	control	samples	at	A)	0	hours,	B)	24	hours	and	C)	72	hours.	D)	Rate	of	cell	
attrition	over	experimental	period	
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Once	again	the	staining	strategy	identified	distinct	populations	and	calculated	cell	numbers	
were	consistent	with	estimated	planned	numbers	as	per	experimental	protocol	(Figure	4-22	
A-C).	As	with	previous	assays,	the	allogeneic	target	population	though	at	lower	numbers	
compared	to	autologous	targets,	and	declined	at	similar	rates	(Figure	4-22	D).	Comparing	
the	absolute	reduction	in	cell	numbers	also	demonstrates	a	similar	effect	on	both	allogeneic	
(98.4%)	and	autologous	(95.9%)	populations,	with	a	67.4%	reduction	in	effector	numbers	
over	the	assessment	period.			
24	HOURS	 72	HOURS	
	 	
	 	
	 	
CyA (250ng/l) CyA (250ng/ml)
SAHA	(0.5µM) SAHA	(0.5µM)
SAHA	(5µM) SAHA	(5µM)
16.75	
68.54	 14.68	
1.96	
95.31	 2.73	
15.63	
69.74	 14.63	
2.50	
94.94	 2.56	
52.81	
3.40	 43.21	
44.68	
4.26	 51.06	
161	
	
	 	
	 	
		
Figure	4-23	Flow	cytometry	raw	data	for	treated	primed	killing	assay	
The	effect	of	CyA	and	HDACi	on	primed	targets	followed	the	general	trend	seen	in	the	
extended	killing	assay	previously.	Review	of	the	raw	data	(Figure	4-23)	suggests	SAHA	at	the	
higher	dose	of	5µM	has	a	significantly	toxic	effect	on	cell	survival	with	a	negligible	number	
of	effector	cells	surviving,	however,	experimental	error	cannot	be	ruled	out	and	it	is	
noteworthy	that	target	cell	numbers	were	consistent	with	prior	data.	With	regards	to	the	
other	compounds	tested,	only	KA1010	[5µM]	appeared	to	have	any	beneficial	advantage	in	
terms	of	preserving	the	T1	allogeneic	population	over	the	autologous	population.	However	
when	absolute	cell	numbers	are	assessed	rather	than	comparative	proportions,	greater	
effects	become	evident.	As	with	previous	data	KA1010	[5µM]	had	the	greatest	effect	at	72	
hours	with	a	7-fold	greater	number	of	allogeneic	cells	surviving	compared	to	control.	SAHA	
[5µM]	also	had	a	notable	effect,	resulting	in	a	5.5-fold	increase.	The	other	compounds	
tested	(CyA	[250ng/ml],	SAHA	[0.5µM]	and	KA1010	[0.5µM])	had	a	far	more	modest	effect	
with	an	approximately	2	to	3-fold	increase	in	allogeneic	survival	over	control.	
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Figure	4-24	Comparative	data	demonstrating	effect	of	compound	on	cell	number	in	
primed	killing	assay	
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Figure	4-25	Relative	effect	of	compound	on	allogeneic	target	population	in	primed	killing	
assay	
Considered	in	its	entirety,	this	MLR	killing	assay	data	supports	the	notion	that	HDAC	
inhibition	has	a	positive	effect	in	the	context	of	suppression	of	allogeneic	responses	in	vitro.	
Both	pan-HDAC	inhibition	(through	SAHA	and	KA172)	and	HDAC-6	specific	inhibition	
(through	KA1010)	proved	more	effective	than	the	well	established	immunosuppressant	
Cyclosporin	(Figure	4-24,	Figure	4-25).		
However,	it	should	be	noted	there	was	a	deficiency	in	these	assays	with	regard	to	allogeneic	
survival.	It	was	expected,	particularly	in	the	extended	assay	and	the	primed	assay	that	there	
would	be	almost,	if	not	complete	killing	of	the	allogeneic	T1	population	with	significant	
preservation	of	the	autologous	T2	population.	The	reasons	for	this	not	occurring	are	
unclear.		
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4.5 MLR	-	ELISA	
In	order	to	quantify	an	allogeneic	response	in	the	MLR	setting	and	to,	therefore,	better	
assess	effect	of	an	immunomodulatory	compound,	an	assay	based	on	IFN-γ	production	was	
developed.	This	involved	measuring	supernatant	IFN-γ	utilising	an	established	ELISA	kit.	The	
basis	for	this	assay	relied	upon	proportional	IFN-γ	production	as	a	marker	of	alloresponse	
secondary	to	proliferating	CD4+	T	helper	cells.	Interestingly	in	the	context	of	this	study,	
evidence	suggests	that	IFN-γ	production	induces	Treg	promotion	(Eljaafari,	Li,	&	Miossec	
2009)	(this	will	be	commented	upon	further	in	the	Discussion).	
4.5.1 Assay	development	
To	standardise,	extrapolate	and	quantify	IFN-γ	production	from	the	ELISA	data,	it	was	first	
necessary	to	establish	a	standard	curve.	This	was	achieved	using	serial	dilution	of	a	known	
concentration	of	IFN-γ.	A	typical	standard	curve	(Figure	4-26)	was	then	plotted	and	the	
quadratic	equation	of	the	trend	line	used	to	interpret	measured	ELISA	data	of	the	MLRs.		
	
IFN-g	(pg/ml) Reading	1 Reading	2 Abs	
2000 1.868729 2.04204 1.955385
1000 1.125734 1.197155 1.161445
500 0.766742 0.792622 0.779682
250 0.6066 0.52418 0.56539
125 0.438903 0.37193 0.405416
62.5 0.32438 0.339284 0.331832
31.25 0.303043 0.274441 0.288742
0 0.27787 0.237559 0.257714
A	
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Figure	4-26	Typical	standard	curve	for	ELISA.	(A)	Raw	data	used	to	plot	a	standard	curve	
(B).	An	R2	value	close	to	1	is	desirable	
The	first	stage	involved	in	developing	this	assay	was	to	assess	the	differential	response	in	
terms	of	IFN-γ	production	between	a	one-way	and	a	two-way	MLR.	This	was	performed	
using	frozen	PBMCs	from	allogeneic	donors,	with	autologous	culture	acting	as	control.	To	
achieve	a	one-way	MLR,	one	of	the	populations	was	irradiated	with	either	10	or	20	Gray,	in	
order	to	maintain	cell	viability,	but	prevent	division.	A	lower	than	standard	dose	of	radiation	
was	used	to	determine	as	to	whether	or	not	there	was	an	effect	of	irradiation	on	IFNγ	
production.	Cells	were	cultured	for	three	days	at	37°C.	The	expected	outcomes	were	as	
follows:	
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10	Gray		 20	Gray		 Expected	outcome		
A	+	A		 A	+	A		 Negative	control	-		No	MLR	(background	IFN-γ	production	
only)		B	+	B		 B	+	B	
A	+	B		 A	+	B		 2-way	MLR	(IFN-γ	production	++)		
AI	+	BI		 AI	+	BI		 Negative	control	-	Both	sides	irradiated	(background	IFN-
γ	production	only)		
A	+	BI		 A	+	BI		
1-way	MLR	(IFN-γ	production	+)		
AI	+	B		 AI	+	B		
	
Table	4-1	Expected	outcomes	for	IFN-γ	production	in	one-way	and	two-way	MLR	(A	=	
donor	A,	B	=	donor	B)	
Unfortunately,	in	reality	these	conditions	resulted	in	negligible	IFN-γ	production.	Therefore,	
the	assay	was	repeated	using	freshly	isolated	PBMCs	from	allogeneic	donors	and	a	positive	
control	incorporated	using	mitogen	stimulation	(in	the	form	of	LPS	or	Con	A)	of	the	
autologous	culture.	PBMCs	were	isolated	from	three	allogeneic	donors	in	order	to	increase	
diversity	and	reduce	the	risk	of	HLA	matching.	An	alternative	media	was	used	(AIM-V	+	10%	
FCS)	and	all	cultures	were	incubated	at	37°C	for	24	hours.	Cells	irradiated	for	one-way	MLR	
were	treated	with	20	Gray.	
Background	autologous	IFN-γ	production	ranged	in	the	order	of	4-80	pg/ml	(Figure	4-27).	
There	was	no	significant	allogeneic	response	with	IFN-γ	levels	of	0-73	pg/ml.	However,	the	
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mitogen-stimulated	positive	control	did	result	in	a	heterogenous	degree	of	production	with	
values	ranging	from	30-900	pg/ml.	Though	the	allogeneic	MLR	disappointingly	did	not	result	
in	an	anticipated	rise	in	IFN-γ	production,	the	results	of	the	positive	control	added	validity	to	
the	proposed	assay.	It	was	therefore	decided	to	increase	the	time	period	to	three	days	over	
which	incubation	was	performed.	In	addition,	a	T	cell-specific	mitogen	in	the	form	of	
Phorbol	Myristate	Acetate	(PMA)	and	Ionomycin	was	adopted	in	an	effort	to	produce	a	
more	‘uniform’	positive	control.		
No	other	conditions	were	changed	from	the	previous	experiment.		
	
	
Figure	4-27	IFN-γ	production	following	24	hour	allogeneic	MLR	(‘	represents	irradiated	
population)	
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Figure	4-28	IFN-γ	production	following	72	hours	allogeneic	MLR	(‘	represents	irradiated	
population)	
Under	these	modified	conditions	the	background	autologous	IFN-γ	production	ranged	from	
0	–	570	pg/ml	(mean	360	pg/ml)	(Figure	4-28).	This	is	a	higher	value	than	in	previous	
experiments	and	suggests	a	longer	incubation	period	provides	more	interpretable	results.	In	
general,	the	unstimulated	allogeneic	assays	resulted	in	a	trend	towards	increased	IFN-γ	
production	over	autologous.	These	values	ranged	from	617	to	1509	pg/ml	with	a	mean	
value	of	1073	pg/ml	(Figure	4-29)	in	the	two-way	MLR	whereby	neither	population	was	
irradiated.	There	was	less	IFN-γ	production	from	the	one-way	group	with	a	mean	of	719	
pg/ml	(range	449-1084	pg/ml),	which	was	still	greater	than	autologous.		
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Figure	4-29	Mean	IFN-γ	production	in	72-hour	MLR	
Mitogen	stimulation	resulted	in	a	considerable	increase	in	IFN-γ	production	with	a	mean	
value	of	2772	pg/ml	(range	1438-3822	pg/ml).	Of	the	stimulants	used,	PMA	+	Ionomycin	
treatment	resulted	in	the	most	consistent	effect	with	a	mean	IFN-γ	production	of	2909	
pg/ml	(SEM	±409	pg/ml).		
4.5.2 Effect	of	KA1010,	SAHA	and	CyA	on	IFN-γ	production	
Overall	this	data	provided	sufficient	evidence,	that	under	these	conditions,	the	assay	
provided	the	basis	for	an	in	vitro	model	of	allotransplantation.		Therefore,	the	next	step	was	
to	assess	the	effect	of	immunosuppression	on	IFN-γ	production.	Autologous	PBMCs	were	
cultured	as	negative	controls	and	PMA	+	Ionomycin	was	again	used	to	stimulate	a	positive	
control.	On	this	occasion,	the	autologous	populations	used	in	the	control	samples	were	
either	irradiated	or	non-irradiated	(i.e.,	there	was	no	one-way	MLR	control)	in	order	to	
assess	the	effect	irradiation	has	on	IFN-γ	production.	For	the	compounds	of	interest	
assessed,	culture	media	was	supplemented	with	CyA	at	250ng/ml	or	KA1010	at	a	range	of	
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doses	from	0.01µM	to	3µM.	Again,	effects	on	a	both	one-way	and	two-way	MLR	were	
measured.		
	
Figure	4-30	Effect	of	compound	on	IFN-γ	production	in	72	hour	MLR	
The	stimulated	positive	control	samples	resulted	in	almost	7000	pg/ml	of	IFN-γ	production	
and	there	was	no	significant	effect	of	irradiation	on	this	figure	(Figure	4-30).	The	negative	
control	(unstimulated	single	donor)	population,	also	produced	anticipated	results	with	less	
than	300	pg/ml	of	IFN-γ	production.	There	was	a	significant	increase	in	IFN-γ	production	of	
the	untreated	MLR	over	negative	control	with	levels	of	around	2400	pg/ml.	Again,	
irradiation	had	no	detectable	effect.		
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With	regards	to	HDAC-6	inhibition	through	KA1010,	there	was	an	apparent	dose-dependent	
effect,	particularly	in	the	two-way	MLR	samples.	At	the	low	doses	of	0.01	and	0.03μM,	IFN-γ	
production	was	approximately	3000	pg/ml	(both	one	and	two-way	MLR).		At	concentrations	
of	0.1μM	and	greater	there	was	a	dose	dependent	reduction	in	IFN-γ	production,	such	that	
treatment	with	3μM	resulted	in	levels	of	just	12%	(377	pg/ml)	of	that	produced	at	0.01μM.	
Treatment	with	CyA,	at	a	concentration	of	250ng/ml	resulted	in	IFN-γ	levels	(300-400	
pg/ml),	comparable	to	that	seen	with	the	higher	dose	of	KA1010.		
In	this	model,	the	effect	of	irradiating	cells	had	no	significant	outcome	on	IFN-γ	production	
in	the	control	samples.	As	this	model	is	designed	to	reflect	allogeneic	transplantation	in	
vitro,	and	in	reality,	both	donor	and	recipient	graft	present	antigen	in	a	two-way	fashion	it	
was	decided	that	subsequent	MLRs	would	not	require	an	irradiated	population.	Therefore,	
further	allogeneic	assays	from	this	point	would	comprise	of	a	two-way	MLR	(unless	
otherwise	stated).		
In	order	to	assess	if	this	apparent	dose-response	was	unique	to	KA1010,	assays	were	
repeated	by	treating	a	two-way	MLR	with	CyA,	SAHA	and	KA1010	at	differing	doses.	All	
experimental	conditions	were	similar	to	those	described	above.		
The	untreated	control	response	produced	a	supernatant	IFN-γ	production	of	approximately	
800pg/ml	(Figure	4-31).	The	addition	of	compound	of	interest	to	the	culture	medium	
resulted	in	a	notable	(and	statistically	significant)	reduction	of	IFN-γ	production	(one-way	
ANOVA	p<0.0001,	F=16.44).	At	a	comparable	dose	of	0.3µM,	CyA	reduced	IFN-γ	release	by	
47%.	Of	the	HDAC	inhibitors,	SAHA	reduced	the	level	by	50%	and	KA1010	by	67%.	At	a	
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higher	dose	of	1µM,	all	compounds	resulted	in	further	significant	reduction	in	IFN-γ,	again	
with	the	HDAC6-selective	KA1010	having	the	greatest	effect,	reducing	production	by	91%.	
	
Figure	4-31	Culturing	allogeneic	PBMCs	for	five	days	in	the	presence	of	CyA	or	HDACi	
results	in	a	statistically	significant	reduction	in	IFN-γ	production	compared	to	an	untreated	
MLR	
	
4.5.3 Dose	response	curves	for	KA1010,	SAHA	and	CyA	
In	order	to	further	demonstrate,	the	dose	dependent	effect	of	CyA	and	HDACi,	a	series	of	
dose	response	MLRs	were	undertaken.	This	was	performed	using	the	compounds	(and	
doses)	in	Table	4-2.	
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Compound	 Dose	(Range)	-	µM	
CyA	 0.001,	0.003,	0.01,	0.03,	0.1,	0.3,	1,3,	10	
SAHA	 0.001,	0.003,	0.01,	0.03,	0.1,	0.3,	1,3,	10	
KA1010	 0.001,	0.003,	0.01,	0.03,	0.1,	0.3,	1,3,	10	
	
Table	4-2	Compounds	and	doses	used	to	produce	dose	response	curves	
As	with	previous	MLR	assays,	fresh	PBMCs	were	isolated	from	allogeneic	donors	and	
cultured	for	72	hours.	The	negative	control	consisted	of	autologous	cell	culture	only.	An	
allogeneic	assay	stimulated	using	PMA	&	Ionomycin	was	used	as	the	positive	control.	
Dose-response	curves	were	produced	by	plotting	IFN-γ	production	against	the	log	of	the	
concentration	of	compound	(Figure	4-32).	From	these	curves,	it	was	then	possible	to	
calculate	the	half	maximal	inhibitory	concentration	(IC50)	for	each	compound.	This	
quantitative	value	reflects	the	potency	of	the	compound	in	question.	It	was	also	possible	to	
calculate	the	Hill	slope	from	this	data.	As	these	compounds	have	an	inhibitory	effect,	this	
number	will	always	be	negative	(Goutelle	et	al.	2008).	The	Hill	slope,	though	not	an	absolute	
measure	of	efficiency	does	provide	an	indication	as	to	compound	function.	Calculated	from	
the	gradient	of	the	dose	response	curve,	the	further	the	value	is	from	1,	suggests	greater	
allosteric	binding	of	the	compound	(Prinz	2010).		
In	this	assay,	KA172	proved	excessively	potent	with	considerable	impairment	of	IFN-γ	
production	at	very	low	doses.	It	was	therefore	excluded	from	further	analysis	(data	not	
shown).		
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In	these	experiments,	both	CyA	and	SAHA	had	relatively	low	Hill	slope	values	(0.35	and	0.31	
respectively)	compared	to	KA1010	which	had	a	value	of	0.89.	This	likely	reflects	the	
specificity	of	HDAC6	inhibition,	compared	to	the	heterogeneity	of	binding	sites	and	differing	
affinities	(Shah	&	Haylett	2000)	of	CyA	and	SAHA.			
With	regards	to	the	dose	response	curves	specifically	(Figure	4-32),	all	compounds	produced	
sigmoid	curves,	demonstrating	a	degree	of	predictability	in	their	dosing.	At	the	higher	doses	
of	CyA	(3	and	10µM),	negligible	IFN-γ	was	detected,	suggesting	there	may	be	toxicity	at	
these	concentrations.	CyA	demonstrated	an	IC50	of	625nM	(consistent	with	published	data	
of	~600nM	(Leonessa	et	al.	2002)).	The	HDACis	were	however	considerably	more	potent	
compared	to	CyA	with	IC50’s	of	82.0nM	and	13.4nM	for	KA1010	and	SAHA	respectively.	Once	
again	the	potentially	toxic	effect	of	SAHA	was	demonstrated	with	no	IFN-γ	production	at	the	
higher	dosages	(>	3µM).	
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Figure	4-32	Dose	response	curves	for	CyA,	SAHA	and	KA1010	on	two-way	MLR	
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4.6 MLR	–	Activation	Markers	
Within	the	activation	process	of	T	cells,	several	surface	molecules	are	expressed	de	novo	
(Figure	4-33).	Evaluation	of	the	expression	of	these	markers	can	describe	the	activation	
status	of	the	lymphocyte.	The	effects	or	biological	activities	of	a	factor	(such	as	a	novel	
compound,	in	this	case,	HDACi)	on	a	T	cell	are	often	studied	by	the	expression	of	these	
antigens.	In	this	series	of	experiments,	the	effect	of	CyA	and	HDACi	on	the	following	
activation	markers	is	assessed:	
• CD69	(Very	early	expression)	
• earliest	inducible	cell	surface	glycoprotein	acquired	during	lymphoid	activation	
• involved	in	lymphocyte	proliferation	and	functions	as	a	signal-transmitting	
receptor	in	lymphocytes,	including	natural	killer	(NK)	cells,	and	platelets	
• CD25	(Early	expression)	
• α-chain	of	the	IL-2	receptor	
• not	involved	in	signal	transduction,	but	is	part	of	the	high	affinity	IL2-R,	
expressed	on	activated	cells	
• HLA-DR	(Mid-late	expression)	
• MHC	Class	II	surface	receptor,	high	levels	of	which	expressed	on	APCs	
• T	cells	also	express	HLA-DR	molecules	upon	activation,	although	with	slower	
kinetics	(when	compared	to	APCs)	
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Figure	4-33	Typical	pattern	of	T	cell	activation	markers	
Once	again,	this	assay	was	based	on	a	typical	two-way	MLR	assay,	using	freshly	isolated	
PBMCs	from	healthy	volunteers.	Cultures	were	incubated	at	37°C	for	three	days.	RPMI	
media	supplemented	with	10%	FCS.	Negative	control	consisted	of	an	autologous	cell	
culture,	and	the	positive	control,	an	allogeneic	culture,	stimulated	using	PHA	at	a	
concentration	of	5µg/ml.	Activation	marker	expression	was	assessed	at	0,24,48	and	72	
hours.	The	flow	cytometry	gating	strategy	(Figure	4-34)	involved,	first	of	all,	isolating	the	
CD4+	population	through	negative	selection	(by	staining	for	CD3+CD8+	cells)	and	then	
subsequent	staining	for	individual	activation	markers.		
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Figure	4-34	Gating	strategy	used	in	assessing	activation	markers	
In	the	initial	control	assay,	CD69	expression	is	relatively	low	(Figure	4-35	A).	CD25	
expression	is	greater	than	CD69	and	levels	are	potentially	falling	having	peaked	around	day	
2.	The	expression	of	HLA-DR	was	expected	to	be	higher	at	day	3,	though	a	moderate	
increase	is	noted.	This	is	not	a	truly	dynamic	study	and	it	is	therefore	difficult	to	establish	
whether	or	not	this	is	pre	or	post-maximal	expression.		
In	the	unstimulated	control	samples,	a	simple	allogeneic	culture	was	not	sufficient	to	elicit	
any	significant	response	in	terms	of	T	cell	marker	activation	(Figure	4-35	A).	However,	
mitogen	stimulation	of	the	assay	(using	PHA)	did	invoke	a	notable	response	(Figure	4-35	B).	
This	was	most	pronounced	in	terms	of	both	CD69	and	CD25	activation	but	also	notable	in	
terms	of	HLA-DR	expression.		
CD69	demonstrated	an	early	response	with	maximum	stimulated	expression	(as	expected)	
at	day	one	compared	to	unstimulated.	Increased	CD69	expression	was	maintained	over	the	
PBMC	Gate
CD3+CD8-
gate
(CD3+CD4+)
CD69 CD25 HLA-DR
CD3	
CD
8	
179	
	
assessed	time	period.	In	contrast,	CD25	expression	increased	over	the	time	period	up	to	the	
end	of	the	assay,	and	the	effect	of	stimulation	on	CD25	expression	may	have	been	more	
significant	over	a	longer	time	course	(published	data	suggests	CD25	expression	returns	to	
baseline	around	day	5	following	activation).	Stimulation	had	a	modest	effect	on	HLA-DR	
expression.	At	day	3,	there	was	a	notable	peak	emerging,	consistent	with	increased	late	
expression	compared	to	CD69	and	CD25.			
These	findings	were,	on	the	whole,	expected	and	consistent	with	published	data	on	T	cell	
activation	markers.		
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Figure	4-35	Control	samples	for	two-way	MLR,	assessing	activation	markers.	Unstimulated	
autologous	vs.	allogeneic	samples	(A).	Unstimulated	allogeneic	vs.	stimulated	allogeneic	
(B)	
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With	effective	controls	established,	it	was	next	possible	to	assess	the	effects	of	CyA	and	
HDACi	on	activation	markers	in	a	two-way	MLR.	
Effect	of	CyA	
	
Figure	4-36	Effect	of	CyA	on	activation	markers	in	a	two-way	MLR	
At	a	concentration	of	5µM,	CyA	(Figure	4-36)	had	a	small	effect	on	CD69	expression	over	
three	days	in	a	stimulated	assay.		
However,	there	was	a	notable	effect	on	CD25	expression.	At	24	hours	a	slight	reduction	in	
CD25	expression	was	observed	and	this	effect	was	further	exacerbated	over	time,	such	that	
at	72	hours	the	CyA	treated,	stimulated	assay	produced	levels	comparable	to	the	
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unstimulated	assay.	Again	this	was	not	an	entirely	unexpected	effect	as	the	T	cell	(including	
Treg)	depleting	effects	of	CyA	are	well	documented	(McMurchy	et	al.	2011).		
Treatment	of	the	assay	with	CyA	also	had	an	effect	on	HLA-DR	expression.	The	baseline,	
unstimulated	levels	of	expression	remained	consistent	over	the	time	period.	With	the	
untreated	stimulated	assay,	a	late,	high	signal	second	peak	was	observed,	which	became	
more	evident	over	time.	The	effect	of	CyA	on	this	peak	was	to	restrict	expression	to	
baseline,	unstimulated	levels.		
Effect	of	SAHA	
	
Figure	4-37	Effect	of	SAHA	on	activation	markers	in	a	two-way	MLR	
The	effect	of	SAHA	(at	a	concentration	of	100nM)	was	assessed.		
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Treatment	with	SAHA	did	demonstrate	an	effect	on	CD69	expression	(in	contrast	to	CyA)	
when	compared	to	an	untreated,	stimulated	population	(Figure	4-37).	This	effect	was	
progressive	over	time,	with	expression	in	the	stimulated	population	maintaining	consistency	
compared	to	a	steady	return	to	baseline	levels	in	the	treated	population.		
A	similar	pattern	of	effect	was	also	noted	on	CD25	expression.	However,	compared	to	CyA	
(and	particularly	at	day	2),	there	was	a	degree	of	preservation	of	CD25	expression	in	the	
treated,	stimulated	population.	This	likely	represents	the	alternative	mechanism	of	action	
demonstrated	by	HDACis	and	suggests	a	degree	of	IL-2	preservation	compared	to	CyA.	
With	regards	to	HLA-DR	expression,	SAHA	treatment	resulted	in	an	early	peak	at	day	1,	
followed	by	a	steady	decline	in	expression	over	time,	the	reasons	for	this	are	unclear.	The	
stimulated,	untreated	assays	demonstrated	the	reverse	of	this	with	a	steady	increase	in	
HLA-DR	expression	over	time.		
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Effect	of	KA1010	
	
Figure	4-38	Effect	of	KA1010	on	activation	markers	in	a	two-way	MLR	
The	effect	of	KA1010	(at	a	concentration	of	1000nM)	was	assessed	(Figure	4-38).		
As	with	CyA,	CD69	expression	was	largely	unaffected	by	the	presence	of	KA1010.	There	was	
only	a	small	shift	toward	CD69	downregulation	at	Day	3.	However,	compared	to	CyA	there	
was	a	degree	of	preservation	of	CD25	expression	over	time	with	the	greatest	effect	at	day	3	
(similar	to	SAHA),	and	this	possibly	reflects	the	HDACi-mediated	preservation	/	
enhancement	of	the	the	Treg	phenotype.	Again	the	pattern	of	HLA-DR	expression	was	similar	
amongst	the	HDACis	with	a	notable	peak	in	expression	detected	at	day	3.		
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Figure	4-39	Comparative	effects	of	CyA	and	HDACi	on	activation	markers	in	a	two-way	
MLR	
By	plotting	the	percentage	change	in	expression	compared	to	the	unstimulated	cells	a	
clearer	picture	emerges	(Figure	4-39).	In	general,	the	expression	of	CD69	is	in	gradual	
decline,	though	the	steepness	of	decline	in	the	HDACi	treated	samples	is	somewhat	greater	
compared	to	untreated	(stimulated)	and	CyA	samples,	suggesting	a	more	rapid	and	
complete	effect.	An	even	greater	effect	is	demonstrated	on	CD25	expression.	All	treatments	
used,	resulted	in	sa	significant	reduction	in	CD25	expression.	The	effect	of	CyA	was	to	
prevent	any	significant	increase	in	expression.	However,	HDACi	treatment	did	permit	a	
transient	rise	in	CD25	expression	at	day	2,	though	not	to	the	extent	of	the	stimulated	
sample.	This	observation	almost	certainly	reflects	the	differing	mechanism	of	action	
between	CyA	and	HDACi.		None	of	the	compounds	assessed	had	any	significantly	differential	
effect	on	HLA-DR	expression	compared	to	control.		
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4.7 Effect	of	HDACi6	treatment	on	cytokine	production	
A	body	of	evidence	exists,	that	demonstrates	one	of	the	potentially	beneficial	effects	of	
HDACis	in	terms	of	transplantation	is	a	reduction	in	the	release	of	pro-inflammatory	
cytokines.	One	such	study	involving	experimental	models	of	allogeneic	haematopoietic	cell	
transplantation	(allo-HCT)	(Reddy	et	al.	2004)	demonstrated	such	an	effect	with	SAHA	
through	induction	of	indoleamine-2,3-dioxygenase	(IDO).	The	likely	mechanism	of	this	is	
through	the	activation	of	signal	transducer	and	activator	of	transcription	3	(STAT-3)	(Reddy	
et	al.	2008;	Sun	et	al.	2009).	More	recently,	SAHA	has	been	demonstrated	to	reduce	
proinflammatory	cytokines	in	the	plasma	of	patients	undergoing	SAHA	treatment	in	a	GVHD	
phase	1/2	trial	(Choi	&	Jeong	2005)	as	well	as	increase	Treg	cell	number.		
However,	the	effect	of	targeted	HDAC	inhibition	on	cytokine	production	in	the	setting	of	an	
allogeneic	response	has	not	been	extensively	studied,	though	one	recent	study	has	reported	
that	Tubastatin	A	(HDAC6	inhibitor)	dampened	the	inflammatory	response	in	a	murine	
model	of	lethal	sepsis	(Li	et	al.	2015).		
Therefore	to	assess	the	effect	of	HDAC6	inhibition	on	cytokine	production	in	a	transplant	
model,	ELISA-based	assays	were	performed	on	plasma	recovered	from	two-way	MLRs.	The	
MLRs	had	been	treated	with	either	CyA,	SAHA	or	KA1010.	The	panel	of	cytokines	selected	
were	based	on	those	typically	associated	with	an	alloresponse	and	are	listed	in	the	table	
below	(Table	4-3).	
Cytokine	 Produced	by	 Role	in	allogeneic	
response	
Effect	on	Tregs	
Tumour	necrosis	
factor	alpha	(TNFα)	
Macrophages,	CD4+	
lymphocytes,	NK	cells,	
Involved	in	
proliferative	
Reduces	FoxP3	
levels(Nie	et	al.	
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PRO-INFLAMMATORY	
mast	cells,	eosinophils	 response	and	
development	of	
cytotoxic	T	cells	
(Lukacs	et	al.	1993)	
2013;Valencia	et	
al.	2006)		
Reduces	
suppressive	
capacity	of	
Tregs(Wang	et	al.	
2008)	
MMP-9	
	
PRO-INFLAMMATORY	
Monocytes,	
macrophages,	
endothelial	cells	
Reduces	surface	
expression	of	CD25	
on	responding	T-cells	
(Ding	et	al.	2009)	
Reduces	Foxp3	
expression	
IL-10	
	
ANTI-INFLAMMATORY	
	
Monocytes,	
Macrophages		
Inhibitor	of	IFNγ,	
TNFα,	IL-1β,	IL-6	and	
IL-8	production	
Downregulates	HLA-
DR	expression	
Produced	by	Tregs	
(Maynard	et	al.	
2007)	
IL-1a	
	
PRO-INFLAMMATORY	
Macrophages,	
neutrophils,	epithelial	
cells	and	endothelial	
cells	
Stimulates	
thymocyte	
proliferation	by	
inducing	IL-2	release.	
Involved	in		
inflammatory	
response	as	
endogenous	
pyrogens	
Unclear		
IL-17	
	
PRO-INFLAMMATORY	
T	cells	(Th17),	
fibroblasts	
associated	with	
allograft	rejection	
(Min	et	al.	2009)	by	
stimulating	
secrenflammatory	
cytokines	such	as	IL6	
Unclear,	but	may	
cause	conversion	
of	Treg	phenotype	
(to	Th17)	
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and	TNFα	
	
Table	4-3	Cytokines	involved	in	alloimmune	response	
The	assay	involved	a	bead-based	multiple	analyte	detection	platform	whereby	antibody	
coated	beads	are	incubated	with	treated	culture	supernatants.	Target	analytes	are	then	
captured	by	specific	antibodies	on	each	bead.	Biotin-conjugated	paired	antibodies	are	
added,	followed	by	Streptavidin-PE	in	order	to	facilitate	detection.	Flow	cytometry	is	then	
used	to	differentiate	specific	populations,	based	on	bead	size	and	fluorescence.		
The	effects	of	the	following	compounds	(and	concentrations)	in	a	human	MLR	were	
assessed:	
- CyA		 0.003,	0.01,	0.03,	0.1,	0.3,	1.0,	3.0,	10.0	µM	
- SAHA	 0.003,	0.01,	0.03,	0.1,	0.3,	1.0,	3.0,	10.0	µM	
- KA1010	 0.003,	0.01,	0.03,	0.1,	0.3,	1.0,	3.0,	10.0	µM		
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Figure	4-40	Two-way	MLR	cytokine	release	following	immunomodulatory	treatment	
The	results	of	these	assays	were	somewhat	variable	(Figure	4-40)	with	very	few	providing	
any	consistent	trends	from	which	to	draw	a	meaningful	conclusion.		
The	data	from	the	TNFα	analysis	would	suggest	that	treatment	with	the	HDACi	compounds	
had	the	effect	of	reducing	production	of	this	cytokine	when	compared	with	CyA.	Though	
interpretation	of	this	data	could	certainly	not	be	considered	reliable,	this	would	appear	
consistent	with	published	data	relating	to	the	effects	of	CyA	(Bunikowski	et	al.	2001)	and	the		
pan-HDACi	Trichostatin	A	(TsA)	(Grabiec	et	al.	2010).		
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A	similar	trend	was	also	observed	in	the	analysis	of	IL-1α,	particularly	at	the	higher	range	of	
doses	of	compounds	used.		At	the	higher	doses	of	CyA	(>0.1µM)	there	is	appreciably	more	
IL-1α	production	(>10,000).	This	finding	goes	against	previously	published	data	(Won,	
Sauder,	&	McKenzie	1994)	which	has	demonstrated	a	3-4	fold	inhibitory	effect	with	a	dose	
of	20µM	CyA.	The	effect	of	HDACi	was	inconsistent,	though	KA1010	treatment	at	all	doses	
resulted	in	reduced	IL-1α	expression,	below	the	4000pg/ml	observed	under	control	
conditions.	These	findings	were	similar	to	those	described	by	Joosten	et	al.	(Joosten	et	al.	
2011)	when	they	treated	synovial	cells	with	the	class	I	and	II	HDAC	inhibitor,	ITF2357	
(givinostat).			
IL-10	expression	did	have	a	slightly	more	predictable	response	to	treatment.	There	was	
generally	a	dose	dependent	effect	seen	with	CyA	and	SAHA	and	this	was	quite	profound	at	
the	higher	doses	(both	treatments	resulted	in	IL-10	production	of	<50pg/ml	at	doses	of	3µM	
and	above,	compared	to	563pg/ml	production	in	the	untreated	control).	Previous	studies	
examining	the	effect	of	HDACi	on	IL-10	production	have	demonstrated	that	treatment	with	
TSA	(Class	I	&	II	inhibitor)	and	Panobinostat	(pan-HDACi)	increased	IL-12	production	with	a	
concomitant	reduction	in	IL-10	production	(Wang	et	al.	2011).	Further	studies	(Cheng	et	al.	
2014),	looking	specifically	at	the	role	of	HDAC6	in	IL-10	production	in	murine	APCs,	found	
that	pan-HDAC	and	Class	II	HDAC	inhibitors	down	regulate	IL-10	production	by	these	cells.	It	
is	somewhat	surprising	therefore	that	KA1010	did	not	appear	to	have	more	of	an	effect.		
Finally,	IL-17	production	was	again	significantly	reduced	with	the	treatment	of	CyA.	At	all	
concentrations,	CyA	reduced	IL-17	production	to	100-150	pg/ml	compared	to	550	pg/ml	in	
the	untreated	control.	It	has	previously	been	reported	that	the	treatment	of	T	cells	with	CyA	
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in	normal	and	rheumatoid	arthritis	patients	reduced	IL-17	production	at	the	protein	and	
mRNA	level.	It	has	been	postulated	that	this	effect	is	due	to	a	similar	response	
The	effect	of	HDACi	on	IL-17	production	was	less	consistent.	SAHA	had	the	least	effect	in	
terms	IL-17	suppression	with	several	mid-range	concentrations	resulting	in	production	
greater	than	baseline	control.	Again	this	was	in	contradiction	to	previously	published	
reports	of	SAHA	causing	significant	reduction	in	IL-17	expression	at	both	gene	and	protein	
levels	in	murine	cardiac	allograft	models	(Zhang	et	al.	2012).		
Overall,	the	outcomes	of	this	multiplex	assay	were	generally	disappointing,	with	significant	
variation	observed	among	individual	cytokines,	making	interpretation	difficult.	There	were	
however,	a	small	number	of	results	which	could	be	cautiously	interpreted	as	described	
above.	Principally	these	were	the	effect	of	HDACi	on	TNFα	and	IL-1α	suppression,	the	dose-
dependent	suppression	of	IL-10	by	CyA	and	SAHA	and	the	uniform	suppression	of	IL-17	by	
CyA.		
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Chapter	5	-	Results	
5 Ex	vivo	effects	of	histone	deacetylase	inhibition	on	
allotransplantation	
5.1 Introduction	
The	previous	two	chapters	reveal	a	potential	role	of	HDACi	in	terms	of	in	vitro	models	of	
transplantation	and	the	MLR	is	a	useful	surrogate	tool.	However	to	further	assess	the	
immunosuppressive	effects	of	KA1010,	an	in	vivo	model	was	required.		
The	utilisation	of	murine	models	has	had	a	pivotal	role	in	transplantation,	and	the	discovery	
and	development	of	numerous	related	aspects	from	evolving	surgical	techniques	to	testing	
new	and	novel	immunosuppressive	treatments.		
Since	the	advent	of	modern	transplantation	and	early	research	by	the	likes	of	Billingham	and	
Medawar,	the	murine	skin	graft	model	has	become	a	mainstay	of	in	vivo	research.	Though	it	
has	limited	transferability	in	terms	of	reproducing	complex	human	alloimmune	processes,	it	
does	provide	a	rapid	and	simple	platform	on	which	to	assess	potentially	
immunosuppressive,	novel	compounds	such	as	KA1010.		
This	chapter	details	the	results	of	untreated	syngeneic	and	allogeneic	skin	transplant	in	mice	
and	defines	the	changes	observed	during	the	rejection	process.	Beyond	this,	the	effect	of	
treating	murine	recipients	with	various	KA1010	regimens	is	observed	both	macroscopically	
and	histologically.		
The	effects	of	treatment	on	several	physiological	parameters	such	as	body	weight	and	
splenic	index	are	also	assessed,	looking	for	any	potential	short	or	longer	term	side	effects	
KA1010	treatment	may	manifest	in	vivo.	
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Finally,	to	support	the	hypothesis,	that	KA1010	mediates	its	immunosuppressive	effect	
through	the	upregulation	of	regulatory	T	cells,	the	effects	of	treatment	on	T	cell	subset	
expression	is	analysed	through	flow	cytometry	
	
5.2 The	Skin	Allograft	Model	
In	order	to	further	assess	the	immunosuppressive	effects	of	KA1010,	an	in	vivo	murine	
model	of	transplantation	was	adopted.	This	was	based	on	an	established	model	using	
allogeneic	skin	grafts	in	mice,	to	investigate	the	immune	mediated	response	of	acute	
allograft	rejection	(Lagodzinski,	Gorski,	&	Wasik	1990;Yun	et	al.	2003).		This	model	has	
several	advantages	in	that	the	procedure	itself	is	quick	and	relatively	simple,	requiring	only	a	
short	period	of	time	to	develop	the	surgical	techniques	required.	Secondly,	skin	is	a	highly	
immunogenic	tissue,	and	the	process	of	skin	graft	rejection	is	well	studied	and	provides	a	
robust	and	reproducible	immunological	reaction.	The	difficulty	with	this	model,	however,	
can	be	in	determining	the	point	at	which	skin	rejection	has	occurred	in	vivo.	In	order	to	
overcome	this,	a	quantitative	scoring	system	based	on	digital	photography,	developed	by	
Schwoebel	et	al.	(Schwoebel	et	al.	2005)	was	used	(Table	5-1).	In	addition,		histological	
analysis	was	also	undertaken	to	determine	further	the	extent	(or	lack	of)	rejection	
microscopically.		
Score	 Graft	rejection	
0	 Intact	graft	
1	 First	clear	signs	of	graft	rejection	
2	 >25%	
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3	 >50%	
4	 >75%	
5	 Complete	rejection	(>95%)	
	
Table	5-1	Quantitative	assessment	scoring	system	for	mouse	skin	transplant	model	
	(adapted	from	Schwoebel	et	al.)	
	
5.2.1 Syngeneic	and	Allogeneic	controls	
A	standard	protocol	based	on	methods	described	by	Garrod	and	Cahalan	was	adapted	
(Garrod	&	Cahalan	2008)	–	see	Materials	&	Methods.	This	model	utilised	two	widely	
available	immunocompetent	inbred	strains	of	mice;	C57BL	(or	C57	black	6)	and	BALB/c.	
These	strains	of	mice	are	commonly	available	and	have	a	robust	history	of	use	in	transplant	
related	research.	A	syngeneic	model	was	used	as	the	positive	control	(would	expect	100%	
survival)	and	an	untreated	allogeneic	model	as	the	negative	control	(Figure	5-1).		
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Figure	5-1	Expected	outcome	for	syngeneic	and	allogeneic	murine	skin	grafts	
In	summary,	the	skin	graft	model	consisted	of	harvesting	skin	samples	from	both	the	ear	
and	the	dorsum	of	donor	mice.	The	donor	skin	samples	were	then	prepared	by	removing	
excess	connective	tissue	and	fat.	Recipient	graft	sites	were	prepared	by	excising	an	area	of	
skin	on	the	dorsal	surface.	Donor	grafts	were	then	placed	on	the	recipient	and	secured	using	
sutures.	A	dressing	was	applied	to	the	graft	site	which	remained	in	situ	until	the	5th	post-
operative	day.		
Controls	were	established	using	syngeneic	and	allogeneic	grafts	in	untreated	recipients.		
Time Time 
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Syngeneic	control	
Donor	skin	was	harvested	from	black	C57/BL	strain	mice	and	grafted	onto	the	dorsum	of	
albino	C57/BL	strain	recipients	(Figure	5-2	A).		
Syngeneic transplant
C57BL	mouse
C57BL	albino	mouse
A	
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Figure	5-2	Syngeneic	murine	skin	graft.	A)	Schematic	representation	of	donor	and	
recipient	graft	sites.	B-E)	Representative	photographs	demonstrating	healing	graft	with	no	
macroscopic	evidence	of	rejection.	F&G)	Histological	appearances	of	syngeneic	graft	
After	28	days	(without	any	form	of	immunosuppressive	treatment)	there	was	no	
macroscopic	evidence	of	rejection	(Figure	5-2	B-E).	Once	the	observation	period	had	been	
completed	the	recipient	subject	was	sacrificed	and	microscopic	analysis	of	the	graft	site	and	
adjacent	skin	/	soft	tissue	undertaken.	Microscopic	analysis	also	demonstrated	no	evidence	
of	histological	rejection	(Figure	5-2	F,	G).		
Allogeneic	control	
Donor	skin	was	harvested	from	white	BALB/c	strain	mice	and	grafted	onto	the	dorsum	of	
black	C57/BL	strain	recipients	(Figure	5-3	A).		
10x	 20x	
F	 G	
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C57BL	
mouse 
BALB/c	mouse 
Allogeneic 
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Figure	5-3	Allogeneic	murine	skin	graft.	A)	Schematic	representation	of	donor	and	
recipient	graft	sites.	B-D)	Representative	photographs	demonstrating	graft	dehiscence	and	
scarring.	F&G)	Histological	appearances	of	allogeneic	graft	(day	14)	
After	7-21	days,	all	allogeneic	grafts	had	undergone	a	complete	rejection	process	(n=6)	
which	resulted	macroscopically	in	graft	dehiscence	and	graft	site	scarring	(Figure	5-3	B-D).	
Histological	appearances	manifested	as	epidermal	ulceration	and	lifting	of	the	graft	
epidermis,	dermal	lymphocyte	infiltration	and	fibroplasia	with	destruction	of	hair	follicles	
(Figure	5-3	E,	F).	
5.2.2 Effect	of	KA1010	treatment	on	allogeneic	model	
In	order	to	assess	the	in	vivo	effect	of	KA1010,	the	same	allogeneic	model	was	adopted.	
Recipients	were	stratified	into	a	number	of	groups	and	treated	accordingly	(Table	5-2)	for	up	
to	70	days.	Macroscopic	rejection	was	analysed	using	the	method	previously	described	
(Schwoebel	et	al.	2005).	Rejection	was	considered	to	have	occurred	at	>50%	graft	
loss.	Following	the	treatment	period,	the	graft	site	was	excised,	and	formalin	fixed	paraffin	
embedded	sections	were	stained	with	Haematoxylin	&	Eosin	and	histological	assessment	
made.	
10x	 20x	
E	 F	
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Arm		 1		 2		 3		
Treatment		 No	Treatment		 KA1010	
[160mg/kg]	ip	od		
KA1010	[80mg/kg]	
ip	od		
Number		 6		 6		 6		
	
Table	5-2	Treatment	groups	for	skin	model	of	allogeneic	transplantation	
Macroscopic	graft	survival	analysis	(Figure	5-4)	demonstrates	that	no	significant	rejection	
was	noted	among	untreated	syngeneic	graft	recipients	(C57BL/6	donor	skin,	grafted	onto	
C57BL/6	albino	recipient).	In	this	series	of	untreated	allogeneic	graft	recipients,	rejection	
occurred	from	day	five	and	all	subjects	had	rejected	by	day	18.		
Assessment	of	allogeneic	recipients	treated	with	single-agent	KA1010	at	a	once-daily	dose	
of	160mg/kg	(edisylate	salt)	[160mg/kg	of	edisylate	salt	is	equivalent	to	100mg/kg	of	free	
base]	via	the	intra-peritoneal	injection	(ip)	route,	resulted	in	significant	graft	survival,	with	
77%	of	recipients	maintaining	a	viable	graft	at	the	end	of	the	treatment	period.	Graft	
survival	reduced	to	50%	in	allogeneic	recipients	receiving	the	lower	dose	of	KA1010	
[80mg/kg	of	edisylate	salt	-	equivalent	to	50mg/kg	of	free	base].	Log-rank	analysis	of	the	
survival	curves	(Mantel-Cox)	demonstrates	a	significant	difference	between	the	curves	with	
a	p	value	<	0.0001.		
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Figure	5-4	Kaplin-Meier	survival	curves	demonstrating	the	macroscopic	effect	of	KA1010	
on	murine	skin	graft	model	
5.3 Effect	of	KA1010	on	subject	weight	
In	addition	to	treating	mice	with	the	single	agent	HDACi	(KA1010),	the	effect	of	
treatmentwith	Rapamycin	(both	in	isolation	and	in	combination	with	KA1010)	was	also	
assessed	(	
Table	5-3).	
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	 Skin	donated	from	BALB/c	mouse	grafted	onto	gender	matched	C57/Bl6	mouse	
Arm		 1		 2		 3		 4		 5		 6		
Treatment		
No	
Treatment		
KA1010	
[160mg/kg]		
ip	od		
KA1010	
[160mg/kg]		
ip	od		
KA1010	
[80mg/kg]		
ip	od	
KA1010	
[80mg/kg]	
+	
Rapamycin	
[50mg/kg]		
ip	od		
Rapamycin	
[50mg/kg]		
ip	od		
Number		 6		 6		 6		 4		 4		 4		
Duration		 28	days		
	
28	days		 70	days	 28	days		 28	days		 28	days		
	
Table	5-3	Treatment	groups	used	to	assess	physiological	effects	of	KA1010	and	Rapamycin	
Treating	mice	with	the	higher	dose	of	KA1010	(160mg/kg)	long-term	(70	days)	had	a	
negative	impact	on	weight	gain	over	time	(Figure	5-5).	Treating	mice	with	the	lower	dose	of	
KA1010	(80mg/kg)	had	no	significant	effect	on	protracted	weight	gain.		
All	subjects	undergoing	the	skin	graft	procedure	lost	an	initial	5-6%	in	weight	over	the	first	
24-48	hours	post-procedure.	Untreated	mice	and	those	treated	with	KA1010	at	a	dose	of	
80mg/kg	gained	weight	at	a	steady	rate	over	the	study	period,	such	that	by	day	14	both	
groups	had	gained	approximately	10%	compared	to	their	initial	weight.	Beyond	this	period	
the	rate	of	weight	gain	in	the	group	treated	with	KA1010	(80mg/kg)	remained	positive	but	
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at	a	rate	less	than	the	untreated	group.	Stopping	treatment	at	28	days	had	little	impact	on	
the	rate	of	weight	gain	(compared	to	the	effect	seen	in	the	group	treated	with	KA1010	at	a	
dose	of	160	mg/kg	for	28	days).		
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Figure	5-5	Effect	of	KA1010	and	Rapamycin	on	weight	gain	in	mice	undergoing	skin	
grafting	
Treatment	with	the	higher	dose	of	KA1010	(160mg/kg)	long	term	(for	a	period	of	70	days)	
resulted	in	weight	loss	to	approximately	90%	of	original	weight.	A	steady	weight	was	
subsequently	maintained	at	this	level	throughout	the	treatment	period.	However,	data	for	
those	mice	treated	for	a	shorter	period	(28	days)	would	appear	to	contradict	this	as	they	
returned	to	initial	weight	after	10	days.	They	continued	to	gain	weight	steadily	throughout	
the	treatment	period	so	that	by	day	28	they	were	approximately	110%	of	their	initial	body	
weight.	The	reasons	for	this	disparity	are	unexplained.	After	stopping	treatment	with	the	
higher	dose	HDACi,	there	was	a	dramatic	increase	in	weight	gain	such	that	subjects	gained	
approximately	10%	of	body	weight	over	a	very	short	period	of	time	(24-48	hours),	again	the	
reasons	for	this	are	unclear.		
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The	effect	of	treating	mice	with	Rapamycin	had	a	slightly	different	effect	compared	to	
KA1010.	In	those	subjects	treated	with	Rapamycin	alone	(at	a	dose	of	50mg/kg)	steady	
weight	gain	was	observed	throughout	the	treatment	period,	such	that	at	28	days	this	group	
had	a	mean	body	weight	which	was	approximately	10%	greater	than	the	untreated	control	
group.	Interestingly,	when	Rapamycin	(50mg/kg)	was	used	in	combination	with	KA1010	
(80mg/kg)	as	treatment,	the	weight	gain	profile	was	almost	identical	to	that	observed	in	the	
single	agent	KA1010	(80mg/kg)	group.		
	
5.4 Effect	of	KA1010	on	lymphoid	organs	
Calculating	the	splenic	index	is	an	established	method	of	assessing		the	effects	of	a	
compound	on	lymphoid	organs	and	potential	immunotoxicity	(Yu	et	al.	2007).	It	is	calculated	
by	the	following	equation:	
Weight	of	spleen	(mg)	/	body	weight	(g)	
This	results	in	a	relative	index	and	allows	comparisons	to	be	made	between	different	
treatment	groups;	however	detailed	immunotoxic	effects	do	need	to	be	assessed	using	
histopathological	techniques	to	assess	lymphoid	tissue	in	detail.		
Previous	studies	assessing	the	potential	role	of	HDACis	as	an	anti-tumour	agent	in	mouse	
models	of	acute	lymphoblastic	leukaemia	(Einsiedel	et	al.	2006),	found	that	SAHA	reduced	
spleen	weight	non-significantly.	This	data	assesses	the	effects	of	KA1010	and	Rapamycin	on	
the	splenic	index	of	mice	undergoing	allogeneic	skin	transplant.		
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Figure	5-6	Effect	of	KA1010	and	Rapamycin	on	mice	splenic	index.	Treatment	period	is	for	
28	days	unless	stated	(n=8	for	each	group)	
A	normal	splenic	index	would	be	expected	to	be	approximately	3.7	(Grass	et	al.	1999).	In	this	
series,	the	untreated	control	group	had	a	mean	splenic	index	of	3.5	(SEM	0.2,	IQR	3.0-3.9).	
Treatment	with	KA1010	(Figure	5-6)	at	a	dose	of	160mg/kg	for	28	days	resulted	in	a	non-
significant	increase	(unpaired	t-test	p=0.37)	in	splenic	index	to	4.2	(SEM	0.8,	IQR	2.9-5.3).	If	
this	treatment	period	was	extended	to	70	days	(same	dose),	the	splenic	index	fell	back	to	a	
value	of	3.2	(SEM	0.2,	IQR	2.7-3.6).	The	effect	of	reducing	the	dose	of	KA1010	to	80mg/kg	
over	28	days	had	less	of	an	effect	compared	to	the	higher	dose	treatment	with	a	splenic	
index	of	3.2	(SEM	0.5,	IQR	2.5-4.2).	Again	this	dose	was	not	significant	(p=0.43)	when	
compared	to	a	dose	of	160mg/kg.		
207	
	
The	effect	of	treatment	with	Rapamycin	in	combination	with	low	dose	KA1010	(80mg/kg)	
for	28	days	resulted	in	the	most	dramatic	change	(though	not	quite	statistically	significant,	
p=	0.08).	Under	these	conditions	a	reduction	in	splenic	index	compared	to	control	was	
observed	with	a	value	of	2.8	(SEM	0.2,	IQR	1.8-3.6).	Treatment	for	28	days	with	Rapamycin	
alone	(50mg/kg)	resulted	in	a	reduction	of	the	splenic	index	to	3.2	(SEM	0.04,	IQR	3.1-3.2).	
This	reduction	was	not	statistically	significant	(p=0.39).	
	
5.5 Effect	of	KA1010	and	Rapamycin	treatment	on	CD4	expression	in	murine	
allogeneic	skin	transplant	model	
To	determine	the	effect	of	HDAC6i	on	the	Treg	population,	the	levels	of	CD4+	T	cells	and	
CD4+FoxP3+	regulatory	T	cells	in	harvested	splenic	tissue	were	compared,	from	treated	and	
untreated	subjects.		
Lymphocytes	were	first	isolated	from	the	splenic	tissue	and	stained	for	CD4+	expression.	The	
proportion	of	CD4+	cells	identified	were	calculated	using	flow	cytometry	(Figure	5-7).		
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Figure	5-7	Example	of	gating	strategy	employed	to	identify	CD4+	T	cells	and	regulatory	
(FoxP3+)	T	cells.	A)	Isolation	of	CD3+	T	cells.	B)	Isolation	of	CD4+	T	cells.	C)	Identification	of	
FoxP3+	T	cells	
Treating	mice	undergoing	skin	transplantation	with	KA1010	(at	a	dose	of	160mg/kg)	for	28	
days	resulted	in	a	non-significant	(p=0.09)	reduction	in	CD4+	expression	from	57.7%	(SEM	
+/-1.9)	to	53.3%	(SEM	+/-1.4)	(Figure	5-8).	If	the	treatment	period	was	extended	to	70	days,	
however,	a	significant	reduction	in	CD4+	T	cells	to	46.9%	of	the	lymphocyte	population	
(p=0.0009)	was	observed.	KA1010	treatment	at	a	dose	of	80mg/kg,	had	a	negligible	effect	
on	CD4+	expression	(reducing	expression	to	55.9%,	SEM	+/-2.4).	However,	treatment	with	
this	dose	in	combination	with	Rapamycin	(50mg/kg)	did	result	in	a	significant	reduction	
C	
A	 B	
209	
	
(p=0.003)	in	CD4+	expression	to	48.1%	(+/-1.4).	This	reduction	is	most	likely	due,	primarily	to	
the	effect	of	Rapamycin	in	this	combination,	as	Rapamycin	alone	has	a	similar	effect	(as	
opposed	to	the	negligible	effect	of	KA1010	at	80mg/kg)	in	reducing	CD4+	expression	to	
51.3%	(+/-	0.9,	p=0.01),	though	the	difference	is	not	statistically	significant.		
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Figure	5-8	CD4	expression	following	HDAC6i	and	Rapamycin	treatment.	Treatment	for	28	
days	unless	stated	(n=5	for	each	group)	
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5.6 Effect	of	KA1010	and	Rapamycin	treatment	on	Treg	expression	in	murine	
allogeneic	skin	transplant	model	
The	findings	observed	with	respect	to	CD4+	expression	were	in	general	converse	to	those	
seen	in	terms	of	regulatory	T	cell	expression.		Once	again,	lymphocytes	were	isolated	from	
splenic	tissue	of	mice	undergoing	identical	treatment	conditions.		Positive	selection	of	CD4+	
T	cells	was	undertaken	and	these	cells	were	then	stained	for	FoxP3	transcription	factor	in	
order	to	identify	the	Treg	subpopulation	(Figure	5-7).			
Within	the	untreated	population,	18.5%	(+/-	0.7)	of	the	CD4+	T	cells	expressed	FoxP3	(Figure	
5-9).	Treatment	with	KA1010	(160mg/kg)	resulted	in	a	significant	increase	in	FoxP3	
expression	to	21.2%	(+/-	0.6,	p=0.02).	As	with	CD4+	expression,	the	apparent	effect	of	
KA1010	at	this	dose	over	an	extended	period	(70	days)	was	amplified,	resulting	in	FoxP3	
expression	proportionally	increasing	to	25.7%	(+/-	0.7,	p=0.0002).		
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Figure	5-9	FoxP3	expression	among	the	CD4+	population,	following	HDAC6i	and	Rapamycin	
treatment.	Treatment	for	28	days	unless	stated	(n=5	for	each	group)	
KA1010	at	the	lower	dose	of	80mg/kg	had	no	effect	with	the	total	proportion	of	FoxP3+	cells	
representing	17.7%	(+/-0.9,	p=0.5)	of	the	CD4+	population.	The	addition	of	Rapamycin	
(50mg/kg)	to	this	treatment	regimen	had	little	effect	(17.3%	+/-1.2,	p=0.4).	Treatment	with	
Rapamycin	(50mg/kg)	alone	also	had	a	limited	effect	in	terms	of	FoxP3	expression,	though	
the	mean	expression	was	slightly	greater	than	control	at	20.1%	(+/-2.3,	p=0.4).		
In	order	to	facilitate	comparisons	between	the	effects	of	compounds	on	T	cell	morphology	
the	relative	proportions	of	FoxP3+	cells	to	CD4+	cells	was	calculated	(Figure	5-10).		
212	
	
Un
tre
ate
d
KA
10
10
(16
0m
g/k
g)
KA
10
10
(16
0m
g/k
g)	
-	fo
r	7
0d
KA
10
10
(80
mg
/kg
)
KA
10
10
(80
mg
/kg
)+R
AP
A(5
0m
g/k
g)
RA
PA
(50
mg
/kg
)
0
20
40
60
CD
4+
Fo
xP
3+
/	C
D4
+ (
%
)
	
Figure	5-10	Effect	of	treatment	on	proportion	of	Treg:CD4+	T	cells	expression	
By	combining	this	data,	to	compare	the	Teff:Treg	ratio,	it	can	be	concluded	
that	the	most	effective	treatment	regimen,	achieving	the	greatest	proportion	of	Treg	
numbers	was	treatment	with	KA1010	(at	a	dose	of	160mg/kg)	for	a	70	day	period	
(statistically	comparing	treatment	regimens	with	control	using	Dunnets	multiple	comparison	
test	demonstrated	this	as	the	only	significant	regimen	with	p<0.05).	
Published	data	suggests,	the	frequency	of	Tregs	in	lymphoid	tissue	of	C57	strain	mice	of	a	
similar	age	to	be	in	the	vicinity	of	15-20%	(Zhao	et	al.	2007)	and	this	would	be	consistent	
with	the	data	above.	It	has	also	been	shown	that	higher	numbers	of	FoxP3	cells	are	directly	
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proportional	to	improved	graft	outcomes	(Brown	et	al.	2007),	which	would	again	be	
consistent	with	this	data.		
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Chapter	6	
6 Discussion	
The	aim	of	this	study	was	to	assess	the	potential	immunosuppressive	role	of	the	histone	
deacetylase	inhibitor	group	of	compounds	as	pharmaceutical	agents	for	use	in	
transplantation.	In	addition	to	this,	identifying	a	specific	compound	from	this	family,	with	
desirable	characteristics	which	could	be	evaluated	further,	with	the	goal	of	taking	it	forward	
for	additional	development	and	even	clinical	trial	has	also	been	achieved.		
Through	Western	blot	analysis	we	have	identified	the	ubiquitous	presence	of	a	number	of	
HDACs	among	T	cell	sub-populations,	including	HDAC6,	the	specific	target	of	KA1010.	This	is	
consistent	with	other	studies	which	have	demonstrated	the	presence	of	all	eleven	HDACs	in	
resting	T	cells	(Keedy	et	al.	2009).	The	presence	of	HDAC	within	the	CD4+CD25+	subset	can	
be	assumed,	through	multiple	studies	demonstrating	an	effect	of	HDACi	on	FoxP3	
acetylation,	however,	no	evidence	can	be	found	which	has	previously	delineated	this	
specifically	through	Western	blot	protein	analysis.	These	results	partially	address	this	by	
demonstrating	the	presence	of	HDACs	2,	3,	4,	6	and	9	within	this	important	and	relevant	
sub-group.		
One	of	the	major	dose-limiting	factors	of	current	immunosuppression	regimens	relates	to	
off-target	toxicity	profiles,	notably	nephrotoxicity.		Clinically	approved	pan-HDACis	such	as	
SAHA,	are	reasonably	well	tolerated	agents,	with	generally	better	side	effect	profiles	
compared	to	CNIs	(Wagner	et	al.	2010).	They	are	of	course	not	without	some	deleterious	
effects.		
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The	main	application	of	pan-HDAC	inhibitors	to	date	has	been	in	an	oncological	setting,	
where	the	broad	target	profile	and	comparatively	high	dosages	administered	have	been	
generally	accepted,	despite	these	side	effects.	Nausea,	fatigue,	cardiac	conductive	
abnormalities	and	thrombocytopenia	(de	Ruijter	et	al.	2003)	have	all	been	associated	with	
the	clinical	use	of	pan-HDAC	inhibitors	such	as	SAHA	and	sodium	valproate,	though	in	
general	these	effects	have	been	found	to	be	reversible.	It	is	unsurprising	that	given	their	
broad	range	of	targets,	a	wide	and	varied	side	effect	profile	among	different	pan-HDACi	
compounds	occurs.	However,	as	the	availability	of	potential	HDAC-specific	drugs	with	
improved	targeting	increases,	through	engineering	and	continued	discovery	of	naturally	
occurring	compounds,	the	side	effect	profiles	would	also	be	expected	to	lessen.		
Despite	being	a	relatively	recently	discovered	class	of	compounds,	the	side	effect	profiles	of	
pan-HDACis		are	fairly	well	documented,	however	the	toxicity	profiles	of	HDACi	at	a	cellular	
level,	in	general,	are	poorly	understood.	This	may	be	because	their	role	to	date	has	been	
limited	to	the	oncological	environment	and	an	effect	which	may	be	deemed	covetable	in	
this	setting	would	possibly	be	seen	as	detrimental	in	an	alternative	clinical	setting,	such	as	
transplantation,	where	therapeutic	dosages	are	likely	to	be	different.	With	this	in	mind,	we	
undertook	a	cell	viability	assay,	in	order	to	ensure	that	any	potential	compounds	we	took	
further	forward	would	not	have	unacceptable	toxicity	that	would	preclude	them	from	any	
potential	clinical	application.	The	basic	toxicity	studies	undertaken	in	this	study,	assessed	
the	effect	of	treatment	on	PBMCs	and	were	found	to	support	the	theory	that	targeted	HDAC	
inhibition	is	potentially	safer.	In	our	study	we	found	evidence	that	SAHA	causes	greater	
toxicity	at	a	dose	of	2µM	compared	with	HDAC	specific	inhibition	in	the	form	of	KA1010	at	
doses	of	10µM.	
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Once	it	had	been	established	that	HDAC	inhibitors	are	generally	safe	up	to	dosages	in	the	
µM	range	in	vitro,	it	was	then	possible	to	establish	which	agents	from	a	panel	of	both	
traditional	and	novel	compounds	had	potential	immunosuppressive	properties,	through	
simple	proliferation	assays	involving	Jurkat	cells	and	PBMCs.	A	panel	of	ten	HDACi	
compounds	were	supplied	by	Karus.	As	investigators,	in	order	to	reduce	interpretive	bias,	
the	only	information	supplied	at	this	stage	was	the	molecular	weight	and	therapeutic	range	
for	each	compound.		
The	effect	of	HDACi	on	Jurkat	cell	proliferation	was	variable	and	no	consistent	pattern	was	
noted.	Though	this	series	of	experiments	provided	few	conclusions	in	terms	of	proliferative	
effect,	it	did	however	provide	a	degree	of	validation	to	the	toxicity	assays	previously	
undertaken.	A	better	examination	on	the	proliferative	effects	of	HDAC	inhibition	was	
undertaken	using	CFSE-dilution	in	PBMCs.	As	well	as	three	blinded	HDACis,	SAHA,	a	pan-
HDACi	which	has	undergone	the	most	research	in	this	group	of	compounds,	was	taken	
forward	for	further	analysis	and	was	there	on	consistently	utilised	as	a	comparator	
throughout	the	in	vitro	sections	of	this	study.	These	proliferation	studies,	revealed	a	dose-
dependent	inhibitory	effect	of	specific	HDAC	inhibition	superior	to	that	seen	with	SAHA	
(p=0.002,	at	the	lower	dose	of	1nM	this	inhibitory	effect	represented	a	4.7%	and	6.8%	
reduction	over	control	for	SAHA	and	KA1010,	respectively.	At	the	higher	dose	of	1000	nM,	
these	figures	increase	to	9.0%	and	22.6%	respectively).	The	presence	of	IL-2	had	a	minimal	
effect.		Although	no	published	data	exists	to	quantitatively	compare	these	findings	too,	the	
inhibitory	effect	is	consistent	with	a	similar	trend	demonstrated	following	the	treatment	of	
CD4+	T	cells	with	a	comparable	dose	range	of	the	selective-HDACi	(Class	I	&	II),	TSA	(Moreira,	
Scheipers,	&	Sorensen	2003).	It	has	been	postulated	that	this	effect	was	mediated	through	
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suppression	of	NF-κB	protein	and	IL-2	gene	expression	levels	(Licciardi	&	Karagiannis	2012).	
The	possible	cellular	mechanisms	by	which	HDACis	may	exert	their	effect	will	be	discussed	in	
further	detail	later	in	this	chapter.				
In	a	number	of	assays	performed	throughout	this	study,	the	effect	of	supplementing	culture	
media	with	IL-2	was	considered.	IL-2	is	of	course,	a	key	cytokine	in	lymphocyte	physiology,	
particularly	in	T	cell	differentiation	and	Treg	function.	The	rationale	for	supplementing	media	
in	many	of	the	assays	performed	therefore	was	a	concern	that	lack	of	IL-2	might	hamper	a	T-
cell	mediated	response.	In	reality,	very	few	effects	of	IL-2	supplementation	were	noted.					
Harnessing	the	immunomodulatory	functions	of	regulatory	T	cells	is	an	ever	increasing	area	
of	interest	to	many	research	groups.	A	number	of	strategies	have	been	tried	in	order	to	
exploit	the	immunomodulatory	function	of	this	cellular	immune	compartment	by	promoting	
their	function,	expansion,	or	adoptive	transfer.	One	such	strategy	of	particular	relevance	is	
the	effect	of	HDACis	on	Tregs.		
The	potential	role	of	HDACi	therapy	in	FoxP3	homeostasis	has	been	discussed	briefly	in	
chapter	1.	During	the	course	of	this	project,	a	number	of	groups	have	also	studied	this	link	
and	the	body	of	evidence	supporting	a	possible	role	for	HDACis	in	bolstering	the	regulatory	
T	cell	population	as	an	immunotherapy	modality	is	gaining	momentum.	Many	of	these	
studies	were	in	the	context	of	inflammation,	and	the	evidence	for	a	role	in	transplantation	
has	generally	been	limited.		
In	two	murine	models	of	colitis	(one	induced	by	treating	with	dextran	sodium	sulphate	and	
the	other	induced	through	the	adoptive	transfer	of	T	cell	dependent	CD45RBhi),	the	pan-
HDACis	TSA	and	SAHA	were	both	reported	to	have	prevented	the	development	of	colitis	(de	
Zoeten	et	al.	2010;	Tao	et	al.	2007).	However,	when	the	mice	were	treated	with	the	potent	
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class	I	HDACi,	MS275	there	was	no	significant	effect	and	the	subjects	proceeded	to	develop	
worsening	colitis	suggesting	the	protective	effect	of	HADCi	is	not	mediated	by	this	particular	
class.	By	depleting	mice	of	Tregs	or	using	a	strain	of	mice	who	have	a	FoxP3	mutation	(Scurfy	
mice),	the	authors	were	able	to	demonstrate	that	the	favourable	effects	of	the	pan-HDACis	
were	regulatory	T	cell	dependent,	as	these	mice	succumbed	to	colitis	despite	previously	
effective	treatment.		
A	similar	effect	has	subsequently	been	demonstrated	several	times	in	vitro	using	pan-
HDACis	(in	the	nanomolar	range)	in	rhesus	macaque	and	human	regulatory	T	cells	(Akimova	
et	al.	2010;	Johnson	et	al.	2008).	When	HDACis	of	other	structural	class	such	as	the	short	
chain	fatty	acid	(valproic	acid)	have	been	tested	however,	their	effect	on	Treg	function	only	
becomes	apparent	at	the	micro-	to	millimolar	ranges.	Interestingly,	and	of	significant	
relevance	to	this	study,	it	was	also	found	that	the	use	HDACi	compounds	specific	to	class	I	
(such	as	the	benzamides)	had	very	little	effect	on	Treg	function,	even	at	high	dosage,	
suggesting	the	apparent	effect	is	mediated	by	class	II	activity.		
In	this	study,	in	order	to	demonstrate	an	HDACi	effect	of	Tregs	we	adopted	and	modified	an	
assay	based	on	Sakaguchi’s	original	Treg	suppression	experiments.	Following	optimisation	of	
the	assay,	we	were	able	to	demonstrate	the	suppressive	capabilities	of	regulatory	T	cells,	
through	increasing	ratios	of	Tregs	to	effector	T	cells.	The	addition	of	HDACi	(four	compounds	
assessed	–	SAHA,	KA185,	KA142	and	KA1010,	at	nanomolar	concentrations)	resulted	in	a	
modest	though	relevant	inhibition	of	responder	cell	proliferation	from	around	75%	in	the	
control	group	to	86-90%	in	the	treatment	groups	(at	a	Treg	to	responder	ratio	of	1:1).	All	of	
the	HDACis	tested	inhibit	class	II,	supporting	the	notion	that	this	is	a	class-specific	effect	and	
that	the	treatment	of	Tregs	does	indeed	potentiate	their	suppressive	ability.		
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Given	that	HDACi	have	an	apparent	effect	on	regulatory	T	cells,	the	final	experiment	
undertaken	in	this	part	of	the	study	considering	basic	T	cell	physiology,	was	to	consider	the	
impact	on	markers	of	lymphocyte	subsets	(CD3,	CD4,	CD8	and	CD19).	There	is	very	little	
evidence	that	this	effect	of	HDACis	has	been	assessed	previously.	In	our	assessment	of	the	
flow	cytometry	data,	we	found	that	the	pan-HDACi,	SAHA	had	a	profound	dose-dependent	
effect	resulting	in	a	large	increase	in	the	CD4	and	CD19	populations	compared	to	control	
(1078.9%	and	181%	respectively)	and	a	decrease	in	the	CD3	and	CD8	populations	(69.2%	
and	88.5%	respectively),	when	treated	at	a	dose	of	1000µΜ.	The	reasons	for	such	a	sizeable	
shift	in	phenotype	are	unclear,	and	if	these	results	are	not	aberrant,	it	may	be	postulated	
that	the	changes	observed	are	due	to	the	non-specific	nature	of	this	compound	or	a	related	
toxic	effect.	The	effect	of	KA1010	on	lymphocyte	phenotype	was	also	interesting.	At	the	
lower	dose	range	(1-100µΜ)	very	little	effect	was	observed.	However	at	the	higher	dose	(of	
1000µΜ)	there	was	a	subtle	shift	resulting	in	a	reduction	in	CD8	expression	by	17.0%	and	a	
corresponding	increase	in	CD4	expression	by	31.1%.	Unfortunately,	the	CD4	population	was	
not	scrutinised	further,	but	given	that	HDAC6	inhibition	appears	to	enhance	the	Treg	
population,	there	is	a	question	as	to	whether	this	result	may	be	due	to	an	expansion	of	this	
subtype.	
Following	on	from	these	initial	studies	on	the	in	vitro	effects	of	HDACi	on	lymphocyte	
physiology	it	was	concluded,	that	the	agent	with	the	greatest	potential	in	terms	of	
immunosuppressive	effect	was	the	HDAC6i,	KA1010.	In	addition	to	the	evidence	presented	
here,	there	has	been	significant	research	into	both	the	selective	inhibition	(in	terms	of	class	
of	HDAC)	and	specific	inhibition	of	individual	HDACs.	Of	particular	interest,	and	with	
relevance	to	transplantation,	were	findings	reported	by	Professor	Wayne	Hancock’s	
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laboratory	in	Philadelphia.	Here	they	found	that	the	HDAC6	protein	was	expressed	at	levels	
a	number	of	fold	higher	in	Tregs,	compared	to	conventional	T	cells	(de	Zoeten	et	al.	2011).	
Around	the	same	time,	they	were	also	able	to	show	that	treating	mice	with	an	alternative	
HDAC6	inhibitor	doubled	the	expression	of	FoxP3	in	regulatory	T	cells	as	well	as	a	number	of	
Treg	associated	genes	(CTLA-4,	IL-10,	PD-1	and	GITR)	and	down-regulated	IL-2	and	IFN-γ	gene	
expression.	However,	this	effect	was	mediated	by	Tubacin,	a	selective	HDAC6i	with	limited	
clinical	relevance	due	to	its	non-drug-like	structure,	difficult	synthesis	and	high	lipophilicity	
(Butler	et	al.	2010)	making	it	more	a	useful	tool	for	research,	rather	than	an	agent	with	
potential	application	in	transplantation.	As	a	result	however,	the	Tubacin	molecule	has	
undergone	subsequent	bioengineering	and	a	new	HDAC6i,	Tubastatin	A	has	been	developed	
(though	less	selective	for	HDAC6	and	therefore	requires	higher	dosing).	Treatment	of	
murine	Tregs	in	vitro	with	this	drug	also	demonstrated	an	increased	suppressive	activity	of	
Tregs	on	a	T	cell	proliferation	assay.	Similar	assays	using	conventional	T	cell	responders	from	
mice	lacking	HDAC6	(HDAC6	knockout	or	HDAC6-/-	mice)	demonstrated	a	similar	result,	
suggesting	the	effect	was	not	dependent	on	HDAC6	expression	in	T	con	cells.	Tubastatin	A	is	
currently	undergoing	testing	as	a	therapy	for	neurodegenerative	disorders.		
Research	using	HDAC6-/-	mice	has	provided	useful	information	into	the	possible	
mechanisms	by	which	HDAC6i	agents	have	an	immunosuppressive	effect.	These	mice	
undergo	normal	lymphocytic	development	though	do	have	higher	than	normal	levels	of	
hyperacetylated	α-tubulin	in	several	tissue	types	(Zhang	et	al.	2008).	Assessment	of	their	
regulatory	T	cells	reveals	an	effector-memory	phenotype	(TREM,	with	typically	reduced	
expression	of	CD44	and	CD62L	and	increased	CD103	expression).	A	feature	of	TREM	cells,	
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relevant	to	the	transplant	setting,	is	that	they	are	capable	of	activation,	expansion	and	
memory	in	response	to	localised	inflammation	(Kleinewietfeld	et	al.	2005).	
More	recently,	another	selective	HDAC6i,	ACY-738,	has	been	tested	in	NZB/W	mice	in	the	
treatment	of	SLE.	It	was	found	to	increase	the	proportion	of	regulatory	T	cells,	while	also	
alleviating	some	of	the	hallmarks	of	SLE	(unpublished	data).	Further	studies,	using	ACY-738	
in	conjunction	with	a	sirtuin	1	inhibitor,	found	there	was	an	increase	in	the	suppressive	
ability	of	Tregs	(Beier	et	al.		2012).		
Given	our	initial	findings	that	HDACi	are	generally	safer	compounds	with	an	inhibitory	effect	
on	proliferation,	and	the	evidence	above,	KA1010	presented	as	a	viable	agent	to	take	
forward	into	in	vitro	and	in	vivo	models	of	transplantation.	The	first	of	these	undertaken	was	
a	one-way	MLR.	These	assays	were	originally	used	in	order	to	test	HLA	matching	and	assess	
whether	or	not	recipient	lymphocytes	would	react	to	donor	alloantigens.	Though	now	
superseded	by	other	more	technological	methods	clinically,	this	assay	still	provides	a	valid,	if	
not	basic	platform	to	assess	the	effects	of	HDACi	treatment.		
The	first	assay	in	this	series	assessed	the	effect	of	cyclosporin,	SAHA	(pan-HDACi)	and	
KA1010	(HDAC6i)	treatment	on	allogeneic	responders.	We	found	that	at	a	dose	of	200ng/ml	
(equivalent	to	the	standard	clinical	range),	CyA	had	a	moderate	inhibitory	effect	reducing	
proliferation	of	the	parent	population	by	18.5%.	Two	doses	of	the	HDACi	compounds	were	
compared.	At	the	lower	dose	of	0.5μM,	neither	had	a	particularly	marked	effect,	though	
SAHA	treatment	did	result	in	a	statistically	significant	reduction	in	proliferation	of	14%.	At	
the	higher	dose	of	5μM	however,	both	compounds	had	a	marked,	statistically	significant	
effect.	Treatment	with	SAHA	elicited	the	greatest	response	with	a	47%	reduction	in	
proliferation,	however,	as	has	become	increasingly	evident	in	this	study,	the	lack	of	
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specificity	associated	with	this	compound	resulted	in	considerable	toxicity	and	much	of	this	
effect	was	likely	due	to	cell	apoptosis.	Though	the	effect	of	KA1010	treatment	was	not	quite	
as	profound	at	31%	it	was	still	statistically	highly	significant.	Closer	examination	of	the	flow	
cytometry	plots	reveals	further	evidence	of	a	toxic	effect	with	high	dose	pan-HDACi	
treatment.	Analysis	demonstrates	a	living	population	in	the	KA1010	treated	sample	of	65-
70%,	consistent	with	the	control,	as	compared	to	20-25%	cells	surviving	SAHA	treatment.		
In	order	to	confirm	that	the	effect	demonstrated	by	these	compounds	was	indeed	a	
dampening	of	the	alloresponse,	and	that	autologous	effector	cells	were	remaining	largely	
unaffected,	a	novel	‘killing’	assay	was	developed,	based	on	the	one-way	MLR.	This	involved	
culturing	both	autologous	and	allogeneic	targets,	with	the	premise	that	the	allogeneic	
population	would	be	affected	preferentially,	and	the	autologous	population	would	be	
relatively	spared.	Though	the	results	of	this	assay	were	not	as	conclusive	as	hoped,	for	
reasons	that	remain	unclear,	they	do	still	support	the	hypothesis.	Rather	unexpectedly	there	
was	a	significant	lack	of	autologous	survival	over	time,	represented	by	a	precipitous	fall	in	
cell	number.	However	we	were	able	to	demonstrate	that	HDACi	treatment	resulted	in	a	
relative	degree	of	allogeneic	preservation	with	a	3.7-fold	increase	and	4.4-fold	increase	in	
allogeneic	cell	number	over	autologous	(SAHA	and	KA1010	at	a	dose	of	5μΜ	respectively)	at	
72	hours.	The	effect	of	SAHA	toxicity	at	this	dose	was	not	assessed	in	this	assay.		
Despite	the	apparent	shortfalls	of	this	novel	assay,	it	did	provide	valid	data	on	
demonstrating	a	relative	immunosuppressive	effect	by	HDACi	compounds.	No	similar	assay	
has	been	reported	and	the	results	warrant	its	further	development	in	terms	of	
methodology.		
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A	one-way	MLR	essentially	represents	the	recipient	response	to	donor	antigen,	but	does	not	
take	into	account	the	reciprocal	effect	of	recipient	antigen	presentation	(as	in	the	indirect	
pathway).	This	assay	may	be	partially	representative	of	chronic	rejection,	but	of	course	in	
reality,	antigen	presentation	and	recognition	occurs	bilaterally,	particularly	in	the	earlier	
stages	following	allotransplantation.		It	could	be	argued	therefore,	that	an	in	vitro	model	of	
transplantation	is	better	represented	by	a	two-way	MLR.		
Freshly-isolated	PBMCs	from	HLA-mismatched	donors	were	used	and	IFN-γ	release	was	
adopted	as	the	measure	of	alloreactivity	in	this	assay.	This	important	pro-inflammatory	
cytokine	has	a	complex	role	in	the	alloresponse,	usually	in	association	with	other	cytokines	
(IL-1β,	TNFα).	It	is	released	primarily	by	activated	T	cells	and	NK	cells	as	part	of	the	effector	
response	during	allorecognition	and	results	in	induction	of	MHC	expression	in	a	number	of	
tissues.	It	has	both	advantageous	and	disadvantageous	roles	in	the	transplant	setting.	For	
example,	it	has	a	pivotal	role	in	the	cellular	immune	response	by	stimulating	macrophages	
to	produce	further	pro-inflammatory	cytokine	responses.	It	also	upregulates	the	expression	
of	certain	chemokines	and	adhesion	molecules	as	well	as	enhancing	MHC	class	II	antigen	
presentation,	resulting	in	increased	effector	cell	recruitment	(Ferrara	et	al.	2009).	
Conversely,	a	number	of	in	vivo	transplant	models	using	subjects	deficient	in	IFN-γ	
demonstrate	a	protective	role	toward	the	graft.	For	example,	islet	transplants	in	mice	
lacking	IFN-γ	receptors	undergo	a	rapid	rejection	process	(Steiger	et	al.	1998)	which	has	
been	suggested,	is	due	to	the	inhibitory	effect	of	IFN-γ	on	the	proliferation	of	lymphocytes	
and	cytotoxic	T	cell	generation	(Hassan	et	al.	1999;	Konieczny	et	al.	1998).	More	recently,	
evidence	has	emerged	suggesting	IFN-γ	may	have	a	role	in	the	promotion	of		Treg	function	
and	/	or	expansion	(Eljaafari,	Li,	&	Miossec	2009).	These	effects	of	IFN-γ	in	the	setting	of	
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transplantation	extend	beyond	the	scope	of	this	study	and	are	made	even	more	complex	
due	to	altered	roles	in	acute	and	chronic	rejection.	They	do	however	pose	further	questions	
regarding	the	role	of	HDACis	(and	their	effect	on	IFN-γ	production)	and	represent	an	area	
for	further	study.	In	the	context	of	this	study,	IFN-γ	release	provides	a	sensitive	and	reliable	
measure	of	alloreactivity.	
In	a	two-way	MLR,	we	found	that	CyA,	SAHA	and	KA1010	all	had	a	statistically	significant	
dose-dependent	inhibitory	effect.	At	the	lower	dose	range	of	0.3μΜ,	IFN-γ	release	was	
reduced	by	47%,	50%	and	67%	(CyA,	SAHA	and	KA1010	respectively).	At	the	higher	dose	
range	of	1μΜ	the	level	of	inhibition	rose	to	72%,	82%	and	91%	respectively.		
These	findings	are	in	keeping	with	published	data	on	the	effect	of	HDACi	on	IFN-γ,	primarily	
in	autoimmune	disease.	In	one	such	model	of	diabetic	disease	using	rat	islet	cells,	the	effect	
of	treatment	with	SAHA	or	TSA	resulted	in	reduced	IFN-γ	mediated	β-cell	destruction	and	
insulin	production	(Larsen	et	al.	2007).		In	another	model	of	GVHD	in	murine	bone	marrow	
transplantation,	treatment	with	pan-HDACi	suppressed	the	release	of	a	number	of	pro-
inflammatory	cytokines,	including	IFN-γ	(as	well	as	IL-1	and	TNF-α)	(Reddy	et	al.	2008a).	A	
further	study,	using	the	synthetic	pan-HDACi,	ITF2357	at	a	dose	of	25nM,	found	IFN-γ	
release	was	reduced	by	50%	(Leoni	et	al.	2005).		
Current	research	suggests	HDACs	have	a	potential	role	in	transplantation	through	both	the	
innate	and	adaptive	immune	systems.	As	many	of	these	roles	are	HDAC-specific,	it	is	likely	
therefore	that	tailoring	HDAC-specific	inhibitors	to	modify	relevant	pathways	is	not	only	
covetable	but	also	increasingly	plausible	in	the	transplant	setting.		
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For	instance,	HDAC5	has	been	shown	to	be	upregulated	during	the	differentiation	of	
monocytes	to	macrophages	(Baek	et	al.	2009).	HDAC3	has	been	shown	to	negatively	
regulate	myeloid	cell	differentiation	(Ueki,	Zhang,	&	Hayman	2008)	and	the	function	of	
dendritic	cells	and	macrophages	have	been	shown	to	be	influenced	by	the	production	of	
HDAC	regulated	inflammatory	mediators.	
In	general,	the	innate	immune	system	is	primarily	regulated	by	Class	I	HDACs	via	regulation	
of	the	production	of	inflammatory	cytokines.	Class	IIa	HDACs	have	a	pivotal	role	in	the	
adaptive	immune	system,	principally	through	the	regulation	of	T	cell	function.	Interestingly,	
it	is	likely	that	HDAC6	has	a	role	in	both	pathways.	
The	role	of	HDACs	in	innate	immunity	
As	part	of	the	innate	immune	response,	HDACs	have	been	demonstrated	to	have	both	
positive	and	negative	regulatory	effects	over	TLR	pathways.	The	specific	role	of	HDAC	
expression	(and	the	specific	HDACs	involved)	in	encoding	for	pro-inflammatory	cytokines	
such	as	IL6,	IL12,	TNF	and	IFN-β	(Bode	et	al.	2007;	Brogdon	et	al.	2007;	Roger	et	al.	2011)	is	
poorly	understood,	though	it	has	been	suggested	that	deacetylation	of	receptors	in	the	TLR	
pathway	are	inherently	implicated.		
HDACs	may	have	a	positive	effect	on	TLR	signalling	through	the	regulation	of	transcription	
factors,	though	this	is	somewhat	controversial.		In	order	for	TLR-induced	production	of	IFN,	
certain	members	of	the	interferon	regulatory	factor	(IRF)	transcription	factor	family	are	
required	(Gabriele	&	Ozato	2007).	A	number	of	HDACs	have	been	demonstrated	to	be	
involved	in	multiple	cell-specific	TLR	pathways,	a	full	description	of	which	goes	beyond	the	
remit	of	this	thesis.	Of	relevance	however	to	the	allogeneic	response	is	the	TLR-mediated	
recruitment	of	nuclear	factor	kappa-light-chain-enhancer	of	activated	B	cells	(NF-κB)	in	
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which	it	has	been	shown	(through	HDAC	inhibition)	that	HDACs	have	a	positive	effect	(Bode,		
et	al.	2007;	Roger	et	al.	2011).	However,	this	is	controversial	and	questioned	by	several	
groups.		
It	is	more	likely	that	the	predominant	role	of	HDAC	regulation	in	TLR	pathways	is	a	negative	
one.	Class	I	HDACs	are	most	likely	to	invoke	a	negative	regulatory	response,	through	
histone-dependent	pathways	resulting	in	transcription	factor	suppression.	HDAC1	is	capable	
of	suppressing	inflammatory	gene	promoter	activity	of	several	inflammatory	cytokines	(eg	
IL-12,	COX2	and	IFN-β).	HDAC2	can	impart	a	similar	cytokine	effect	through	the	
sequestration	of	specific	transcriptional	activators	(Shakespear,	Halili,	Irvine,	Fairlie,	&	Sweet	
2011).	HDAC1,	2	and	3	are	also	capable	of	deacetylating	NF-κB	(normally	activated	by	TLR-
ligation)	allowing	the	binding	of	IκBα	(an	inhibitory	subunit)	and	switching	off	NF-κB	
dependent	responses	(Chen	&	Greene	2003).		
The	role	of	HDACis	with	regard	to	interferon	release	is	of	particular	relevance	to	this	study	
and	has	been	mentioned	briefly.	The	exact	mechanism	by	which	Class	I	HDACs	are	involved	
is	not	clearly	understood,	though	in	contrast	to	their	often	transcriptional	regression	role,	it	
would	appear	that	they	are	necessary	for	the	expression	of	IFN-stimulated	genes	(ISGs).	The	
signal	transducer	and	activator	of	transcription	(STAT),	regulates	both	type	I	IFN	signalling	
(IFN-α	and	IFN-β)	and	type	II	(IFN-γ)	which	subsequently	regulates	the	expression	of	ISGs	
(Tang	et	al.	2007).	It	is	likely	that	class	I	HDACs	are	involved	in	the	acetylation	of	STAT	but	
conclusive	evidence	on	their	precise	involvement	remains	elusive.		
In	addition	to	the	role	of	Class	I	HDACs	in	the	innate	pathway,	there	is	also	increasing,	
putative	evidence	of	Class	IIa	involvement	(principally	HDAC7)	though	this	would	appear	to	
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be	a	myeloid-specific	role	in	terms	of	chemokine	regulation	and	unrelated	to	lymphocytes	
(Barneda-Zahonero	et	al.	2013).	
Recent	data	has	implicated	a	possible	role	of	HDAC6	in	the	innate	system	through	the	
regulation	of	macrophage	responses.	Macrophages	are	complex	cells	with	both	anti-
inflammatory	and	pro-inflammatory	roles	depending	upon	their	subtype	(M1	or	M2).	In	a	
study	involving	tubacin	treated	macrophages	stimulated	with	LPS	it	was	found	that	
activation	and	production	of	pro-inflammatory	cytokines	was	significantly	reduced	(Yan	et	
al.	2014).	It	is	likely	that	the	role	of	HDAC6	in	microtubule	acetylation	is	responsible	for	this	
effect.	
The	role	of	HDACs	in	adaptive	immunity	
Class	II	HDACs	have	an	inherent	role	in	the	development	and	function	of	T	cells.		
HDAC7	has	an	important	role	in	cytotoxic	T	lymphocyte	(CTL)	function	through	the	
regulation	of	expression	of	adhesion	molecules,	cytokines	and	cytokine	receptors	(Navarro	
et	al.	2011;	Sweet	et	al.	2012).	In	activated	T	cells,	the	nuclear	export	of	HDAC4	is	critical	in	
the	expression	of	IL-5.		
Of	particular	interest	in	the	context	of	this	study	is	the	role	HDAC9	has	in	Treg	homeostasis	
through	its	interaction	with	FoxP3.	Increased	numbers	of	Tregs	have	been	demonstrated	in	
HDAC9	knockout	mice	(de	Zoeten,	Wang,	Sai,	Dillmann,	&	Hancock	2010).	As	the	results	
described	above	and	others	have	demonstrated,	pan-HDAC	inhibition	results	in	increased	
numbers	and	function	of	Tregs	and	this	effect,	at	least	in	part,	may	well	be	due	to	an	
inhibitory	effect	on	HDAC9.	Unfortunately	however,	the	clinical	manipulation	of	this	
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mechanism	is	likely	to	remain	elusive	due	to	a	current	lack	of	HDAC9-specific	inhibitor	
molecule.		
Pivotal	to	this	study	is	the	role	of	HDAC6	and	its	effect	on	Tregs.	The	exact	mechanism	by	
which	HDAC6	inhibition	exerts	an	enhancing	effect	on	Tregs	is	not	well	understood.	It	is	likely	
its	effect	is	not	mediated	through	direct	interaction	with	FoxP3	(as	is	the	case	with	HDAC9),	
but	rather	through	HSP90	and	HSF1	as	part	of	a	multifaceted	deacetylase-dependent	and	
independent	effect	(these	effects	have	been	described	in	the	Introduction).		
In	terms	of	evidence	of	a	deacetylase-dependent	role,	HSP-90	in	Tregs	from	HDAC6-/-	mice	
have	been	shown	to	be	hyperacetylated	and	several	associated	HSF1	regulated	genes	
upregulated	(Hancock	et	al.	2012).	The	same	study	also	demonstrated	that	in	HDAC6-/-	Tregs,	
another	heat-shock	protein,	HSP-70	forms	a	complex	with	FoxP3	(as	a	chaperone	protein)	
which	results	in	increased	Treg	function	and	survival	(Figure	6-1).	In	addition,	they	also	
demonstrated	that	inhibiting	HSP-70	results	in	defective	function	and	reduced	survival	and	
that	upregulating	HSP-70	has	the	opposite	effect	under	cell	stress	conditions.	Further	
evidence	supporting	this	mechanism	of	action	can	be	demonstrated	through	the	effects	of	
HSP90	inhibitors	resulting	in	similar	Treg	effects.		
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Figure	6-1	Potential	mechanisms	by	which	HDAC6i	may	potentiate	regulatory	T	cells	
	
We	further	demonstrated	a	predictable,	dose-dependent	effect	of	HDACi	on	the	two-way	
MLR	by	producing	dose	response	curves.	In	this	in	vitro	model	we	found	an	IC50	for	CyA	of	
625nM,	which	was	comparable	to	the	published	data.	The	effect	of	HDACi	treatment	was	
considerably	more	potent	with	an	IC50	of	82nM	and	13nM	for	KA1010	and	SAHA	
respectively.	We	also	assessed	the	specificity	of	these	compounds	by	calculating	the	Hill	
slope	value	for	each	(0.89	for	KA1010,	0.31	for	SAHA	and	0.35	for	CyA).	This	value	is	a	
marker	of	efficiency	in	terms	of	binding	and	almost	certainly	is	a	reflection	of	the	specificity	
of	the	tested	compounds	with	a	more	targeted	effect	of	KA1010.		
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As	has	been	described,	we	have	demonstrated	several	HDACi-mediated	effects	on	cellular	
proliferation.	Therefore,	as	part	of	the	two-way	MLR	we	considered	if	CyA	or	HDACi	altered	
the	expression	of	resting	CD4+	T	cell	activation	markers.	To	achieve	this	we	evaluated	a	
standard	panel	of	surface	markers,	namely	CD69,	CD25	and	HLA-DR.	We	demonstrated	a	
slightly	superior	effect	of	HDACi	over	CyA	in	reducing	CD69	expression.	In	terms	of	CD25	
expression,	all	HDACi	permitted	a	transient	rise	at	day	two	(as	would	be	expected)	with	CyA	
treatment	inhibiting	any	significant	expression	at	all.	None	of	the	compounds	had	any	effect	
on	expression	of	HLA-DR.	These	observations,	particularly	those	seen	in	CD25	expression	
likely	reflect	the	different	mechanisms	of	action	for	CyA	(via	its	effect	on	IL-2)	and	HDACi	
(modulation	of	Tregs).	
The	final	group	of	experiments	presented	here	examine	the	effect	of	KA1010	on	an	in	vivo	
murine	skin	graft	model	of	transplantation.	First	described	by	Medawar	in	1955,	this	highly	
immunogenic	model	provides	a	well	established	platform	with	which	to	assess	the	effect	of	
MHC-disparate	donor	antigen	presentation	on	recipient	T	cell	responses.	The	procedure	
itself	is	relatively	quick	and	straightforward	to	perform	and	is	highly	reproducible.	The	
nature	of	the	model	allows	assessment	at	both	the	macroscopic	level	through	continued	
visual	assessment	and	at	a	histological	level	through	well	characterised	responses.		
In	this	study,	we	found	that	the	untreated	allogeneic	graft	was	macro-	and	microscopically	
rejected	in	7-21	days	while	the	syngeneic	graft	demonstrated	negligible	evidence	of	
rejection	up	to	the	end	of	the	assessed	time	period	(up	to	70	days).	At	a	dose	of	160mg/kg,	
treatment	with	KA1010	resulted	in	graft	survival	of	77%	at	70	days	and	at	the	lower	dose	of	
80mg/kg	graft	survival	of	50%.		
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In	terms	of	systemic	effects,	KA1010	was	generally	well	tolerated.	The	effect	of	sustained	
treatment	(daily	ip	injection	for	70	days)	was	to	prevent	normal	weight	gain	and	maintain	it	
at	around	80%	birth	weight.	However	interpretation	of	this	observation	requires	caution,	as	
mice	treated	with	KA1010	for	a	shorter	period	of	time	(28days)	gained	weight	at	a	rate	
similar	to	control	subjects.	The	reason	for	the	disparity	observed	is	not	easily	explained.	
There	were	no	other	statistically	significant	effects	of	HDACi	treatment	on	weight.	
Rapamycin	(Sirolimus)	is	a	naturally-derived	macrolide	with	both	immunosuppressive	and	
anti-proliferative	effects.	The	initial	enthusiasm	for	rapamycin	as	an	alternative	de	novo	
immunosuppressant	has	waned	over	recent	years	due	to	its	side	effect	profile	and	its	
potential	role	in	transplantation	remains	uncertain.		It	has	been	studied	extensively,	in	
particular	as	a	possible	adjunct	or	even	alternative	to	current	calcineurin-inhibitors	though	
the	potential	advantage	in	terms	of	reduced	nephrotoxicity	and	risk	of	malignancy,	
compared	to	CNIs	have	often	been	offset	by	other	side	effects	such	as	impaired	wound	
healing,	hyperlipidaemia	and	thrombocytopenia.		
Rapamycin	shares	many	structural	similarities	to	Tacrolimus,	but	rather	than	blocking	the	
calcineurin	pathway,	it	inhibits	B	and	T	cell	proliferation	by	blocking	the	cytokine	stimulated	
mTOR	pathway.	Interestingly,	a	number	of	studies	have	demonstrated	a	positive	effect	of	
rapamycin	on	Treg	expansion	(Battaglia,	Stabilini,	&	Tresoldi	2012;	Gao	et	al.	2007;	Segundo	
et	al.	2006).	As	the	potential	effect	of	HDACi	therapy	is	to	mediate	an	immunosuppressive	
effect	through	upregulation	of	regulatory	T	cells,	via	an	alternative	mechanism,	the	
potential	effect	of	combining	these	two	agents,	but	at	lower	dosage	(in	theory	reducing	
potential	side	effects)	was	assessed.		
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In	terms	of	systemic	effects,	Rapamycin	at	a	dose	of	50mg/kg	either	as	a	single	agent	or	in	
combination	with	low	dose	KA1010	had	no	significant	effect	on	weight	or	splenic	index	as	
compared	to	control.	In	order	to	assess	the	potential	in	vivo	effects	of	KA1010	and	
rapamycin,	CD4+	and	CD4+CD25+	expression	was	evaluated.	We	found	that	rapamycin	alone	
resulted	in	a	significant	reduction	in	CD4+	expression	from	57.7%	to	51.3%	(representing	an	
11.1%	reduction),	though	low	dose	KA1010	(80mg/kg)	had	a	negligible	effect.	Rapamycin	
treatment	in	combination	with	low	dose	KA1010	resulted	in	a	slightly	greater	effect	(to	
48.1%)	but	this	apparent	synergistic	effect	was	not	significantly	superior	to	rapamycin	alone.	
The	effect	on	CD4+CD25+	expression	was	essentially	reciprocal,	though	not	significant.	
Rapamycin	treatment	alone	resulted	in	a	marginal	increase	in	expression	from	18.5%	to	
20.1%.	Low	dose	KA1010	and	combination	treatment	had	no	effect.		
The	role	of	rapamycin,	in	conjunction	with	specific	HDAC6i,	requires	further	investigation.	In	
this	study,	we	found	that	rapamycin	treatment	reduced	the	proportion	of	CD4+	T	cells	but	
had	a	minimal	effect	on	Treg	numbers	in	vivo.	Due	to	the	plasticity	between	various	T	cell	
subsets,	there	is	a	differential	response	between	Teff	cells	and	Tregs	to	rapamycin.	These	data	
are	consistent	with	the	previously	published	observations	demonstrating	a	relative	
increased	suppressive	effect	on	effector	T-cells	over	regulatory	populations	(Zeiser	et	al.	
2008),	(Keating	et	al.	2013).		
The	most	significant	effect	on	CD4+	and	CD4+CD25+	expression	resulted	from	KA1010	
treatment	at	a	dose	of	160mg/kg.	Treatment	for	70	days	significantly	impaired	CD4+	
expression	by	16.2%	and	had	a	corresponding	positive	effect	on	CD4+CD25+,	increasing	
expression	by	18.0%.		
233	
	
These	observations	support	the	hypothesis	that	KA1010	enhances	the	immunomodulatory	
effect	of	regulatory	T	cells	and	as	a	result	proliferation	of	the	effector	T	cell	population	is	
impaired.		These	findings	are	consistent	with	the	limited	published	data	assessing	HDAC6-
specific	inhibition	(as	already	described	-	HDAC6-/-	knockout	mice	and	in	mice	treated	with	
HDAC6i	in	models	of	inflammation	and	autoimmunity	(Beier	et	al.	2011;	Beier	et	al.	2012;	de	
Zoeten	et	al.	2010).	
	
6.1 Summary	
Enormous	advancements	have	been	made	over	the	last	50	years	in	terms	of	
immunosuppression	and	the	agents	currently	available	today	have	evolved	significantly	
resulting	in	improved	graft	survival.	However	current	immunosuppressive	regimens,	based	
on	the	ELITE-Symphony	study	(Ekberg	et	al.	2007)	are	far	from	perfect	and	little	has	changed	
over	the	last	twenty	years	in	terms	of	side	effects	and	graft	survival	rates.	As	the	evolution	
of	transplantation	continues	and	the	boundaries	of	what	is	possible	are	pushed	further	(for	
example	composite	tissue	transplantation),	it	is	likely	that	newer,	cleaner	and	more	efficient	
immunosuppressants	are	going	to	be	needed	to	keep	pace.	One	such	group	of	compounds	
which	has	shown	potential	in	this	respect	are	the	histone	deacetylase	inhibitors.	Though	
their	clinical	role	has	been	limited	to	haematological	malignancies	at	present,	pre-clinically	
they	have	shown	great	potential	in	the	management	of	a	number	of	other	malignancies	and	
inflammatory	conditions.		
As	a	result	of	this	interest	in	HDACi,	discussions	with	Karus	therapeutics	led	to	the	
development	of	an	academic-industrial	partnership	which	has	resulted	in	this	study.	They	
were	able	to	provide	us	with	a	panel	of	optimised,	novel	engineered	molecules	with	specific	
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targets,	upon	which	we	were	able	to	perform	a	number	of	step-wise	investigations.	Firstly,	
we	assessed	simple	effect	and	toxicity	at	a	cellular	level	and	considered	mechanistic	
elements	of	an	apparent	inhibitory	function.	We	then	used	robust	in	vitro	models	of	
alloreactivity,	many	of	which	have	been	used	in	the	development	of	current	
immunosuppressants,	and	compared	the	effects	of	our	candidate	novel	compound	with	
appropriate	well	characterised	compounds.	This	revealed	a	potent	and	predictable	
immunomodulatory	effect	for	KA1010	with	apparently	reduced	toxic	effects	compared	to	
less	specific	HDACi.		Finally	we	used	a	murine	model	of	transplantation	to	demonstrate	the	
immunosuppressive	effectiveness	and	tolerability	of	HDAC6i	treatment.	
In	attempting	to	elucidate	a	mechanism	of	action,	we	have	considered	a	number	of	likely	
contributory	factors.	The	likely	mechanism	of	action	of	KA1010	in	terms	of	its	clinical	
application	is	almost	certainly	a	combination	of	both	acetylase	dependent	and	independent	
effects.	In	this	study,	we	found	that	there	was	a	significant	effect	on	the	function	and	
number	of	regulatory	T	cells	and	it	is	likely	this	is	mediated	through	the	HSP90/HSF1	
pathway	described	above.		
Overall,	this	study	adds	weight	to	the	argument	that	HDACi	analogues	have	clinical	utility,	
with	potentially	favourable	toxicity	profiles	compared	with	existing	immunosuppressive	
agents.		The	availability	for	safer	treatment	regimens	has	the	potential	to	enhance	organ	
survival	and	permit	broader	application	of	organ	replacement	for	patients	with	organ	
failure.	
6.2 Limitations	of	the	study	
The	primary	limitations	in	this	study	involved	the	in	vivo	model	used.	There	are	obvious	
limitations	to	this	murine	model	and	translating	the	above	findings	into	the	clinical	setting	is	
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somewhat	limited	by	the	differences	in	human	and	mouse	physiology,	genetics	and	
immunology.	The	graft	itself	is	essentially	non-vascularised	and	therefore,	ischaemia	may	
contribute	significantly	to	the	immune	response.	In	addition	to	this,	as	well	as	tissue-specific	
antigens	the	skin	also	contains	Langerhans	cells	(specific	antigen	presenting	cells	within	the	
skin)	which	may	skew	the	immune	response	by	activating	host	T	cells.	One	further	
consideration	is	graft	size.	It	has	been	suggested	that	larger	grafts	contain	a	larger	number	
of	APCs	and,	therefore,	may	invoke	altered	host	responses	(Sun	et	al.	1996).	However,	
further	detailed	research	comparing	pancreatic	islet,	cardiac	and	skin	transplant	rejection	
found	that	numbers	of	APCs	or	tissue	specific	antigens	had	little	effect	on	the	degree	of	the	
host	T	cell	response.	Rather,	it	has	been	suggested	that	factors	such	as	graft	micro-
environment	and	size	have	more	of	an	important	role	in	rejection	than	number	of	APCs	
(Jones	et	al.	2001).	Therefore,	a	standardised	protocol	was	used	when	grafting	to	ensure	
skin	samples	were	similar	and	minimise	this	potential	factor.		
Further	limitations	of	this	study	concern	the	established	immunosuppressants	used	as	
comparison	to	the	novel	compounds	tested.	Though	CyA	is	a	very	well	characterised	drug,	
its	use	in	modern	immunosuppression	is	dwindling.	In	hindsight	comparing	effects	with	
Tacrolimus	would	have	been	favoured.	Fortunately	both	CyA	and	Tacrolimus	have	similar	
mechanisms	of	action	and	the	findings	therefore	remain	valid.		
Finally,	the	novel	MLR	killing	assay	has	shortcomings	which	we	were	unable	to	overcome.	
For	reasons	unkown,	the	autologous	population	underwent	significant	inhibition	when	it	
would	have	been	expected	to	be	better	preserved.	Fortunately	a	differential	effect	was	
demonstrated.	With	some	modifications	and	assay	development,	this	could	become	a	useful	
tool.		
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6.3 Further	studies		
Throughout	this	study,	the	targeted	inhibition	of	specific	HDACs	has	been	central.	Of	
particular	interest	in	the	context	of	transplantation	is	the	potential	role	of	an	HDAC9i	
molecule.	Internationally,	many	groups	are	focussing	their	efforts	on	harnessing	the	
inhibitory	effects	of	regulatory	T	cells	for	a	number	of	therapeutic	applications.	From	the	
studies	reviewed	here,	the	role	of	HDAC9	(through	HDAC9	knockout	studies)	in	Treg	
regulation	may	be	of	significant	benefit.	Unfortunately,	no	compound	is	yet	available	which	
can	target	HDAC9	specifically.	If	one	were	to	be	developed,	it	may	represent	a	potential	
therapeutic	drug	which	could	be	effective	in	its	own	right	or	in	combination	with	HDAC6	
targeting.	
The	potential	role	of	Rapamycin	has	been	briefly	assessed	in	this	project,	but	was	only	
considered	at	the	in	vivo	stage.	Further	assessment	of	its	potential	use	as	a	combination	
drug	with	HDAC6i	may	reveal	a	possible	novel	role.	
Though	the	skin	graft	model	adopted	for	this	study	was	useful	in	the	initial	assessment	of	
our	novel	compound,	the	next	stage	would	be	to	examine	its	effects	in	a	vascularised	model.	
Previous	studies	have	demonstrated	a	difference	in	rejection	mechanism	between	
vascularised	and	non-vascularised	models,	particularly	in	terms	of	routes	of	migration	of	
donor	dendritic	cells	(in	the	skin	graft	model,	donor	DCs	tend	to	migrate	via	lymphatic	
drainage	before	vascular	connections	have	been	established).	A	large	number	of	
vascularised	graft	models	would	be	appropriate.	In	terms	of	this	project,	a	murine	sub-
capsular	foetal	pancreatic	islets	model	is	planned	as	well	as	a	rat	cardiac	allograft	model.		
	 	
237	
	
References	
	
	1994a,	"A	comparison	of	tacrolimus	(FK	506)	and	cyclosporine	for	immunosuppression	in	
liver	transplantation.	The	U.S.	Multicenter	FK506	Liver	Study	Group",	N	Engl	J	Med,	vol.	331,	
no.	17,	pp.	1110-1115.	
	1994b,	"Randomised	trial	comparing	tacrolimus	(FK506)	and	cyclosporin	in	prevention	of	
liver	allograft	rejection.	European	FK506	Multicentre	Liver	Study	Group",	Lancet,	vol.	344,	
no.	8920,	pp.	423-428.	
Acuto,	O.	&	Michel,	F.	2003,	"CD28-mediated	co-stimulation:	a	quantitative	support	for	TCR	
signalling",	Nat.Rev.Immunol.,	vol.	3,	no.	12,	pp.	939-951.	
Akimova,	T.,	Beier,	U.	H.,	Liu,	Y.,	Wang,	L.,	&	Hancock,	W.	W.	2012,	"Histone/protein	
deacetylases	and	T-cell	immune	responses",	Blood,	vol.	119,	no.	11,	pp.	2443-2451.	
Akimova,	T.,	Ge,	G.,	Golovina,	T.,	Mikheeva,	T.,	Wang,	L.,	Riley,	J.	L.,	&	Hancock,	W.	W.	2010,	
"Histone/protein	deacetylase	inhibitors	increase	suppressive	functions	of	human	FOXP3+	
Tregs",	Clin.Immunol.,	vol.	136,	no.	3,	pp.	348-363.	
Ali,	A.,	Bluteau,	O.,	Messaoudi,	K.,	Palazzo,	A.,	Boukour,	S.,	Lordier,	L.,	Lecluse,	Y.,	Rameau,	
P.,	Kraus-Berthier,	L.,	Jacquet-Bescond,	A.,	Lelievre,	H.,	Depil,	S.,	Dessen,	P.,	Solary,	E.,	
Raslova,	H.,	Vainchenker,	W.,	Plo,	I.,	&	Debili,	N.	2013,	"Thrombocytopenia	induced	by	the	
histone	deacetylase	inhibitor	abexinostat	involves	p53-dependent	and	-independent	
mechanisms",	Cell	Death.Dis.,	vol.	4,	p.	e738.	
Allfrey,	V.	G.,	Faulkner,	R.,	&	Mirsky,	A.	E.	1964,	"Acetylation	and	methylation	of	histones	
and	their	possible	role	in	the	regulation	of	RNA	synthesis",	Proc.Natl.Acad.Sci	U.S.A,	vol.	51,	
pp.	786-794.	
Apostolou,	I.,	Sarukhan,	A.,	Klein,	L.,	&	von,	B.	H.	2002,	"Origin	of	regulatory	T	cells	with	
known	specificity	for	antigen",	Nat.Immunol.,	vol.	3,	no.	8,	pp.	756-763.	
Apostolou,	I.	&	von,	B.	H.	2004,	"In	vivo	instruction	of	suppressor	commitment	in	naive	T	
cells",	J	Exp.Med,	vol.	199,	no.	10,	pp.	1401-1408.	
Bach,	F.	&	Hirschhorn,	K.	1964,	"Lymphocyte	interaction:	a	potential	histocompatibility	test	
in	vitro",	Science,	vol.	143,	no.	3608,	pp.	813-814.	
Baek,	Y.	S.,	Haas,	S.,	Hackstein,	H.,	Bein,	G.,	Hernandez-Santana,	M.,	Lehrach,	H.,	Sauer,	S.,	&	
Seitz,	H.	2009,	"Identification	of	novel	transcriptional	regulators	involved	in	macrophage	
differentiation	and	activation	in	U937	cells",	BMC.Immunol.,	vol.	10,	p.	18.	
Bain,	B.,	Vas,	M.	R.,	&	Lowenstein,	L.	1964,	"The	development	of	large	immature	
mononuclear	cells	in	mixed	leukocyte	cultures",	Blood,	vol.	23,	pp.	108-116.	
Barneda-Zahonero,	B.,	Roman-Gonzalez,	L.,	Collazo,	O.,	Rafati,	H.,	Islam,	A.	B.,	Bussmann,	L.	
H.,	di,	T.	A.,	De,	A.	L.,	Graf,	T.,	Lopez-Bigas,	N.,	Mahmoudi,	T.,	&	Parra,	M.	2013,	"HDAC7	is	a	
238	
	
repressor	of	myeloid	genes	whose	downregulation	is	required	for	transdifferentiation	of	
pre-B	cells	into	macrophages",	PLoS.Genet.,	vol.	9,	no.	5,	p.	e1003503.	
Bates,	W.	D.,	Davies,	D.	R.,	Welsh,	K.,	Gray,	D.	W.,	Fuggle,	S.	V.,	&	Morris,	P.	J.	1999,	"An	
evaluation	of	the	Banff	classification	of	early	renal	allograft	biopsies	and	correlation	with	
outcome",	Nephrol.Dial.Transplant.,	vol.	14,	no.	10,	pp.	2364-2369.	
Battaglia,	M.,	Stabilini,	A.,	&	Tresoldi,	E.	2012,	"Expanding	human	T	regulatory	cells	with	the	
mTOR-inhibitor	rapamycin",	Methods	Mol.Biol.,	vol.	821,	pp.	279-293.	
Beier,	U.	H.,	Wang,	L.,	Bhatti,	T.	R.,	Liu,	Y.,	Han,	R.,	Ge,	G.,	&	Hancock,	W.	W.	2011,	"Sirtuin-1	
targeting	promotes	Foxp3+	T-regulatory	cell	function	and	prolongs	allograft	survival",	
Mol.Cell	Biol.,	vol.	31,	no.	5,	pp.	1022-1029.	
Beier,	U.	H.,	Wang,	L.,	Han,	R.,	Akimova,	T.,	Liu,	Y.,	&	Hancock,	W.	W.	2012,	"Histone	
deacetylases	6	and	9	and	sirtuin-1	control	Foxp3+	regulatory	T	cell	function	through	shared	
and	isoform-specific	mechanisms",	Sci	Signal.,	vol.	5,	no.	229,	p.	ra45.	
Bennett,	C.	L.,	Christie,	J.,	Ramsdell,	F.,	Brunkow,	M.	E.,	Ferguson,	P.	J.,	Whitesell,	L.,	Kelly,	T.	
E.,	Saulsbury,	F.	T.,	Chance,	P.	F.,	&	Ochs,	H.	D.	2001,	"The	immune	dysregulation,	
polyendocrinopathy,	enteropathy,	X-linked	syndrome	(IPEX)	is	caused	by	mutations	of	
FOXP3",	Nat.Genet.,	vol.	27,	no.	1,	pp.	20-21.	
Bertos,	N.	R.,	Gilquin,	B.,	Chan,	G.	K.,	Yen,	T.	J.,	Khochbin,	S.,	&	Yang,	X.	J.	2004,	"Role	of	the	
tetradecapeptide	repeat	domain	of	human	histone	deacetylase	6	in	cytoplasmic	retention",	
J	Biol.Chem.,	vol.	279,	no.	46,	pp.	48246-48254.	
Bode,	K.	A.,	Schroder,	K.,	Hume,	D.	A.,	Ravasi,	T.,	Heeg,	K.,	Sweet,	M.	J.,	&	Dalpke,	A.	H.	
2007,	"Histone	deacetylase	inhibitors	decrease	Toll-like	receptor-mediated	activation	of	
proinflammatory	gene	expression	by	impairing	transcription	factor	recruitment",	
Immunology,	vol.	122,	no.	4,	pp.	596-606.	
Boenisch,	O.,	Sayegh,	M.	H.,	&	Najafian,	N.	2008,	"Negative	T-cell	costimulatory	pathways:	
their	role	in	regulating	alloimmune	responses",	Curr.Opin.Organ	Transplant.,	vol.	13,	no.	4,	
pp.	373-378.	
Bopp,	T.,	Becker,	C.,	Klein,	M.,	Klein-Hessling,	S.,	Palmetshofer,	A.,	Serfling,	E.,	Heib,	V.,	
Becker,	M.,	Kubach,	J.,	Schmitt,	S.,	Stoll,	S.,	Schild,	H.,	Staege,	M.	S.,	Stassen,	M.,	Jonuleit,	H.,	
&	Schmitt,	E.	2007,	"Cyclic	adenosine	monophosphate	is	a	key	component	of	regulatory	T	
cell-mediated	suppression",	J	Exp.Med,	vol.	204,	no.	6,	pp.	1303-1310.	
Borel,	J.	F.,	Feurer,	C.,	Gubler,	H.	U.,	&	Stahelin,	H.	1976,	"Biological	effects	of	cyclosporin	A:	
a	new	antilymphocytic	agent",	Agents	Actions,	vol.	6,	no.	4,	pp.	468-475.	
Boyault,	C.,	Gilquin,	B.,	Zhang,	Y.,	Rybin,	V.,	Garman,	E.,	Meyer-Klaucke,	W.,	Matthias,	P.,	
Muller,	C.	W.,	&	Khochbin,	S.	2006,	"HDAC6-p97/VCP	controlled	polyubiquitin	chain	
turnover",	EMBO	J,	vol.	25,	no.	14,	pp.	3357-3366.	
239	
	
Brogdon,	J.	L.,	Xu,	Y.,	Szabo,	S.	J.,	An,	S.,	Buxton,	F.,	Cohen,	D.,	&	Huang,	Q.	2007,	"Histone	
deacetylase	activities	are	required	for	innate	immune	cell	control	of	Th1	but	not	Th2	
effector	cell	function",	Blood,	vol.	109,	no.	3,	pp.	1123-1130.	
Brown,	J.	B.	Homografting	of	skin:	with	report	of	success	in	identical	twins.	Surgery	1,	558-
563.	1937.		
Brown,	K.,	Moxham,	V.,	Karegli,	J.,	Phillips,	R.,	Sacks,	S.	H.,	&	Wong,	W.	2007,	"Ultra-
localization	of	Foxp3+	T	cells	within	renal	allografts	shows	infiltration	of	tubules	mimicking	
rejection",	Am.J	Pathol.,	vol.	171,	no.	6,	pp.	1915-1922.	
Brunkow,	M.	E.,	Jeffery,	E.	W.,	Hjerrild,	K.	A.,	Paeper,	B.,	Clark,	L.	B.,	Yasayko,	S.	A.,	
Wilkinson,	J.	E.,	Galas,	D.,	Ziegler,	S.	F.,	&	Ramsdell,	F.	2001,	"Disruption	of	a	new	
forkhead/winged-helix	protein,	scurfin,	results	in	the	fatal	lymphoproliferative	disorder	of	
the	scurfy	mouse",	Nat.Genet.,	vol.	27,	no.	1,	pp.	68-73.	
Bunikowski,	R.,	Gerhold,	K.,	Brautigam,	M.,	Hamelmann,	E.,	Renz,	H.,	&	Wahn,	U.	2001,	
"Effect	of	low-dose	cyclosporin	a	microemulsion	on	disease	severity,	interleukin-6,	
interleukin-8	and	tumor	necrosis	factor	alpha	production	in	severe	pediatric	atopic	
dermatitis",	Int.Arch.Allergy	Immunol.,	vol.	125,	no.	4,	pp.	344-348.	
Busch,	G.	J.,	Galvanek,	E.	G.,	&	Reynolds,	E.	S.,	Jr.	1971,	"Human	renal	allografts.	Analysis	of	
lesions	in	long-term	survivors",	Hum.Pathol.,	vol.	2,	no.	2,	pp.	253-298.	
Butler,	K.	V.,	Kalin,	J.,	Brochier,	C.,	Vistoli,	G.,	Langley,	B.,	&	Kozikowski,	A.	P.	2010,	"Rational	
design	and	simple	chemistry	yield	a	superior,	neuroprotective	HDAC6	inhibitor,	tubastatin	
A",	J	Am.Chem.Soc.,	vol.	132,	no.	31,	pp.	10842-10846.	
Cabrero,	J.	R.,	Serrador,	J.	M.,	Barreiro,	O.,	Mittelbrunn,	M.,	Naranjo-Suarez,	S.,	Martin-
Cofreces,	N.,	Vicente-Manzanares,	M.,	Mazitschek,	R.,	Bradner,	J.	E.,	Avila,	J.,	Valenzuela-
Fernandez,	A.,	&	Sanchez-Madrid,	F.	2006,	"Lymphocyte	chemotaxis	is	regulated	by	histone	
deacetylase	6,	independently	of	its	deacetylase	activity",	Mol.Biol.Cell,	vol.	17,	no.	8,	pp.	
3435-3445.	
Calne,	R.,	Collier,	D.	S.,	&	Thiru,	S.	1987,	"Observations	about	FK-506	in	primates",	
Transplant.Proc.,	vol.	19,	no.	5	Suppl	6,	p.	63.	
Calne,	R.	Y.	1960,	"The	rejection	of	renal	homografts.	Inhibition	in	dogs	by	6-
mercaptopurine",	Lancet,	vol.	1,	no.	7121,	pp.	417-418.	
Calne,	R.	Y.	1961,	"Inhibition	of	the	rejection	of	renal	homografts	in	dogs	by	purine	
analogues",	Transplant.Bull.,	vol.	28,	pp.	65-81.	
Calne,	R.	Y.	&	Murray,	J.	E.	1961,	"Inhibition	of	the	rejection	of	renal	homografts	in	dogs	by	
Burroughs	Wellcome	57-322",	Surg.Forum,	vol.	12,	pp.	118-120.	
Calne,	R.	Y.,	Rolles,	K.,	White,	D.	J.,	Thiru,	S.,	Evans,	D.	B.,	McMaster,	P.,	Dunn,	D.	C.,	
Craddock,	G.	N.,	Henderson,	R.	G.,	Aziz,	S.,	&	Lewis,	P.	1979,	"Cyclosporin	A	initially	as	the	
240	
	
only	immunosuppressant	in	34	recipients	of	cadaveric	organs:	32	kidneys,	2	pancreases,	and	
2	livers",	Lancet,	vol.	2,	no.	8151,	pp.	1033-1036.	
Calne,	R.	Y.,	White,	D.	J.,	Rolles,	K.,	Smith,	D.	P.,	&	Herbertson,	B.	M.	1978a,	"Prolonged	
survival	of	pig	orthotopic	heart	grafts	treated	with	cyclosporin	A",	Lancet,	vol.	1,	no.	8075,	
pp.	1183-1185.	
Calne,	R.	Y.,	White,	D.	J.,	Thiru,	S.,	Evans,	D.	B.,	McMaster,	P.,	Dunn,	D.	C.,	Craddock,	G.	N.,	
Pentlow,	B.	D.,	&	Rolles,	K.	1978b,	"Cyclosporin	A	in	patients	receiving	renal	allografts	from	
cadaver	donors",	Lancet,	vol.	2,	no.	8104-5,	pp.	1323-1327.	
Calne,	R.	Y.	&	White,	D.	J.	G.	Cyclosporin	A	–	A	powerful	immunosuppressant	in	dogs	with	
renal	allographs.	IRCS	Med	Sci	5,	595.	1977.		
Caridade,	M.,	Graca,	L.,	&	Ribeiro,	R.	M.	2013,	"Mechanisms	Underlying	CD4+	Treg	Immune	
Regulation	in	the	Adult:	From	Experiments	to	Models",	Front	Immunol.,	vol.	4,	p.	378.	
Caron,	H.,	van,	S.	B.,	van	der,	M.	M.,	Baas,	F.,	Riggins,	G.,	van,	S.	P.,	Hermus,	M.	C.,	van,	A.	R.,	
Boon,	K.,	Voute,	P.	A.,	Heisterkamp,	S.,	van,	K.	A.,	&	Versteeg,	R.	2001,	"The	human	
transcriptome	map:	clustering	of	highly	expressed	genes	in	chromosomal	domains	
1",	Science,	vol.	291,	no.	5507,	pp.	1289-1292.	
Chandraker,	A.,	Sayegh,	M.	H.,	&	Singh,	A.	K.	2012,	Core	Concepts	in	Renal	Transplantation	
Springer.	
Chatila,	T.,	Silverman,	L.,	Miller,	R.,	&	Geha,	R.	1989,	"Mechanisms	of	T	cell	activation	by	the	
calcium	ionophore	ionomycin",	J	Immunol.,	vol.	143,	no.	4,	pp.	1283-1289.	
Chatila,	T.	A.,	Blaeser,	F.,	Ho,	N.,	Lederman,	H.	M.,	Voulgaropoulos,	C.,	Helms,	C.,	&	
Bowcock,	A.	M.	2000,	"JM2,	encoding	a	fork	head-related	protein,	is	mutated	in	X-linked	
autoimmunity-allergic	disregulation	syndrome",	J	Clin.Invest,	vol.	106,	no.	12,	p.	R75-R81.	
Chaturvedi,	V.,	Collison,	L.	W.,	Guy,	C.	S.,	Workman,	C.	J.,	&	Vignali,	D.	A.	2011,	"Cutting	
edge:	Human	regulatory	T	cells	require	IL-35	to	mediate	suppression	and	infectious	
tolerance",	J	Immunol.,	vol.	186,	no.	12,	pp.	6661-6666.	
Chen,	L.	F.	&	Greene,	W.	C.	2003,	"Regulation	of	distinct	biological	activities	of	the	NF-
kappaB	transcription	factor	complex	by	acetylation",	J	Mol.Med	(Berl),	vol.	81,	no.	9,	pp.	
549-557.	
Cheng,	F.,	Lienlaf,	M.,	Perez-Villarroel,	P.,	Wang,	H.	W.,	Lee,	C.,	Woan,	K.,	Woods,	D.,	Knox,	
T.,	Bergman,	J.,	Pinilla-Ibarz,	J.,	Kozikowski,	A.,	Seto,	E.,	Sotomayor,	E.	M.,	&	Villagra,	A.	
2014,	"Divergent	roles	of	histone	deacetylase	6	(HDAC6)	and	histone	deacetylase	11	
(HDAC11)	on	the	transcriptional	regulation	of	IL10	in	antigen	presenting	cells",	
Mol.Immunol.,	vol.	60,	no.	1,	pp.	44-53.	
Choi,	Y.	S.	&	Jeong,	S.	2005,	"PI3-kinase	and	PDK-1	regulate	HDAC1-mediated	transcriptional	
repression	of	transcription	factor	NF-kappaB",	Mol.Cells,	vol.	20,	no.	2,	pp.	241-246.	
241	
	
Collier,	D.	S.,	Thiru,	S.,	&	Calne,	R.	1987,	"Kidney	transplantation	in	the	dog	receiving	FK-
506",	Transplant.Proc.,	vol.	19,	no.	5	Suppl	6,	p.	62.	
Colvin,	R.	B.	2007,	"Antibody-mediated	renal	allograft	rejection:	diagnosis	and	
pathogenesis",	J	Am.Soc.Nephrol.,	vol.	18,	no.	4,	pp.	1046-1056.	
Colvin,	R.	B.	2009,	"Pathology	of	chronic	humoral	rejection",	Contrib.Nephrol.,	vol.	162,	pp.	
75-86.	
Crevel,	G.,	Bates,	H.,	Huikeshoven,	H.,	&	Cotterill,	S.	2001,	"The	Drosophila	Dpit47	protein	is	
a	nuclear	Hsp90	co-chaperone	that	interacts	with	DNA	polymerase	alpha",	J	Cell	Sci,	vol.	
114,	no.	Pt	11,	pp.	2015-2025.	
de	la	Rutz,	R.	M.,	S.,	Dorninger,	H.,	&	Scheffold,	A.	2004,	"Interleukin-2	is	essential	for	
CD4+CD25+	regulatory	T	cell	function",	Eur.J	Immunol.,	vol.	34,	no.	9,	pp.	2480-2488.	
de	Ruijter,	A.	J.,	van	Gennip,	A.	H.,	Caron,	H.	N.,	Kemp,	S.,	&	van	Kuilenburg,	A.	B.	2003,	
"Histone	deacetylases	(HDACs):	characterization	of	the	classical	HDAC	family",	Biochem.J,	
vol.	370,	no.	Pt	3,	pp.	737-749.	
De	Serres,	S.	A.,	Sayegh,	M.	H.,	&	Najafian,	N.	2009,	"Immunosuppressive	drugs	and	Tregs:	a	
critical	evaluation!",	Clin.J	Am.Soc.Nephrol.,	vol.	4,	no.	10,	pp.	1661-1669.	
de	Zoeten,	E.	F.,	Wang,	L.,	Butler,	K.,	Beier,	U.	H.,	Akimova,	T.,	Sai,	H.,	Bradner,	J.	E.,	
Mazitschek,	R.,	Kozikowski,	A.	P.,	Matthias,	P.,	&	Hancock,	W.	W.	2011,	"Histone	deacetylase	
6	and	heat	shock	protein	90	control	the	functions	of	Foxp3(+)	T-regulatory	cells",	Mol.Cell	
Biol.,	vol.	31,	no.	10,	pp.	2066-2078.	
de	Zoeten,	E.	F.,	Wang,	L.,	Sai,	H.,	Dillmann,	W.	H.,	&	Hancock,	W.	W.	2010,	"Inhibition	of	
HDAC9	increases	T	regulatory	cell	function	and	prevents	colitis	in	mice",	Gastroenterology,	
vol.	138,	no.	2,	pp.	583-594.	
Deaglio,	S.,	Dwyer,	K.	M.,	Gao,	W.,	Friedman,	D.,	Usheva,	A.,	Erat,	A.,	Chen,	J.	F.,	Enjyoji,	K.,	
Linden,	J.,	Oukka,	M.,	Kuchroo,	V.	K.,	Strom,	T.	B.,	&	Robson,	S.	C.	2007,	"Adenosine	
generation	catalyzed	by	CD39	and	CD73	expressed	on	regulatory	T	cells	mediates	immune	
suppression",	J	Exp.Med,	vol.	204,	no.	6,	pp.	1257-1265.	
Ding,	Y.,	Xu,	D.,	Feng,	G.,	Bushell,	A.,	Muschel,	R.	J.,	&	Wood,	K.	J.	2009,	"Mesenchymal	stem	
cells	prevent	the	rejection	of	fully	allogenic	islet	grafts	by	the	immunosuppressive	activity	of	
matrix	metalloproteinase-2	and	-9",	Diabetes,	vol.	58,	no.	8,	pp.	1797-1806.	
Durrbach,	A.,	Francois,	H.,	Jacquet,	A.,	Beaudreuil,	S.,	&	Charpentier,	B.	2010,	"Co-signals	in	
organ	transplantation",	Curr.Opin.Organ	Transplant.,	vol.	15,	no.	4,	pp.	474-480.	
Einsiedel,	H.	G.,	Kawan,	L.,	Eckert,	C.,	Witt,	O.,	Fichtner,	I.,	Henze,	G.,	&	Seeger,	K.	2006,	
"Histone	deacetylase	inhibitors	have	antitumor	activity	in	two	NOD/SCID	mouse	models	of	
B-cell	precursor	childhood	acute	lymphoblastic	leukemia",	Leukemia,	vol.	20,	no.	8,	pp.	
1435-1436.	
242	
	
Ekberg,	H.,	Tedesco-Silva,	H.,	Demirbas,	A.,	Vitko,	S.,	Nashan,	B.,	Gurkan,	A.,	Margreiter,	R.,	
Hugo,	C.,	Grinyo,	J.	M.,	Frei,	U.,	Vanrenterghem,	Y.,	Daloze,	P.,	&	Halloran,	P.	F.	2007,	
"Reduced	exposure	to	calcineurin	inhibitors	in	renal	transplantation",	N	Engl	J	Med,	vol.	357,	
no.	25,	pp.	2562-2575.	
Eljaafari,	A.,	Li,	Y.	P.,	&	Miossec,	P.	2009,	"IFN-gamma,	as	secreted	during	an	alloresponse,	
induces	differentiation	of	monocytes	into	tolerogenic	dendritic	cells,	resulting	in	FoxP3+	
regulatory	T	cell	promotion",	J	Immunol.,	vol.	183,	no.	5,	pp.	2932-2945.	
Fallarino,	F.,	Grohmann,	U.,	Hwang,	K.	W.,	Orabona,	C.,	Vacca,	C.,	Bianchi,	R.,	Belladonna,	M.	
L.,	Fioretti,	M.	C.,	Alegre,	M.	L.,	&	Puccetti,	P.	2003,	"Modulation	of	tryptophan	catabolism	
by	regulatory	T	cells",	Nat.Immunol.,	vol.	4,	no.	12,	pp.	1206-1212.	
Feng,	G.,	Nadig,	S.	N.,	Backdahl,	L.,	Beck,	S.,	Francis,	R.	S.,	Schiopu,	A.,	Whatcott,	A.,	Wood,	
K.	J.,	&	Bushell,	A.	2011a,	"Functional	regulatory	T	cells	produced	by	inhibiting	cyclic	
nucleotide	phosphodiesterase	type	3	prevent	allograft	rejection",	Sci	Transl.Med,	vol.	3,	no.	
83,	p.	83ra40.	
Ferrara,	J.	L.,	Levine,	J.	E.,	Reddy,	P.,	&	Holler,	E.	2009,	"Graft-versus-host	disease",	Lancet,	
vol.	373,	no.	9674,	pp.	1550-1561.	
Floess,	S.,	Freyer,	J.,	Siewert,	C.,	Baron,	U.,	Olek,	S.,	Polansky,	J.,	Schlawe,	K.,	Chang,	H.	D.,	
Bopp,	T.,	Schmitt,	E.,	Klein-Hessling,	S.,	Serfling,	E.,	Hamann,	A.,	&	Huehn,	J.	2007,	
"Epigenetic	control	of	the	foxp3	locus	in	regulatory	T	cells",	PLoS.Biol.,	vol.	5,	no.	2,	p.	e38.	
Fontenot,	J.	D.,	Gavin,	M.	A.,	&	Rudensky,	A.	Y.	2003,	"Foxp3	programs	the	development	and	
function	of	CD4+CD25+	regulatory	T	cells",	Nat.Immunol.,	vol.	4,	no.	4,	pp.	330-336.	
Gabriele,	L.	&	Ozato,	K.	2007,	"The	role	of	the	interferon	regulatory	factor	(IRF)	family	in	
dendritic	cell	development	and	function",	Cytokine	Growth	Factor	Rev.,	vol.	18,	no.	5-6,	pp.	
503-510.	
Game,	D.	S.	&	Lechler,	R.	I.	2002,	"Pathways	of	allorecognition:	implications	for	
transplantation	tolerance",	Transpl.Immunol.,	vol.	10,	no.	2-3,	pp.	101-108.	
Gao,	W.,	Lu,	Y.,	El,	E.	B.,	Oukka,	M.,	Kuchroo,	V.	K.,	&	Strom,	T.	B.	2007,	"Contrasting	effects	
of	cyclosporine	and	rapamycin	in	de	novo	generation	of	alloantigen-specific	regulatory	T	
cells",	Am.J	Transplant.,	vol.	7,	no.	7,	pp.	1722-1732.	
Garbrecht,	F.	C.,	Russo,	C.,	&	Weksler,	M.	E.	1988,	"Long-term	growth	of	human	T	cell	lines	
and	clones	on	anti-CD3	antibody-treated	tissue	culture	plates",	J	Immunol.Methods,	vol.	
107,	no.	1,	pp.	137-142.	
Garrod,	K.	R.	&	Cahalan,	M.	D.	2008,	"Murine	skin	transplantation",	J	Vis.Exp.	no.	11.	
Gaston,	R.	S.,	Kaplan,	B.,	Shah,	T.,	Cibrik,	D.,	Shaw,	L.	M.,	Angelis,	M.,	Mulgaonkar,	S.,	Meier-
Kriesche,	H.	U.,	Patel,	D.,	&	Bloom,	R.	D.	2009,	"Fixed-	or	controlled-dose	mycophenolate	
mofetil	with	standard-	or	reduced-dose	calcineurin	inhibitors:	the	Opticept	trial",	Am.J	
Transplant.,	vol.	9,	no.	7,	pp.	1607-1619.	
243	
	
Gershon,	R.	K.	&	Kondo,	K.	1970,	"Cell	interactions	in	the	induction	of	tolerance:	the	role	of	
thymic	lymphocytes",	Immunology,	vol.	18,	no.	5,	pp.	723-737.	
Gibson,	T.	&	Medawar,	P.	B.	1943,	"The	fate	of	skin	homografts	in	man",	J.Anat.,	vol.	77,	no.	
Pt	4,	pp.	299-310.	
Godfrey,	D.	I.,	Kennedy,	J.,	Suda,	T.,	&	Zlotnik,	A.	1993,	"A	developmental	pathway	involving	
four	phenotypically	and	functionally	distinct	subsets	of	CD3-CD4-CD8-	triple-negative	adult	
mouse	thymocytes	defined	by	CD44	and	CD25	expression",	J	Immunol.,	vol.	150,	no.	10,	pp.	
4244-4252.	
Gondek,	D.	C.,	Lu,	L.	F.,	Quezada,	S.	A.,	Sakaguchi,	S.,	&	Noelle,	R.	J.	2005,	"Cutting	edge:	
contact-mediated	suppression	by	CD4+CD25+	regulatory	cells	involves	a	granzyme	B-
dependent,	perforin-independent	mechanism",	J	Immunol.,	vol.	174,	no.	4,	pp.	1783-1786.	
Gorer,	P.	A.,	Lyman,	S.,	&	Snell,	G.	D.	1948,	"Studies	on	the	Genetic	and	Antigenic	Basis	of	
Tumour	Transplantation.	Linkage	between	a	Histocompatibility	Gene	and	'Fused'	in	Mice",	
Proceedings	of	the	Royal	Society	of	London.Series	B	-	Biological	Sciences,	vol.	135,	no.	881,	
pp.	499-505.	
Goutelle,	S.,	Maurin,	M.,	Rougier,	F.,	Barbaut,	X.,	Bourguignon,	L.,	Ducher,	M.,	&	Maire,	P.	
2008,	"The	Hill	equation:	a	review	of	its	capabilities	in	pharmacological	modelling",	
Fundam.Clin.Pharmacol.,	vol.	22,	no.	6,	pp.	633-648.	
Grabiec,	A.	M.,	Krausz,	S.,	de,	J.	W.,	Burakowski,	T.,	Groot,	D.,	Sanders,	M.	E.,	Prakken,	B.	J.,	
Maslinski,	W.,	Eldering,	E.,	Tak,	P.	P.,	&	Reedquist,	K.	A.	2010,	"Histone	deacetylase	
inhibitors	suppress	inflammatory	activation	of	rheumatoid	arthritis	patient	synovial	
macrophages	and	tissue",	J	Immunol.,	vol.	184,	no.	5,	pp.	2718-2728.	
Grass,	J.	A.,	Wafa,	T.,	Reames,	A.,	Wages,	D.,	Corash,	L.,	Ferrara,	J.	L.,	&	Lin,	L.	1999,	
"Prevention	of	transfusion-associated	graft-versus-host	disease	by	photochemical	
treatment",	Blood,	vol.	93,	no.	9,	pp.	3140-3147.	
Grossman,	W.	J.,	Verbsky,	J.	W.,	Barchet,	W.,	Colonna,	M.,	Atkinson,	J.	P.,	&	Ley,	T.	J.	2004,	
"Human	T	regulatory	cells	can	use	the	perforin	pathway	to	cause	autologous	target	cell	
death",	Immunity.,	vol.	21,	no.	4,	pp.	589-601.	
Groux,	H.,	O'Garra,	A.,	Bigler,	M.,	Rouleau,	M.,	Antonenko,	S.,	de	Vries,	J.	E.,	&	Roncarolo,	M.	
G.	1997,	"A	CD4+	T-cell	subset	inhibits	antigen-specific	T-cell	responses	and	prevents	
colitis",	Nature,	vol.	389,	no.	6652,	pp.	737-742.	
Grozinger,	C.	M.,	Hassig,	C.	A.,	&	Schreiber,	S.	L.	1999,	"Three	proteins	define	a	class	of	
human	histone	deacetylases	related	to	yeast	Hda1p",	Proc.Natl.Acad.Sci	U.S.A,	vol.	96,	no.	
9,	pp.	4868-4873.	
Guani-Guerra,	E.,	Santos-Mendoza,	T.,	Lugo-Reyes,	S.	O.,	&	Teran,	L.	M.	2010,	"Antimicrobial	
peptides:	general	overview	and	clinical	implications	in	human	health	and	disease",	
Clin.Immunol.,	vol.	135,	no.	1,	pp.	1-11.	
244	
	
Halloran,	P.	F.	2004a,	"Immunosuppressive	drugs	for	kidney	transplantation",	N	Engl	J	Med,	
vol.	351,	no.	26,	pp.	2715-2729.	
Hamburger,	J.,	Vaysse,	J.,	Crosnier,	J.,	Auvert,	J.,	Lalanne,	C.	M.,	&	Hopper,	J.,	Jr.	1962,	
"Renal	homotransplantation	in	man	after	radiation	of	the	recipient.	Experience	with	six	
patients	since	1959",	Am.J	Med,	vol.	32,	pp.	854-871.	
Han,	Q.,	Bagheri,	N.,	Bradshaw,	E.	M.,	Hafler,	D.	A.,	Lauffenburger,	D.	A.,	&	Love,	J.	C.	2012,	
"Polyfunctional	responses	by	human	T	cells	result	from	sequential	release	of	cytokines",	
Proc.Natl.Acad.Sci	U.S.A,	vol.	109,	no.	5,	pp.	1607-1612.	
Hancock,	W.	W.,	Akimova,	T.,	Beier,	U.	H.,	Liu,	Y.,	&	Wang,	L.	2012,	"HDAC	inhibitor	therapy	
in	autoimmunity	and	transplantation",	Ann.Rheum.Dis.,	vol.	71	Suppl	2,	p.	i46-i54.	
Hassan,	A.	T.,	Dai,	Z.,	Konieczny,	B.	T.,	Ring,	G.	H.,	Baddoura,	F.	K.,	bou-Dahab,	L.	H.,	El-
Sayed,	A.	A.,	&	Lakkis,	F.	G.	1999,	"Regulation	of	alloantigen-mediated	T-cell	proliferation	by	
endogenous	interferon-gamma:	implications	for	long-term	allograft	acceptance",	
Transplantation,	vol.	68,	no.	1,	pp.	124-129.	
Herrera,	O.	B.,	Golshayan,	D.,	Tibbott,	R.,	Salcido,	O.	F.,	James,	M.	J.,	Marelli-Berg,	F.	M.,	&	
Lechler,	R.	I.	2004,	"A	novel	pathway	of	alloantigen	presentation	by	dendritic	cells",	J	
Immunol.,	vol.	173,	no.	8,	pp.	4828-4837.	
Hester,	J.,	Schiopu,	A.,	Nadig,	S.	N.,	&	Wood,	K.	J.	2012,	"Low-dose	rapamycin	treatment	
increases	the	ability	of	human	regulatory	T	cells	to	inhibit	transplant	arteriosclerosis	in	
vivo",	Am.J	Transplant.,	vol.	12,	no.	8,	pp.	2008-2016.	
Hori,	S.,	Nomura,	T.,	&	Sakaguchi,	S.	2003,	"Control	of	regulatory	T	cell	development	by	the	
transcription	factor	Foxp3",	Science,	vol.	299,	no.	5609,	pp.	1057-1061.	
Hubbert,	C.,	Guardiola,	A.,	Shao,	R.,	Kawaguchi,	Y.,	Ito,	A.,	Nixon,	A.,	Yoshida,	M.,	Wang,	X.	
F.,	&	Yao,	T.	P.	2002,	"HDAC6	is	a	microtubule-associated	deacetylase",	Nature,	vol.	417,	no.	
6887,	pp.	455-458.	
Humar,	A.,	Payne,	W.	D.,	Sutherland,	D.	E.,	&	Matas,	A.	J.	2000,	"Clinical	determinants	of	
multiple	acute	rejection	episodes	in	kidney	transplant	recipients",	Transplantation,	vol.	69,	
no.	11,	pp.	2357-2360.	
Hume,	D.	M.,	Merrill,	J.	P.,	Miller,	B.	F.,	&	Thorn,	G.	W.	1955,	"Experiences	with	renal	
homotransplantation	in	the	human:	report	of	nine	cases",	J.Clin.Invest,	vol.	34,	no.	2,	pp.	
327-382.	
Ito,	T.,	Hanabuchi,	S.,	Wang,	Y.	H.,	Park,	W.	R.,	Arima,	K.,	Bover,	L.,	Qin,	F.	X.,	Gilliet,	M.,	&	
Liu,	Y.	J.	2008,	"Two	functional	subsets	of	FOXP3+	regulatory	T	cells	in	human	thymus	and	
periphery",	Immunity.,	vol.	28,	no.	6,	pp.	870-880.	
Jamieson,	N.	V.,	Joysey,	V.,	Friend,	P.	J.,	Marcus,	R.,	Ramsbottom,	S.,	Baglin,	T.,	Johnston,	P.	
S.,	Williams,	R.,	&	Calne,	R.	Y.	1991,	"Graft-versus-host	disease	in	solid	organ	
transplantation",	Transpl.Int.,	vol.	4,	no.	2,	pp.	67-71.	
245	
	
Janke,	C.	&	Bulinski,	J.	C.	2011,	"Post-translational	regulation	of	the	microtubule	
cytoskeleton:	mechanisms	and	functions",	Nat.Rev.Mol.Cell	Biol.,	vol.	12,	no.	12,	pp.	773-
786.	
Jardine,	A.	G.,	Fellstrom,	B.,	Logan,	J.	O.,	Cole,	E.,	Nyberg,	G.,	Gronhagen-Riska,	C.,	Madsen,	
S.,	Neumayer,	H.	H.,	Maes,	B.,	Ambuhl,	P.,	Olsson,	A.	G.,	Pedersen,	T.,	&	Holdaas,	H.	2005a,	
"Cardiovascular	risk	and	renal	transplantation:	post	hoc	analyses	of	the	Assessment	of	
Lescol	in	Renal	Transplantation	(ALERT)	Study",	Am.J	Kidney	Dis.,	vol.	46,	no.	3,	pp.	529-536.	
Jenkins,	M.	K.,	Taylor,	P.	S.,	Norton,	S.	D.,	&	Urdahl,	K.	B.	1991,	"CD28	delivers	a	
costimulatory	signal	involved	in	antigen-specific	IL-2	production	by	human	T	cells",	J	
Immunol.,	vol.	147,	no.	8,	pp.	2461-2466.	
Johnson,	J.,	Pahuja,	A.,	Graham,	M.,	Hering,	B.,	Hancock,	W.	W.,	&	Bansal-Pakala,	P.	2008,	
"Effects	of	histone	deacetylase	inhibitor	SAHA	on	effector	and	FOXP3+regulatory	T	cells	in	
rhesus	macaques",	Transplant.Proc.,	vol.	40,	no.	2,	pp.	459-461.	
Jones,	N.	D.,	Turvey,	S.	E.,	Van,	M.	A.,	Hara,	M.,	Kingsley,	C.	I.,	Smith,	C.	H.,	Mellor,	A.	L.,	
Morris,	P.	J.,	&	Wood,	K.	J.	2001,	"Differential	susceptibility	of	heart,	skin,	and	islet	allografts	
to	T	cell-mediated	rejection",	J	Immunol.,	vol.	166,	no.	4,	pp.	2824-2830.	
Joosten,	L.	A.,	Leoni,	F.,	Meghji,	S.,	&	Mascagni,	P.	2011,	"Inhibition	of	HDAC	activity	by	
ITF2357	ameliorates	joint	inflammation	and	prevents	cartilage	and	bone	destruction	in	
experimental	arthritis",	Mol.Med,	vol.	17,	no.	5-6,	pp.	391-396.	
Kaye,	J.,	Hsu,	M.	L.,	Sauron,	M.	E.,	Jameson,	S.	C.,	Gascoigne,	N.	R.,	&	Hedrick,	S.	M.	1989,	
"Selective	development	of	CD4+	T	cells	in	transgenic	mice	expressing	a	class	II	MHC-
restricted	antigen	receptor",	Nature,	vol.	341,	no.	6244,	pp.	746-749.	
Keating,	R.,	Hertz,	T.,	Wehenkel,	M.,	Harris,	T.	L.,	Edwards,	B.	A.,	McClaren,	J.	L.,	Brown,	S.	
A.,	Surman,	S.,	Wilson,	Z.	S.,	Bradley,	P.,	Hurwitz,	J.,	Chi,	H.,	Doherty,	P.	C.,	Thomas,	P.	G.,	&	
McGargill,	M.	A.	2013,	"The	kinase	mTOR	modulates	the	antibody	response	to	provide	cross-
protective	immunity	to	lethal	infection	with	influenza	virus",	Nat.Immunol.,	vol.	14,	no.	12,	
pp.	1266-1276.	
Keedy,	K.	S.,	Archin,	N.	M.,	Gates,	A.	T.,	Espeseth,	A.,	Hazuda,	D.	J.,	&	Margolis,	D.	M.	2009,	
"A	limited	group	of	class	I	histone	deacetylases	acts	to	repress	human	immunodeficiency	
virus	type	1	expression",	J	Virol.,	vol.	83,	no.	10,	pp.	4749-4756.	
Keir,	M.	E.	&	Sharpe,	A.	H.	2005,	"The	B7/CD28	costimulatory	family	in	autoimmunity",	
Immunol.Rev.,	vol.	204,	pp.	128-143.	
Kelly,	W.	K.,	Richon,	V.	M.,	O'Connor,	O.,	Curley,	T.,	Gregor-Curtelli,	B.,	Tong,	W.,	Klang,	M.,	
Schwartz,	L.,	Richardson,	S.,	Rosa,	E.,	Drobnjak,	M.,	Cordon-Cordo,	C.,	Chiao,	J.	H.,	Rifkind,	
R.,	Marks,	P.	A.,	&	Scher,	H.	2003,	"Phase	I	clinical	trial	of	histone	deacetylase	inhibitor:	
suberoylanilide	hydroxamic	acid	administered	intravenously",	Clin.Cancer	Res.,	vol.	9,	no.	10	
Pt	1,	pp.	3578-3588.	
246	
	
Khattri,	R.,	Cox,	T.,	Yasayko,	S.	A.,	&	Ramsdell,	F.	2003,	"An	essential	role	for	Scurfin	in	
CD4+CD25+	T	regulatory	cells",	Nat.Immunol.,	vol.	4,	no.	4,	pp.	337-342.	
Kino,	T.,	Hatanaka,	H.,	Hashimoto,	M.,	Nishiyama,	M.,	Goto,	T.,	Okuhara,	M.,	Kohsaka,	M.,	
Aoki,	H.,	&	Imanaka,	H.	1987,	"FK-506,	a	novel	immunosuppressant	isolated	from	a	
Streptomyces.	I.	Fermentation,	isolation,	and	physico-chemical	and	biological	
characteristics",	J	Antibiot.(Tokyo),	vol.	40,	no.	9,	pp.	1249-1255.	
Kinugasa,	F.,	Nagatomi,	I.,	Nakanishi,	T.,	Noto,	T.,	Mori,	H.,	Matsuoka,	H.,	Sudo,	Y.,	&	Mutoh,	
S.	2009,	"Effect	of	the	immunosuppressant	histone	deacetylase	inhibitor	FR276457	in	a	
canine	renal	transplant	model",	Transpl.Immunol.,	vol.	21,	no.	4,	pp.	198-202.	
Kinugasa,	F.,	Yamada,	T.,	Noto,	T.,	Matsuoka,	H.,	Mori,	H.,	Sudo,	Y.,	&	Mutoh,	S.	2008,	
"Effect	of	a	new	immunosuppressant	histon	deacetylase	(HDAC)	inhibitor	FR276457	in	a	rat	
cardiac	transplant	model",	Biol.Pharm.Bull.,	vol.	31,	no.	9,	pp.	1723-1726.	
Klein,	J.	&	Sato,	A.	2000a,	"The	HLA	system.	First	of	two	parts",	N	Engl	J	Med,	vol.	343,	no.	
10,	pp.	702-709.	
Klein,	J.	&	Sato,	A.	2000b,	"The	HLA	system.	Second	of	two	parts",	N	Engl	J	Med,	vol.	343,	no.	
11,	pp.	782-786.	
Kleinewietfeld,	M.,	Puentes,	F.,	Borsellino,	G.,	Battistini,	L.,	Rotzschke,	O.,	&	Falk,	K.	2005,	
"CCR6	expression	defines	regulatory	effector/memory-like	cells	within	the	CD25(+)CD4+	T-
cell	subset",	Blood,	vol.	105,	no.	7,	pp.	2877-2886.	
Kohm,	A.	P.,	Carpentier,	P.	A.,	Anger,	H.	A.,	&	Miller,	S.	D.	2002,	"Cutting	edge:	CD4+CD25+	
regulatory	T	cells	suppress	antigen-specific	autoreactive	immune	responses	and	central	
nervous	system	inflammation	during	active	experimental	autoimmune	encephalomyelitis",	J	
Immunol.,	vol.	169,	no.	9,	pp.	4712-4716.	
Konieczny,	B.	T.,	Dai,	Z.,	Elwood,	E.	T.,	Saleem,	S.,	Linsley,	P.	S.,	Baddoura,	F.	K.,	Larsen,	C.	P.,	
Pearson,	T.	C.,	&	Lakkis,	F.	G.	1998,	"IFN-gamma	is	critical	for	long-term	allograft	survival	
induced	by	blocking	the	CD28	and	CD40	ligand	T	cell	costimulation	pathways",	J	Immunol.,	
vol.	160,	no.	5,	pp.	2059-2064.	
Kovacs,	J.	J.,	Murphy,	P.	J.,	Gaillard,	S.,	Zhao,	X.,	Wu,	J.	T.,	Nicchitta,	C.	V.,	Yoshida,	M.,	Toft,	
D.	O.,	Pratt,	W.	B.,	&	Yao,	T.	P.	2005,	"HDAC6	regulates	Hsp90	acetylation	and	chaperone-
dependent	activation	of	glucocorticoid	receptor",	Mol.Cell,	vol.	18,	no.	5,	pp.	601-607.	
Kretschmer,	K.,	Apostolou,	I.,	Hawiger,	D.,	Khazaie,	K.,	Nussenzweig,	M.	C.,	&	von,	B.	H.	
2005,	"Inducing	and	expanding	regulatory	T	cell	populations	by	foreign	antigen",	
Nat.Immunol.,	vol.	6,	no.	12,	pp.	1219-1227.	
Kruisbeek,	A.	M.,	Mond,	J.	J.,	Fowlkes,	B.	J.,	Carmen,	J.	A.,	Bridges,	S.,	&	Longo,	D.	L.	1985,	
"Absence	of	the	Lyt-2-,L3T4+	lineage	of	T	cells	in	mice	treated	neonatally	with	anti-I-A	
correlates	with	absence	of	intrathymic	I-A-bearing	antigen-presenting	cell	function",	J	
Exp.Med,	vol.	161,	no.	5,	pp.	1029-1047.	
247	
	
Kuss,	R.,	Legrain,	M.,	MATHE,	G.,	Nedey,	R.,	&	Camey,	M.	1962,	"Homologous	human	kidney	
transplantation.	Experience	with	six	patients",	Postgrad.Med	J,	vol.	38,	pp.	528-531.	
Lagodzinski,	Z.,	Gorski,	A.,	&	Wasik,	M.	1990,	"Effect	of	FK506	and	cyclosporine	on	primary	
and	secondary	skin	allograft	survival	in	mice",	Immunology,	vol.	71,	no.	1,	pp.	148-150.	
Larsen,	C.	P.,	Knechtle,	S.	J.,	Adams,	A.,	Pearson,	T.,	&	Kirk,	A.	D.	2006,	"A	new	look	at	
blockade	of	T-cell	costimulation:	a	therapeutic	strategy	for	long-term	maintenance	
immunosuppression",	Am.J	Transplant.,	vol.	6,	no.	5	Pt	1,	pp.	876-883.	
Larsen,	C.	P.,	Morris,	P.	J.,	&	Austyn,	J.	M.	1990,	"Migration	of	dendritic	leukocytes	from	
cardiac	allografts	into	host	spleens.	A	novel	pathway	for	initiation	of	rejection",	J	Exp.Med,	
vol.	171,	no.	1,	pp.	307-314.	
Larsen,	C.	P.,	Steinman,	R.	M.,	Witmer-Pack,	M.,	Hankins,	D.	F.,	Morris,	P.	J.,	&	Austyn,	J.	M.	
1990,	"Migration	and	maturation	of	Langerhans	cells	in	skin	transplants	and	explants",	J	
Exp.Med,	vol.	172,	no.	5,	pp.	1483-1493.	
Larsen,	L.,	Tonnesen,	M.,	Ronn,	S.	G.,	Storling,	J.,	Jorgensen,	S.,	Mascagni,	P.,	Dinarello,	C.	A.,	
Billestrup,	N.,	&	Mandrup-Poulsen,	T.	2007,	"Inhibition	of	histone	deacetylases	prevents	
cytokine-induced	toxicity	in	beta	cells",	Diabetologia,	vol.	50,	no.	4,	pp.	779-789.	
Lechler,	R.	I.	&	Batchelor,	J.	R.	1982a,	"Immunogenicity	of	retransplanted	rat	kidney	
allografts.	Effect	of	inducing	chimerism	in	the	first	recipient	and	quantitative	studies	on	
immunosuppression	of	the	second	recipient",	J	Exp.Med,	vol.	156,	no.	6,	pp.	1835-1841.	
Lechler,	R.	I.,	Lombardi,	G.,	Batchelor,	J.	R.,	Reinsmoen,	N.,	&	Bach,	F.	H.	1990,	"The	
molecular	basis	of	alloreactivity",	Immunol.Today,	vol.	11,	no.	3,	pp.	83-88.	
Leonessa,	F.,	Kim,	J.	H.,	Ghiorghis,	A.,	Kulawiec,	R.	J.,	Hammer,	C.,	Talebian,	A.,	&	Clarke,	R.	
2002,	"C-7	analogues	of	progesterone	as	potent	inhibitors	of	the	P-glycoprotein	efflux	
pump",	J	Med	Chem.,	vol.	45,	no.	2,	pp.	390-398.	
Leoni,	F.,	Fossati,	G.,	Lewis,	E.	C.,	Lee,	J.	K.,	Porro,	G.,	Pagani,	P.,	Modena,	D.,	Moras,	M.	L.,	
Pozzi,	P.,	Reznikov,	L.	L.,	Siegmund,	B.,	Fantuzzi,	G.,	Dinarello,	C.	A.,	&	Mascagni,	P.	2005,	
"The	histone	deacetylase	inhibitor	ITF2357	reduces	production	of	pro-inflammatory	
cytokines	in	vitro	and	systemic	inflammation	in	vivo",	Mol.Med,	vol.	11,	no.	1-12,	pp.	1-15.	
Levings,	M.	K.,	Sangregorio,	R.,	&	Roncarolo,	M.	G.	2001,	"Human	cd25(+)cd4(+)	t	regulatory	
cells	suppress	naive	and	memory	T	cell	proliferation	and	can	be	expanded	in	vitro	without	
loss	of	function",	J	Exp.Med,	vol.	193,	no.	11,	pp.	1295-1302.	
Li,	X.	C.,	Rothstein,	D.	M.,	&	Sayegh,	M.	H.	2009,	"Costimulatory	pathways	in	
transplantation:	challenges	and	new	developments",	Immunol.Rev.,	vol.	229,	no.	1,	pp.	271-
293.	
Li,	Y.,	Zhao,	T.,	Liu,	B.,	Halaweish,	I.,	Mazitschek,	R.,	Duan,	X.,	&	Alam,	H.	B.	2015,	"Inhibition	
of	histone	deacetylase	6	improves	long-term	survival	in	a	lethal	septic	model",	J	Trauma	
Acute.Care	Surg.,	vol.	78,	no.	2,	pp.	378-385.	
248	
	
Liang,	B.,	Workman,	C.,	Lee,	J.,	Chew,	C.,	Dale,	B.	M.,	Colonna,	L.,	Flores,	M.,	Li,	N.,	
Schweighoffer,	E.,	Greenberg,	S.,	Tybulewicz,	V.,	Vignali,	D.,	&	Clynes,	R.	2008,	"Regulatory	T	
cells	inhibit	dendritic	cells	by	lymphocyte	activation	gene-3	engagement	of	MHC	class	II",	J	
Immunol.,	vol.	180,	no.	9,	pp.	5916-5926.	
Licciardi,	P.	V.	&	Karagiannis,	T.	C.	2012,	"Regulation	of	immune	responses	by	histone	
deacetylase	inhibitors",	ISRN.Hematol.,	vol.	2012,	p.	690901.	
Long,	M.,	Park,	S.	G.,	Strickland,	I.,	Hayden,	M.	S.,	&	Ghosh,	S.	2009,	"Nuclear	factor-kappaB	
modulates	regulatory	T	cell	development	by	directly	regulating	expression	of	Foxp3	
transcription	factor",	Immunity.,	vol.	31,	no.	6,	pp.	921-931.	
Lucas,	J.	L.,	Mirshahpanah,	P.,	Haas-Stapleton,	E.,	Asadullah,	K.,	Zollner,	T.	M.,	&	Numerof,	R.	
P.	2009,	"Induction	of	Foxp3+	regulatory	T	cells	with	histone	deacetylase	inhibitors",	Cell	
Immunol.,	vol.	257,	no.	1-2,	pp.	97-104.	
Lukacs,	N.	W.,	Kunkel,	S.	L.,	Burdick,	M.	D.,	&	Strieter,	R.	M.	1993,	"The	production	of	
chemotactic	cytokines	in	an	allogeneic	response.	The	role	of	intercellular	adhesion	
molecule-1	and	lymphocyte	function-associated	antigen-3",	Am.J	Pathol.,	vol.	143,	no.	4,	pp.	
1179-1188.	
Malek,	T.	R.,	Yu,	A.,	Vincek,	V.,	Scibelli,	P.,	&	Kong,	L.	2002,	"CD4	regulatory	T	cells	prevent	
lethal	autoimmunity	in	IL-2Rbeta-deficient	mice.	Implications	for	the	nonredundant	function	
of	IL-2",	Immunity.,	vol.	17,	no.	2,	pp.	167-178.	
Maloy,	K.	J.,	Salaun,	L.,	Cahill,	R.,	Dougan,	G.,	Saunders,	N.	J.,	&	Powrie,	F.	2003,	"CD4+CD25+	
T(R)	cells	suppress	innate	immune	pathology	through	cytokine-dependent	mechanisms",	J	
Exp.Med,	vol.	197,	no.	1,	pp.	111-119.	
Marie,	J.	C.,	Letterio,	J.	J.,	Gavin,	M.,	&	Rudensky,	A.	Y.	2005,	"TGF-beta1	maintains	
suppressor	function	and	Foxp3	expression	in	CD4+CD25+	regulatory	T	cells",	J	Exp.Med,	vol.	
201,	no.	7,	pp.	1061-1067.	
Marusic-Galesic,	S.,	Longo,	D.	L.,	&	Kruisbeek,	A.	M.	1989,	"Preferential	differentiation	of	T	
cell	receptor	specificities	based	on	the	MHC	glycoproteins	encountered	during	
development.	Evidence	for	positive	selection",	J	Exp.Med,	vol.	169,	no.	5,	pp.	1619-1630.	
Matevossian,	E.,	Kern,	H.,	Huser,	N.,	Doll,	D.,	Snopok,	Y.,	Nahrig,	J.,	Altomonte,	J.,	Sinicina,	I.,	
Friess,	H.,	&	Thorban,	S.	2009,	"Surgeon	Yurii	Voronoy	(1895-1961)	-	a	pioneer	in	the	history	
of	clinical	transplantation:	in	memoriam	at	the	75th	anniversary	of	the	first	human	kidney	
transplantation",	Transpl.Int.,	vol.	22,	no.	12,	pp.	1132-1139.	
Maynard,	C.	L.,	Harrington,	L.	E.,	Janowski,	K.	M.,	Oliver,	J.	R.,	Zindl,	C.	L.,	Rudensky,	A.	Y.,	&	
Weaver,	C.	T.	2007,	"Regulatory	T	cells	expressing	interleukin	10	develop	from	Foxp3+	and	
Foxp3-	precursor	cells	in	the	absence	of	interleukin	10",	Nat.Immunol.,	vol.	8,	no.	9,	pp.	931-
941.	
McMurchy,	A.	N.,	Bushell,	A.,	Levings,	M.	K.,	&	Wood,	K.	J.	2011,	"Moving	to	tolerance:	
clinical	application	of	T	regulatory	cells",	Semin.Immunol.,	vol.	23,	no.	4,	pp.	304-313.	
249	
	
Medawar,	P.	B.	1944,	"The	behaviour	and	fate	of	skin	autografts	and	skin	homografts	in	
rabbits:	A	report	to	the	War	Wounds	Committee	of	the	Medical	Research	Council",	J.Anat.,	
vol.	78,	no.	Pt	5,	pp.	176-199.	
Meier-Kriesche,	H.	U.,	Schold,	J.	D.,	Srinivas,	T.	R.,	&	Kaplan,	B.	2004a,	"Lack	of	improvement	
in	renal	allograft	survival	despite	a	marked	decrease	in	acute	rejection	rates	over	the	most	
recent	era",	Am.J	Transplant.,	vol.	4,	no.	3,	pp.	378-383.	
Meier-Kriesche,	H.	U.,	Schold,	J.	D.,	Srinivas,	T.	R.,	&	Kaplan,	B.	2004b,	"Lack	of	improvement	
in	renal	allograft	survival	despite	a	marked	decrease	in	acute	rejection	rates	over	the	most	
recent	era",	Am.J	Transplant.,	vol.	4,	no.	3,	pp.	378-383.	
Merrill,	J.	P.,	Murray,	J.	E.,	Harrison,	J.	H.,	Friedman,	E.	A.,	Dealy,	J.	B.	J.,	&	Dammin,	G.	J.	
Successful	homotransplantation	of	the	kidney	between	non-identical	twins.	N	Engl	J	Med	
262,	1251-1260.	1960.		
Merrill,	J.	P.,	Murray,	J.	E.,	Harrison,	J.	H.,	&	Guild,	W.	R.	1956,	"Successful	
homotransplantation	of	the	human	kidney	between	identical	twins",	J.Am.Med.Assoc.,	vol.	
160,	no.	4,	pp.	277-282.	
Min,	S.	I.,	Ha,	J.,	Park,	C.	G.,	Won,	J.	K.,	Park,	Y.	J.,	Min,	S.	K.,	&	Kim,	S.	J.	2009,	"Sequential	
evolution	of	IL-17	responses	in	the	early	period	of	allograft	rejection",	Exp.Mol.Med,	vol.	41,	
no.	10,	pp.	707-716.	
Minucci,	S.	&	Pelicci,	P.	G.	2006,	"Histone	deacetylase	inhibitors	and	the	promise	of	
epigenetic	(and	more)	treatments	for	cancer",	Nat.Rev.Cancer,	vol.	6,	no.	1,	pp.	38-51.	
Miyara,	M.	&	Sakaguchi,	S.	2007,	"Natural	regulatory	T	cells:	mechanisms	of	suppression",	
Trends	Mol.Med,	vol.	13,	no.	3,	pp.	108-116.	
Miyara,	M.,	Yoshioka,	Y.,	Kitoh,	A.,	Shima,	T.,	Wing,	K.,	Niwa,	A.,	Parizot,	C.,	Taflin,	C.,	Heike,	
T.,	Valeyre,	D.,	Mathian,	A.,	Nakahata,	T.,	Yamaguchi,	T.,	Nomura,	T.,	Ono,	M.,	Amoura,	Z.,	
Gorochov,	G.,	&	Sakaguchi,	S.	2009,	"Functional	delineation	and	differentiation	dynamics	of	
human	CD4+	T	cells	expressing	the	FoxP3	transcription	factor",	Immunity.,	vol.	30,	no.	6,	pp.	
899-911.	
Moreira,	J.	M.,	Scheipers,	P.,	&	Sorensen,	P.	2003,	"The	histone	deacetylase	inhibitor	
Trichostatin	A	modulates	CD4+	T	cell	responses",	BMC.Cancer,	vol.	3,	p.	30.	
Morris,	P.	J.	2004,	"Transplantation--a	medical	miracle	of	the	20th	century",	N.Engl.J.Med.,	
vol.	351,	no.	26,	pp.	2678-2680.	
Morris,	P.	J.,	Johnson,	R.	J.,	Fuggle,	S.	V.,	Belger,	M.	A.,	&	Briggs,	J.	D.	1999,	"Analysis	of	
factors	that	affect	outcome	of	primary	cadaveric	renal	transplantation	in	the	UK.	HLA	Task	
Force	of	the	Kidney	Advisory	Group	of	the	United	Kingdom	Transplant	Support	Service	
Authority	(UKTSSA)",	Lancet,	vol.	354,	no.	9185,	pp.	1147-1152.	
250	
	
Murase,	N.,	Todo,	S.,	Lee,	P.	H.,	Lai,	H.	S.,	Chapman,	F.,	Nalesnik,	M.	A.,	Makowka,	L.,	&	
Starzl,	T.	E.	1987,	"Heterotopic	heart	transplantation	in	the	rat	receiving	FK-506	alone	or	
with	cyclosporine",	Transplant.Proc.,	vol.	19,	no.	5	Suppl	6,	pp.	71-75.	
Murray,	J.	E.,	Merrill,	J.	P.,	&	Harrison,	J.	H.	1958,	"Kidney	transplantation	between	seven	
pairs	of	identical	twins",	Ann.Surg.,	vol.	148,	no.	3,	pp.	343-359.	
Murray,	J.	E.,	Merrill,	J.	P.,	Harrison,	J.	H.,	Wilson,	R.	E.,	&	Dammin,	G.	J.	1963,	"Prolonged	
survival	of	human-kidney	homografts	by	immunosuppressive	drug	therapy",	N	Engl	J	Med,	
vol.	268,	pp.	1315-1323.	
Murray,	J.	E.,	Wilson,	R.	E.,	&	O'Connor,	N.	E.	1967,	"Evaluation	of	long-functioning	human	
kidney	transplants",	Surg.Gynecol.Obstet.,	vol.	124,	no.	3,	pp.	509-520.	
na-Masangkay,	G.	I.	&	Sakamoto,	K.	M.	2011,	"The	role	of	HDAC6	in	cancer",	J	
Biomed.Biotechnol.,	vol.	2011,	p.	875824.	
Naesens,	M.,	Kuypers,	D.	R.,	&	Sarwal,	M.	2009,	"Calcineurin	inhibitor	nephrotoxicity",	Clin.J	
Am.Soc.Nephrol.,	vol.	4,	no.	2,	pp.	481-508.	
Nankivell,	B.	J.	&	Alexander,	S.	I.	2010,	"Rejection	of	the	kidney	allograft",	N	Engl	J	Med,	vol.	
363,	no.	15,	pp.	1451-1462.	
Navarro,	M.	N.,	Goebel,	J.,	Feijoo-Carnero,	C.,	Morrice,	N.,	&	Cantrell,	D.	A.	2011,	
"Phosphoproteomic	analysis	reveals	an	intrinsic	pathway	for	the	regulation	of	histone	
deacetylase	7	that	controls	the	function	of	cytotoxic	T	lymphocytes",	Nat.Immunol.,	vol.	12,	
no.	4,	pp.	352-361.	
Nie,	H.,	Zheng,	Y.,	Li,	R.,	Guo,	T.	B.,	He,	D.,	Fang,	L.,	Liu,	X.,	Xiao,	L.,	Chen,	X.,	Wan,	B.,	Chin,	Y.	
E.,	&	Zhang,	J.	Z.	2013,	"Phosphorylation	of	FOXP3	controls	regulatory	T	cell	function	and	is	
inhibited	by	TNF-alpha	in	rheumatoid	arthritis",	Nat.Med,	vol.	19,	no.	3,	pp.	322-328.	
O'Donovan,	P.,	Perrett,	C.	M.,	Zhang,	X.,	Montaner,	B.,	Xu,	Y.	Z.,	Harwood,	C.	A.,	McGregor,	J.	
M.,	Walker,	S.	L.,	Hanaoka,	F.,	&	Karran,	P.	2005,	"Azathioprine	and	UVA	light	generate	
mutagenic	oxidative	DNA	damage",	Science,	vol.	309,	no.	5742,	pp.	1871-1874.	
O'Flaherty,	E.,	Wong,	W.	K.,	Pettit,	S.	J.,	Seymour,	K.,	Ali,	S.,	&	Kirby,	J.	A.	2000,	"Regulation	
of	T-cell	apoptosis:	a	mixed	lymphocyte	reaction	model",	Immunology,	vol.	100,	no.	3,	pp.	
289-299.	
Ojo,	A.	O.,	Held,	P.	J.,	Port,	F.	K.,	Wolfe,	R.	A.,	Leichtman,	A.	B.,	Young,	E.	W.,	Arndorfer,	J.,	
Christensen,	L.,	&	Merion,	R.	M.	2003a,	"Chronic	renal	failure	after	transplantation	of	a	
nonrenal	organ",	N	Engl	J	Med,	vol.	349,	no.	10,	pp.	931-940.	
Opelz,	G.,	Mytilineos,	J.,	Scherer,	S.,	Dunckley,	H.,	Trejaut,	J.,	Chapman,	J.,	Middleton,	D.,	
Savage,	D.,	Fischer,	O.,	Bignon,	J.	D.,	&	.	1991,	"Survival	of	DNA	HLA-DR	typed	and	matched	
cadaver	kidney	transplants.	The	Collaborative	Transplant	Study",	Lancet,	vol.	338,	no.	8765,	
pp.	461-463.	
251	
	
Opelz,	G.,	Wujciak,	T.,	Dohler,	B.,	Scherer,	S.,	&	Mytilineos,	J.	1999,	"HLA	compatibility	and	
organ	transplant	survival.	Collaborative	Transplant	Study",	Rev.Immunogenet.,	vol.	1,	no.	3,	
pp.	334-342.	
Ozkaynak,	E.,	Gao,	W.,	Shemmeri,	N.,	Wang,	C.,	Gutierrez-Ramos,	J.	C.,	Amaral,	J.,	Qin,	S.,	
Rottman,	J.	B.,	Coyle,	A.	J.,	&	Hancock,	W.	W.	2001,	"Importance	of	ICOS-B7RP-1	
costimulation	in	acute	and	chronic	allograft	rejection",	Nat.Immunol.,	vol.	2,	no.	7,	pp.	591-
596.	
Padgett,	E.	D.	Is	iso-skin	grafting	practicable?	South	Med	J	25,	895-900.	1932.		
Parra,	M.	&	Verdin,	E.	2010,	"Regulatory	signal	transduction	pathways	for	class	IIa	histone	
deacetylases",	Curr.Opin.Pharmacol.,	vol.	10,	no.	4,	pp.	454-460.	
Paust,	S.,	Lu,	L.,	McCarty,	N.,	&	Cantor,	H.	2004,	"Engagement	of	B7	on	effector	T	cells	by	
regulatory	T	cells	prevents	autoimmune	disease",	Proc.Natl.Acad.Sci	U.S.A,	vol.	101,	no.	28,	
pp.	10398-10403.	
Pazin,	M.	J.	&	Kadonaga,	J.	T.	1997,	"What's	up	and	down	with	histone	deacetylation	and	
transcription?",	Cell,	vol.	89,	no.	3,	pp.	325-328.	
Phillips,	D.	M.	1963,	"The	presence	of	acetyl	groups	of	histones",	Biochem.J,	vol.	87,	pp.	258-
263.	
Pratt,	J.	R.,	Basheer,	S.	A.,	&	Sacks,	S.	H.	2002,	"Local	synthesis	of	complement	component	
C3	regulates	acute	renal	transplant	rejection",	Nat.Med,	vol.	8,	no.	6,	pp.	582-587.	
Prinz,	H.	2010,	"Hill	coefficients,	dose-response	curves	and	allosteric	mechanisms",	J	
Chem.Biol.,	vol.	3,	no.	1,	pp.	37-44.	
Quah,	B.	J.,	Warren,	H.	S.,	&	Parish,	C.	R.	2007a,	"Monitoring	lymphocyte	proliferation	in	
vitro	and	in	vivo	with	the	intracellular	fluorescent	dye	carboxyfluorescein	diacetate	
succinimidyl	ester",	Nat.Protoc.,	vol.	2,	no.	9,	pp.	2049-2056.	
Reddy,	P.,	Maeda,	Y.,	Hotary,	K.,	Liu,	C.,	Reznikov,	L.	L.,	Dinarello,	C.	A.,	&	Ferrara,	J.	L.	2004,	
"Histone	deacetylase	inhibitor	suberoylanilide	hydroxamic	acid	reduces	acute	graft-versus-
host	disease	and	preserves	graft-versus-leukemia	effect",	Proc.Natl.Acad.Sci	U.S.A,	vol.	101,	
no.	11,	pp.	3921-3926.	
Reddy,	P.,	Sun,	Y.,	Toubai,	T.,	Duran-Struuck,	R.,	Clouthier,	S.	G.,	Weisiger,	E.,	Maeda,	Y.,	
Tawara,	I.,	Krijanovski,	O.,	Gatza,	E.,	Liu,	C.,	Malter,	C.,	Mascagni,	P.,	Dinarello,	C.	A.,	&	
Ferrara,	J.	L.	2008a,	"Histone	deacetylase	inhibition	modulates	indoleamine	2,3-
dioxygenase-dependent	DC	functions	and	regulates	experimental	graft-versus-host	disease	
in	mice",	J	Clin.Invest,	vol.	118,	no.	7,	pp.	2562-2573.	
Reilly,	C.	M.,	Thomas,	M.,	Gogal,	R.,	Jr.,	Olgun,	S.,	Santo,	A.,	Sodhi,	R.,	Samy,	E.	T.,	Peng,	S.	L.,	
Gilkeson,	G.	S.,	&	Mishra,	N.	2008,	"The	histone	deacetylase	inhibitor	trichostatin	A	
upregulates	regulatory	T	cells	and	modulates	autoimmunity	in	NZB/W	F1	mice",	J	
Autoimmun.,	vol.	31,	no.	2,	pp.	123-130.	
252	
	
Richon,	V.	M.	&	O'Brien,	J.	P.	2002a,	"Histone	deacetylase	inhibitors:	a	new	class	of	potential	
therapeutic	agents	for	cancer	treatment",	Clin.Cancer	Res.,	vol.	8,	no.	3,	pp.	662-664.	
Richter,	N.,	Raddatz,	G.,	Graeter,	T.,	Schafers,	H.	J.,	&	Schlitt,	H.	J.	1995,	"Allogeneic	
lymphocyte	chimerism	after	clinical	lung	transplantation",	Transpl.Immunol.,	vol.	3,	no.	1,	
pp.	74-80.	
Richter,	N.,	Raddatz,	G.,	Steinhoff,	G.,	Schafers,	H.	J.,	&	Schlitt,	H.	J.	1994,	"Transmission	of	
donor	lymphocytes	in	clinical	lung	transplantation",	Transpl.Int.,	vol.	7,	no.	6,	pp.	414-419.	
Robey,	E.	&	Fowlkes,	B.	J.	1994,	"Selective	events	in	T	cell	development",	
Annu.Rev.Immunol.,	vol.	12,	pp.	675-705.	
Roger,	T.,	Lugrin,	J.,	Le,	R.	D.,	Goy,	G.,	Mombelli,	M.,	Koessler,	T.,	Ding,	X.	C.,	Chanson,	A.	L.,	
Reymond,	M.	K.,	Miconnet,	I.,	Schrenzel,	J.,	Francois,	P.,	&	Calandra,	T.	2011,	"Histone	
deacetylase	inhibitors	impair	innate	immune	responses	to	Toll-like	receptor	agonists	and	to	
infection",	Blood,	vol.	117,	no.	4,	pp.	1205-1217.	
Roncarolo,	M.	G.	&	Battaglia,	M.	2007,	"Regulatory	T-cell	immunotherapy	for	tolerance	to	
self	antigens	and	alloantigens	in	humans",	Nat.Rev.Immunol.,	vol.	7,	no.	8,	pp.	585-598.	
Roy,	A.,	Krzykwa,	E.,	Lemieux,	R.,	&	Neron,	S.	2001,	"Increased	efficiency	of	gamma-
irradiated	versus	mitomycin	C-treated	feeder	cells	for	the	expansion	of	normal	human	cells	
in	long-term	cultures",	J	Hematother.Stem	Cell	Res.,	vol.	10,	no.	6,	pp.	873-880.	
Sakaguchi,	S.,	Sakaguchi,	N.,	Asano,	M.,	Itoh,	M.,	&	Toda,	M.	1995,	"Immunologic	self-
tolerance	maintained	by	activated	T	cells	expressing	IL-2	receptor	alpha-chains	(CD25).	
Breakdown	of	a	single	mechanism	of	self-tolerance	causes	various	autoimmune	diseases",	J	
Immunol.,	vol.	155,	no.	3,	pp.	1151-1164.	
Schlitt,	H.	J.,	Kanehiro,	H.,	Raddatz,	G.,	Steinhoff,	G.,	Richter,	N.,	Nashan,	B.,	Ringe,	B.,	
Wonigeit,	K.,	&	Pichlmayr,	R.	1993a,	"Persistence	of	donor	lymphocytes	in	liver	allograft	
recipients",	Transplantation,	vol.	56,	no.	4,	pp.	1001-1007.	
Schlitt,	H.	J.,	Raddatz,	G.,	Steinhoff,	G.,	Wonigeit,	K.,	&	Pichlmayr,	R.	1993b,	"Passenger	
lymphocytes	in	human	liver	allografts	and	their	potential	role	after	transplantation",	
Transplantation,	vol.	56,	no.	4,	pp.	951-955.	
Schlitt,	H.	J.,	Tischler,	H.	J.,	Ringe,	B.,	Raddatz,	G.,	Maschek,	H.,	Dietrich,	H.,	Kuse,	E.,	
Pichlmayr,	R.,	&	Link,	H.	1995,	"Allogeneic	liver	transplantation	for	hepatic	veno-occlusive	
disease	after	bone	marrow	transplantation--clinical	and	immunological	considerations",	
Bone	Marrow	Transplant.,	vol.	16,	no.	3,	pp.	473-478.	
Schwartz,	R.	&	Dameshek,	W.	1959,	"Drug-induced	immunological	tolerance",	Nature,	vol.	
183,	no.	4676,	pp.	1682-1683.	
Schwoebel,	F.,	Barsig,	J.,	Wendel,	A.,	&	Hamacher,	J.	2005,	"Quantitative	assessment	of	
mouse	skin	transplant	rejection	using	digital	photography",	Lab	Anim,	vol.	39,	no.	2,	pp.	209-
214.	
253	
	
Segundo,	D.	S.,	Ruiz,	J.	C.,	Izquierdo,	M.,	Fernandez-Fresnedo,	G.,	Gomez-Alamillo,	C.,	
Merino,	R.,	Benito,	M.	J.,	Cacho,	E.,	Rodrigo,	E.,	Palomar,	R.,	Lopez-Hoyos,	M.,	&	Arias,	M.	
2006,	"Calcineurin	inhibitors,	but	not	rapamycin,	reduce	percentages	of	CD4+CD25+FOXP3+	
regulatory	T	cells	in	renal	transplant	recipients",	Transplantation,	vol.	82,	no.	4,	pp.	550-557.	
Seigneurin-Berny,	D.,	Verdel,	A.,	Curtet,	S.,	Lemercier,	C.,	Garin,	J.,	Rousseaux,	S.,	&	
Khochbin,	S.	2001,	"Identification	of	components	of	the	murine	histone	deacetylase	6	
complex:	link	between	acetylation	and	ubiquitination	signaling	pathways	
15",	Mol.Cell	Biol.,	vol.	21,	no.	23,	pp.	8035-8044.	
Serrador,	J.	M.,	Cabrero,	J.	R.,	Sancho,	D.,	Mittelbrunn,	M.,	Urzainqui,	A.,	&	Sanchez-Madrid,	
F.	2004,	"HDAC6	deacetylase	activity	links	the	tubulin	cytoskeleton	with	immune	synapse	
organization",	Immunity.,	vol.	20,	no.	4,	pp.	417-428.	
Shah,	M.	&	Haylett,	D.	G.	2000,	"The	pharmacology	of	hSK1	Ca2+-activated	K+	channels	
expressed	in	mammalian	cell	lines",	Br.J	Pharmacol.,	vol.	129,	no.	4,	pp.	627-630.	
Shakespear,	M.	R.,	Halili,	M.	A.,	Irvine,	K.	M.,	Fairlie,	D.	P.,	&	Sweet,	M.	J.	2011,	"Histone	
deacetylases	as	regulators	of	inflammation	and	immunity",	Trends	Immunol.,	vol.	32,	no.	7,	
pp.	335-343.	
Shevach,	E.	M.	2009,	"Mechanisms	of	foxp3+	T	regulatory	cell-mediated	suppression",	
Immunity.,	vol.	30,	no.	5,	pp.	636-645.	
Skapenko,	A.,	Kalden,	J.	R.,	Lipsky,	P.	E.,	&	Schulze-Koops,	H.	2005,	"The	IL-4	receptor	alpha-
chain-binding	cytokines,	IL-4	and	IL-13,	induce	forkhead	box	P3-expressing	CD25+CD4+	
regulatory	T	cells	from	CD25-CD4+	precursors",	J	Immunol.,	vol.	175,	no.	9,	pp.	6107-6116.	
Skov,	S.,	Rieneck,	K.,	Bovin,	L.	F.,	Skak,	K.,	Tomra,	S.,	Michelsen,	B.	K.,	&	Odum,	N.	2003,	
"Histone	deacetylase	inhibitors:	a	new	class	of	immunosuppressors	targeting	a	novel	signal	
pathway	essential	for	CD154	expression",	Blood,	vol.	101,	no.	4,	pp.	1430-1438.	
Sojka,	D.	K.,	Huang,	Y.	H.,	&	Fowell,	D.	J.	2008,	"Mechanisms	of	regulatory	T-cell	suppression	
-	a	diverse	arsenal	for	a	moving	target",	Immunology,	vol.	124,	no.	1,	pp.	13-22.	
Son,	Y.	M.,	Song,	K.	D.,	Park,	S.	M.,	Han,	S.	H.,	&	Yun,	C.	H.	2013,	"Lipoteichoic	acid	
suppresses	effector	T	cells	induced	by	Staphylococcus	aureus-pulsed	dendritic	cells",	J	
Microbiol.Biotechnol.,	vol.	23,	no.	7,	pp.	1023-1030.	
Souba,	A.	A.,	Fink,	M.	P.,	Jurkovich,	G.	J.,	Kaiser,	L.	P.,	Pearce,	W.	H.,	Pemberton,	J.	H.,	&	
Soper,	N.	J.	2013,	ACS	Surgery	Principles	and	Practice,	6	edn,	American	College	of	Surgeons.	
Starzl,	T.	E.,	Marchioro,	T.	L.,	&	Waddell,	W.	R.	1963,	"The	reversal	of	rejection	in	human	
renal	homografts	with	subsequent	development	of	homograft	tolerance",	
Surg.Gynecol.Obstet.,	vol.	117,	pp.	385-395.	
Starzl,	T.	E.,	Weil,	R.,	III,	Iwatsuki,	S.,	Klintmalm,	G.,	Schroter,	G.	P.,	Koep,	L.	J.,	Iwaki,	Y.,	
Terasaki,	P.	I.,	&	Porter,	K.	A.	1980,	"The	use	of	cyclosporin	A	and	prednisone	in	cadaver	
kidney	transplantation",	Surg.Gynecol.Obstet.,	vol.	151,	no.	1,	pp.	17-26.	
254	
	
Steiger,	J.	U.,	Nickerson,	P.	W.,	Hermle,	M.,	Thiel,	G.,	&	Heim,	M.	H.	1998,	"Interferon-
gamma	receptor	signaling	is	not	required	in	the	effector	phase	of	the	alloimmune	
response",	Transplantation,	vol.	65,	no.	12,	pp.	1649-1652.	
Steinberger,	P.,	Majdic,	O.,	Derdak,	S.	V.,	Pfistershammer,	K.,	Kirchberger,	S.,	Klauser,	C.,	
Zlabinger,	G.,	Pickl,	W.	F.,	Stockl,	J.,	&	Knapp,	W.	2004,	"Molecular	characterization	of	
human	4Ig-B7-H3,	a	member	of	the	B7	family	with	four	Ig-like	domains",	J	Immunol.,	vol.	
172,	no.	4,	pp.	2352-2359.	
Strevel,	E.	L.,	Ing,	D.	J.,	&	Siu,	L.	L.	2007,	"Molecularly	targeted	oncology	therapeutics	and	
prolongation	of	the	QT	interval",	J	Clin.Oncol.,	vol.	25,	no.	22,	pp.	3362-3371.	
Sun,	J.,	Sheil,	A.	G.,	Wang,	C.,	Wang,	L.,	Rokahr,	K.,	Sharland,	A.,	Jung,	S.	E.,	Li,	L.,	
McCaughan,	G.	W.,	&	Bishop,	G.	A.	1996,	"Tolerance	to	rat	liver	allografts:	IV.	Acceptance	
depends	on	the	quantity	of	donor	tissue	and	on	donor	leukocytes",	Transplantation,	vol.	62,	
no.	12,	pp.	1725-1730.	
Sun,	Y.,	Chin,	Y.	E.,	Weisiger,	E.,	Malter,	C.,	Tawara,	I.,	Toubai,	T.,	Gatza,	E.,	Mascagni,	P.,	
Dinarello,	C.	A.,	&	Reddy,	P.	2009,	"Cutting	edge:	Negative	regulation	of	dendritic	cells	
through	acetylation	of	the	nonhistone	protein	STAT-3",	J	Immunol.,	vol.	182,	no.	10,	pp.	
5899-5903.	
Sweet,	M.	J.,	Shakespear,	M.	R.,	Kamal,	N.	A.,	&	Fairlie,	D.	P.	2012,	"HDAC	inhibitors:	
modulating	leukocyte	differentiation,	survival,	proliferation	and	inflammation",	
Immunol.Cell	Biol.,	vol.	90,	no.	1,	pp.	14-22.	
Takahashi,	T.,	Kuniyasu,	Y.,	Toda,	M.,	Sakaguchi,	N.,	Itoh,	M.,	Iwata,	M.,	Shimizu,	J.,	&	
Sakaguchi,	S.	1998,	"Immunologic	self-tolerance	maintained	by	CD25+CD4+	naturally	
anergic	and	suppressive	T	cells:	induction	of	autoimmune	disease	by	breaking	their	
anergic/suppressive	state",	Int.Immunol.,	vol.	10,	no.	12,	pp.	1969-1980.	
Takemoto,	S.	K.,	Terasaki,	P.	I.,	Gjertson,	D.	W.,	&	Cecka,	J.	M.	2000,	"Twelve	years'	
experience	with	national	sharing	of	HLA-matched	cadaveric	kidneys	for	transplantation",	N	
Engl	J	Med,	vol.	343,	no.	15,	pp.	1078-1084.	
Tan,	J.,	Cang,	S.,	Ma,	Y.,	Petrillo,	R.	L.,	&	Liu,	D.	2010,	"Novel	histone	deacetylase	inhibitors	in	
clinical	trials	as	anti-cancer	agents",	J	Hematol.Oncol.,	vol.	3,	p.	5.	
Tang,	X.,	Gao,	J.	S.,	Guan,	Y.	J.,	McLane,	K.	E.,	Yuan,	Z.	L.,	Ramratnam,	B.,	&	Chin,	Y.	E.	2007,	
"Acetylation-dependent	signal	transduction	for	type	I	interferon	receptor",	Cell,	vol.	131,	no.	
1,	pp.	93-105.	
Tao,	R.,	de	Zoeten,	E.	F.,	Ozkaynak,	E.,	Chen,	C.,	Wang,	L.,	Porrett,	P.	M.,	Li,	B.,	Turka,	L.	A.,	
Olson,	E.	N.,	Greene,	M.	I.,	Wells,	A.	D.,	&	Hancock,	W.	W.	2007a,	"Deacetylase	inhibition	
promotes	the	generation	and	function	of	regulatory	T	cells",	Nat.Med,	vol.	13,	no.	11,	pp.	
1299-1307.	
Tao,	R.	&	Hancock,	W.	W.	2008,	"Resistance	of	Foxp3+	regulatory	T	cells	to	Nur77-induced	
apoptosis	promotes	allograft	survival",	PLoS.One.,	vol.	3,	no.	5,	p.	e2321.	
255	
	
Taunton,	J.,	Hassig,	C.	A.,	&	Schreiber,	S.	L.	1996,	"A	mammalian	histone	deacetylase	related	
to	the	yeast	transcriptional	regulator	Rpd3p",	Science,	vol.	272,	no.	5260,	pp.	408-411.	
Taylor,	P.	A.,	Lees,	C.	J.,	&	Blazar,	B.	R.	2002,	"The	infusion	of	ex	vivo	activated	and	expanded	
CD4(+)CD25(+)	immune	regulatory	cells	inhibits	graft-versus-host	disease	lethality	",	Blood,	
vol.	99,	no.	10,	pp.	3493-3499.	
Teh,	H.	S.,	Kisielow,	P.,	Scott,	B.,	Kishi,	H.,	Uematsu,	Y.,	Bluthmann,	H.,	&	von,	B.	H.	1988,	
"Thymic	major	histocompatibility	complex	antigens	and	the	alpha	beta	T-cell	receptor	
determine	the	CD4/CD8	phenotype	of	T	cells",	Nature,	vol.	335,	no.	6187,	pp.	229-233.	
Terasaki,	P.	&	Mizutani,	K.	2006,	"Antibody	mediated	rejection:	update	2006",	Clin.J	
Am.Soc.Nephrol.,	vol.	1,	no.	3,	pp.	400-403.	
Thornton,	A.	M.,	Donovan,	E.	E.,	Piccirillo,	C.	A.,	&	Shevach,	E.	M.	2004,	"Cutting	edge:	IL-2	is	
critically	required	for	the	in	vitro	activation	of	CD4+CD25+	T	cell	suppressor	function",	J	
Immunol.,	vol.	172,	no.	11,	pp.	6519-6523.	
Thornton,	A.	M.	&	Shevach,	E.	M.	1998,	"CD4+CD25+	immunoregulatory	T	cells	suppress	
polyclonal	T	cell	activation	in	vitro	by	inhibiting	interleukin	2	production",	J	Exp.Med,	vol.	
188,	no.	2,	pp.	287-296.	
Thornton,	A.	M.	&	Shevach,	E.	M.	2000,	"Suppressor	effector	function	of	CD4+CD25+	
immunoregulatory	T	cells	is	antigen	nonspecific",	J	Immunol.,	vol.	164,	no.	1,	pp.	183-190.	
Tiemessen,	M.	M.,	Jagger,	A.	L.,	Evans,	H.	G.,	van	Herwijnen,	M.	J.,	John,	S.,	&	Taams,	L.	S.	
2007,	"CD4+CD25+Foxp3+	regulatory	T	cells	induce	alternative	activation	of	human	
monocytes/macrophages",	Proc.Natl.Acad.Sci	U.S.A,	vol.	104,	no.	49,	pp.	19446-19451.	
Todo,	S.,	Fung,	J.	J.,	Starzl,	T.	E.,	Tzakis,	A.,	Demetris,	A.	J.,	Kormos,	R.,	Jain,	A.,	Alessiani,	M.,	
Takaya,	S.,	&	Shapiro,	R.	1990,	"Liver,	kidney,	and	thoracic	organ	transplantation	under	FK	
506",	Ann.Surg.,	vol.	212,	no.	3,	pp.	295-305.	
Todo,	S.,	Podesta,	L.,	ChapChap,	P.,	Kahn,	D.,	Pan,	C.	E.,	Ueda,	Y.,	Okuda,	K.,	Imventarza,	O.,	
Casavilla,	A.,	Demetris,	A.	J.,	&	.	1987,	"Orthotopic	liver	transplantation	in	dogs	receiving	FK-
506",	Transplant.Proc.,	vol.	19,	no.	5	Suppl	6,	pp.	64-67.	
Ueki,	N.,	Zhang,	L.,	&	Hayman,	M.	J.	2008,	"Ski	can	negatively	regulates	macrophage	
differentiation	through	its	interaction	with	PU.1",	Oncogene,	vol.	27,	no.	3,	pp.	300-307.	
Ullman,	E.	1914,	"Tissue	and	Organ	Transplantation",	Ann.Surg.,	vol.	60,	no.	2,	pp.	195-219.	
Valencia,	X.,	Stephens,	G.,	Goldbach-Mansky,	R.,	Wilson,	M.,	Shevach,	E.	M.,	&	Lipsky,	P.	E.	
2006,	"TNF	downmodulates	the	function	of	human	CD4+CD25hi	T-regulatory	cells",	Blood,	
vol.	108,	no.	1,	pp.	253-261.	
Verdel,	A.,	Curtet,	S.,	Brocard,	M.	P.,	Rousseaux,	S.,	Lemercier,	C.,	Yoshida,	M.,	&	Khochbin,	
S.	2000,	"Active	maintenance	of	mHDA2/mHDAC6	histone-deacetylase	in	the	cytoplasm",	
Curr.Biol.,	vol.	10,	no.	12,	pp.	747-749.	
256	
	
Verdel,	A.	&	Khochbin,	S.	1999,	"Identification	of	a	new	family	of	higher	eukaryotic	histone	
deacetylases.	Coordinate	expression	of	differentiation-dependent	chromatin	modifiers",	J	
Biol.Chem.,	vol.	274,	no.	4,	pp.	2440-2445.	
Vieira,	P.	L.,	Christensen,	J.	R.,	Minaee,	S.,	O'Neill,	E.	J.,	Barrat,	F.	J.,	Boonstra,	A.,	Barthlott,	
T.,	Stockinger,	B.,	Wraith,	D.	C.,	&	O'Garra,	A.	2004,	"IL-10-secreting	regulatory	T	cells	do	not	
express	Foxp3	but	have	comparable	regulatory	function	to	naturally	occurring	CD4+CD25+	
regulatory	T	cells",	J	Immunol.,	vol.	172,	no.	10,	pp.	5986-5993.	
Vincenti,	F.,	Larsen,	C.,	Durrbach,	A.,	Wekerle,	T.,	Nashan,	B.,	Blancho,	G.,	Lang,	P.,	Grinyo,	J.,	
Halloran,	P.	F.,	Solez,	K.,	Hagerty,	D.,	Levy,	E.,	Zhou,	W.,	Natarajan,	K.,	&	Charpentier,	B.	
2005,	"Costimulation	blockade	with	belatacept	in	renal	transplantation",	N	Engl	J	Med,	vol.	
353,	no.	8,	pp.	770-781.	
Vincenti,	F.,	Larsen,	C.	P.,	Alberu,	J.,	Bresnahan,	B.,	Garcia,	V.	D.,	Kothari,	J.,	Lang,	P.,	Urrea,	
E.	M.,	Massari,	P.,	Mondragon-Ramirez,	G.,	Reyes-Acevedo,	R.,	Rice,	K.,	Rostaing,	L.,	
Steinberg,	S.,	Xing,	J.,	Agarwal,	M.,	Harler,	M.	B.,	&	Charpentier,	B.	2012,	"Three-year	
outcomes	from	BENEFIT,	a	randomized,	active-controlled,	parallel-group	study	in	adult	
kidney	transplant	recipients",	Am.J	Transplant.,	vol.	12,	no.	1,	pp.	210-217.	
von,	B.	H.	&	Jaeckel,	E.	2001,	"Peripheral	tolerance	and	organ	specific	autoimmunity",	
Adv.Exp.Med	Biol.,	vol.	490,	pp.	41-48.	
Wagner,	J.	M.,	Hackanson,	B.,	Lubbert,	M.,	&	Jung,	M.	2010b,	"Histone	deacetylase	(HDAC)	
inhibitors	in	recent	clinical	trials	for	cancer	therapy",	Clin.Epigenetics.,	vol.	1,	no.	3-4,	pp.	
117-136.	
Wagner,	J.	M.,	Hackanson,	B.,	Lubbert,	M.,	&	Jung,	M.	2010a,	"Histone	deacetylase	(HDAC)	
inhibitors	in	recent	clinical	trials	for	cancer	therapy",	Clin.Epigenetics.,	vol.	1,	no.	3-4,	pp.	
117-136.	
Wang,	H.,	Cheng,	F.,	Woan,	K.,	Sahakian,	E.,	Merino,	O.,	Rock-Klotz,	J.,	Vicente-Suarez,	I.,	
Pinilla-Ibarz,	J.,	Wright,	K.	L.,	Seto,	E.,	Bhalla,	K.,	Villagra,	A.,	&	Sotomayor,	E.	M.	2011,	
"Histone	deacetylase	inhibitor	LAQ824	augments	inflammatory	responses	in	macrophages	
through	transcriptional	regulation	of	IL-10",	J	Immunol.,	vol.	186,	no.	7,	pp.	3986-3996.	
Wang,	J.,	van,	D.	H.,	Scherer,	H.	U.,	Huizinga,	T.	W.,	&	Toes,	R.	E.	2008,	"Suppressor	activity	
among	CD4+,CD25++	T	cells	is	discriminated	by	membrane-bound	tumor	necrosis	factor	
alpha",	Arthritis	Rheum.,	vol.	58,	no.	6,	pp.	1609-1618.	
Wang,	L.,	de	Zoeten,	E.	F.,	Greene,	M.	I.,	&	Hancock,	W.	W.	2009,	"Immunomodulatory	
effects	of	deacetylase	inhibitors:	therapeutic	targeting	of	FOXP3+	regulatory	T	cells",	
Nat.Rev.Drug	Discov.,	vol.	8,	no.	12,	pp.	969-981.	
Weiner,	H.	L.	2001,	"Induction	and	mechanism	of	action	of	transforming	growth	factor-beta-
secreting	Th3	regulatory	cells",	Immunol.Rev.,	vol.	182,	pp.	207-214.	
Weyermann,	J.,	Lochmann,	D.,	&	Zimmer,	A.	2005,	"A	practical	note	on	the	use	of	
cytotoxicity	assays",	Int.J	Pharm.,	vol.	288,	no.	2,	pp.	369-376.	
257	
	
Wildin,	R.	S.,	Ramsdell,	F.,	Peake,	J.,	Faravelli,	F.,	Casanova,	J.	L.,	Buist,	N.,	Levy-Lahad,	E.,	
Mazzella,	M.,	Goulet,	O.,	Perroni,	L.,	Bricarelli,	F.	D.,	Byrne,	G.,	McEuen,	M.,	Proll,	S.,	
Appleby,	M.,	&	Brunkow,	M.	E.	2001,	"X-linked	neonatal	diabetes	mellitus,	enteropathy	and	
endocrinopathy	syndrome	is	the	human	equivalent	of	mouse	scurfy",	Nat.Genet.,	vol.	27,	
no.	1,	pp.	18-20.	
Wing,	K.,	Fehervari,	Z.,	&	Sakaguchi,	S.	2006,	"Emerging	possibilities	in	the	development	and	
function	of	regulatory	T	cells",	Int.Immunol.,	vol.	18,	no.	7,	pp.	991-1000.	
Won,	Y.	H.,	Sauder,	D.	N.,	&	McKenzie,	R.	C.	1994,	"Cyclosporin	A	inhibits	keratinocyte	
cytokine	gene	expression",	Br.J	Dermatol.,	vol.	130,	no.	3,	pp.	312-319.	
Wood,	K.	J.	&	Sakaguchi,	S.	2003,	"Regulatory	T	cells	in	transplantation	tolerance",	
Nat.Rev.Immunol.,	vol.	3,	no.	3,	pp.	199-210.	
Workman,	C.	J.,	Szymczak-Workman,	A.	L.,	Collison,	L.	W.,	Pillai,	M.	R.,	&	Vignali,	D.	A.	2009,	
"The	development	and	function	of	regulatory	T	cells",	Cell	Mol.Life	Sci,	vol.	66,	no.	16,	pp.	
2603-2622.	
Wu,	H.	&	Parsons,	J.	T.	1993,	"Cortactin,	an	80/85-kilodalton	pp60src	substrate,	is	a	
filamentous	actin-binding	protein	enriched	in	the	cell	cortex",	J	Cell	Biol.,	vol.	120,	no.	6,	pp.	
1417-1426.	
Xu,	W.	S.,	Parmigiani,	R.	B.,	&	Marks,	P.	A.	2007,	"Histone	deacetylase	inhibitors:	molecular	
mechanisms	of	action",	Oncogene,	vol.	26,	no.	37,	pp.	5541-5552.	
Yamada,	A.,	Salama,	A.	D.,	Sho,	M.,	Najafian,	N.,	Ito,	T.,	Forman,	J.	P.,	Kewalramani,	R.,	
Sandner,	S.,	Harada,	H.,	Clarkson,	M.	R.,	Mandelbrot,	D.	A.,	Sharpe,	A.	H.,	Oshima,	H.,	Yagita,	
H.,	Chalasani,	G.,	Lakkis,	F.	G.,	Auchincloss,	H.,	Jr.,	&	Sayegh,	M.	H.	2005,	"CD70	signaling	is	
critical	for	CD28-independent	CD8+	T	cell-mediated	alloimmune	responses	in	vivo",	J	
Immunol.,	vol.	174,	no.	3,	pp.	1357-1364.	
Yamaguchi,	T.,	Cubizolles,	F.,	Zhang,	Y.,	Reichert,	N.,	Kohler,	H.,	Seiser,	C.,	&	Matthias,	P.	
2010,	"Histone	deacetylases	1	and	2	act	in	concert	to	promote	the	G1-to-S	progression",	
Genes	Dev.,	vol.	24,	no.	5,	pp.	455-469.	
Yan,	B.,	Xie,	S.,	Liu,	Z.,	Ran,	J.,	Li,	Y.,	Wang,	J.,	Yang,	Y.,	Zhou,	J.,	Li,	D.,	&	Liu,	M.	2014,	
"HDAC6	deacetylase	activity	is	critical	for	lipopolysaccharide-induced	activation	of	
macrophages",	PLoS.One.,	vol.	9,	no.	10,	p.	e110718.	
Yang,	X.	J.	&	Seto,	E.	2007,	"HATs	and	HDACs:	from	structure,	function	and	regulation	to	
novel	strategies	for	therapy	and	prevention",	Oncogene,	vol.	26,	no.	37,	pp.	5310-5318.	
Yu,	F.,	Yu,	F.,	McGuire,	P.	M.,	Li,	R.,	&	Wang,	R.	2007,	"Effects	of	Hydrocotyle	sibthorpioides	
extract	on	transplanted	tumors	and	immune	function	in	mice",	Phytomedicine.,	vol.	14,	no.	
2-3,	pp.	166-171.	
258	
	
Yun,	S.	Y.,	Hur,	Y.	G.,	Kang,	M.	A.,	Lee,	J.,	Ahn,	C.,	&	Won,	J.	2003,	"Synergistic	
immunosuppressive	effects	of	rosmarinic	acid	and	rapamycin	in	vitro	and	in	vivo",	
Transplantation,	vol.	75,	no.	10,	pp.	1758-1760.	
Zantvoort,	F.	A.,	D'Amaro,	J.,	Persijn,	G.	G.,	Cohen,	B.,	Schreuder,	G.	M.,	Van	Rood,	J.	J.,	&	
Thorogood,	J.	1996,	"The	impact	of	HLA-A	matching	on	long-term	survival	of	renal	
allografts",	Transplantation,	vol.	61,	no.	5,	pp.	841-844.	
Zeiser,	R.,	Leveson-Gower,	D.	B.,	Zambricki,	E.	A.,	Kambham,	N.,	Beilhack,	A.,	Loh,	J.,	Hou,	J.	
Z.,	&	Negrin,	R.	S.	2008,	"Differential	impact	of	mammalian	target	of	rapamycin	inhibition	on	
CD4+CD25+Foxp3+	regulatory	T	cells	compared	with	conventional	CD4+	T	cells",	Blood,	vol.	
111,	no.	1,	pp.	453-462.	
Zhang,	C.,	Zhang,	J.,	Yang,	B.,	&	Wu,	C.	2008a,	"Cyclosporin	A	inhibits	the	production	of	IL-17	
by	memory	Th17	cells	from	healthy	individuals	and	patients	with	rheumatoid	arthritis",	
Cytokine,	vol.	42,	no.	3,	pp.	345-352.	
Zhang,	X.,	Han,	S.,	Kang,	Y.,	Guo,	M.,	Hong,	S.,	Liu,	F.,	Fu,	S.,	Wang,	L.,	&	Wang,	Q.	X.	2012,	
"SAHA,	an	HDAC	inhibitor,	synergizes	with	tacrolimus	to	prevent	murine	cardiac	allograft	
rejection",	Cell	Mol.Immunol.,	vol.	9,	no.	5,	pp.	390-398.	
Zhang,	X.,	Yuan,	Z.,	Zhang,	Y.,	Yong,	S.,	Salas-Burgos,	A.,	Koomen,	J.,	Olashaw,	N.,	Parsons,	J.	
T.,	Yang,	X.	J.,	Dent,	S.	R.,	Yao,	T.	P.,	Lane,	W.	S.,	&	Seto,	E.	2007,	"HDAC6	modulates	cell	
motility	by	altering	the	acetylation	level	of	cortactin",	Mol.Cell,	vol.	27,	no.	2,	pp.	197-213.	
Zhang,	Y.,	Gilquin,	B.,	Khochbin,	S.,	&	Matthias,	P.	2006,	"Two	catalytic	domains	are	required	
for	protein	deacetylation",	J	Biol.Chem.,	vol.	281,	no.	5,	pp.	2401-2404.	
Zhang,	Y.,	Kwon,	S.,	Yamaguchi,	T.,	Cubizolles,	F.,	Rousseaux,	S.,	Kneissel,	M.,	Cao,	C.,	Li,	N.,	
Cheng,	H.	L.,	Chua,	K.,	Lombard,	D.,	Mizeracki,	A.,	Matthias,	G.,	Alt,	F.	W.,	Khochbin,	S.,	&	
Matthias,	P.	2008b,	"Mice	lacking	histone	deacetylase	6	have	hyperacetylated	tubulin	but	
are	viable	and	develop	normally",	Mol.Cell	Biol.,	vol.	28,	no.	5,	pp.	1688-1701.	
Zhang,	Y.,	Li,	N.,	Caron,	C.,	Matthias,	G.,	Hess,	D.,	Khochbin,	S.,	&	Matthias,	P.	2003,	"HDAC-6	
interacts	with	and	deacetylates	tubulin	and	microtubules	in	vivo",	EMBO	J,	vol.	22,	no.	5,	pp.	
1168-1179.	
Zhao,	L.,	Sun,	L.,	Wang,	H.,	Ma,	H.,	Liu,	G.,	&	Zhao,	Y.	2007,	"Changes	of	CD4+CD25+Foxp3+	
regulatory	T	cells	in	aged	Balb/c	mice",	J	Leukoc.Biol.,	vol.	81,	no.	6,	pp.	1386-1394.	
Zilberman,	Y.,	Ballestrem,	C.,	Carramusa,	L.,	Mazitschek,	R.,	Khochbin,	S.,	&	Bershadsky,	A.	
2009,	"Regulation	of	microtubule	dynamics	by	inhibition	of	the	tubulin	deacetylase	HDAC6",	
J	Cell	Sci,	vol.	122,	no.	Pt	19,	pp.	3531-3541.	
Zou,	H.,	Wu,	Y.,	Navre,	M.,	&	Sang,	B.	C.	2006,	"Characterization	of	the	two	catalytic	
domains	in	histone	deacetylase	6",	Biochem.Biophys.Res.Commun.,	vol.	341,	no.	1,	pp.	45-
50.	
	
	
259	
	
Publications	/	Presentations	related	to	this	study	
Publications	
× Ellis,	J.,	Inston,	N.,	Ready,	A.,	Jenkinson,	E.,	Drayson,	M.,	Shuttleworth,	S.	&	Cobbold,	
M.	(2016)	Inhibition	of	Histone	Deacetylase	6	reveals	a	potent	Immunosuppressant	
effect	in	an	in	vitro	model	of	transplantation	–	Published	in	Transplantation	(Aug	
2016)	
(see	Appendix	1)	
Oral	Presentations	
× A	Novel	Histone	Deacetylase-6	Inhibitior	Reveals	a	Potent	Immunosuppressant	Effect	
–	World	Transplant	Congress,	San	Francisco,	USA	(July	2014)	
× Inhibition	of	Histone	Deacetylase	6	reveals	a	potent	immunosuppressive	effect	in	an	
in	vitro	model	of	transplantation	-	16th	Congress	of	the	European	Society	for	
Organ	Transplantation,	Vienna,	Austria	(September	2013)	
× Histone	Deacetylase	Inhibition	reveals	a	potent	immunosuppressant	effect	in	an	in	
vitro	model	of	Transplantation	–	15th	Congress	of	the	European	Society	for	Organ	
Transplantation,	Glasgow,	UK	(September	2011)	
× Histone	Deacetylase-6	(HDAC6)	plays	a	critical	role	in	Dendritic	Cell	maturation	and	
reveals	a	new	mechanism	for	HDAC-targeted	immunosuppression	-	15th	Congress	
of	the	European	Society	for	Organ	Transplantation,	Glasgow,	UK	(September	
2011)	
260	
	
× Immunosuppressive	effect	of	novel	histone	deacetylase	inhibitors	and	their	potential	
role	in	renal	transplantation	–	European	Society	for	Surgical	Research	45th	Annual	
Congress,	Geneva,	Switzerland	(June	2010)	
Poster	Presentations	
× Histone	Deacetylase	Inhibition	reveals	a	potent	immunosuppressant	effect	in	an	in	
vitro	model	of	Transplantation	-	XII	TTS	Basic	Science	Symposium	and	II	ESOT	
Basic	Science	Meeting,	Boston,	USA	(June	2011)	
	 	
261	
	
7 Appendix	1	
Paper	published	in	Transplantation	
	
Ellis,	J.,	Neil,	D.,	Inston,	N.,	Jenkinson,	E.,	Drayson,	M.,	Hampson,	P.,	Shuttleworth,	S.,	Ready,	
A.	&	Cobbold,	M.	(2016)	Inhibition	of	Histone	Deacetylase	6	Reveals	a	Potent	
Immunosuppressant	Effect	in	Models	of	Transplantation.	Transplantation,	vol.	100(8):1667-
74.	doi:	10.1097/TP.0000000000001208.	
	 	
262	
	
263	
	
264	
	
265	
	
266	
	
267	
	
268	
	
269	
	
	
